Increased Survival in Pancreatic Cancer with nab-Paclit

New England Journal of Medicine
369, 1691-1703
DOI: 10.1056/nejmoa1304369

Citation Report

#	Article	IF	Citations
1	ADDENBROOKE'S HOSPITAL. , 0, , 148-153.		1
2	Recent Treatment Advances and Novel Therapies in Pancreas Cancer: A Review. Journal of Gastrointestinal Cancer, 2014, 45, 190-201.	0.6	24
3	Pain management and palliative care in pancreatic cancer. Current Problems in Cancer, 2013, 37, 266-272.	1.0	15
5	Standing on the shoulders of mice, making an iMPACT on pancreatic cancer. Nature Reviews Clinical Oncology, 2013, 10, 665-665.	12.5	1
6	Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. OncoTargets and Therapy, 2013, 7, 33.	1.0	66
7	Diagnosing pancreatic cancer earlier in primary care. Independent Nurse, 2014, 2014, 24-25.	0.0	0
8	Efficacy and Safety of Gemcitabine-Fluorouracil Combination Therapy in the Management of Advanced Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2014, 9, e104346.	1.1	39
9	Evaluation of Uric Acid as a Prognostic Blood-Based Marker in a Large Cohort of Pancreatic Cancer Patients. PLoS ONE, 2014, 9, e104730.	1.1	39
10	A Bayesian Meta-Analysis of Multiple Treatment Comparisons of Systemic Regimens for Advanced Pancreatic Cancer. PLoS ONE, 2014, 9, e108749.	1.1	37
11	Ask ACCC's Community Resource Centers: Pancreatic Cancer. Oncology Issues, 2014, 29, 60-62.	0.0	0
12	Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer. OncoTargets and Therapy, 2014, 7, 187.	1.0	25
13	Encapsulated Cells Expressing a Chemotherapeutic Activating Enzyme Allow the Targeting of Subtoxic Chemotherapy and Are Safe and Efficacious: Data from Two Clinical Trials in Pancreatic Cancer. Pharmaceutics, 2014, 6, 447-466.	2.0	24
14	Neoadjuvant therapy for pancreas cancer: Past lessons and future therapies. World Journal of Gastroenterology, 2014, 20, 15564.	1.4	39
16	Assessing the role of the EGF receptor in the development and progression of pancreatic cancer. Gastrointestinal Cancer: Targets and Therapy, 2014, , 23.	5.5	3
17	Pancreatic Cancer Treatment. Journal of Drug Metabolism & Toxicology, 2014, 05, .	0.1	3
18	Management of borderline and locally advanced pancreatic cancer: Where do we stand?. World Journal of Gastroenterology, 2014, 20, 2255.	1.4	76
19	The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Enhances the Antitumoral Activity of Gemcitabine in Human Pancreatic Cancer Cell Lines. Journal of Integrative Oncology, 2014, 04, .	0.3	0
20	A Near-Complete Response to Treatment with Gemcitabine plus nabÂ®-Paclitaxel in a Patient with Metastatic Pancreatic Cancer and Poor Performance Status: A Case Report. Case Reports in Oncology, 2014, 7, 711-717.	0.3	5

#	Article	IF	Citations
21	Complex role for the immune system in initiation and progression of pancreatic cancer. World Journal of Gastroenterology, 2014, 20, 11160.	1.4	111
22	Druggable Targets in Pancreatic Adenocarcinoma. Forum on Immunopathological Diseases and Therapeutics, 2014, 5, 195-214.	0.1	0
23	Ten Weeks to Live: a Population-Based Study on Treatment and Survival of Patients with Metastatic Pancreatic Cancer in the South of the Netherlands. Annals of Oncology, 2014, 25, iv237.	0.6	0
24	Beyond first-line chemotherapy for advanced pancreatic cancer: An expanding array of therapeutic options?. World Journal of Gastroenterology, 2014, 20, 2224.	1.4	51
26	N-methylhemeanthidine chloride, a novel Amaryllidaceae alkaloid, inhibits pancreatic cancer cell proliferation via down-regulating AKT activation. Toxicology and Applied Pharmacology, 2014, 280, 475-483.	1.3	27
27	AACR Cancer Progress Report 2014. Clinical Cancer Research, 2014, 20, S1-S112.	3.2	48
28	Albumin-Bound Paclitaxel plus Gemcitabine in Pancreatic Cancer. New England Journal of Medicine, 2014, 370, 478-480.	13.9	52
29	Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. Cancer Research, 2014, 74, 2913-2921.	0.4	5,433
30	Chemotherapy and Targeted Therapy in Advanced Biliary Tract Carcinoma: A Pooled Analysis of Clinical Trials. Chemotherapy, 2014, 60, 13-23.	0.8	40
31	Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?. World Journal of Surgical Oncology, 2014, 12, 347.	0.8	21
33	New Option for the Initial Management of Metastatic Pancreatic Cancer?. Journal of Clinical Oncology, 2014, 32, 2405-2407.	0.8	12
34	Safety and efficacy evaluation of albumin-bound paclitaxel. Expert Opinion on Drug Safety, 2014, 13, 511-520.	1.0	29
35	Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Clinical Cancer Research, 2014, 20, 5937-5945.	3.2	255
36	Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer. Expert Review of Gastroenterology and Hepatology, 2014, 8, 739-747.	1.4	32
37	Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. British Journal of Cancer, 2014, 110, 1943-1949.	2.9	59
38	Advanced stage pancreatic cancer: novel therapeutic options. Expert Review of Clinical Pharmacology, 2014, 7, 487-498.	1.3	14
39	Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo. British Journal of Cancer, 2014, 111, 318-325.	2.9	21
40	A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells. Cell Cycle, 2014, 13, 3839-3856.	1.3	26

#	Article	IF	Citations
41	Reply: â€˜Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancerâ€™. British Journal of Cancer, 2014, 111, 1677-1678.	2.9	2
42	Intra-patient heterogeneity of BRAF mutation status: fact or fiction?. British Journal of Cancer, 2014, 111, 1678-1679.	2.9	9
43	Advanced Pancreatic Cancer: Flourishing Novel Approaches in the Era of Biological Therapy. Oncologist, 2014, 19, 937-950.	1.9	9
44	Desmoplasia and Chemoresistance in Pancreatic Cancer. Cancers, 2014, 6, 2137-2154.	1.7	121
45	A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. Annals of Oncology, 2014, 25, 1750-1755.	0.6	164
46	Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer. Frontiers in Physiology, 2014, 5, 2.	1.3	57
47	Stratified Medicine for Pancreatic Cancer. , 2014, , 807-814.		0
48	FOLFIRINOX â€“ a new paradigm in the treatment of pancreatic cancer. Expert Review of Anticancer Therapy, 2014, 14, 1115-1125.	1.1	14
49	nab-Paclitaxel Plus Gemcitabine Regimen for Pancreatic Cancer. Hospital Pharmacy, 2014, 49, 18-22.	0.4	3
50	Neoadjuvant Therapy in Pancreatic Cancer: An Emerging Strategy. Gastroenterology Research and Practice, 2014, 2014, 1-9.	0.7	31
51	Nanoparticle Albumin-Bound-Paclitaxel in the Treatment of Metastatic Urethral Adenocarcinoma: The Significance of Molecular Profiling and Targeted Therapy. Case Reports in Urology, 2014, 2014, 1-3.	0.1	5
52	Antitumor Effect of Water Decoctions ofTaxusCuspidate on Pancreatic Cancer. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-11.	0.5	13
53	Role of pancreatic stellate cells in chemoresistance in pancreatic cancer. Frontiers in Physiology, 2014, 5, 141.	1.3	122
54	Stars and stripes in pancreatic cancer: role of stellate cells and stroma in cancer progression. Frontiers in Physiology, 2014, 5, 52.	1.3	71
55	Safety Study of Photodynamic Therapy Using Talaporfin Sodium in the Pancreas and Surrounding Tissues in the Syrian Golden Hamster. International Journal of Photoenergy, 2014, 2014, 1-7.	1.4	1
56	Stressing Mitosis to Death. Frontiers in Oncology, 2014, 4, 140.	1.3	39
57	Progress in the knowledge and treatment of advanced pancreatic cancer: From benchside to bedside. Cancer Treatment Reviews, 2014, 40, 1039-1047.	3.4	86
58	The management of locally advanced pancreatic cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona. Annals of Oncology, 2014, 25, ii1-ii4.	0.6	3

#	Article	IF	Citations
59	Can we move towards personalised pancreatic cancer therapy?. Expert Review of Gastroenterology and Hepatology, 2014, 8, 335-338.	1.4	5
60	Phase <scp>II</scp> study of <scp>FOLFIRINOX</scp> for chemotherapyâ€naÃ¯ve Japanese patients with metastatic pancreatic cancer. Cancer Science, 2014, 105, 1321-1326.	1.7	156
61	Comparative Effectiveness Questions in Oncology. New England Journal of Medicine, 2014, 370, 1478-1481.	13.9	39
63	nab-Paclitaxel: Novel Clinical and Experimental Evidence in Pancreatic Cancer. Zeitschrift Fur Gastroenterologie, 2014, 52, 360-366.	0.2	28
64	Parpâ€1 genetic ablation in Elaâ€“myc mice unveils novel roles for Parpâ€1 in pancreatic cancer. Journal of Pathology, 2014, 234, 214-227.	2.1	14
65	Adenocarcinoma of the pancreas. Seminars in Diagnostic Pathology, 2014, 31, 443-451.	1.0	42
66	Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort. Scandinavian Journal of Gastroenterology, 2014, 49, 1480-1485.	0.6	2
67	Loss of membranous expression of the intracellular domain of Ep<scp>CAM</scp> is a frequent event and predicts poor survival in patients with pancreatic cancer. Histopathology, 2014, 64, 683-692.	1.6	34
68	Smarter drugs emerging in pancreatic cancer therapy. Annals of Oncology, 2014, 25, 1260-1270.	0.6	72
69	Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer. Radiotherapy and Oncology, 2014, 113, 35-40.	0.3	13
70	Improved survival with combined gemcitabine and <scp>S</scp>â€1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies. Journal of Hepato-Biliary-Pancreatic Sciences, 2014, 21, 761-766.	1.4	25
71	Systematic review of irreversible electroporation in the treatment of advanced pancreatic cancer. European Journal of Surgical Oncology, 2014, 40, 1598-1604.	0.5	67
72	Î±-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. British Journal of Cancer, 2014, 111, 1917-1923.	2.9	119
73	Pharmacokinetics and pharmacodynamics of nab â€paclitaxel in patients with solid tumors: Disposition kinetics and pharmacology distinct from solventâ€based paclitaxel. Journal of Clinical Pharmacology, 2014, 54, 1097-1107.	1.0	94
74	Risk factors for covered metallic stent migration in patients with distal malignant biliary obstruction due to pancreatic cancer. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1744-1749.	1.4	57
75	Phase <scp>II</scp> trial of nanoparticle albuminâ€bound paclitaxel as secondâ€line chemotherapy for unresectable or recurrent gastric cancer. Cancer Science, 2014, 105, 812-817.	1.7	74
76	Pancreatic cancer: current standards, working towards a new therapeutic approach. Expert Review of Anticancer Therapy, 2014, 14, 495-497.	1.1	8
77	Response to <scp>GEMOX</scp> plus erlotinib in pancreatic cancer is associated with <scp>ERCC</scp>1 overexpression. European Journal of Clinical Investigation, 2014, 44, 958-964.	1.7	9

#	Article	IF	Citations
78	Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabineâ€based therapy with or without bevacizumab. Cancer, 2014, 120, 1780-1786.	2.0	23
79	Enhancement of Nab-Paclitaxel Antitumor Activity through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer. Molecular Cancer Therapeutics, 2014, 13, 1032-1043.	1.9	19
80	Nanomedicine: The Promise and Challenges in Cancer Chemotherapy. Advances in Experimental Medicine and Biology, 2014, 811, 207-233.	0.8	19
81	A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2014, 74, 911-915.	1.1	7
83	Stereotactic body radiation therapy in pancreatic cancer: the new frontier. Expert Review of Anticancer Therapy, 2014, 14, 1461-1475.	1.1	31
84	SMAD4 Loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells. BMC Cancer, 2014, 14, 181.	1.1	50
85	Taxanes. Anti-Cancer Drugs, 2014, 25, 584-592.	0.7	18
86	Value of Intraoperative Neck Margin Analysis During Whipple for Pancreatic Adenocarcinoma. Annals of Surgery, 2014, 260, 494-503.	2.1	88
87	Gemcitabine and CHK1 Inhibition Potentiate EGFR-Directed Radioimmunotherapy against Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2014, 20, 3187-3197.	3.2	32
88	Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer. Case Reports in Oncology, 2014, 7, 648-655.	0.3	19
90	Metronomic Chemotherapy Regimens Using Microtubule-Targeting Agents: Mechanisms of Action, Preclinical Activity and Future Developments. , 2014, , 69-90.		0
91	Unintended Consequences of Expensive Cancer Therapeuticsâ€"The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity. JAMA Otolaryngology - Head and Neck Surgery, 2014, 140, 1225.	1.2	263
92	Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer. Expert Review of Anticancer Therapy, 2014, 14, 511-521.	1.1	15
93	Pancreatic Adenocarcinoma: Treating a Systemic Disease With Systemic Therapy. Journal of the National Cancer Institute, 2014, 106, dju011-dju011.	3.0	141
94	Pancreatic cancer, treatment options, and GI-4000. Human Vaccines and Immunotherapeutics, 2014, 10, 3347-3353.	1.4	16
95	The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study. European Journal of Cancer, 2014, 50, 1422-1429.	1.3	28
96	Polychemotherapy or gemcitabine in advanced pancreatic cancer: A meta-analysis. Digestive and Liver Disease, 2014, 46, 452-459.	0.4	19
97	Will Detection of MicroRNA Biomarkers in Blood Improve the Diagnosis and Survival of Patients With Pancreatic Cancer?. JAMA - Journal of the American Medical Association, 2014, 311, 363.	3.8	10

#	Article	IF	Citations
98	A clinical update of using albumin as a drug vehicle â€" A commentary. Journal of Controlled Release, 2014, 190, 331-336.	4.8	263
100	A phase I trial of combination therapy using gemcitabine and S-1 concurrent with full-dose radiation for resectable pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2014, 73, 309-315.	1.1	25
102	Neoadjuvant Chemotherapy for Localized Pancreatic Cancer: Too Little or Too Long?. Annals of Surgical Oncology, 2014, 21, 1508-1509.	0.7	1
103	MicroRNA Biomarkers in Whole Blood for Detection of Pancreatic Cancer. JAMA - Journal of the American Medical Association, 2014, 311, 392.	3.8	380
104	Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea Cancer Center Hospital experience. Pediatric Blood and Cancer, 2014, 61, 1376-1381.	0.8	47
105	Preclinical evaluation of nanoparticle albuminâ€bound paclitaxel for treatment of pediatric bone sarcoma. Pediatric Blood and Cancer, 2014, 61, 2096-2098.	0.8	24
106	The complex landscape of pancreatic cancer metabolism. Carcinogenesis, 2014, 35, 1441-1450.	1.3	104
107	Opportunities for translation: Targeting DNA repair pathways in pancreatic cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 45-54.	3.3	8
108	Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. British Journal of Cancer, 2014, 110, 1698-1704.	2.9	316
109	Resectable, Borderline Resectable, and Locally Advanced Pancreatic Cancer: What Does It Matter?. Current Oncology Reports, 2014, 16, 366.	1.8	26
110	Multimodal Therapies for Pancreatic Cancer. , 2014, , 39-73.		0
111	Progress in the delivery of nanoparticle constructs: towards clinical translation. Current Opinion in Pharmacology, 2014, 18, 120-128.	1.7	43
112	A Pilot Study to Develop a Diagnostic Test for Pancreatic Ductal Adenocarcinoma Based on Differential Expression of Select miRNA in Plasma and Bile. American Journal of Gastroenterology, 2014, 109, 1942-1952.	0.2	100
113	Prognostic value of systemic inflammationâ€based markers in advanced pancreatic cancer. Internal Medicine Journal, 2014, 44, 676-682.	0.5	99
114	Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 187 T AGEO randomised phase II study (FIRGEM). European Journal of Cancer, 2014, 50, 3116-3124.	1.3	27
115	FOLFIRINOX for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: The Royal Marsden Experience. Clinical Colorectal Cancer, 2014, 13, 232-238.	1.0	60
117	Nab-paclitaxel: A flattering facelift. Critical Reviews in Oncology/Hematology, 2014, 92, 166-180.	2.0	35
118	Albumin-Bound Paclitaxel: A Review of Its Use for the First-Line Combination Treatment of Metastatic Pancreatic Cancer. Drugs, 2014, 74, 1757-1768.	4.9	30

#	Article	IF	Citations
119	Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma. Expert Opinion on Investigational Drugs, 2014, 23, 1499-1515.	1.9	18
120	Experimental virotherapy of chemoresistant pancreatic carcinoma using infectivity-enhanced fiber-mosaic oncolytic adenovirus. Cancer Gene Therapy, 2014, 21, 264-274.	2.2	6
121	Specificity Delivers: Therapeutic Role of Tumor Antigen-Specific Antibodies in Pancreatic Cancer. Seminars in Oncology, 2014, 41, 559-575.	0.8	3
122	Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1Î±-VEGF mediated angiogenesis. Cancer Letters, 2014, 355, 281-287.	3.2	44
123	SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. Annals of Oncology, 2014, 25, 1025-1032.	0.6	66
124	Response to Nab-Paclitaxel plus Gemcitabine in a Patient with Primary Resistance to FOLFIRINOX. Journal of Gastrointestinal Cancer, 2014, 45, 278-281.	0.6	2
125	Peritoneal cancer treatment. Expert Opinion on Pharmacotherapy, 2014, 15, 623-636.	0.9	41
126	Oncology Scanâ€"Novel Treatment Strategies for Gastrointestinal Cancers. International Journal of Radiation Oncology Biology Physics, 2014, 89, 699-703.	0.4	4
128	Targeting the C-terminal focal adhesion kinase scaffold in pancreatic cancer. Cancer Letters, 2014, 353, 281-289.	3.2	15
129	Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. Cancer Discovery, 2014, 4, 998-1013.	7.7	1,341
130	Progress Against GI Cancer During the American Society of Clinical Oncology's First 50 Years. Journal of Clinical Oncology, 2014, 32, 1521-1530.	0.8	36
131	A targeting ligand enhances infectivity and cytotoxicity of an oncolytic adenovirus in human pancreatic cancer tissues. Journal of Controlled Release, 2014, 192, 284-293.	4.8	16
132	American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes. Journal of Clinical Oncology, 2014, 32, 1277-1280.	0.8	354
133	Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2014, 15, 829-840.	5.1	296
134	Progression-free survival as an end-point in solid tumours â€“ Perspectives from clinical trials and clinical practice. European Journal of Cancer, 2014, 50, 2303-2308.	1.3	32
135	Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. European Journal of Pharmacology, 2014, 741, 8-16.	1.7	409
136	Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx. European Journal of Cancer, 2014, 50, 2263-2270.	1.3	8
137	Screening for Pancreatic Cancer. Advances in Surgery, 2014, 48, 115-136.	0.6	20

#	Article	IF	Citations
138	Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nature Reviews Drug Discovery, 2014, 13, 655-672.	21.5	1,261
139	Stromal response to Hedgehog signaling restrains pancreatic cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E3091-100.	3.3	421
140	Locally Advanced Pancreatic Cancer: The Role of Definitive Chemoradiotherapy. Clinical Oncology, 2014, 26, 560-568.	0.6	42
141	The Role of Radiotherapy in the Management of Upper Gastrointestinal and Hepato-biliary and Pancreatic Cancers: Current Status and Future Directions. Clinical Oncology, 2014, 26, 519-521.	0.6	1
142	Oncogenic KRAS signalling in pancreatic cancer. British Journal of Cancer, 2014, 111, 817-822.	2.9	423
143	Stromal reengineering to treat pancreas cancer. Carcinogenesis, 2014, 35, 1451-1460.	1.3	108
145	pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104. BMC Cancer, 2014, 14, 624.	1.1	29
146	Pancreatic Adenocarcinoma. New England Journal of Medicine, 2014, 371, 1039-1049.	13.9	1,821
147	Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Cancer Chemotherapy and Pharmacology, 2014, 74, 333-340.	1.1	12
148	A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. Investigational New Drugs, 2014, 32, 739-745.	1.2	96
149	Prognostic Impact of CA 19-9 on Outcome after Neoadjuvant Chemoradiation in Patients with Locally Advanced Pancreatic Cancer. Annals of Surgical Oncology, 2014, 21, 2801-2807.	0.7	31
150	Quality-adjusted survival with combination nab-paclitaxelâ€‰+â€‰gemcitabine vs gemcitabine alone in metastatic pancreatic cancer: a Q-TWiST analysis. Journal of Medical Economics, 2014, 17, 338-346.	1.0	22
151	Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial. Journal of Clinical Oncology, 2014, 32, 2423-2429.	0.8	397
152	Comparison of Gemcitabine Combined With Targeted Agent Therapy Versus Gemcitabine Monotherapy in the Management of Advanced Pancreatic Cancer. Clinical Therapeutics, 2014, 36, 1054-1063.	1.1	10
153	Antitumor effects of baculovirus-infected dendritic cells against human pancreatic carcinoma. Gene Therapy, 2014, 21, 849-854.	2.3	10
154	Management Options in Locally Advanced Pancreatic Cancer. Current Oncology Reports, 2014, 16, 388.	1.8	29
155	TTD consensus document on the diagnosis and management of exocrine pancreatic cancer. Clinical and Translational Oncology, 2014, 16, 865-878.	1.2	5
156	Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer. Molecular Cancer, 2014, 13, 126.	7.9	31

#	Article	IF	Citations
157	Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor. Journal of Controlled Release, 2014, 192, 29-39.	4.8	48
158	Advances in patient-derived tumor xenografts: From target identification to predicting clinical response rates in oncology. Biochemical Pharmacology, 2014, 91, 135-143.	2.0	153
159	One-Electron Oxidation of Gemcitabine and Analogs: Mechanism of Formation of C3â€² and C2â€² Sugar Radicals. Journal of the American Chemical Society, 2014, 136, 15646-15653.	6.6	15
160	Sequence-responsive unzipping DNA cubes with tunable cellular uptake profiles. Chemical Science, 2014, 5, 2449-2455.	3.7	67
161	Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer. Biomaterials, 2014, 35, 7077-7087.	5.7	137
163	Chronic stress accelerates pancreatic cancer growth and invasion: A critical role for beta-adrenergic signaling in the pancreatic microenvironment. Brain, Behavior, and Immunity, 2014, 40, 40-47.	2.0	192
164	Chemotherapy for advanced pancreatic adenocarcinoma in elderly patients (â‰¥70 years of age): A retrospective cohort study at the National Center for Tumor Diseases Heidelberg. Pancreatology, 2014, 14, 211-215.	0.5	25
165	MiR-148a- and miR-216a-regulated Oncolytic Adenoviruses Targeting Pancreatic Tumors Attenuate Tissue Damage Without Perturbation of miRNA Activity. Molecular Therapy, 2014, 22, 1665-1677.	3.7	33
166	Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2014, 32, 129-160.	0.8	74
167	Nanoparticle albumin-bound paclitaxel (nab-paclitaxel): extending its indications. Expert Opinion on Drug Safety, 2014, 13, 1-5.	1.0	17
168	Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: Translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody. European Journal of Cancer, 2014, 50, 1891-1899.	1.3	31
169	Stereotactic Body Radiation Therapy: A New Standard Option for Pancreatic Cancer?. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1489-1493.	2.3	12
170	Novel strategies for managing pancreatic cancer. World Journal of Gastroenterology, 2014, 20, 14717.	1.4	15
171	Selection criteria in resectable pancreatic cancer: A biological and morphological approach. World Journal of Gastroenterology, 2014, 20, 11210.	1.4	31
172	Risks and Benefits of Phase 1 Clinical Trial Participation. Cancer Control, 2014, 21, 193-199.	0.7	17
173	Palliative Endoscopic Treatment Options in Malignancies of the Biliopancreatic System. Viszeralmedizin, 2014, 30, 238-243.	0.0	7
174	Nab-Paclitaxel for Metastatic Pancreatic Cancer: Clinical Outcomes and Potential Mechanisms of Action. Oncology Research and Treatment, 2014, 37, 128-134.	0.8	26
175	Calreticulin mutated prefibrotic-stage myelofibrosis and PMF represent an independent clone from coexisting CLL. Blood, 2014, 124, 1691-1692.	0.6	7

#	Article	IF	Citations
177	Novel Pancreatic Cancer Vaccines Could Unleash the Army Within. Cancer Control, 2014, 21, 242-246.	0.7	16
178	Evolving Treatment Options for Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 167-172.	2.3	4
179	Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials, 2015, 16, 575.	0.7	28
181	Nanomedicines Targeting the Tumor Microenvironment. Cancer Journal (Sudbury, Mass), 2015, 21, 314-321.	1.0	64
182	Pancreatic cancer and FOLFIRINOX : a new era and new questions. Cancer Medicine, 2015, 4, 853-863.	1.3	35
183	Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer. Cancer Medicine, 2015, 4, 1171-1177.	1.3	94
184	Catecholâ€•O â€•methyltransferase, a new target for pancreatic cancer therapy. Cancer Science, 2015, 106, 576-583.	1.7	15
185	Randomized phase <scp>II</scp>/<scp>III</scp> clinical trial of elpamotide for patients with advanced pancreatic cancer: <scp>PEGASUS</scp>â€‹<scp>PC</scp> Study. Cancer Science, 2015, 106, 883-890.	1.7	78
186	Overexpression of heat shock protein 27 (<scp>HSP</scp>27) increases gemcitabine sensitivity in pancreatic cancer cells through Sâ€phase arrest and apoptosis. Journal of Cellular and Molecular Medicine, 2015, 19, 340-350.	1.6	45
188	Is repeating <scp>FOLFIRINOX</scp> in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?. Cancer Science, 2015, 106, 1100-1100.	1.7	1
189	New Advances in the Treatment of Metastatic Pancreatic Cancer. Digestion, 2015, 92, 175-184.	1.2	18
190	A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma. Hpb, 2015, 17, 587-593.	0.1	11
191	Treatment of Advanced Pancreatic Cancer. , 2015, , 451-470.		0
192	Efficacy of Prophylactic G-CSF in Patients Receiving FOLFIRINOX: A Preliminary Retrospective Study. Internal Medicine, 2015, 54, 2969-2973.	0.3	12
193	Antitumor potential of a synthetic interferon-alpha/PLGF-2 positive charge peptide hybrid molecule in pancreatic cancer cells. Scientific Reports, 2015, 5, 16975.	1.6	12
194	Cryptotanshinone suppresses the proliferation and induces the apoptosis of pancreatic cancer cells via the STAT3 signaling pathway. Molecular Medicine Reports, 2015, 12, 7782-7788.	1.1	44
195	Characterization of pancreatic ductal adenocarcinoma using whole transcriptome sequencing and copy number analysis by single-nucleotide polymorphism array. Molecular Medicine Reports, 2015, 12, 7479-7484.	1.1	20
196	Cholesterolâ€loaded nanoparticles ameliorate synaptic and cognitive function in <scp>H</scp> untington's disease mice. EMBO Molecular Medicine, 2015, 7, 1547-1564.	3.3	84

#	Article	IF	Citations
198	Pancreatic Cancer: Progress in Systemic Therapy. Gastrointestinal Tumors, 2014, 1, 167-179.	0.3	11
199	Management of the Primary Tumor and Limited Metastases in Patients With Metastatic Pancreatic Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, e29-e36.	2.3	15
200	Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies. Journal of Visualized Experiments, 2015, , e52801.	0.2	17
201	Chemotherapy-induced neutropenia as a prognostic factor in patients with unresectable pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 1217-1224.	1.1	15
207	Reinvention of chemotherapy. Current Opinion in Oncology, 2015, 27, 232-242.	1.1	12
208	A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial. BMC Cancer, 2015, 15, 653.	1.1	9
209	Rationale and design of the Adapted Physical Activity in advanced Pancreatic Cancer patients (APACaP) GERCOR (Groupe CoopÃ©rateur Multidisciplinaire en Oncologie) trial: study protocol for a randomized controlled trial. Trials, 2015, 16, 454.	0.7	17
210	Characterization of novel carcinoma cell lines for the analysis of therapeutical strategies fighting pancreatic cancer. Cell and Bioscience, 2015, 5, 51.	2.1	14
211	Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity. Experimental Hematology and Oncology, 2015, 4, 29.	2.0	49
212	Reply to Letter. Annals of Surgery, 2015, 262, e103-e104.	2.1	2
213	Access to â€˜investigationalâ€™ cancer drugs: perspective of a trainee. Internal Medicine Journal, 2015, 45, 235-235.	0.5	0
214	Clinical Sequencing Contributes to aBRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 835-845.	2.3	3
215	Multidisciplinary Management of Pancreatic Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 700-702.	2.3	9
216	Treatment of 200 Locally Advanced (Stage III) Pancreatic Adenocarcinoma Patients With Irreversible Electroporation. Annals of Surgery, 2015, 262, 486-494.	2.1	330
217	Impact of Smoking on Pancreatic Cancer Patients Receiving Current Chemotherapy. Pancreas, 2015, 44, 1155-1160.	0.5	5
218	Initial testing (stage 1) of the tubulin binding agent nanoparticle albuminâ€bound (nab) paclitaxel (Abraxane^{Â®}) by the Pediatric Preclinical Testing Program (PPTP). Pediatric Blood and Cancer, 2015, 62, 1214-1221.	0.8	29
219	Prognostic Value of Altered N-Glycosylation of Circulating Glycoproteins in Patients With Unresectable Pancreatic Cancer Treated With Gemcitabine. Pancreas, 2015, 44, 551-556.	0.5	7
220	Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma. Pancreas, 2015, 44, 1141-1147.	0.5	64

#	Article	IF	Citations
221	Pancreatic Adenocarcinoma Treated With Irreversible Electroporation Case Report. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.4	16
222	Prognostic significance of DNA cytometry for adjuvant therapy response in pancreatic cancer. Journal of Surgical Oncology, 2015, 112, 66-71.	0.8	2
223	Author reply. Internal Medicine Journal, 2015, 45, 234-235.	0.5	0
224	Describing Patterns of Care in Pancreatic Cancer. Pancreas, 2015, 44, 1259-1265.	0.5	30
225	Management of cancer of the exocrine pancreas. , 0, , 212-223.		0
226	Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas. Ecancermedicalscience, 2015, 9, 563.	0.6	38
227	Emerging therapies for pancreatic ductal carcinoma. Journal of Solid Tumors, 2015, 6, .	0.1	1
228	The Pathogenesis, Diagnosis, and Management of Pancreatic Cancer. , 2015, 05, .		0
230	Combined Therapy for Gastrointestinal Carcinomas: Exploiting Synergies Between Gene Therapy and Classical Chemo-Radiotherapy. Current Gene Therapy, 2015, 15, 151-160.	0.9	8
231	An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line. International Journal of Nanomedicine, 2015, 10, 6825.	3.3	63
232	The Pathogenesis, Diagnosis, and Management of Pancreatic Cancer. , 2015, 05, .		0
233	Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014. Current Oncology, 2015, 22, 305-315.	0.9	0
234	Molecular Mechanisms by Which a Fucus vesiculosus Extract Mediates Cell Cycle Inhibition and Cell Death in Pancreatic Cancer Cells. Marine Drugs, 2015, 13, 4470-4491.	2.2	28
235	Multifunctional Nanomaterials and Their Applications in Drug Delivery and Cancer Therapy. Nanomaterials, 2015, 5, 1690-1703.	1.9	111
236	Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Design, Development and Therapy, 2015, 9, 3529.	2.0	135
237	Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug Design, Development and Therapy, 2015, 9, 3767.	2.0	189
238	A Phase I Dose-Escalation Study of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer. PLoS ONE, 2015, 10, e0121197.	1.1	8
239	Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial. PLoS ONE, 2015, 10, e0125350.	1.1	7

#	Article	IF	Citations
240	Update on the management of pancreatic cancer: Surgery is not enough. World Journal of Gastroenterology, 2015, 21, 3157-3165.	1.4	147
241	Nursing Implications of Chemotherapy Agents and Their Associated Side Effects in Patients With Pancreatic Cancer. Clinical Journal of Oncology Nursing, 2015, 19, 751-757.	0.3	1
242	Emerging role of microRNAs in the treatment of hepatocellular carcinoma. Gastrointestinal Cancer: Targets and Therapy, 2015, , 89.	5.5	0
243	Chinese Herbal Medicines as an Adjunctive Therapy for Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-15.	0.5	14
244	Prolonged Complete Response in a Patient with Metastatic Pancreatic Adenocarcinoma after FOLFIRINOX Chemotherapy and Maintenance with FOLFIRI. Case Reports in Oncological Medicine, 2015, 2015, 1-4.	0.2	4
245	The Clinical and Pathological Significance of Nectin-2 and DDX3 Expression in Pancreatic Ductal Adenocarcinomas. Disease Markers, 2015, 2015, 1-8.	0.6	33
246	Making Sense of Current and Emerging Therapies in Pancreatic Cancer: Balancing Benefit and Value. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e222-e227.	1.8	1
247	Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Oncotarget, 2015, 6, 18162-18173.	0.8	90
248	Current status and progress of pancreatic cancer in China. World Journal of Gastroenterology, 2015, 21, 7988.	1.4	221
249	Pancreatic cancer vaccine: a unique potential therapy. Gastrointestinal Cancer: Targets and Therapy, 2015, , 1.	5.5	0
250	RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. Oncotarget, 2015, 6, 24560-24570.	0.8	244
251	Fine-Needle Aspirates v2.0 â€" The Molecular Era. , 2015, , .		0
252	Pancreatic Cancer With Malignant Ascites. Pancreas, 2015, 44, 380-385.	0.5	35
253	Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer. Cancer Biology and Therapy, 2015, 16, 438-449.	1.5	46
254	Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut, 2015, 64, 1476-1484.	6.1	444
255	Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract. Journal of Translational Medicine, 2015, 13, 115.	1.8	60
256	Pancreatic cancer stromal biology and therapy. Genes and Diseases, 2015, 2, 133-143.	1.5	110
257	Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. Journal of Hematology and Oncology, 2015, 8, 44.	6.9	40

#	Article	IF	Citations
258	The lymphocyte to monocyte ratio in peripheral blood represents a novel prognostic marker in patients with pancreatic cancer. Clinical Chemistry and Laboratory Medicine, 2015, 53, 499-506.	1.4	68
259	Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models. Molecular Cancer Therapeutics, 2015, 14, 1532-1539.	1.9	54
260	Pancreatic Stellate Cells. , 2015, , 271-306.		4
261	The Quest for an Effective Treatment for an Intractable Cancer. Advances in Cancer Research, 2015, 127, 283-306.	1.9	10
262	Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma. Hematology/Oncology Clinics of North America, 2015, 29, 717-726.	0.9	6
263	Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. British Journal of Cancer, 2015, 112, 1428-1434.	2.9	49
264	Host systemic inflammatory response influences outcome in pancreatic cancer. Pancreatology, 2015, 15, 327-330.	0.5	19
265	Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albuminâ€“bound paclitaxel in patients with advanced solid tumors. Cancer, 2015, 121, 1817-1826.	2.0	11
266	Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma. Journal of Surgical Oncology, 2015, 111, 771-775.	0.8	220
267	Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer. Langenbeck's Archives of Surgery, 2015, 400, 477-485.	0.8	24
268	Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. International Journal of Clinical Oncology, 2015, 20, 518-524.	1.0	26
269	Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study. Investigational New Drugs, 2015, 33, 963-968.	1.2	45
270	A phase II clinical study of using nab-paclitaxel as second-line chemotherapy for Chinese patients with advanced non-small cell lung cancer. Medical Oncology, 2015, 32, 498.	1.2	20
271	Aldoxorubicin for the treatment of advanced soft tissue sarcoma. Expert Opinion on Orphan Drugs, 2015, 3, 457-466.	0.5	0
272	Systemic therapy for advanced pancreatic cancer: individualising cytotoxic therapy. Expert Opinion on Pharmacotherapy, 2015, 16, 851-861.	0.9	8
273	CCR 20th Anniversary Commentary: Setting the Stage for Nanoparticle Albumin-Bound Paclitaxelâ€”How Far Science Has Come. Clinical Cancer Research, 2015, 21, 1975-1977.	3.2	2
274	Patient-Derived Xenograft Models for Pancreatic Adenocarcinoma Demonstrate Retention of Tumor Morphology through Incorporation of Murine Stromal Elements. American Journal of Pathology, 2015, 185, 1297-1303.	1.9	93
275	Therapeutic Advances in Pancreatic Cancer: Miles to Go Before We Sleep. Journal of the National Cancer Institute, 2015, 107, dju439-dju439.	3.0	6

#	Article	IF	Citations
276	The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells. Gut, 2015, 64, 1936-1948.	6.1	123
277	Nanoparticle albumin-bound (nab)-paclitaxel for the treatment of pancreas ductal adenocarcinoma. Gastrointestinal Cancer: Targets and Therapy, 0, , 11.	5.5	5
278	Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer. Cancer Medicine, 2015, 4, 1224-1239.	1.3	16
279	Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer. Cancer Journal (Sudbury, Mass), 2015, 21, 299-306.	1.0	70
280	Choosing Wisely: Where's the Beef?. Journal of Oncology Practice, 2015, 11, 325-326.	2.5	0
281	microRNA: Cancer. Advances in Experimental Medicine and Biology, 2015, , .	0.8	2
282	Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial. Japanese Journal of Clinical Oncology, 2015, 45, 439-448.	0.6	29
283	Tumor targeted mesoporous silica-coated gold nanorods facilitate detection of pancreatic tumors using Multispectral optoacoustic tomography. Nano Research, 2015, 8, 3864-3877.	5.8	26
284	The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1). Clinical Cancer Research, 2015, 21, 5563-5577.	3.2	51
286	Initial Metastatic Site as a Prognostic Factor in Patients With Stage IV Pancreatic Ductal Adenocarcinoma. Medicine (United States), 2015, 94, e1012.	0.4	18
287	A New Scalpel for the Treatment of Pancreatic Cancer: Targeting Stromal-Derived STAT3 Signaling. Gastroenterology, 2015, 149, 1685-1688.	0.6	4
290	Adjuvant/Perioperative Therapy in Pancreatic and Periampullary Cancer. Indian Journal of Surgery, 2015, 77, 403-408.	0.2	2
291	Pancreatic Cancer: a Challenge to Cure. Indian Journal of Surgery, 2015, 77, 350-357.	0.2	5
292	Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors. Journal of Controlled Release, 2015, 216, 103-110.	4.8	28
293	Pancreatic acinar cell carcinoma with bilateral ovarian metastases, panniculitis and polyarthritis treated with FOLFIRINOX chemotherapy regimen. A case report and review of the literature. Pancreatology, 2015, 15, 440-444.	0.5	16
294	Insights into the Role of microRNAs in Pancreatic Cancer Pathogenesis: Potential for Diagnosis, Prognosis, and Therapy. Advances in Experimental Medicine and Biology, 2015, 889, 71-87.	0.8	49
297	Patterns of care and outcomes of older versus younger patients with metastatic pancreatic cancer: A Fox Chase Cancer Center experience. Journal of Geriatric Oncology, 2015, 6, 454-461.	0.5	15
298	Use of a novel herbal medicine in a 75-year-old woman with multi-metastatic pancreatic cancer: A case report and review of the literature. Oncology Letters, 2015, 10, 263-267.	0.8	8

#	Article	IF	Citations
299	CT-guided high-dose-rate brachytherapy in the interdisciplinary treatment of patients with liver metastases of pancreatic cancer. Hepatobiliary and Pancreatic Diseases International, 2015, 14, 530-538.	0.6	19
300	Pathogenic PALB2 mutation in metastatic pancreatic adenocarcinoma and neuroendocrine tumour: A case report. Molecular and Clinical Oncology, 2015, 3, 817-819.	0.4	10
301	HES 1 is essential for chemoresistance induced by stellate cells and is associated with poor prognosis in pancreatic cancer. Oncology Reports, 2015, 33, 1883-1889.	1.2	40
302	A newly developed anti-Mucin 13 monoclonal antibody targets pancreatic ductal adenocarcinoma cells. International Journal of Oncology, 2015, 46, 1781-1787.	1.4	19
304	A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer. European Journal of Cancer, 2015, 51, 27-36.	1.3	56
305	Survival Among Patients With Pancreatic Cancer and Long-Standing or Recent-Onset Diabetes Mellitus. Journal of Clinical Oncology, 2015, 33, 29-35.	0.8	83
306	Pancreatic Ductal Adenocarcinoma Treatmentâ€"The Past, Present, and Future. Seminars in Oncology, 2015, 42, 4-7.	0.8	1
307	Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer. Journal of Controlled Release, 2015, 201, 90-99.	4.8	120
308	Loss of SOD3 (EcSOD) Expression Promotes an Aggressive Phenotype in Human Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2015, 21, 1741-1751.	3.2	58
309	Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer. Cancer Letters, 2015, 358, 59-66.	3.2	48
310	Novel Pullulan Bioconjugate for Selective Breast Cancer Bone Metastases Treatment. Bioconjugate Chemistry, 2015, 26, 489-501.	1.8	35
311	nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial. Journal of the National Cancer Institute, 2015, 107, dju413-dju413.	3.0	487
312	Pancreatic cancer: diagnosis and treatments. Tumor Biology, 2015, 36, 1375-1384.	0.8	39
313	Sep(t)arate or not â€“ how some cells take septin-independent routes through cytokinesis. Journal of Cell Science, 2015, 128, 1877-1886.	1.2	41
314	Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation. Journal of Clinical Oncology, 2015, 33, 244-250.	0.8	1,473
315	Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle. MAbs, 2015, 7, 42-52.	2.6	21
316	Metabolism of the taxanes including nab-paclitaxel. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 691-702.	1.5	25
317	Salinomycin inhibits growth of pancreatic cancer and cancer cell migration by disruption of actin stress fiber integrity. Cancer Letters, 2015, 358, 161-169.	3.2	56

#	Article	IF	Citations
318	The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal. Cancer and Metastasis Reviews, 2015, 34, 97-114.	2.7	69
319	Pancreatic cancer genomics: where can the science take us?. Clinical Genetics, 2015, 88, 213-219.	1.0	13
320	First-in-man Phase 1 Clinical Trial of Gene Therapy for Advanced Pancreatic Cancer: Safety, Biodistribution, and Preliminary Clinical Findings. Molecular Therapy, 2015, 23, 779-789.	3.7	93
321	Pancreatic cancer stem cells: New insight into a stubborn disease. Cancer Letters, 2015, 357, 429-437.	3.2	73
322	Recent advances in targeted nanoparticles drug delivery to melanoma. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 769-794.	1.7	94
323	Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Therapeutic Advances in Medical Oncology, 2015, 7, 68-84.	1.4	123
324	Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer. Oncologist, 2015, 20, 143-150.	1.9	123
325	Reappraisal of Peritoneal Washing Cytology in 984 Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Margin-Negative Resection. Journal of Gastrointestinal Surgery, 2015, 19, 6-14.	0.9	51
326	Gene and cell therapy for pancreatic cancer. Expert Opinion on Biological Therapy, 2015, 15, 505-516.	1.4	18
327	Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms. Clinical Cancer Research, 2015, 21, 2325-2337.	3.2	170
328	Preoperative gemcitabine-based chemoradiation therapy for pancreatic ductal adenocarcinoma of the body and tail: Impact of splenic vessels involvement on operative outcome and pattern of recurrence. Surgery, 2015, 157, 484-495.	1.0	15
329	A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial. Annals of Oncology, 2015, 26, 921-927.	0.6	132
330	Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients. Journal of Gastroenterology, 2015, 50, 694-702.	2.3	63
331	Radiotherapy for SMAD4-negative musculoskeletal lesions from pancreatic cancer. Strahlentherapie Und Onkologie, 2015, 191, 67-72.	1.0	0
333	PBI-05204, a supercritical CO2 extract of Nerium oleander, inhibits growth of human pancreatic cancer via targeting the PI3K/mTOR pathway. Investigational New Drugs, 2015, 33, 271-279.	1.2	38
334	Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study. Cancer Chemotherapy and Pharmacology, 2015, 75, 683-690.	1.1	19
335	Kinesins and Cancer. , 2015, , .		16
336	Effect of NF-ÎºB inhibition on chemoresistance in biliaryâ€“pancreatic cancer. Surgery Today, 2015, 45, 1481-1488.	0.7	22

#	Article	IF	Citations
337	Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma. British Journal of Cancer, 2015, 112, 1027-1036.	2.9	43
338	Phase I pilot study of Wilms tumor gene 1 peptideâ€pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer. Cancer Science, 2015, 106, 397-406.	1.7	65
339	Metformin for pancreatic cancer. Lancet Oncology, The, 2015, 16, 748-749.	5.1	7
340	SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial. Clinical Cancer Research, 2015, 21, 4811-4818.	3.2	117
341	Bioorthogonal labeling cell-surface proteins expressed in pancreatic cancer cells to identify potential diagnostic/therapeutic biomarkers. Cancer Biology and Therapy, 2015, 16, 1557-1565.	1.5	22
342	Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study. Clinical Therapeutics, 2015, 37, 1301-1316.	1.1	26
343	Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 579-589.	0.7	10
345	Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine â€“ Results from the CONKO-001 trial. European Journal of Cancer, 2015, 51, 1546-1554.	1.3	40
347	Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients. Clinical Lung Cancer, 2015, 16, 466-474.e4.	1.1	43
348	Potential prognostic significance of a new proteomic profile in patients with advanced pancreatic adenocarcinoma. Pancreatology, 2015, 15, 525-530.	0.5	0
349	Survival and clinical outcome after endoscopic duodenal stent placement for malignant gastric outlet obstruction: comparison of pancreatic cancer and nonpancreatic cancer. Gastrointestinal Endoscopy, 2015, 82, 460-468.e2.	0.5	55
350	An ultrasensitive LCâ€“MS/MS method with liquid phase extraction to determine paclitaxel in both cell culture medium and lysate promising quantification of drug nanocarriers release in vitro. Journal of Pharmaceutical and Biomedical Analysis, 2015, 115, 300-306.	1.4	17
351	Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter?. Advances in Biological Regulation, 2015, 59, 19-35.	1.4	65
352	Genetics and Biology of Pancreatic Ductal Adenocarcinoma. Hematology/Oncology Clinics of North America, 2015, 29, 595-608.	0.9	58
353	Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles. Translational Oncology, 2015, 8, 196-203.	1.7	21
354	Systemic therapy in stage IV pancreatic cancer: a population-based analysis using the National Cancer Data Base. Therapeutic Advances in Medical Oncology, 2015, 7, 198-205.	1.4	28
355	A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. Annals of Oncology, 2015, 26, 1194-1200.	0.6	78
356	Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2015, 76, 489-498.	1.1	59

#	Article	IF	Citations
357	Treatment Approaches to Locally Advanced Pancreatic Adenocarcinoma. Hematology/Oncology Clinics of North America, 2015, 29, 741-759.	0.9	9
358	Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma. Hematology/Oncology Clinics of North America, 2015, 29, 761-776.	0.9	11
359	A Randomized Phase II Study of Erlotinib Plus Nab-PaclitaxelVersusErlotinib Alone as Second-Line Therapy for Chinese Patients with Advanced EGFR Wild-Type Non-Small-Cell Lung Cancer. Cancer Investigation, 2015, 33, 241-245.	0.6	4
361	Targeted Inhibition of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Sensitizes Pancreatic Cancer Cells to Doxorubicin without Exacerbating Cardiac Toxicity. Molecular Pharmacology, 2015, 88, 512-523.	1.0	12
362	Non-Biological Complex Drugs. AAPS Advances in the Pharmaceutical Sciences Series, 2015, , .	0.2	17
363	A phase II study of sorafenib, oxaliplatin, and 2Âdays of high-dose capecitabine in advanced pancreas cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 317-323.	1.1	9
364	Targeting pancreatic cancer cells by a novel hydroxamate-based histone deacetylase (HDAC) inhibitor ST-3595. Tumor Biology, 2015, 36, 9015-9022.	0.8	12
365	Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta OncolÃ³gica, 2015, 54, 979-985.	0.8	212
366	Nanotechnology in bladder cancer: current state of development and clinical practice. Nanomedicine, 2015, 10, 1189-1201.	1.7	35
367	A Meta-analysis of Randomized Clinical Trials of Chemoradiation Therapy in Locally Advanced Pancreatic Cancer. Journal of Gastrointestinal Cancer, 2015, 46, 284-290.	0.6	14
368	Pancreatic cancer, treatment options, and GI-4000. Human Vaccines and Immunotherapeutics, 2015, 11, 931-937.	1.4	14
370	Pancreatic cancer: Patient and caregiver perceptions on diagnosis, psychological impact, and importance of support. Pancreatology, 2015, 15, 701-707.	0.5	32
371	Targeting KRAS and the vitamin D receptor via microtubules. Nature Reviews Clinical Oncology, 2015, 12, 442-444.	12.5	4
372	5-Fluorouracil derivatives: a patent review (2012 â€“ 2014). Expert Opinion on Therapeutic Patents, 2015, 25, 1131-1144.	2.4	35
373	FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 3512-3521.	0.7	135
374	Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncology, The, 2015, 16, 839-847.	5.1	321
375	Clinical Translation of Nanomedicine. Chemical Reviews, 2015, 115, 11147-11190.	23.0	619
376	Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer. Annals of Oncology, 2015, 26, 804-811.	0.6	83

#	Article	IF	Citations
377	Nanoparticle Albumin-Bound Anticancer Agents. AAPS Advances in the Pharmaceutical Sciences Series, 2015, , 335-354.	0.2	4
378	Immunotherapy of Pancreatic Cancer. , 2015, , 237-248.		1
379	A patient-derived subrenal capsule xenograft model can predict response to adjuvant therapy for cancers in the head of the pancreas. Pancreatology, 2015, 15, 397-404.	0.5	9
380	Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 4402-4410.	0.7	187
381	Pharmacologic Sensitivity of Paclitaxel to Its Delivery Vehicles Drives Distinct Clinical Outcomes of Paclitaxel Formulations. Molecular Pharmaceutics, 2015, 12, 1308-1317.	2.3	39
382	Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials. Hepatobiliary and Pancreatic Diseases International, 2015, 14, 124-131.	0.6	15
383	Approach to Patients With Pancreatic Cancer Without Detectable Metastases. Journal of Clinical Oncology, 2015, 33, 1770-1778.	0.8	117
385	Examining the utility of patient-derived xenograft mouse models. Nature Reviews Cancer, 2015, 15, 311-316.	12.8	300
386	Progress in the Treatment of Metastatic Pancreatic Cancer and the Search for Next Opportunities. Journal of Clinical Oncology, 2015, 33, 1779-1786.	0.8	66
387	Growth inhibition and apoptosis induction by alternol in pancreatic carcinoma cells. World Journal of Gastroenterology, 2015, 21, 4526-4535.	1.4	7
388	Ten weeks to live: A population-based study on treatment and survival of patients with metastatic pancreatic cancer in the south of the Netherlands. Acta OncolÃ³gica, 2015, 54, 403-410.	0.8	30
389	Cys34-PEGylated Human Serum Albumin for Drug Binding and Delivery. Bioconjugate Chemistry, 2015, 26, 941-949.	1.8	41
390	Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers. Expert Opinion on Investigational Drugs, 2015, 24, 781-794.	1.9	4
391	Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer. British Journal of Cancer, 2015, 112, 1301-1305.	2.9	19
392	Nanoparticle albumin-bound-paclitaxel: a limited improvement under the current therapeutic paradigm of pancreatic cancer. Expert Opinion on Pharmacotherapy, 2015, 16, 943-947.	0.9	24
393	Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma. Cancer Immunology, Immunotherapy, 2015, 64, 727-736.	2.0	47
394	The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients. Journal of Cancer Research and Clinical Oncology, 2015, 141, 933-939.	1.2	21
395	A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy. Journal of Cancer Research and Clinical Oncology, 2015, 141, 1653-1660.	1.2	22

#	Article	IF	Citations
396	Sustained Disease Control with TOMOXIRI Regimen in a Patient with Metastatic Pancreatic Adenocarcinoma. Journal of Gastrointestinal Cancer, 2015, 46, 327-331.	0.6	1
397	Assessing novel prognostic serum biomarkers in advanced pancreatic cancer: the role of CYFRA 21-1, serum amyloid A, haptoglobin, and 25-OH vitamin D3. Tumor Biology, 2015, 36, 2631-2640.	0.8	12
398	Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenesâ€“Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 2015, 33, 1325-1333.	0.8	490
399	Stage III pancreatic cancer and the role of irreversible electroporation. BMJ, The, 2015, 350, h521-h521.	3.0	38
400	Improved Long-Term Outcomes After Resection of Pancreatic Adenocarcinoma: A Comparison Between Two Time Periods. Annals of Surgical Oncology, 2015, 22, 1160-1167.	0.7	55
401	The role of solvent swelling in the self-assembly of squalene based nanomedicines. Soft Matter, 2015, 11, 4173-4179.	1.2	8
402	Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. Cancer Immunology Research, 2015, 3, 399-411.	1.6	387
403	Which patients with resectable pancreatic cancer truly benefit from oncological resection: is it destiny or biology?. Cancer Biology and Therapy, 2015, 16, 360-362.	1.5	8
404	Recent advances in pancreatic cancer: biology, treatment, and prevention. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1856, 13-27.	3.3	60
405	Use of a Lipid-Coated Mesoporous Silica Nanoparticle Platform for Synergistic Gemcitabine and Paclitaxel Delivery to Human Pancreatic Cancer in Mice. ACS Nano, 2015, 9, 3540-3557.	7.3	367
406	Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival. Cancer Chemotherapy and Pharmacology, 2015, 75, 457-464.	1.1	16
407	The role of SPARC expression in pancreatic cancer progression and patient survival. Scandinavian Journal of Gastroenterology, 2015, 50, 1170-1174.	0.6	35
408	Hybrid Paclitaxel and Gold Nanorod-Loaded Human Serum Albumin Nanoparticles for Simultaneous Chemotherapeutic and Photothermal Therapy on 4T1 Breast Cancer Cells. ACS Applied Materials & Interfaces, 2015, 7, 7101-7111.	4.0	80
409	Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 93, 52-79.	2.0	1,278
410	Non-motor Spindle Proteins as Cancer Chemotherapy Targets. , 2015, , 223-249.		0
411	Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: A subgroup analysis from AIO-PK0104. Acta OncolÃ³gica, 2015, 54, 993-1000.	0.8	7
412	Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets. Critical Reviews in Oncology/Hematology, 2015, 95, 318-336.	2.0	18
413	Metabolic Dependencies in RAS-Driven Cancers. Clinical Cancer Research, 2015, 21, 1828-1834.	3.2	192

#	Article	IF	Citations
414	Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer. Clinical Cancer Research, 2015, 21, 3561-3568.	3.2	456
415	Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nature Reviews Clinical Oncology, 2015, 12, 319-334.	12.5	489
416	Ormeloxifene Suppresses Desmoplasia and Enhances Sensitivity of Gemcitabine in Pancreatic Cancer. Cancer Research, 2015, 75, 2292-2304.	0.4	67
417	Pancreatic cancer: The microenvironment needs attention too!. Pancreatology, 2015, 15, S32-S38.	0.5	69
418	Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma. Cancer, 2015, 121, 673-680.	2.0	41
419	The addition of S-1 to gemcitabine-based chemotherapy improves survival with increased toxicity for patients with advanced pancreatic cancer: Combined meta-analysis of efficacy and safety profile. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 254-260.	0.7	7
420	Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2015, 33, 1475-1481.	0.8	152
421	Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer. Cancer Research, 2015, 75, 1091-1101.	0.4	68
422	Slug contributes to gemcitabine resistance through epithelial-mesenchymal transition in CD133+ pancreatic cancer cells. Human Cell, 2015, 28, 167-174.	1.2	36
423	New avenues for improving pancreatic ductal adenocarcinoma (PDAC) treatment: Selective stroma depletion combined with nano drug delivery. Cancer Letters, 2015, 369, 266-273.	3.2	38
424	Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure. Expert Review of Anticancer Therapy, 2015, 15, 1183-1198.	1.1	11
425	IP-10/CXCL10 attracts regulatory T cells: Implication for pancreatic cancer. OncoImmunology, 2015, 4, e1027473.	2.1	71
426	A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naÃ¯ve patients with metastatic melanoma. Annals of Oncology, 2015, 26, 2267-2274.	0.6	67
427	Î²-Lapachone and Paclitaxel Combination Micelles with Improved Drug Encapsulation and Therapeutic Synergy as Novel Nanotherapeutics for NQO1-Targeted Cancer Therapy. Molecular Pharmaceutics, 2015, 12, 3999-4010.	2.3	40
428	Membrane-to-Nucleus Signals and Epigenetic Mechanisms for Myofibroblastic Activation and Desmoplastic Stroma: Potential Therapeutic Targets for Liver Metastasis?. Molecular Cancer Research, 2015, 13, 604-612.	1.5	41
429	Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. British Journal of Cancer, 2015, 113, 989-995.	2.9	151
430	Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nature Medicine, 2015, 21, 1163-1171.	15.2	349
431	Improving pancreatic cancer diagnosis using circulating tumor cells: prospects for staging and single-cell analysis. Expert Review of Molecular Diagnostics, 2015, 15, 1491-1504.	1.5	42

#	Article	IF	Citations
432	Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells. Journal of Pharmacokinetics and Pharmacodynamics, 2015, 42, 477-496.	0.8	27
433	Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study. Pancreatology, 2015, 15, 674-680.	0.5	95
434	Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer. Japanese Journal of Clinical Oncology, 2015, 45, hyv141.	0.6	9
435	AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-Î¤B mediated uPAR activation. Molecular Cancer, 2015, 14, 146.	7.9	6
436	Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 2015, 33, 4284-4292.	0.8	431
437	Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Pancreatology, 2015, 15, 667-673.	0.5	73
438	Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. Critical Reviews in Oncology/Hematology, 2015, 96, 483-497.	2.0	41
439	Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort. Annals of Surgical Oncology, 2015, 22, 1196-1205.	0.7	70
440	Radioimmunotherapyâ€"a potential novel tool for pancreatic cancer therapy?. Tumor Biology, 2015, 36, 4053-4062.	0.8	11
441	A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer. Medical Oncology, 2015, 32, 216.	1.2	16
442	Phase I study of combination of pasireotide LARÂ+Âgemcitabine in locally advanced or metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 481-487.	1.1	11
443	Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer. Clinical Cancer Research, 2015, 21, 4569-4575.	3.2	12
444	High expression of DDR1 is associated with the poor prognosis in Chinese patients with pancreatic ductal adenocarcinoma. Journal of Experimental and Clinical Cancer Research, 2015, 34, 88.	3.5	38
445	Taxane-related nail toxicity. Lancet Oncology, The, 2015, 16, e310-e311.	5.1	8
446	Predicting a response to FOLFIRINOX in pancreatic cancer. Journal of the National Cancer Institute, 2015, 107, djv175-djv175.	3.0	1
447	Cancer-associated fibroblasts as target and tool in cancer therapeutics and diagnostics. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 367-382.	1.4	37
448	Concise Review: Stem Cells in Pancreatic Cancer: From Concept to Translation. Stem Cells, 2015, 33, 2893-2902.	1.4	31
449	Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer. Cancer Immunology, Immunotherapy, 2015, 64, 1553-1563.	2.0	25

#	Article	IF	Citations
450	Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma. Cell Death and Disease, 2015, 6, e1913-e1913.	2.7	90
451	PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors. Oncogenesis, 2015, 4, e169-e169.	2.1	47
452	Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades. Hepatic Oncology, 2015, 2, 39-50.	4.2	10
453	Importance of resectability status in neoadjuvant treatment for pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Sciences, 2015, 22, 563-570.	1.4	27
454	Treatment, Outcomes, and Clinical Trial Participation in Elderly Patients With Metastatic Pancreas Adenocarcinoma. Clinical Colorectal Cancer, 2015, 14, 269-276.e1.	1.0	23
455	A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics. DMM Disease Models and Mechanisms, 2015, 8, 1201-1211.	1.2	14
456	GEMMs as preclinical models for testing pancreatic cancer therapies. DMM Disease Models and Mechanisms, 2015, 8, 1185-1200.	1.2	92
457	A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Annals of Oncology, 2015, 26, 1547-1573.	0.6	635
459	The future of patient-derived tumor xenografts in cancer treatment. Pharmacogenomics, 2015, 16, 1671-1683.	0.6	43
460	Biweekly gemcitabine plus S-1 for locally advanced and metastatic pancreatic cancer: a preliminary feasibility study. Journal of Hepato-Biliary-Pancreatic Sciences, 2015, 22, 692-698.	1.4	4
461	Quercetin 3-O-glucoside suppresses epidermal growth factorâ€“induced migration by inhibiting EGFR signaling in pancreatic cancer cells. Tumor Biology, 2015, 36, 9385-9393.	0.8	49
462	Design considerations for nanotherapeutics in oncology. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 1893-1907.	1.7	208
463	The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2. DNA and Cell Biology, 2015, 34, 610-617.	0.9	15
464	Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency. Clinical Cancer Research, 2015, 21, 2084-2095.	3.2	205
465	Does the cost of robotic cholecystectomy translate to a financial burden?. Surgical Endoscopy and Other Interventional Techniques, 2015, 29, 2115-2120.	1.3	23
466	Cancer-associated fibroblasts in pancreatic adenocarcinoma. Future Oncology, 2015, 11, 2603-2610.	1.1	39
467	State of the art and future directions of pancreatic ductal adenocarcinoma therapy. , 2015, 155, 80-104.		82
468	Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. Journal of Clinical Oncology, 2015, 33, 4039-4047.	0.8	230

#	Article	IF	Citations
469	Multidisciplinary management of locally advanced pancreatic ductal adenocarcinoma. Current Problems in Surgery, 2015, 52, 362-398.	0.6	8
470	Trial Watch: Adoptive cell transfer for oncological indications. OncoImmunology, 2015, 4, e1046673.	2.1	29
471	Hereditary Pancreatic Cancer Syndromes. Surgical Oncology Clinics of North America, 2015, 24, 733-764.	0.6	28
472	Cancer targeted therapeutics: From molecules to drug delivery vehicles. Journal of Controlled Release, 2015, 219, 632-643.	4.8	89
473	Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer. Molecular Oncology, 2015, 9, 889-905.	2.1	51
474	Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration. Cancer Chemotherapy and Pharmacology, 2015, 76, 699-712.	1.1	81
475	Personalized medicine in pancreatic cancer: the revolution has begun. Personalized Medicine, 2015, 12, 515-523.	0.8	1
476	Vitamin D and pancreatic cancer. Cancer Letters, 2015, 368, 1-6.	3.2	31
477	Predictive In Vivo Models for Oncology. Handbook of Experimental Pharmacology, 2015, 232, 203-221.	0.9	9
478	90 Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. European Journal of Cancer, 2015, 51, 1857-1864.	1.3	26
479	Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. Cancer Biology and Therapy, 2015, 16, 1726-1737.	1.5	75
480	Novel directions in neoadjuvant therapy for pancreas adenocarcinoma. Expert Review of Gastroenterology and Hepatology, 2015, 9, 585-601.	1.4	3
481	Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer. British Journal of Surgery, 2015, 102, 182-193.	0.1	143
482	Targeted Oncolytic Herpes Simplex Virus Type 1 Eradicates Experimental Pancreatic Tumors. Human Gene Therapy, 2015, 26, 104-113.	1.4	25
483	Multiple Layerâ€byâ€Layer Lipidâ€Polymer Hybrid Nanoparticles for Improved FOLFIRINOX Chemotherapy in Pancreatic Tumor Models. Advanced Functional Materials, 2015, 25, 788-798.	7.8	96
484	Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1855, 61-82.	3.3	46
485	Addressing the challenges of pancreatic cancer: Future directions for improving outcomes. Pancreatology, 2015, 15, 8-18.	0.5	404
486	Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer. Cancer Letters, 2015, 356, 819-827.	3.2	75

#	Article	IF	Citations
487	A novel biosensor for quantitative monitoring of on-target activity of paclitaxel. Nanoscale, 2015, 7, 1127-1135.	2.8	4
488	Nanodelivery of parthenolide using functionalized nanographene enhances its anticancer activity. RSC Advances, 2015, 5, 2411-2420.	1.7	25
489	Usnic acid induces apoptosis via an ROS-dependent mitochondrial pathway in human breast cancer cells in vitro and in vivo. RSC Advances, 2015, 5, 153-162.	1.7	34
491	Epidemiological-molecular evidence of metabolic reprogramming on proliferation, autophagy and cell signaling in pancreas cancer. Cancer Letters, 2015, 356, 281-288.	3.2	24
492	MUC1 Promoterâ€"Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer. Molecular Cancer Research, 2015, 13, 439-448.	1.5	18
493	miRNAs in pancreatic cancer: Therapeutic potential, delivery challenges and strategies. Advanced Drug Delivery Reviews, 2015, 81, 34-52.	6.6	77
494	Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2015, 49, 177-191.	2.9	120
495	Genomic Applications in Pathology. , 2015, , .		1
496	Adenocarcinoma of the ampulla of Vater metastasising into the right ventricle. BMJ Case Reports, 2016, 2016, bcr2015212650.	0.2	0
497	Erhaltungstherapie bei metastasiertem Pankreaskarzinom. Karger Kompass Onkologie, 2016, 3, 80-81.	0.0	0
498	Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. World Journal of Gastroenterology, 2016, 22, 10124.	1.4	27
499	Nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreatic cancer: utility and experience from the clinic. Gastrointestinal Cancer: Targets and Therapy, 2016, , 13.	5.5	2
500	Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma. OncoTargets and Therapy, 2016, Volume 9, 4681-4686.	1.0	9
501	Tremelimumab: research and clinical development. OncoTargets and Therapy, 2016, 9, 1767.	1.0	51
502	Dysregulation of signaling pathways associated with innate antibacterial immunity in patients with pancreatic cancer. Central-European Journal of Immunology, 2016, 4, 404-418.	0.4	3
503	Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians. World Journal of Clinical Oncology, 2016, 7, 27.	0.9	71
504	Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan. International Journal of Nanomedicine, 2016, 11, 1225.	3.3	32
505	Irreversible electroporation in the treatment of locally advanced pancreas and liver metastases of colorectal carcinoma. Wspolczesna Onkologia, 2016, 1, 39-44.	0.7	3

#	Article	IF	Citations
506	nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors. OncoTargets and Therapy, 2017, Volume 10, 101-112.	1.0	60
507	Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma. Oncotarget, 2016, 7, 81110-81122.	0.8	64
508	Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment. Journal of Cancer, 2016, 7, 1497-1514.	1.2	71
509	Nanotherapeutic Platforms for Cancer Treatment: From Preclinical Development to Clinical Application. , 2016, , 813-869.		5
510	Liposomal Irinotecan in the Treatment of Refractory Pancreatic Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2016, 11, 376-383.	0.8	1
511	Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016. Current Oncology, 2016, 23, 605-614.	0.9	6
512	Multimodality Therapy in Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Importance of Locoregional Therapies for a Systemic Disease. Journal of Oncology Practice, 2016, 12, 915-923.	2.5	19
513	The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer. Oncotarget, 2016, 7, 48265-48279.	0.8	10
514	Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer. World Journal of Gastroenterology, 2016, 22, 2441.	1.4	71
515	Concomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer. Yonsei Medical Journal, 2016, 57, 1124.	0.9	23
516	MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer. Oncotarget, 2016, 7, 4760-4769.	0.8	56
517	Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer?. Journal of Gastrointestinal Oncology, 2016, 7, 727-737.	0.6	2
518	How grim is pancreatic cancer?. Oncology Reviews, 2016, 10, 294.	0.8	38
519	Nab-paclitaxel as alternative treatment regimen in advanced cholangiocellular carcinoma. Journal of Gastrointestinal Oncology, 2016, 7, 588-594.	0.6	6
520	Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?. Journal of Gastrointestinal Oncology, 2016, 7, 738-749.	0.6	14
521	Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma. Przeglad Gastroenterologiczny, 2016, 3, 155-162.	0.3	9
522	An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts. Molecules and Cells, 2016, 39, 77-86.	1.0	110
523	Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. Journal of Gastrointestinal Oncology, 2016, 7, 469-478.	0.6	48

#	Article	IF	Citations
524	Developmental Pathways Direct Pancreatic Cancer Initiation from Its Cellular Origin. Stem Cells International, 2016, 2016, 1-8.	1.2	28
525	Clinically Meaningful Use of Blood Tumor Markers in Oncology. BioMed Research International, 2016, 2016, 1-10.	0.9	49
526	Functionalized milk-protein-coated magnetic nanoparticles for MRI-monitored targeted therapy of pancreatic cancer. International Journal of Nanomedicine, 2016, Volume 11, 3087-3099.	3.3	15
527	MicroRNA Targeted Therapeutic Approach for Pancreatic Cancer. International Journal of Biological Sciences, 2016, 12, 326-337.	2.6	71
528	Systemic Chemotherapy in Advanced Pancreatic Cancer. Gut and Liver, 2016, 10, 340-7.	1.4	57
529	Evolving Evidence of the Efficacy and Safety of nab-Paclitaxel in the Treatment of Cancers with Squamous Histologies. Journal of Cancer, 2016, 7, 268-275.	1.2	15
530	Pancreatic Cancer from Molecular Pathways to Treatment Opinion. Journal of Cancer, 2016, 7, 1328-1339.	1.2	30
531	The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma. Journal of Clinical Medicine, 2016, 5, 59.	1.0	27
532	Emerging Therapeutic Potential of Nanoparticles in Pancreatic Cancer: A Systematic Review of Clinical Trials. Biomedicines, 2016, 4, 20.	1.4	24
533	The Clinical Significance of Phosphorylated Heat Shock Protein 27 (HSPB1) in Pancreatic Cancer. International Journal of Molecular Sciences, 2016, 17, 137.	1.8	16
534	Managing Pancreatic Adenocarcinoma: A Special Focus in MicroRNA Gene Therapy. International Journal of Molecular Sciences, 2016, 17, 718.	1.8	20
535	Current Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/Angiogenesis. Molecules, 2016, 21, 1468.	1.7	44
536	Targeted polyethylene glycol gold nanoparticles for the treatment of pancreatic cancer: from synthesis to proof-of-concept in vitro studies. International Journal of Nanomedicine, 2016, 11, 791.	3.3	86
537	Overview of DNA repair pathways, current targets, and clinical trials bench to clinic. , 2016, , 1-54.		6
539	The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms. International Journal of Biological Sciences, 2016, 12, 273-282.	2.6	89
540	Nanobiomaterials in cancer therapy. , 2016, , 57-89.		8
542	Clinical impact of chemotherapy to improve tumor microenvironment of pancreatic cancer. World Journal of Gastrointestinal Oncology, 2016, 8, 786.	0.8	12
543	Molecular-targeted Therapies in Gastrointestinal Cancer. The Journal of the Japanese Society of Internal Medicine, 2016, 105, 1051-1060.	0.0	0

#	Article	IF	Citations
544	C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer. Pancreas, 2016, 45, 110-116.	0.5	37
545	Low Stromal Area and High Stromal Microvessel Density Predict Poor Prognosis in Pancreatic Cancer. Pancreas, 2016, 45, 593-600.	0.5	18
546	Reliable Detection of Somatic Mutations in Fine Needle Aspirates of Pancreatic Cancer With Next-generation Sequencing. Annals of Surgery, 2016, 263, 153-161.	2.1	45
547	Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 614-618.	0.6	14
548	Gemcitabine-Based Regional Intra-Arterial Infusion Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma. Medicine (United States), 2016, 95, e3098.	0.4	24
549	Firstâ€line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors. International Journal of Cancer, 2016, 139, 938-945.	2.3	38
550	Control of Apoptosis in Treatment and Biology of Pancreatic Cancer. Journal of Cellular Biochemistry, 2016, 117, 279-288.	1.2	37
551	Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis. Journal of Surgical Oncology, 2016, 114, 451-455.	0.8	14
552	Treatment Strategy for Borderline Resectable Pancreatic Cancer With Radiographic Artery Involvement. Pancreas, 2016, 45, 1438-1446.	0.5	40
553	The preclinical evaluation of TIC10/ONC201 as an anti-pancreatic cancer agent. Biochemical and Biophysical Research Communications, 2016, 476, 260-266.	1.0	27
554	Advances in Molecular Pathology and Treatment of Periampullary Cancers. Pancreas, 2016, 45, 32-39.	0.5	18
555	C8-T1 Radiculopathy Due to an Intradural Extramedullary Metastasis of a Pancreatic Neuroendocrine Tumor. Pancreas, 2016, 45, 772-779.	0.5	5
556	Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic Adenocarcinoma. Pancreas, 2016, 45, 1131-1135.	0.5	47
557	S-1 plus nab -paclitaxel is a promising regimen for pancreatic cancer in a preclinical model. Journal of Surgical Oncology, 2016, 113, 413-419.	0.8	14
558	Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy?. European Journal of Surgical Oncology, 2016, 42, 1533-1539.	0.5	104
559	Preoperative Gemcitabine-based Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer. Annals of Surgery, 2016, 264, 1091-1097.	2.1	53
560	Patientâ€derived xenografts as tools in pharmaceutical development. Clinical Pharmacology and Therapeutics, 2016, 99, 612-621.	2.3	50
561	Prognosis after surgical treatment for pancreatic cancer in patients aged 80Âyears or older: a multicenter study. Journal of Hepato-Biliary-Pancreatic Sciences, 2016, 23, 188-197.	1.4	40

#	Article	IF	Citations
562	FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 619-622.	0.6	12
563	A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas, 2016, 45, 370-375.	0.5	175
564	Interstitial lung disease associated with gemcitabine: A <scp>J</scp>apanese retrospective cohort study. Respirology, 2016, 21, 338-343.	1.3	25
565	Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3â€“MYC Interactions as a Target in Pancreatic Cancer. Clinical Cancer Research, 2016, 22, 6153-6163.	3.2	56
566	Controlling the Stealth Effect of Nanocarriers through Understanding the Protein Corona. Angewandte Chemie - International Edition, 2016, 55, 8806-8815.	7.2	215
567	Die Steuerung des Stealthâ€Effekts von NanotrÃgern durch das VerstÃndnis der Proteinkorona. Angewandte Chemie, 2016, 128, 8950-8959.	1.6	11
568	Evaluation of Modified Glasgow Prognostic Score for Pancreatic Cancer. Pancreas, 2016, 45, 211-217.	0.5	69
569	Second-Line Treatment in Pancreatic Cancer Patients. Pancreas, 2016, 45, 601-605.	0.5	22
570	The Incidental Use of High-Dose Vitamin D3 in Pancreatic Cancer. Case Reports in Pancreatic Cancer, 2016, 2, 32-35.	0.1	5
571	Patient-Derived Xenograft: An Adjuvant Technology for the Treatment of Metastatic Disease. Pathobiology, 2016, 83, 170-176.	1.9	24
572	Clinical Decision-Making in Pancreatic Cancer. , 2016, , 1-32.		0
573	Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study. Digestion, 2016, 94, 222-229.	1.2	16
574	Reply to the comment on â€˜Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohortâ€™. British Journal of Cancer, 2016, 114, e9-e9.	2.9	3
575	Current and Evolving Therapies for Metastatic Pancreatic Cancer: Are We Stuck With Cytotoxic Chemotherapy?. Journal of Oncology Practice, 2016, 12, 797-805.	2.5	10
576	SEOM Clinical Guideline for the treatment of pancreatic cancer (2016). Clinical and Translational Oncology, 2016, 18, 1172-1178.	1.2	27
577	Case of Six-Year Disease-Free Survival with Undifferentiated Carcinoma of the Pancreas. Case Reports in Gastroenterology, 2016, 10, 472-478.	0.3	14
579	Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42. Neoplasia, 2016, 18, 765-774.	2.3	16
580	Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database. BMC Cancer, 2016, 16, 443.	1.1	23

#	Article	IF	Citations
581	Clinical Insights Into the Biology and Treatment of Pancreatic Cancer. Journal of Oncology Practice, 2016, 12, 17-23.	2.5	15
582	Coix seed emulsion synergistically enhances the antitumor activity of gemcitabine in pancreatic cancer through abrogation of NF-ÎºB signaling. Oncology Reports, 2016, 36, 1517-1525.	1.2	14
583	Wilmsâ€™ tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer. Immunotherapy, 2016, 8, 1309-1320.	1.0	14
584	NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice. BMC Cancer, 2016, 16, 709.	1.1	48
585	Recommendations for the diagnosis, staging and treatment of pre-malignant lesions and pancreatic adenocarcinoma. Medicina ClÃ¡nica (English Edition), 2016, 147, 465.e1-465.e8.	0.1	1
586	A Single Talent Immunogenic Membrane Antigen and Novel Prognostic Predictor: voltage-dependent anion channel 1 (VDAC1) in Pancreatic Cancer. Scientific Reports, 2016, 6, 33648.	1.6	10
587	Transtuzumab induced organizing pneumonia: a case report. SpringerPlus, 2016, 5, 1964.	1.2	3
588	Commentary on â€œEpithelialâ€“toâ€“Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancerâ€. Cancer Research, 2016, 76, 7075-7077.	0.4	2
589	Home-based specialized palliative care in patients with advanced cancer: A systematic review. Palliative and Supportive Care, 2016, 14, 713-724.	0.6	30
590	Dermatological adverse events with taxane chemotherapy. European Journal of Dermatology, 2016, 26, 427-443.	0.3	148
591	Chemotherapy for Advanced Pancreatic Cancer. , 2016, , 1-48.		0
592	Role of Radiotherapy in Locally Advanced Pancreatic Cancer. , 2016, , 1-26.		0
593	Triple bypass for advanced pancreatic head cancer associated with biliary stricture, duodenal stenosis, and recurrent obstructive pancreatitis. Surgical Case Reports, 2016, 2, 79.	0.2	2
595	Any progress in pancreatic cancer?. Acta OncolÃ³gica, 2016, 55, 255-258.	0.8	2
596	Conversion therapy for pancreatic cancer with peritoneal metastases using intravenous and intraperitoneal paclitaxel with S-1. Molecular and Clinical Oncology, 2016, 5, 779-782.	0.4	4
597	Mind the gap: An analysis of foregone health gains from unfunded cancer medicines in New Zealand. Seminars in Oncology, 2016, 43, 625-637.	0.8	13
598	Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review. Oncology Letters, 2016, 12, 4505-4509.	0.8	0
599	Glaucarubinone Combined with Gemcitabine Improves Pancreatic Cancer Survival in an Immunocompetent Orthotopic Murine Model. Journal of Investigative Surgery, 2016, 29, 366-372.	0.6	4

#	Article	IF	Citations
600	New Approaches to Drug Discovery. Handbook of Experimental Pharmacology, 2016, , .	0.9	5
601	Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncology, The, 2016, 17, 651-662.	5.1	557
602	Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Molecular Therapy, 2016, 24, 1150-1158.	3.7	114
603	Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer. Expert Review of Anticancer Therapy, 2016, 16, 485-492.	1.1	19
604	Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. British Journal of Cancer, 2016, 114, 737-743.	2.9	159
605	A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458). International Journal of Radiation Oncology Biology Physics, 2016, 96, 296-303.	0.4	61
606	A novel small-molecule YLT256 inhibits proliferation and induces apoptosis both in vitro and in vivo in solid tumors. Biomedicine and Pharmacotherapy, 2016, 81, 482-490.	2.5	1
607	Hypofractionated radiotherapy in pancreatic cancer: Lessons from the past in the era of stereotactic body radiation therapy. Critical Reviews in Oncology/Hematology, 2016, 103, 49-61.	2.0	26
608	Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. Radiotherapy and Oncology, 2016, 119, 312-318.	0.3	51
609	A pancreatic cancer multidisciplinary clinic: insights and outcomes. Journal of Surgical Research, 2016, 202, 246-252.	0.8	16
610	Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer. Medical Oncology, 2016, 33, 48.	1.2	20
611	Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study. Pancreatology, 2016, 16, 658-664.	0.5	28
612	Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. Drug Resistance Updates, 2016, 27, 14-29.	6.5	511
613	Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment. Clinical Therapeutics, 2016, 38, 1622-1635.	1.1	18
614	Recent advances in pancreatic cancer: updates and insights from the 2015 annual meeting of the American Society of Clinical Oncology. Therapeutic Advances in Gastroenterology, 2016, 9, 141-151.	1.4	11
615	Volume matters in the systemic treatment of metastatic pancreatic cancer: a population-based study in the Netherlands. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1353-1360.	1.2	42
616	Treatment of Pancreatic Adenocarcinoma in Elderly Patients over 75ÂYears of Age: A Retrospective Series of 129 Patients. Journal of Gastrointestinal Cancer, 2016, 47, 15-19.	0.6	10
617	A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma. Biomaterials, 2016, 93, 71-82.	5.7	35

#	Article	IF	Citations
618	Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines. International Journal of Oncology, 2016, 48, 45-54.	1.4	38
619	Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size data. Cancer Chemotherapy and Pharmacology, 2016, 77, 927-938.	1.1	10
620	Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis. Nature Cell Biology, 2016, 18, 549-560.	4.6	329
621	Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience. Medical Oncology, 2016, 33, 37.	1.2	1
622	Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. Pancreatology, 2016, 16, 593-598.	0.5	58
623	Safety of palliative chemotherapy in advanced pancreatic cancer. Expert Opinion on Drug Safety, 2016, 15, 947-954.	1.0	8
624	Natural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive Agents. Medical Principles and Practice, 2016, 25, 41-59.	1.1	473
625	Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT). European Journal of Cancer, 2016, 52, 85-91.	1.3	36
626	Surgical Oncology Manual. , 2016, , .		1
628	Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer. Expert Opinion on Pharmacotherapy, 2016, 17, 1413-1420.	0.9	16
629	Adenocarcinoma of the Pancreas. , 2016, , 251-266.		0
630	Optimizing Treatment for Locally Advanced Pancreas Cancer. JAMA - Journal of the American Medical Association, 2016, 315, 1837.	3.8	12
631	Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib. JAMA - Journal of the American Medical Association, 2016, 315, 1844.	3.8	801
632	Targeted Nanoparticles for the Delivery of Novel Bioactive Molecules to Pancreatic Cancer Cells. Journal of Medicinal Chemistry, 2016, 59, 5209-5220.	2.9	39
633	Comment on: â€˜Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohortâ€™. British Journal of Cancer, 2016, 114, e8-e8.	2.9	1
635	Is alcohol required for effective pancreatic cyst ablation? The prospective randomized CHARM trial pilot study. Endoscopy International Open, 2016, 04, E603-E607.	0.9	47
636	Computational Methods in Systems Biology. Lecture Notes in Computer Science, 2016, , .	1.0	5
637	Does finding early recurrence improve outcomes, and at what cost?. Journal of Surgical Oncology, 2016, 114, 329-335.	0.8	5

#	Article	IF	Citations
638	Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma. BMC Cancer, 2016, 16, 632.	1.1	130
639	Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. British Journal of Cancer, 2016, 115, 789-796.	2.9	56
640	In Response to â€œSerum Tumor Marker Use in Patients With Advanced Solid Tumorsâ€• Journal of Oncology Practice, 2016, 12, 273-274.	2.5	4
641	Honokiol suppresses pancreatic tumor growth, metastasis and desmoplasia by interfering with tumorâ€“stromal cross-talk. Carcinogenesis, 2016, 37, 1052-1061.	1.3	28
642	Formal Modeling and Analysis of Pancreatic Cancer Microenvironment. Lecture Notes in Computer Science, 2016, , 289-305.	1.0	16
643	Short-chain C6 ceramide sensitizes AT406-induced anti-pancreatic cancer cell activity. Biochemical and Biophysical Research Communications, 2016, 479, 166-172.	1.0	11
644	Advances in Nanomedicine for Head and Neck Cancer. , 2016, , 827-844.		3
645	Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. British Journal of Cancer, 2016, 115, 188-194.	2.9	76
647	Ultrasound-triggered drug delivery for cancer treatment using drug delivery systems: From theoretical considerations to practical applications. Journal of Controlled Release, 2016, 241, 144-163.	4.8	204
648	Radiological evaluation of response to neoadjuvant treatment in pancreatic cancer. Diagnostic and Interventional Imaging, 2016, 97, 1225-1232.	1.8	34
649	Calpain inhibitor calpeptin suppresses pancreatic cancer by disrupting cancerâ€“stromal interactions in a mouse xenograft model. Cancer Science, 2016, 107, 1443-1452.	1.7	21
650	The mitochondrion interfering compound NPC-26 exerts potent anti-pancreatic cancer cell activity in vitro and in vivo. Tumor Biology, 2016, 37, 15053-15063.	0.8	11
651	Molecular signatures of mu opioid receptor and somatostatin receptor 2 in pancreatic cancer. Molecular Biology of the Cell, 2016, 27, 3659-3672.	0.9	26
652	Improvement in advanced pancreatic cancer survival with novel chemotherapeutic strategies â€“ experience of a community based hospital. Zeitschrift Fur Gastroenterologie, 2016, 54, 1138-1142.	0.2	6
653	Cancer du pancrÃ©as et traitement nÃ©oadjuvantÂ: Ã©valuation de la rÃ©ponse en imagerie. Diagnostic and Interventional Imaging, 2016, 97, 501-508.	0.0	0
655	Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a027094.	2.9	119
656	The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsone: from rash mitigation to the increase in anti-tumor activity. Current Medical Research and Opinion, 2016, 32, 1839-1848.	0.9	16
657	Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma. Advances in Surgery, 2016, 50, 115-128.	0.6	6

#	Article	IF	Citations
658	FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience. British Journal of Cancer, 2016, 115, 649-654.	2.9	40
659	Update on the Management of Pancreatic Cancer in Older Adults. Current Oncology Reports, 2016, 18, 60.	1.8	8
660	Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer. British Journal of Cancer, 2016, 115, 442-453.	2.9	39
661	Inhibition of DACH1 activity by short hairpin RNA represses cell proliferation and tumor invasion in pancreatic cancer. Oncology Reports, 2016, 36, 745-754.	1.2	7
662	Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial. Journal of Surgical Oncology, 2016, 114, 336-341.	0.8	8
663	Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial. Cancer Chemotherapy and Pharmacology, 2016, 78, 719-726.	1.1	22
664	Recent Advances and Prospects for Multimodality Therapy in Pancreatic Cancer. Seminars in Radiation Oncology, 2016, 26, 320-337.	1.0	21
666	Distal bile duct carcinomas and pancreatic ductal adenocarcinomas: postulating a common tumor entity. Cancer Medicine, 2016, 5, 88-99.	1.3	45
667	Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma. Journal of Pathology, 2016, 239, 286-296.	2.1	98
668	A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2016, 78, 577-584.	1.1	12
669	Deviations from Expected Treatment of Pancreatic Cancer in Octogenarians: Analysis of Patient and Surgeon Factors. Annals of Surgical Oncology, 2016, 23, 4149-4155.	0.7	31
670	Human pancreatic cancer progression: an anarchy among CCN-siblings. Journal of Cell Communication and Signaling, 2016, 10, 207-216.	1.8	15
671	Pancreatic Cancer. Gastroenterology Clinics of North America, 2016, 45, 429-445.	1.0	73
672	New treatment strategy with nuclear factor-Î²B inhibitor for pancreatic cancer. Journal of Surgical Research, 2016, 206, 1-8.	0.8	13
673	Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer. European Journal of Cancer, 2016, 65, 11-20.	1.3	19
674	A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma. , 2016, 4, 45.		89
675	InÂvitro investigation of multidrug nanoparticles for combined therapy with gemcitabine and a tyrosine kinase inhibitor: Together is not better. Biochimie, 2016, 130, 4-13.	1.3	6
676	Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nature Reviews Clinical Oncology, 2016, 13, 750-765.	12.5	181

#	Article	IF	Citations
677	The small-molecule IAP antagonist AT406 inhibits pancreatic cancer cells inÂvitro and inÂvivo. Biochemical and Biophysical Research Communications, 2016, 478, 293-299.	1.0	12
678	Molecular profiles in foregut oncology. Cancer Genetics, 2016, 209, 537-553.	0.2	0
679	Enhanced tumor targeting of cRGD peptide-conjugated albumin nanoparticles in the BxPC-3 cell line. Scientific Reports, 2016, 6, 31539.	1.6	25
681	Principles of Chemotherapy. , 2016, , 171-185.e2.		0
682	Duodenal stenting followed by systemic chemotherapy for patients with pancreatic cancer and gastric outlet obstruction. Pancreatology, 2016, 16, 1085-1091.	0.5	21
683	Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases: a Bi-institutional Analysis. Journal of Gastrointestinal Surgery, 2016, 20, 1830-1835.	0.9	70
684	Current management and future directions in metastatic pancreatic adenocarcinoma. Cancer, 2016, 122, 3765-3775.	2.0	18
685	Anticancer nanoparticulate polymerâ€drug conjugate. Bioengineering and Translational Medicine, 2016, 1, 277-296.	3.9	71
686	PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy. Journal of Clinical Oncology, 2016, 34, 3914-3920.	0.8	210
687	Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma. Digestion, 2016, 94, 44-49.	1.2	28
688	Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer. Pharmacological Research, 2016, 111, 577-591.	3.1	46
689	Leiodermatolide, a novel marine natural product, has potent cytotoxic and antimitotic activity against cancer cells, appears to affect microtubule dynamics, and exhibits antitumor activity. International Journal of Cancer, 2016, 139, 2116-2126.	2.3	28
690	Paralytic ileus due to a novel anticancer drug, nab-paclitaxel: A case report. Molecular and Clinical Oncology, 2016, 4, 824-826.	0.4	1
691	A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer. Investigational New Drugs, 2016, 34, 733-739.	1.2	31
692	Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma. British Journal of Cancer, 2016, 115, 290-296.	2.9	29
693	A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2016, 78, 541-545.	1.1	20
694	Antibody-targeted nanoparticles for cancer treatment. Immunotherapy, 2016, 8, 941-958.	1.0	53
695	Adjuvant and Neoadjuvant Therapy for Resectable Pancreatic and Periampullary Cancer. Surgical Clinics of North America, 2016, 96, 1287-1300.	0.5	14

#	Article	IF	Citations
696	Management of Locally Advanced Pancreatic Cancer. Surgical Clinics of North America, 2016, 96, 1371-1389.	0.5	16
697	Management of Metastatic Pancreatic Adenocarcinoma. Surgical Clinics of North America, 2016, 96, 1391-1414.	0.5	10
698	Genetics of Pancreatic Cancer and Its Implications on Therapy. Surgical Clinics of North America, 2016, 96, 1207-1221.	0.5	12
699	Early nontumorous CT findings after irreversible electroporation of locally advanced pancreatic cancer. Abdominal Radiology, 2016, 41, 2142-2149.	1.0	12
700	A case of hemorrhagic cystitis caused by nab-paclitaxel. International Cancer Conference Journal, 2016, 5, 187-191.	0.2	4
701	Derived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancer. Oncology Letters, 2016, 11, 3441-3445.	0.8	41
702	Health services research of integrative oncology in palliative care of patients with advanced pancreatic cancer. BMC Cancer, 2016, 16, 579.	1.1	29
703	Pancreatic cancer and liver metastases: state of the art. Updates in Surgery, 2016, 68, 247-251.	0.9	29
704	Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated?. Journal of Surgical Oncology, 2016, 114, 581-586.	0.8	23
705	Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT). BMC Cancer, 2016, 16, 817.	1.1	28
706	Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5. , 2016, 4, 33.		11
707	Nanoparticle Albumin-Bound Paclitaxel (AbraxaneÂ®). , 2016, , 101-119.		27
708	An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nature Communications, 2016, 7, 13443.	5.8	156
709	CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma. Cancer Immunology Research, 2016, 4, 968-982.	1.6	192
710	Pancreatic cancer. Nature Reviews Disease Primers, 2016, 2, 16022.	18.1	1,301
711	Metastatic progression is associated with dynamic changes in the local microenvironment. Nature Communications, 2016, 7, 12819.	5.8	99
712	Systemic Therapy in Pancreatic Cancer. , 2016, , 247-273.		1
713	Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials. British Journal of Cancer, 2016, 115, 1520-1529.	2.9	20

#	Article	IF	Citations
714	Paeoniflorin Potentiates the Inhibitory Effects of Erlotinib in Pancreatic Cancer Cell Lines by Reducing ErbB3 Phosphorylation. Scientific Reports, 2016, 6, 32809.	1.6	22
715	Management of Advanced Pancreatic Cancer in Daily Clinical Practice. Tumori, 2016, 102, 51-58.	0.6	0
716	Biomarkers and Targeted Therapy in Pancreatic Cancer. Biomarkers in Cancer, 2016, 8s1, BIC.S34414.	3.6	44
717	Comparing assessment frameworks for cancer drugs between Canada and Europe: What can we learn from the differences?. ESMO Open, 2016, 1, e000124.	2.0	7
718	Cost-Effectiveness Analysis of Treatments for Metastatic Pancreatic Cancer Based on Prodige and MPACT Trials. Tumori, 2016, 102, 294-300.	0.6	14
719	Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma. Digestive Surgery, 2016, 33, 343-350.	0.6	13
720	LTP-1, a novel antimitotic agent and Stat3 inhibitor, inhibits human pancreatic carcinomas in vitro and in vivo. Scientific Reports, 2016, 6, 27794.	1.6	9
721	Doubly blind: a systematic review of gender in randomised controlled trials. Global Health Action, 2016, 9, 29597.	0.7	60
722	Incorporating Yttrium-90 trans-arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcioma: a single center experience. BMC Cancer, 2016, 16, 492.	1.1	24
723	Precision Medicine and Pancreatic Cancer. Pancreas, 2016, 45, 1485-1493.	0.5	9
724	Severe hyponatremia caused by nab-paclitaxel-induced syndrome of inappropriate antidiuretic hormone secretion. Medicine (United States), 2016, 95, e4006.	0.4	3
725	Stereotactic Body Radiation Therapy for Pancreatic Cancer. Cancer Journal (Sudbury, Mass), 2016, 22, 290-295.	1.0	9
727	Masitinib plus gemcitabine for personalized treatment of PDAC patients with overexpression of ACOX1. Expert Review of Precision Medicine and Drug Development, 2016, 1, 479-485.	0.4	0
728	Evolution of novel therapeutic options for pancreatic cancer. Current Opinion in Gastroenterology, 2016, 32, 401-407.	1.0	14
729	A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer, 2016, 122, 2158-2167.	2.0	277
730	nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial. Advances in Therapy, 2016, 33, 747-759.	1.3	18
731	The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy. Expert Review of Anticancer Therapy, 2016, 16, 697-703.	1.1	106
733	Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials. JAMA Oncology, 2016, 2, 1209.	3.4	55

#	Article	IF	Citations
734	Prognostic impact of carcinoembryonic antigen (CEA) on patients with metastatic pancreatic cancer: A retrospective cohort study. Pancreatology, 2016, 16, 859-864.	0.5	30
735	Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2016, 34, 2784-2796.	0.8	267
736	Integrating patient reported measures as predictive parameters into decisionmaking about palliative chemotherapy: a pilot study. BMC Palliative Care, 2016, 15, 25.	0.8	7
737	Hyperthermic Oncology from Bench to Bedside. , 2016, , .		5
738	Nab-paclitaxel-induced cystoid macular edema in a patient with pre-existing optic neuropathy. Anti-Cancer Drugs, 2016, 27, 580-584.	0.7	11
739	Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites. Investigational New Drugs, 2016, 34, 636-642.	1.2	28
740	Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival. Journal of Clinical Oncology, 2016, 34, 2899-2905.	0.8	49
741	Locally advanced pancreatic cancer: maybe not so local. Lancet Oncology, The, 2016, 17, 694-695.	5.1	2
742	Targeting the microenvironment of pancreatic cancer: overcoming treatment barriers and improving local immune responses. Clinical and Translational Oncology, 2016, 18, 653-659.	1.2	8
743	Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2016, 34, 2654-2668.	0.8	292
744	Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet, The, 2016, 388, 248-257.	6.3	799
745	Drug costs and benefits of medical treatments in high-unmet need solid tumours in the Nordic countries. Journal of Cancer Policy, 2016, 7, 12-22.	0.6	4
746	Evofosfamide, a new horizon in the treatment of pancreatic cancer. Anti-Cancer Drugs, 2016, 27, 723-725.	0.7	17
747	DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma. BMC Cancer, 2016, 16, 21.	1.1	16
748	Autologous cytokine-induced killer cell transfusion increases overall survival in advanced pancreatic cancer. Journal of Hematology and Oncology, 2016, 9, 6.	6.9	31
749	Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2016, 34, 2541-2556.	0.8	302
750	Clinical Use of High-Intensity Focused Ultrasound (HIFU) for Tumor and Pain Reduction in Advanced Pancreatic Cancer. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2016, 188, 662-670.	0.7	39
751	CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer. Cell Reports, 2016, 15, 2719-2732.	2.9	217

#	Article	IF	Citations
752	Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2016, 78, 1101-1111.	1.1	25
753	Targeting tumor tolerance: A new hope for pancreatic cancer therapy?. , 2016, 166, 9-29.		33
754	Modified Appleby Procedure for Pancreatic Adenocarcinoma: Does Improved Neoadjuvant Therapy Warrant Such an Aggressive Approach?. Annals of Surgical Oncology, 2016, 23, 3757-3764.	0.7	56
755	Pancreatic cancer: yesterday, today and tomorrow. Future Oncology, 2016, 12, 1929-1946.	1.1	286
756	A phase 1, dose-finding and pharmacokinetic study of gemcitabine with nab-paclitaxel in patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology, 2016, 78, 289-294.	1.1	7
757	InÂVivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Cell Reports, 2016, 16, 133-147.	2.9	114
758	Nab-paclitaxel plus gemcitabine as first-line palliative chemotherapy in a patient with metastatic pancreatic cancer with Eastern Cooperative Oncology Group performance status of 2. Oncology Letters, 2016, 12, 727-730.	0.8	8
759	Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models. Pancreas, 2016, 45, 425-433.	0.5	14
760	Pancreatic Adenocarcinoma in the FinistÃ¨re Area, France, Between 2002 and 2011 (1002 Cases). Pancreas, 2016, 45, 953-960.	0.5	7
761	Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis?. Surgery Today, 2016, 46, 139-148.	0.7	13
762	The acinar regulator Gata6 suppressesKrasG12V-driven pancreatic tumorigenesis in mice. Gut, 2016, 65, 476-486.	6.1	83
763	Early Detection and Treatment Opportunities in Pancreatic Adenocarcinoma. Journal of Oncology Practice, 2016, 12, 31-32.	2.5	0
764	Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer. Pancreatology, 2016, 16, 249-258.	0.5	17
765	Ability of simple organotin polyethers to inhibit pancreatic cancer. Journal of Macromolecular Science - Pure and Applied Chemistry, 2016, 53, 63-71.	1.2	5
766	Analysis of Response-Related and Time-to-event Endpoints in Randomized Trials of Gemcitabine-Based Treatment Versus Gemcitabine Alone as First-Line Treatment of Patients With Advanced Pancreatic Cancer. Clinical Colorectal Cancer, 2016, 15, 264-276.	1.0	8
767	Algenpantucel-L immunotherapy in pancreatic adenocarcinoma. Immunotherapy, 2016, 8, 117-125.	1.0	22
768	Pancreatic cancer. Lancet, The, 2016, 388, 73-85.	6.3	1,826
769	Changing the course of pancreatic cancer â€“ Focus on recent translational advances. Cancer Treatment Reviews, 2016, 44, 17-25.	3.4	21

#	Article	IF	Citations
770	Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer. Clinical Cancer Research, 2016, 22, 2848-2854.	3.2	272
771	Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients: a single institute experience. Medical Oncology, 2016, 33, 4.	1.2	1
772	Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer. Molecular Oncology, 2016, 10, 635-643.	2.1	131
773	Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2016, 77, 35-41.	1.1	14
774	Circulating Metabolites and Survival Among Patients With Pancreatic Cancer. Journal of the National Cancer Institute, 2016, 108, djv409.	3.0	31
775	Meta-analyses of treatment standards for pancreatic cancer. Molecular and Clinical Oncology, 2016, 4, 315-325.	0.4	31
776	CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Annals of Oncology, 2016, 27, 654-660.	0.6	87
777	The value of surrogate endpoints for predicting real-world survival across five cancer types. Current Medical Research and Opinion, 2016, 32, 731-739.	0.9	6
778	Pancreatic cancer: Current research and future directions. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 123-132.	3.3	65
780	Taxane anticancer agents: a patent perspective. Expert Opinion on Therapeutic Patents, 2016, 26, 1-20.	2.4	162
781	Treatment regimens of classical and newer taxanes. Cancer Chemotherapy and Pharmacology, 2016, 77, 221-233.	1.1	36
782	Impact of Metformin on Advanced Pancreatic Cancer Survival: Too Little, Too Late?. Clinical Cancer Research, 2016, 22, 1031-1033.	3.2	8
783	Pancreatic cancer: Update on immunotherapies and algenpantucel-L. Human Vaccines and Immunotherapeutics, 2016, 12, 563-575.	1.4	30
784	Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 340-345.	0.6	20
785	Pancreatic Adenocarcinoma: The Emperor of All Cancer Maladies. Journal of Oncology Practice, 2016, 12, 29-30.	2.5	3
786	Proteomic strategies in the search for novel pancreatic cancer biomarkers and drug targets: recent advances and clinical impact. Expert Review of Proteomics, 2016, 13, 383-394.	1.3	7
787	The â€˜SPARCâ€™ of life: Analysis of the role of osteonectin/SPARC in pancreatic cancer (Review). International Journal of Oncology, 2016, 48, 1765-1771.	1.4	19
788	A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers. Investigational New Drugs, 2016, 34, 319-328.	1.2	17

#	Article	IF	Citations
789	Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight. Cancer Science, 2016, 107, 569-575.	1.7	106
790	High-intensity focused ultrasound (HIFU) for pancreatic carcinoma: evaluation of feasibility, reduction of tumour volume and pain intensity. European Radiology, 2016, 26, 4047-4056.	2.3	67
791	Genetics and biology of pancreatic ductal adenocarcinoma. Genes and Development, 2016, 30, 355-385.	2.7	416
792	Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2016, 77, 595-603.	1.1	131
793	Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer. Cancer Immunology Research, 2016, 4, 225-233.	1.6	21
794	Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature. Future Oncology, 2016, 12, 901-908.	1.1	14
795	Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. Annals of Oncology, 2016, 27, 648-653.	0.6	36
796	Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1-13.	1.4	39
797	Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study.. European Journal of Cancer, 2016, 54, 96-103.	1.3	26
798	New drug for pancreatic cancer highlights the dual effect of regulatory approvals. Nature Reviews Clinical Oncology, 2016, 13, 205-206.	12.5	7
799	Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Pancreatic Ductal Adenocarcinoma. Nutrition and Cancer, 2016, 68, 234-240.	0.9	12
800	CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nature Medicine, 2016, 22, 278-287.	15.2	184
801	Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer. Molecular Oncology, 2016, 10, 481-493.	2.1	75
802	Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinomaâ€"An Infrequent Event: Elucidation of Risk Factors and Management Implications. Clinical Colorectal Cancer, 2016, 15, 24-31.	1.0	13
803	Adjuvant therapy for pancreas cancer in an era of value based cancer care. Cancer Treatment Reviews, 2016, 42, 10-17.	3.4	16
804	Choline Kinase Alpha (CHKÎ±) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors. Molecular Cancer Therapeutics, 2016, 15, 323-333.	1.9	25
805	Immunotherapy for pancreatic cancer. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1795-1805.	1.2	27
806	Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. Critical Reviews in Oncology/Hematology, 2016, 98, 309-324.	2.0	35

#	Article	IF	Citations
807	Current standards and new innovative approaches for treatment of pancreatic cancer. European Journal of Cancer, 2016, 57, 10-22.	1.3	138
808	Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse. Clinical and Translational Oncology, 2016, 18, 988-995.	1.2	16
809	Does chemotherapy improve health-related quality of life in advanced pancreatic cancer? A systematic review. Critical Reviews in Oncology/Hematology, 2016, 99, 286-298.	2.0	44
811	Palliative Management of Unresectable Pancreas Cancer. Surgical Oncology Clinics of North America, 2016, 25, 327-337.	0.6	12
812	Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?. OncoImmunology, 2016, 5, e1112942.	2.1	19
813	Using next-generation sequencing to determine potential molecularly guided therapy options for patients with resectable pancreatic adenocarcinoma. American Journal of Surgery, 2016, 211, 506-511.	0.9	9
814	Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer. Surgical Oncology Clinics of North America, 2016, 25, 311-326.	0.6	19
815	Exceptional Response to Nanoparticle Albumin-Bound Paclitaxel and Gemcitabine in a Patient with a Refractory Adenocarcinoma of the Ampulla of Vater. Case Reports in Oncology, 2016, 9, 15-24.	0.3	6
816	SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts. Molecular Cancer Therapeutics, 2016, 15, 680-688.	1.9	49
817	Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics, 2016, 15, 1043-1052.	1.9	85
818	Single-Institution Experience with Irreversible Electroporation for T4 Pancreatic Cancer: First 50 Patients. Annals of Surgical Oncology, 2016, 23, 1736-1743.	0.7	90
819	The Role of MicroRNAs in Resistance to Current Pancreatic Cancer Treatment: Translational Studies and Basic Protocols for Extraction and PCR Analysis. Methods in Molecular Biology, 2016, 1395, 163-187.	0.4	10
820	A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study. Cancer Chemotherapy and Pharmacology, 2016, 77, 693-701.	1.1	10
821	Optimizing initial chemotherapy for metastatic pancreatic cancer. Future Oncology, 2016, 12, 1125-1133.	1.1	5
822	Dermal Drug Delivery for Cutaneous Malignancies: Literature at a Glance. Journal of Pharmaceutical Innovation, 2016, 11, 1-33.	1.1	6
823	Use of PERCIST for Prediction of Progression-Free and Overall Survival After Radioembolization for Liver Metastases from Pancreatic Cancer. Journal of Nuclear Medicine, 2016, 57, 355-360.	2.8	22
824	Initial Characterization of Integrase-Defective Lentiviral Vectors for Pancreatic Cancer Gene Therapy. Human Gene Therapy, 2016, 27, 184-192.	1.4	7
825	18F-FLT PET imaging of cellular proliferation in pancreatic cancer. Critical Reviews in Oncology/Hematology, 2016, 99, 158-169.	2.0	10

#	Article	IF	Citations
826	Stereotactic Body Radiation Therapy as an Emerging Option for Localized Pancreatic Cancer. , 2016, , 125-141.		1
827	Systemic Immune Activity Predicts Overall Survival in Treatment-NaÃ¯ve Patients with Metastatic Pancreatic Cancer. Clinical Cancer Research, 2016, 22, 2565-2574.	3.2	80
828	Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2016, 77, 477-484.	1.1	13
829	Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities. European Journal of Cancer, 2016, 54, 75-83.	1.3	145
830	MM-398 (nanoliposomal irinotecan): emergence of a novel therapy for the treatment of advanced pancreatic cancer. Future Oncology, 2016, 12, 453-464.	1.1	33
831	Does long-term survival exist in pancreatic adenocarcinoma?. Acta OncolÃ³gica, 2016, 55, 259-264.	0.8	22
832	A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer. Annals of Oncology, 2016, 27, 502-508.	0.6	34
833	Emerging Systemic and Targeted Therapies. , 2016, , 159-168.		1
834	Is There a Role for Laparoscopic and/or Robotic Techniques for Borderline Resectable Tumors?. , 2016, , 187-202.		0
835	The Role and Techniques of Vascular Resection. , 2016, , 203-222.		0
836	The Role of the Appleby Operation and Arterial Resection in the Multimodality Management of Borderline Resectable Pancreatic Cancer. , 2016, , 247-264.		1
837	Overview of Multimodality Therapy. , 2016, , 73-89.		0
838	Role of Systemic Therapy. , 2016, , 91-106.		0
839	Role of Radiation Therapy. , 2016, , 107-124.		0
840	Assessment of Response to Preoperative Therapy. , 2016, , 143-157.		0
841	Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory Mechanisms and Improve Treatment Outcomes in Pancreatic Cancer. Cancer Research, 2016, 76, 1066-1077.	0.4	104
843	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet, The, 2016, 387, 545-557.	6.3	878
844	Prognostic and predictive markers in pancreatic adenocarcinoma. Digestive and Liver Disease, 2016, 48, 223-230.	0.4	105

#	Article	IF	Citations
845	Application of albumin-based nanoparticles in the management of cancer. Journal of Materials Science: Materials in Medicine, 2016, 27, 4.	1.7	24
846	Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents. Annals of Oncology, 2016, 27, 373-378.	0.6	50
847	Hemocompatible curcuminâ€“dextran micelles as pH sensitive pro-drugs for enhanced therapeutic efficacy in cancer cells. Carbohydrate Polymers, 2016, 137, 497-507.	5.1	69
848	Key role of pancreatic stellate cells in pancreatic cancer. Cancer Letters, 2016, 381, 194-200.	3.2	103
849	Gemcitabine-resistant pancreatic cancer: a second-line option. Lancet, The, 2016, 387, 507-508.	6.3	14
850	International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. Pancreatology, 2016, 16, 14-27.	0.5	81
851	Pancreatic Masses. , 2016, , .		0
852	Minimally Invasive Pancreaticoduodenectomy Does Not Improve Use or Time to Initiation of Adjuvant Chemotherapy for Patients With Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2016, 23, 1026-1033.	0.7	63
853	The Promise of Gene Therapy for Pancreatic Cancer. Human Gene Therapy, 2016, 27, 127-133.	1.4	13
854	The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells. Oncogene, 2016, 35, 2529-2541.	2.6	96
855	Cancer Imaging for Therapy Assessment. Biosystems and Biorobotics, 2016, , 387-405.	0.2	0
857	Minnelide Overcomes Oxaliplatin Resistance by Downregulating the DNA Repair Pathway in Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2016, 20, 13-24.	0.9	32
858	A proposed approach for analyzing post-study therapy effect in survival analysis. Journal of Biopharmaceutical Statistics, 2016, 26, 790-800.	0.4	1
859	Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. Gastroenterology, 2016, 150, 48-63.	0.6	90
860	Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells. Immunopharmacology and Immunotoxicology, 2016, 38, 50-60.	1.1	8
861	Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy. International Journal of Clinical Oncology, 2016, 21, 118-125.	1.0	28
862	A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clinical Cancer Research, 2016, 22, 61-68.	3.2	105
864	Molecular Pathogenesis and Targeted Therapy of Pancreatic Cancer. Annals of Surgical Oncology, 2016, 23, 197-205.	0.7	39

#	Article	IF	Citations
865	Intravenous Ï‰-3 Fatty Acids Plus Gemcitabine. Journal of Parenteral and Enteral Nutrition, 2017, 41, 398-403.	1.3	18
866	Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 552-554.	0.6	19
867	Downregulation of STAT3/NFâ€ÎºB potentiates gemcitabine activity in pancreatic cancer cells. Molecular Carcinogenesis, 2017, 56, 402-411.	1.3	32
868	Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2017, 9, e1416.	3.3	299
869	Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis. Annals of Surgery, 2017, 265, 397-401.	2.1	86
870	Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 507-511.	0.6	61
871	Double trouble for tumours. Nature, 2017, 542, 34-35.	13.7	2
872	Antibody Drug and Radionuclide Conjugates for GI Cancers. , 2017, , 79-99.		1
873	Inhibition of group 1 p21â€activated kinases suppresses pancreatic stellate cell activation and increases survival of mice with pancreatic cancer. International Journal of Cancer, 2017, 140, 2101-2111.	2.3	32
874	Advanced pancreatic adenocarcinoma outcomes with transition from devolved to centralised care in a regional Cancer Centre. British Journal of Cancer, 2017, 116, 424-431.	2.9	11
875	Cost-Effectiveness Analysis of Systemic Therapies in Advanced Pancreatic Cancer in the Canadian Health Care System. Value in Health, 2017, 20, 586-592.	0.1	16
876	Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer. Cancer Cell, 2017, 31, 5-19.	7.7	309
877	Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: <scp>VENUS</scp>â€<scp>PC</scp> study. Cancer Science, 2017, 108, 73-80.	1.7	54
878	Second-Line Combination Therapies in Pancreatic Cancer: Where Are We Now?. Journal of Clinical Oncology, 2017, 35, 1370-1371.	0.8	5
879	A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review. American Journal of Gastroenterology, 2017, 112, 537-554.	0.2	123
880	A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance. Scientific Reports, 2017, 7, 41615.	1.6	58
881	Feasibility of alternating induction and maintenance chemotherapy in pancreatic cancer. Scientific Reports, 2017, 7, 41549.	1.6	13
882	Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK. British Journal of Cancer, 2017, 116, 609-619.	2.9	205

#	Article	IF	Citations
883	Pancreatic cancer: Stroma and its current and emerging targeted therapies. Cancer Letters, 2017, 391, 38-49.	3.2	136
884	Long-term Survival Outcomes With Intravesical Nanoparticle Albumin-bound Paclitaxel for Recurrent Nonâ€“muscle-invasive Bladder Cancer After Previous Bacillus Calmette-GuÃ©rin Therapy. Urology, 2017, 103, 149-153.	0.5	37
885	Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. British Journal of Cancer, 2017, 116, 464-471.	2.9	21
886	Chasing Surgical Value. American Journal of Surgery, 2017, 213, 439-442.	0.9	1
887	Elderly patients diagnosed with hepatopancreatobiliary malignancies: A challenge beyond resection. Cancer, 2017, 123, 888-890.	2.0	2
888	Metastatic Pancreatic Cancer. , 2017, , 117-135.		0
889	Resveratrol and capsaicin used together as food complements reduce tumor growth and rescue full efficiency of low dose gemcitabine in a pancreatic cancer model. Cancer Letters, 2017, 390, 91-102.	3.2	50
890	Cancer cell chemokines direct chemotaxis of activated stellate cells in pancreatic ductal adenocarcinoma. Laboratory Investigation, 2017, 97, 302-317.	1.7	30
891	Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer. Cancer Immunology Research, 2017, 5, 182-190.	1.6	126
892	Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet, The, 2017, 389, 1011-1024.	6.3	1,475
893	Locally advanced pancreatic cancer successfully treated by distal pancreatectomy with celiac axis resection (DP-CAR) after S-1 with radiation therapy followed by gemcitabine/nab-paclitaxel therapy: a case report. Surgical Case Reports, 2017, 3, 15.	0.2	6
894	Intraoperative radiation therapy (IORT) in pancreatic cancer. Radiation Oncology, 2017, 12, 8.	1.2	41
895	Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study. Digestive and Liver Disease, 2017, 49, 692-696.	0.4	23
896	The significance of Trk receptors in pancreatic cancer. Tumor Biology, 2017, 39, 101042831769225.	0.8	8
897	Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity inKRASwild-type tumors. International Journal of Cancer, 2017, 140, 2331-2343.	2.3	30
898	Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1053-1059.	1.2	24
899	Management and outcomes following pancreaticoduodenectomy for ampullary adenocarcinoma. American Journal of Surgery, 2017, 214, 856-861.	0.9	19
900	Emerging protein kinase inhibitors for treating pancreatic cancer. Expert Opinion on Emerging Drugs, 2017, 22, 77-86.	1.0	11

#	Article	IF	Citations
901	A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. BMC Cancer, 2017, 17, 137.	1.1	47
902	Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. The Lancet Gastroenterology and Hepatology, 2017, 2, 277-287.	3.7	141
903	Ku70 inhibits gemcitabine-induced DNA damage and pancreatic cancer cell apoptosis. Biochemical and Biophysical Research Communications, 2017, 484, 746-752.	1.0	13
904	Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy. Therapeutic Advances in Medical Oncology, 2017, 9, 159-170.	1.4	26
905	Pancreatic cancer stroma: controversies and current insights. Scandinavian Journal of Gastroenterology, 2017, 52, 641-646.	0.6	40
906	Gemcitabineâ€“erlotinib versus gemcitabineâ€“erlotinibâ€“capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group. European Journal of Cancer, 2017, 75, 73-82.	1.3	15
907	Tackling pancreatic cancer with metronomic chemotherapy. Cancer Letters, 2017, 394, 88-95.	3.2	8
908	Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy. Cancer Chemotherapy and Pharmacology, 2017, 79, 595-602.	1.1	12
909	Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial. The Lancet Gastroenterology and Hepatology, 2017, 2, 337-346.	3.7	28
910	Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials. Acta OncolÃ³gica, 2017, 56, 377-383.	0.8	46
911	Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. Lancet Oncology, The, 2017, 18, 486-499.	5.1	60
912	Pancreatic, Rectal, and Liver Cancers: Out With the Old, In With the New. International Journal of Radiation Oncology Biology Physics, 2017, 97, 643-650.	0.4	0
913	Targeted therapy of pancreatic cancer: biomarkers are needed. Lancet Oncology, The, 2017, 18, 421-422.	5.1	11
914	Multimodal treatment of resectable pancreatic ductal adenocarcinoma. Critical Reviews in Oncology/Hematology, 2017, 111, 152-165.	2.0	28
915	Multifunctionalized iron oxide nanoparticles for selective targeting of pancreatic cancer cells. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 1597-1605.	1.1	67
916	Prognostic impact of nodal statuses in patients with pancreatic ductal adenocarcinoma. Pancreatology, 2017, 17, 279-284.	0.5	9
917	Designing a bio-inspired biomimetic in vitro system for the optimization of ex vivo studies of pancreatic cancer. Drug Discovery Today, 2017, 22, 690-701.	3.2	27
918	GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. Gut, 2017, 66, 1665-1676.	6.1	212

#	Article	IF	Citations
919	An Oncogenic ALK Fusion and an RRAS Mutation in KRAS Mutation-Negative Pancreatic Ductal Adenocarcinoma. Oncologist, 2017, 22, 158-164.	1.9	24
920	The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer. Cancer Letters, 2017, 397, 94-102.	3.2	50
921	Emerging antibodies for the treatment of pancreatic cancer. Expert Opinion on Emerging Drugs, 2017, 22, 39-51.	1.0	9
922	Immunotherapy in pancreatic cancer treatment: a new frontier. Therapeutic Advances in Gastroenterology, 2017, 10, 168-194.	1.4	73
923	Oligometastatic Disease in Pancreatic Cancer - How to Proceed. Visceral Medicine, 2017, 33, 36-41.	0.5	34
924	The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines. Oncology Reports, 2017, 37, 1545-1554.	1.2	103
925	JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer. OncoImmunology, 2017, 6, e1291106.	2.1	119
926	Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. Journal of Hematology and Oncology, 2017, 10, 82.	6.9	105
927	Can protein science solve the unmet needs in pancreatic cancer diagnosis and therapy?. Expert Review of Proteomics, 2017, 14, 469-471.	1.3	0
928	Surrogate End Points for Overall Survival in Metastatic, Locally Advanced, or Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis of 24 Randomized Controlled Trials. Annals of Surgical Oncology, 2017, 24, 2371-2378.	0.7	10
930	Oncolytic viral therapy for pancreatic cancer. Journal of Surgical Oncology, 2017, 116, 94-103.	0.8	34
931	Biotechnology and Production of Anti-Cancer Compounds. , 2017, , .		8
932	Predictive risk factors for peritoneal recurrence after pancreatic cancer resection and strategies for its prevention. Surgery Today, 2017, 47, 1434-1442.	0.7	20
933	Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer. Pancreas, 2017, 46, 335-340.	0.5	75
934	Hippo pathway mediates resistance to cytotoxic drugs. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E3729-E3738.	3.3	57
935	Utilizing Salmonella to treat solid malignancies. Journal of Surgical Oncology, 2017, 116, 75-82.	0.8	7
936	Asymptomatic Pancreatic Cancer: Does Incidental Detection Impact Long-Term Outcomes?. Journal of Gastrointestinal Surgery, 2017, 21, 1287-1295.	0.9	21
937	Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Cancer, 2017, 123, 3486-3493.	2.0	103

#	Article	IF	Citations
938	Chemotherapy-induced neutropenia as a prognostic factor in patients with metastatic pancreatic cancer treated with gemcitabine. European Journal of Clinical Pharmacology, 2017, 73, 1033-1039.	0.8	15
939	Multiâ€disciplinary management of locally advanced pancreatic cancer with irreversible electroporation. Journal of Surgical Oncology, 2017, 116, 35-45.	0.8	8
940	The basal nutritional state of PDAC patients is the dominant factor for completing adjuvant chemotherapy. Surgery Today, 2017, 47, 1361-1371.	0.7	21
941	Health-Related Quality of Life in Patients with Metastatic Pancreatic Cancer. Journal of Gastrointestinal Cancer, 2017, 48, 103-109.	0.6	19
942	Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncology, The, 2017, 18, 770-778.	5.1	167
943	Targeting metabolism in pancreatic cancer. Lancet Oncology, The, 2017, 18, 699-700.	5.1	8
944	Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?. Critical Reviews in Oncology/Hematology, 2017, 115, 1-12.	2.0	26
945	Inhibition of Sp1 prevents ER homeostasis and causes cell death by lysosomal membrane permeabilization in pancreatic cancer. Scientific Reports, 2017, 7, 1564.	1.6	25
946	The Role of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer. Pancreas, 2017, 46, 341-346.	0.5	33
947	Paclitaxel: What has been done and the challenges remain ahead. International Journal of Pharmaceutics, 2017, 526, 474-495.	2.6	286
948	What treatment in 2017 for inoperable pancreatic cancers?. Annals of Oncology, 2017, 28, 1473-1483.	0.6	30
949	Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2017, 18, 755-769.	5.1	18
950	Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer. International Journal of Cancer, 2017, 141, 572-582.	2.3	53
952	Does adjuvant therapy improve overall survival for stage IA/B pancreatic adenocarcinoma?. Hpb, 2017, 19, 587-594.	0.1	13
953	High prevalence of incidental and symptomatic venous thromboembolic events in patients with advanced pancreatic cancer under palliative chemotherapy: A retrospective cohort study. Pancreatology, 2017, 17, 629-634.	0.5	16
954	Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data. British Journal of Cancer, 2017, 116, 1544-1550.	2.9	18
955	Epidemiology of pancreatic cancer in France: descriptive study from the French national hospital database. European Journal of Gastroenterology and Hepatology, 2017, 29, 904-908.	0.8	14
956	Prognostic Scoring System for Patients Who Present with a Gastric Outlet Obstruction Caused by Advanced Pancreatic Adenocarcinoma. World Journal of Surgery, 2017, 41, 2619-2624.	0.8	16

#	Article	IF	Citations
957	Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer. Seminars in Cancer Biology, 2017, 44, 43-59.	4.3	89
958	Surveillance after resection of pancreatic ductal adenocarcinoma with curative intent â€“ a multicenter survey in Germany and review of the literature. Zeitschrift Fur Gastroenterologie, 2017, 55, 657-666.	0.2	4
959	Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer. British Journal of Cancer, 2017, 116, 1462-1469.	2.9	25
960	How Plants Can Contribute to the Supply of Anticancer Compounds. , 2017, , 39-72.		3
961	CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. European Radiology, 2017, 27, 3104-3116.	2.3	123
962	Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?. Annals of Surgical Oncology, 2017, 24, 1406-1413.	0.7	45
963	Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells. Molecular Cancer Therapeutics, 2017, 16, 1819-1830.	1.9	34
964	Letter to the Editor Re: Ahn DH, Krishna K, Blazer M, et al. â€œA modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis.â€•Ther Adv Med Oncol https://doi.org/10.1177/1758834016676011. Therapeutic Advances in Medical Oncology, 2017, 9, 441-443.	1.4	0
965	Biomarkers in pancreatic ductal adenocarcinoma. Clinical and Translational Oncology, 2017, 19, 1430-1437.	1.2	10
966	Pancreatic ductal adenocarcinoma: metastatic disease. Clinical and Translational Oncology, 2017, 19, 1423-1429.	1.2	7
967	The efficacy of a new high intensity focused ultrasound therapy for locally advanced pancreatic cancer. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2105-2111.	1.2	29
968	The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings. Surgical Oncology Clinics of North America, 2017, 26, 431-453.	0.6	34
969	A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea. Medicine (United States), 2017, 96, e5702.	0.4	17
970	Current and future biomarkers for pancreatic adenocarcinoma. Tumor Biology, 2017, 39, 101042831769223.	0.8	62
971	Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer. Cancer, 2017, 123, 3816-3824.	2.0	35
972	Specialized palliative care in advanced cancer: What is the efficacy? A systematic review. Palliative and Supportive Care, 2017, 15, 724-740.	0.6	26
973	Pretreatment C-reactive protein to albumin ratio for predicting overall survival in advanced pancreatic cancer patients. Scientific Reports, 2017, 7, 2993.	1.6	40
974	Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework. Value in Health, 2017, 20, 866-875.	0.1	69

#	Article	IF	Citations
975	Effects of microRNA-183 on epithelial-mesenchymal transition, proliferation, migration, invasion and apoptosis in human pancreatic cancer SW1900 cells by targeting MTA1. Experimental and Molecular Pathology, 2017, 102, 522-532.	0.9	19
976	Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer. Oncologist, 2017, 22, 925-933.	1.9	42
977	Surgical strategies and novel therapies for locally advanced pancreatic cancer. Journal of Surgical Oncology, 2017, 116, 16-24.	0.8	12
978	Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. OncoImmunology, 2017, 6, e1310358.	2.1	111
979	[ARTICLE WITHDRAWN] Upregulation of MicroRNA-935 Promotes the Malignant Behaviors of Pancreatic Carcinoma PANC-1 Cells via Targeting Inositol Polyphosphate 4-Phosphatase Type I Gene (INPP4A). Oncology Research, 2017, 25, 559-569.	0.6	17
980	A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C. Investigational New Drugs, 2017, 35, 634-641.	1.2	25
981	Chemosensitization and inhibition of pancreatic cancer stem cellÂproliferation by overexpression of microRNA-205. Cancer Letters, 2017, 402, 1-8.	3.2	88
982	Failure to Treat: Audit of an Institutional Cancer Registry Database at a Large Comprehensive Cancer Center Reveals Factors Affecting the Treatment of Pancreatic Cancer. Annals of Surgical Oncology, 2017, 24, 2387-2396.	0.7	11
983	WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death. Science Advances, 2017, 3, e1700090.	4.7	102
984	Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer. Pancreas, 2017, 46, 143-150.	0.5	10
985	CT Density in the Pancreas is a Promising Imaging Predictor for Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2017, 24, 2762-2769.	0.7	41
986	Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20). Current Oncology Reports, 2017, 19, 47.	1.8	100
987	Combination therapy with gemcitabine and nab-paclitaxel for locally advanced unresectable pancreatic cancer. Molecular and Clinical Oncology, 2017, 6, 963-967.	0.4	21
988	Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report. Oncology Letters, 2017, 13, 4445-4452.	0.8	5
989	Treatment outcomes of concurrent hyperthermia and chemoradiotherapy for pancreatic cancer: Insights into the significance of hyperthermia treatment. Oncology Letters, 2017, 13, 4959-4964.	0.8	15
990	Cell Division Machinery and Disease. Advances in Experimental Medicine and Biology, 2017, , .	0.8	4
991	The microbiome and hepatobiliary-pancreatic cancers. Cancer Letters, 2017, 402, 9-15.	3.2	105
992	Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus. Clinical Cancer Research, 2017, 23, 5846-5857.	3.2	108

#	Article	IF	Citations
993	Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via interfering the hypoxia environment by targeting HIF-1Î± pathway. European Journal of Medicinal Chemistry, 2017, 137, 45-62.	2.6	37
994	Impact of Intraoperative Re-resection to Achieve R0 Status on Survival in Patients With Pancreatic Cancer. Annals of Surgery, 2017, 265, 1219-1225.	2.1	39
995	Neoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives. Oncology Letters, 2017, 13, 3975-3981.	0.8	11
996	Clinicopathologic features and prognostic implications of MYBL2 protein expression in pancreatic ductal adenocarcinoma. Pathology Research and Practice, 2017, 213, 964-968.	1.0	16
997	Clinical Development of Anti-mitotic Drugs in Cancer. Advances in Experimental Medicine and Biology, 2017, 1002, 125-152.	0.8	22
998	The pancreatic cancer microenvironment: A true double agent. Journal of Surgical Oncology, 2017, 116, 7-15.	0.8	57
999	Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2017, 80, 195-202.	1.1	11
1000	Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis. Japanese Journal of Clinical Oncology, 2017, 47, 832-839.	0.6	9
1001	Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma. Oncology Letters, 2017, 13, 4917-4924.	0.8	25
1002	Diagnostic Laparoscopy Prior to Neoadjuvant Therapy in Pancreatic Cancer Is High Yield: an Analysis of Outcomes and Costs. Journal of Gastrointestinal Surgery, 2017, 21, 1420-1427.	0.9	22
1003	A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2017, 24, 2777-2784.	0.7	44
1004	Accelerating progress in the fight against pancreatic cancer Proceedings of the 2017 Leo and Anne Albert Symposium for Pancreatic Cancer Research. Journal of Surgical Oncology, 2017, 116, 5-6.	0.8	0
1005	Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the <scp>YAP</scp>â€<scp>TEAD</scp> complex. Cancer Science, 2017, 108, 478-487.	1.7	163
1006	Pancreatic Cancer: â€œA Riddle Wrapped in a Mystery inside an Enigmaâ€• Clinical Cancer Research, 2017, 23, 1629-1637.	3.2	38
1007	Pancreatic cancer: moving forward, step by step. The Lancet Gastroenterology and Hepatology, 2017, 2, 315-316.	3.7	1
1008	Reirradiation with stereotactic body radiation therapy after prior conventional fractionation radiation for locally recurrent pancreatic adenocarcinoma. Advances in Radiation Oncology, 2017, 2, 27-36.	0.6	21
1009	Adjunctive role of preoperative liver magnetic resonance imaging for potentially resectable pancreatic cancer. Surgery, 2017, 161, 1579-1587.	1.0	37
1010	ACR Appropriateness CriteriaÂ® Resectable Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 109-117.	0.6	7

#	Article	IF	Citations
1011	Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Science Translational Medicine, 2017, 9, .	5.8	208
1012	Strategies for Increasing Pancreatic Tumor Immunogenicity. Clinical Cancer Research, 2017, 23, 1656-1669.	3.2	131
1013	Current and Emerging Therapies in Metastatic Pancreatic Cancer. Clinical Cancer Research, 2017, 23, 1670-1678.	3.2	114
1014	Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma. Journal of the National Cancer Institute, 2017, 109, .	3.0	35
1015	FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer. European Journal of Surgical Oncology, 2017, 43, 1061-1067.	0.5	36
1016	Using a novel NQO1 bioactivatable drug, betaâ€lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer. Journal of Surgical Oncology, 2017, 116, 83-88.	0.8	24
1017	CAR Tâ€cell therapy for pancreatic cancer. Journal of Surgical Oncology, 2017, 116, 63-74.	0.8	69
1018	Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. Drugs and Aging, 2017, 34, 331-357.	1.3	7
1019	Drug resistance in pancreatic cancer: Impact of altered energy metabolism. Critical Reviews in Oncology/Hematology, 2017, 114, 139-152.	2.0	205
1020	SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer. Oncogene, 2017, 36, 4288-4298.	2.6	77
1021	Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma - in vitro and in vivo. BMC Cancer, 2017, 17, 216.	1.1	11
1022	Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis. Targeted Oncology, 2017, 12, 309-321.	1.7	37
1023	A randomized placebo-controlled clinical study of nab-paclitaxel as second-line chemotherapy for patients with advanced non-small cell lung cancer in China. Bioscience Reports, 2017, 37, .	1.1	10
1024	Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-linenab-paclitaxel plus gemcitabine or FOLFIRINOX. Expert Review of Clinical Pharmacology, 2017, 10, 559-565.	1.3	19
1026	A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2017, 79, 775-781.	1.1	22
1027	Systemic Combination Chemotherapy in Elderly Pancreatic Cancer: a Review. Journal of Gastrointestinal Cancer, 2017, 48, 121-128.	0.6	40
1028	Survival benefit of intravenous and intraperitoneal paclitaxel with S-1 in pancreatic ductal adenocarcinoma patients with peritoneal metastasis: a retrospective study in a single institution. Journal of Hepato-Biliary-Pancreatic Sciences, 2017, 24, 289-296.	1.4	9
1029	New Interventional Treatment Model for Pancreatic Neoplasms Using Gemcitabine-Eluting Hydrogel Devices: In Vitro and In Vivo Results. CardioVascular and Interventional Radiology, 2017, 40, 1246-1254.	0.9	1

#	Article	IF	Citations
1030	Ultrasound mediated delivery of oxygen and LLL12 loaded stimuli responsive microdroplets for the treatment of hypoxic cancer cells. Scientific Reports, 2017, 7, 44908.	1.6	10
1031	Current status of biomarker and targeted nanoparticle development: The precision oncology approach for pancreatic cancer therapy. Cancer Letters, 2017, 388, 139-148.	3.2	54
1032	Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer. Journal of Medical Economics, 2017, 20, 345-352.	1.0	25
1033	Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer. Clinical Cancer Research, 2017, 23, 3129-3138.	3.2	191
1034	Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors. Nature Medicine, 2017, 23, 235-241.	15.2	263
1035	Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer. Annals of Oncology, 2017, 28, 354-361.	0.6	50
1037	A Phase I/II Study of Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck. Cancer Investigation, 2017, 35, 23-31.	0.6	11
1038	Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert Review of Anticancer Therapy, 2017, 17, 175-186.	1.1	96
1039	Patient-Derived Xenografts in Oncology. Cancer Drug Discovery and Development, 2017, , 13-40.	0.2	0
1040	A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients With New-Onset Diabetes. Gastroenterology, 2017, 152, 840-850.e3.	0.6	133
1041	EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer. Gastrointestinal Endoscopy, 2017, 86, 161-169.	0.5	58
1042	micorRNA-101 silences DNA-PKcs and sensitizes pancreatic cancer cells to gemcitabine. Biochemical and Biophysical Research Communications, 2017, 483, 725-731.	1.0	19
1043	Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker. Clinical Cancer Research, 2017, 23, 116-123.	3.2	205
1044	Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy. JAMA Oncology, 2017, 3, 516.	3.4	142
1045	Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. Clinical and Translational Oncology, 2017, 19, 667-681.	1.2	27
1046	Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. Targeted Oncology, 2017, 12, 97-109.	1.7	56
1047	Advances in managing and preventing thromboembolic disease in cancer patients. Current Opinion in Supportive and Palliative Care, 2017, 11, 347-354.	0.5	5
1048	Efficacy and Safety of Pancreas-Targeted Hydrodynamic Gene Delivery in Rats. Molecular Therapy - Nucleic Acids, 2017, 9, 80-88.	2.3	11

#	Article	IF	Citations
1049	Multifaceted peptide assisted one-pot synthesis of gold nanoparticles for plectin-1 targeted gemcitabine delivery in pancreatic cancer. Nanoscale, 2017, 9, 15622-15634.	2.8	46
1050	Phase I study of a chloroquineâ€“gemcitabine combination in patients with metastatic or unresectable pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2017, 80, 1005-1012.	1.1	61
1051	Management of Hypersensitivity Reactions to Taxanes. Immunology and Allergy Clinics of North America, 2017, 37, 679-693.	0.7	51
1052	A novel intestinal rotation method for digestive reconstruction after combined pancreaticoduodenectomy and extended right hemicolectomy: A case report and surgical technique. International Journal of Surgery Case Reports, 2017, 39, 51-55.	0.2	0
1053	Gastrojejunostomy versus duodenal stent placement for gastric outlet obstruction in patients with unresectable pancreatic cancer. Pancreatology, 2017, 17, 983-989.	0.5	33
1054	Clinical Trials in Pancreatic Cancer: A Long Slog. Oncologist, 2017, 22, 1424-1426.	1.9	7
1055	Hypoxia-Targeting, Tumor Microenvironment Responsive Nanocluster Bomb for Radical-Enhanced Radiotherapy. ACS Nano, 2017, 11, 10159-10174.	7.3	142
1056	Algorithm guided outlining of 105 pancreatic cancer liver metastases in Ultrasound. Scientific Reports, 2017, 7, 12779.	1.6	3
1057	Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer. Memo - Magazine of European Medical Oncology, 2017, 10, 136-140.	0.3	5
1058	Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4). Oncology, 2017, 93, 367-376.	0.9	43
1059	Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics Perspective. Public Health Genomics, 2017, 20, 81-91.	0.6	10
1060	FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1. Oncology Reports, 2017, 38, 2069-2077.	1.2	23
1061	Current Standards of Chemotherapy for Pancreatic Cancer. Clinical Therapeutics, 2017, 39, 2125-2134.	1.1	80
1062	Targeted drug delivery using iRGD peptide for solid cancer treatment. Molecular Systems Design and Engineering, 2017, 2, 370-379.	1.7	42
1063	Resection of Locally Advanced Pancreatic Neoplasms after Neoadjuvant Chemotherapy with Nab-Paclitaxel and Gemcitabine following FOLFIRINOX Failure. Case Reports in Gastroenterology, 2017, 11, 422-427.	0.3	6
1064	GDC-0449 improves the antitumor activity of nano-doxorubicin in pancreatic cancer in a fibroblast-enriched microenvironment. Scientific Reports, 2017, 7, 13379.	1.6	26
1065	Pancreatic Cancer: Current Status and Challenges. Current Pharmacology Reports, 2017, 3, 396-408.	1.5	15
1066	Survival of pancreatic cancer cells lacking KRAS function. Nature Communications, 2017, 8, 1090.	5.8	131

#	Article	IF	Citations
1067	ESMO-Magnitude of Clinical Benefit Scale version 1.1. Annals of Oncology, 2017, 28, 2340-2366.	0.6	451
1068	Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. Annals of Oncology, 2017, 28, 2786-2792.	0.6	87
1069	Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?. Annals of Oncology, 2017, 28, 2950-2961.	0.6	78
1070	Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies. Cancer Treatment Reviews, 2017, 60, 32-43.	3.4	116
1071	Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions. Therapeutic Advances in Gastroenterology, 2017, 10, 631-645.	1.4	39
1072	Second line treatment options for pancreatic cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 1607-1617.	0.9	11
1073	A phase 1/1B trial of ADIâ€PEG 20 plus nabâ€paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma. Cancer, 2017, 123, 4556-4565.	2.0	61
1074	PD-1/PD-L1 and immunotherapy for pancreatic cancer. Cancer Letters, 2017, 407, 57-65.	3.2	235
1075	Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy, 2017, 17, 951-964.	1.1	2
1076	Commentary: Pancreatic cancer: is the worst to come?. International Journal of Epidemiology, 2017, 46, 1774-1775.	0.9	14
1077	Effect of Neoadjuvant Nab-Paclitaxel plus Gemcitabine Therapy on Overall Survival in Patients with Borderline Resectable Pancreatic Cancer: A Prospective Multicenter Phase II Trial (NAC-GA Trial). Oncology, 2017, 93, 343-346.	0.9	19
1078	Trends in Neoadjuvant Approaches in Pancreatic Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1070-1077.	2.3	22
1079	Safety Study of Targeted and Localized Intra-Arterial Delivery of Gemcitabine in Patients with Locally Advanced Pancreatic Adenocarcinoma. Journal of Pancreatic Cancer, 2017, 3, 58-65.	1.6	1
1080	Patients Treated with Preoperative Chemoradiation for Pancreatic Ductal Adenocarcinoma have Impaired Bone Density, a Predictor of Distant Metastasis. Annals of Surgical Oncology, 2017, 24, 3715-3724.	0.7	10
1081	Recent Advances in Pancreatic Cancer Surgery. Current Treatment Options in Gastroenterology, 2017, 15, 520-537.	0.3	14
1082	Autophagy inhibition enhances antiproliferative effect of salinomycin in pancreatic cancer cells. Pancreatology, 2017, 17, 990-996.	0.5	22
1083	Recent advances in proteomic profiling of pancreatic ductal adenocarcinoma and the road ahead. Expert Review of Proteomics, 2017, 14, 963-971.	1.3	5
1084	How to treat pancreatic adenocarcinoma in elderly: How far can we go in 2017?. Journal of Geriatric Oncology, 2017, 8, 407-412.	0.5	10

#	Article	IF	Citations
1085	Overcoming key biological barriers to cancer drug delivery and efficacy. Journal of Controlled Release, 2017, 267, 15-30.	4.8	92
1086	Pancreatic Cancer Arising From the Remnant Pancreas. Pancreas, 2017, 46, 1083-1090.	0.5	8
1087	Caveolae-Mediated Endocytosis Is Critical for Albumin Cellular Uptake and Response to Albumin-Bound Chemotherapy. Cancer Research, 2017, 77, 5925-5937.	0.4	119
1088	A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial. Oncologist, 2017, 22, 1427-e129.	1.9	40
1089	Radiofrequency ablation for hepatic oligometastatic pancreatic cancer: An analysis of safety and efficacy. Pancreatology, 2017, 17, 967-973.	0.5	40
1090	Induction of apoptosis by Galectin-9 in liver metastatic cancer cells: In vitro study. International Journal of Oncology, 2017, 51, 607-614.	1.4	11
1091	EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer. Molecular Pharmaceutics, 2017, 14, 3121-3133.	2.3	43
1092	Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. British Journal of Cancer, 2017, 117, 572-582.	2.9	26
1093	Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer. Scientific Reports, 2017, 7, 5708.	1.6	49
1094	Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure. Medicine (United States), 2017, 96, e6769.	0.4	20
1095	A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent. Cancer Chemotherapy and Pharmacology, 2017, 80, 497-505.	1.1	13
1096	PETâ€“Computed Tomography and Precision Medicine in Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Tumors. PET Clinics, 2017, 12, 407-421.	1.5	8
1097	Impact of Patient Age on the Postoperative Survival in Pancreatic Head Cancer. Annals of Surgical Oncology, 2017, 24, 3220-3228.	0.7	23
1098	Establishment and characterization of a novel murine model of pancreatic cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 824-838.	2.9	99
1099	A cascade enzymatic reaction activatable gemcitabine prodrug with an AIE-based intracellular light-up apoptotic probe for in situ self-therapeutic monitoring. Chemical Communications, 2017, 53, 9214-9217.	2.2	41
1100	Recent advances in nanoparticle-mediated drug delivery. Journal of Drug Delivery Science and Technology, 2017, 41, 260-268.	1.4	127
1101	Bioinformatoryâ€assisted analysis of nextâ€generation sequencing data for precision medicine in pancreatic cancer. Molecular Oncology, 2017, 11, 1413-1429.	2.1	20
1102	A preoperative score to predict early death after pancreatic cancer resection. Digestive and Liver Disease, 2017, 49, 1050-1056.	0.4	28

#	Article	IF	Citations
1103	Thermosensitive Liposomal Codelivery of HSAâ€“Paclitaxel and HSAâ€“Ellagic Acid Complexes for Enhanced Drug Perfusion and Efficacy Against Pancreatic Cancer. ACS Applied Materials & Interfaces, 2017, 9, 25138-25151.	4.0	55
1104	Patterns of Care for Locally Advanced Pancreatic Adenocarcinoma Using the National Cancer Database. Pancreas, 2017, 46, 904-912.	0.5	12
1105	Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review. Cancer, 2017, 123, 4158-4167.	2.0	88
1106	ActualizaciÃ³n en cÃ¡ncer de pÃ¡ncreas y de vÃas biliares. Medicine, 2017, 12, 1919-1928.	0.0	0
1107	Factors influencing survival of patients with pancreatic adenocarcinoma and synchronous liver metastases receiving palliative care. Pancreatology, 2017, 17, 773-781.	0.5	14
1108	Targeted dianthin is a powerful toxin to treat pancreatic carcinoma when applied in combination with the glycosylated triterpene <scp>SO</scp>1861. Molecular Oncology, 2017, 11, 1527-1543.	2.1	11
1109	The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna. ESMO Open, 2017, 2, e000166.	2.0	4
1110	Terminating the criminal collaboration in pancreatic cancer: Nanoparticle-based synergistic therapy for overcoming fibroblast-induced drug resistance. Biomaterials, 2017, 144, 105-118.	5.7	53
1111	A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer. Drug Resistance Updates, 2017, 31, 43-51.	6.5	43
1112	Inhibition of Aurora Kinase A Induces Necroptosis inÂPancreaticÂCarcinoma. Gastroenterology, 2017, 153, 1429-1443.e5.	0.6	137
1113	Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma. Clinical and Translational Oncology, 2017, 19, 1193-1198.	1.2	3
1114	Predictors of Early Mortality After Surgical Resection of Pancreatic Adenocarcinoma in the Era of Neoadjuvant Treatment. Pancreas, 2017, 46, 183-189.	0.5	13
1115	Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine. Pancreas, 2017, 46, 203-208.	0.5	24
1116	Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study. ESMO Open, 2017, 2, e000151.	2.0	9
1117	Plasma membrane expression of ZNF185 is a prognostic factor in pancreatic ductal carcinoma. Oncology Letters, 2017, 14, 3633-3640.	0.8	4
1118	New therapeutic directions for advanced pancreatic cancer: cell cycle inhibitors, stromal modifiers and conjugated therapies. Expert Opinion on Emerging Drugs, 2017, 22, 223-233.	1.0	25
1119	Thromboembolisms in Advanced Pancreatic Cancer. Pancreas, 2017, 46, 1069-1075.	0.5	18
1120	Short- and Long-Term Survival in Metastatic Pancreatic Adenocarcinoma, 1993â€“2013. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1022-1027.	2.3	42

#	Article	IF	Citations
1121	Randomized Clinical Trials in Pancreatic Cancer. Surgical Oncology Clinics of North America, 2017, 26, 767-790.	0.6	7
1122	Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer. ACS Nano, 2017, 11, 8690-8706.	7.3	108
1123	Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer. Therapeutic Advances in Gastroenterology, 2017, 10, 563-572.	1.4	24
1124	The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: AÂnew scoring system. European Journal of Surgical Oncology, 2017, 43, 2112-2118.	0.5	22
1125	The Safety and Efficacy of an Alcohol-Free Pancreatic Cyst Ablation Protocol. Gastroenterology, 2017, 153, 1295-1303.	0.6	77
1126	Secondâ€line treatment in patients with pancreatic ductal adenocarcinoma: A metaâ€analysis. Cancer, 2017, 123, 4680-4686.	2.0	29
1127	Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX. Expert Review of Clinical Pharmacology, 2017, 10, 1153-1160.	1.3	36
1128	89Zr-anti-Î³H2AX-TAT but not 18F-FDG Allows Early Monitoring of Response to Chemotherapy in a Mouse Model of Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2017, 23, 6498-6504.	3.2	20
1129	Loss of <scp>AMPK</scp> activation promotes the invasion and metastasis of pancreatic cancer through an <scp>HSF</scp>1â€dependent pathway. Molecular Oncology, 2017, 11, 1475-1492.	2.1	67
1130	Clinical Management. Cancer Journal (Sudbury, Mass), 2017, 23, 343-349.	1.0	14
1131	Ablative Radiotherapy Doses for Locally Advanced. Cancer Journal (Sudbury, Mass), 2017, 23, 350-354.	1.0	14
1132	High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis: Mechanisms and a Phase I/IIa study. Scientific Reports, 2017, 7, 17188.	1.6	94
1133	Berries and other natural products in pancreatic cancer chemoprevention in human clinical trials. Journal of Berry Research, 2017, 7, 147-161.	0.7	45
1134	Clinical Management. Cancer Journal (Sudbury, Mass), 2017, 23, 355-361.	1.0	0
1135	Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results. Oncologist, 2017, 22, 1429-e139.	1.9	31
1136	DNA methyltransferase 3a modulates chemosensitivity to gemcitabine and oxaliplatin via CHK1 and AKT in p53â€deficient pancreatic cancer cells. Molecular Medicine Reports, 2018, 17, 117-124.	1.1	4
1137	Advances in the Genetics and Biology of Pancreatic Cancer. Cancer Journal (Sudbury, Mass), 2017, 23, 315-320.	1.0	17
1138	Understanding Disease Biology and Informing the Management of Pancreas Cancer With Preclinical Model Systems. Cancer Journal (Sudbury, Mass), 2017, 23, 326-332.	1.0	4

#	Article	IF	Citations
1139	Successful Evidence-Based Treatment of Patients with Advanced Pancreatic Cancer in Community-Based Oncology Group Practices. Oncology Research and Treatment, 2017, 40, 784-788.	0.8	2
1140	Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer. Cancer Medicine, 2017, 6, 2840-2849.	1.3	41
1141	miR-3656 expression enhances the chemosensitivity of pancreatic cancer to gemcitabine through modulation of the RHOF/EMT axis. Cell Death and Disease, 2017, 8, e3129-e3129.	2.7	33
1142	A successful case of locally advanced pancreatic cancer undergoing curative distal pancreatectomy with en bloc celiac axis resection after combination chemotherapy of nab-paclitaxel with gemcitabine. Clinical Journal of Gastroenterology, 2017, 10, 551-557.	0.4	9
1143	MZB1 in borderline resectable pancreatic cancer resected after neoadjuvant chemoradiotherapy. Journal of Surgical Research, 2017, 220, 391-401.	0.8	17
1144	Longâ€term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. Cancer Medicine, 2017, 6, 1552-1562.	1.3	19
1145	A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo. Cancer Chemotherapy and Pharmacology, 2017, 80, 307-315.	1.1	9
1146	Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma. Anti-Cancer Drugs, 2017, 28, 127-132.	0.7	4
1147	The role of irreversible electroporation (IRE) for locally advanced pancreatic cancer: a systematic review of safety and efficacy. Scandinavian Journal of Gastroenterology, 2017, 52, 1165-1171.	0.6	63
1148	MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Cancer Cell, 2017, 32, 71-87.e7.	7.7	373
1149	Major effect of transcytosis on nano drug delivery to pancreatic cancer. Molecular and Cellular Oncology, 2017, 4, e1335273.	0.3	8
1150	SPARC gene variants predict clinical outcome in locally advanced and metastatic pancreatic cancer patients. Medical Oncology, 2017, 34, 136.	1.2	7
1151	Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer: A systematic review. European Journal of Cancer, 2017, 81, 174-182.	1.3	12
1152	Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study. Annals of Oncology, 2017, 28, 2429-2435.	0.6	89
1153	Pancreatic adenocarcinoma: A simple CT score for predicting margin-positive resection in patients with resectable disease. European Journal of Radiology, 2017, 95, 33-38.	1.2	13
1154	Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. Cancer Letters, 2017, 403, 296-304.	3.2	20
1155	Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre. European Journal of Surgical Oncology, 2017, 43, 1711-1717.	0.5	28
1156	Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel. Scientific Reports, 2017, 7, 4851.	1.6	5

#	Article	IF	Citations
1157	Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer. Molecular and Clinical Oncology, 2017, 7, 125-130.	0.4	11
1158	Targeting the Wnt Pathway in Cancer: A Review of Novel Therapeutics. Targeted Oncology, 2017, 12, 623-641.	1.7	47
1159	Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma. Medicine (United States), 2017, 96, e6544.	0.4	18
1160	Hereditary pancreatic cancer: related syndromes and clinical perspective. Hereditary Cancer in Clinical Practice, 2017, 15, 9.	0.6	29
1161	Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells. Cancer Research, 2017, 77, 4460-4471.	0.4	87
1162	Efficacy of chemotherapy in elderly patients with unresectable pancreatic cancer: a multicenter review of 895 patients. BMC Gastroenterology, 2017, 17, 66.	0.8	34
1163	Single-cell mRNA profiling reveals transcriptional heterogeneity among pancreatic circulating tumour cells. BMC Cancer, 2017, 17, 390.	1.1	36
1164	Preoperative predictors for early recurrence of resectable pancreatic cancer. World Journal of Surgical Oncology, 2017, 15, 16.	0.8	80
1165	PAP/REG3A favors perineural invasion in pancreatic adenocarcinoma and serves as a prognostic marker. Cellular and Molecular Life Sciences, 2017, 74, 4231-4243.	2.4	20
1166	Does â€œOPTINABâ€•strategy (â€œstop-and-goâ€) work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxelâ€“gemcitabine?. Cancer Chemotherapy and Pharmacology, 2017, 80, 371-375.	1.1	11
1167	Babaodan Capsule (å…«å®ï¸¹èƒ¶å›Š) combined with Qingyi Huaji Formula (æ¸…èƒ°åŒ–ç§¯æ–¹) in advanced pancreatic cancerâ€”a feas study. Chinese Journal of Integrative Medicine, 2017, 23, 937-942.	0.7	13
1168	Whatâ€™s new in treatment of pancreatic cancer: a patent review (2010â€“2017). Expert Opinion on Therapeutic Patents, 2017, 27, 1251-1266.	2.4	13
1169	Antibodyâ€“drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies. , 2017, 170, 8-13.		11
1170	CA19-9-Low&Lewis (+) pancreatic cancer: A unique subtype. Cancer Letters, 2017, 385, 46-50.	3.2	15
1171	Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. JAMA Oncology, 2017, 3, 774.	3.4	221
1172	Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression. Cancer Letters, 2017, 385, 225-233.	3.2	89
1173	Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. Journal of Gastrointestinal Surgery, 2017, 21, 164-174.	0.9	124
1174	Organic nanoparticle systems for spatiotemporal control of multimodal chemotherapy. Expert Opinion on Drug Delivery, 2017, 14, 427-446.	2.4	21

#	Article	IF	Citations
1175	Chemoradiation for Locally Advanced Unresectable Pancreatic Cancerâ€"What Now?. JAMA Oncology, 2017, 3, 850.	3.4	2
1176	Endoscopic management of combined malignant biliary and gastric outlet obstruction. Digestive Endoscopy, 2017, 29, 16-25.	1.3	62
1177	Hyaluronic acid-coated, prodrug-based nanostructured lipid carriers for enhanced pancreatic cancer therapy. Drug Development and Industrial Pharmacy, 2017, 43, 160-170.	0.9	39
1178	Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216. Pharmacogenomics Journal, 2017, 17, 452-460.	0.9	15
1179	Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells. Oncogene, 2017, 36, 1770-1778.	2.6	553
1180	Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma. Pancreatology, 2017, 17, 95-102.	0.5	23
1181	A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis. Therapeutic Advances in Medical Oncology, 2017, 9, 75-82.	1.4	46
1182	Chemotherapy and radiation components of neoadjuvant treatment of pancreatic head adenocarcinoma: Impact on perioperative mortality and long-term survival. European Journal of Surgical Oncology, 2017, 43, 351-357.	0.5	17
1183	Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial. Cancer Chemotherapy and Pharmacology, 2017, 79, 9-16.	1.1	12
1184	Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact. Cancer Chemotherapy and Pharmacology, 2017, 79, 37-47.	1.1	49
1185	Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis. Journal of Clinical Oncology, 2017, 35, 515-522.	0.8	325
1186	Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review. Pharmacoeconomics, 2017, 35, 83-95.	1.7	11
1187	Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patientâ€"Derived Xenografts and Mesothelin as a Biomarker of Tumor Response. Clinical Cancer Research, 2017, 23, 1564-1574.	3.2	32
1188	Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Overlo	1.4	
1189	In-depth assessment of an interactive graph-based approach for the segmentation for pancreatic metastasis in ultrasound acquisitions of the liver with two specialists in Internal Medicine. , 2017, , .		1
1190	Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy. BMJ Open, 2017, 7, e018175.	0.8	58
1191	The ribosome inhibiting protein riproximin shows antineoplastic activity in experimental pancreatic cancer liver metastasis. Oncology Letters, 2017, 15, 1441-1448.	0.8	7
1192	Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer â€œin a Koreanâ€•population: A single-center cohort study. Seminars in Oncology, 2017, 44, 420-427.	0.8	16

#	Article	IF	Citations
1193	EGFRExon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed byT790M-Mediated Resistance. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1085-1089.	2.3	2
1194	Effect of pretreatment psoas muscle mass on survival for patients with unresectable pancreatic cancer undergoing systemic chemotherapy. Oncology Letters, 2017, 14, 6059-6065.	0.8	14
1195	Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient. BMC Gastroenterology, 2017, 17, 143.	0.8	17
1196	Nanoliposomal irinotecan for patients with metastatic pancreatic cancer. Drug Delivery System, 2017, 32, 109-118.	0.0	1
1197	Safety Study of Targeted and Localized Intra-Arterial Delivery of Gemcitabine in Patients with Locally Advanced Pancreatic Adenocarcinoma. Journal of Pancreatic Cancer, 2017, 3, 58-65.	1.6	6
1198	Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy. Gut and Liver, 2017, 11, 298-305.	1.4	10
1199	Reply to A. Braillon. Journal of Clinical Oncology, 2017, 35, 1136-1137.	0.8	0
1200	Anaplastic Lymphoma Kinase Rearrangement and Response to Crizotinib in Pancreatic Ductal Adenocarcinoma. JCO Precision Oncology, 2017, 1, 1-5.	1.5	6
1201	10. Gastrointestinale Onkologie im Alter. , 2017, , .		0
1202	Postoperative Neutrophil-to-Lymphocyte Ratio as a Predictor of Long-Term Prognosis after Pancreatectomy for Pancreatic Carcinoma: A Retrospective Analysis. American Surgeon, 2017, 83, 610-616.	0.4	11
1203	Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer. Journal of Clinical Investigation, 2017, 127, 2007-2018.	3.9	168
1204	The Potential for Circulating Tumor Cells in Pancreatic Cancer Management. Frontiers in Physiology, 2017, 8, 381.	1.3	30
1205	The Development of a Novel Therapeutic Strategy to Target Hyaluronan in the Extracellular Matrix of Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences, 2017, 18, 600.	1.8	29
1206	New Mild and Simple Approach to Isothiocyanates: A Class of Potent Anticancer Agents. Molecules, 2017, 22, 773.	1.7	14
1207	Crizotinib, a MET inhibitor, prevents peritoneal dissemination in pancreatic cancer. International Journal of Oncology, 2017, 51, 184-192.	1.4	19
1208	Chemotherapy and radiotherapy for pancreatic cancer. , 2017, , 1032-1041.e3.		0
1209	Nanotechnologies in Pancreatic Cancer Therapy. Pharmaceutics, 2017, 9, 39.	2.0	36
1210	Selective cytotoxicity of vanadium complexes on human pancreatic ductal adenocarcinoma cell line by inducing necroptosis, apoptosis and mitotic catastrophe process. Oncotarget, 2017, 8, 60324-60341.	0.8	40

#	Article	IF	Citations
1211	Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions. Cancers, 2017, 9, 19.	1.7	694
1212	Pancreatic Cancer Chemoresistance to Gemcitabine. Cancers, 2017, 9, 157.	1.7	316
1213	Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 2017, 18, 909.	1.8	21
1214	Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes. International Journal of Molecular Sciences, 2017, 18, 1231.	1.8	31
1215	Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. International Journal of Molecular Sciences, 2017, 18, 1338.	1.8	431
1216	Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits. International Journal of Molecular Sciences, 2017, 18, 1622.	1.8	92
1217	Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer. International Journal of Oncology, 2017, 51, 686-694.	1.4	44
1218	Targeting Cancer Stem Cells and Their Niche: Current Therapeutic Implications and Challenges in Pancreatic Cancer. Stem Cells International, 2017, 2017, 1-9.	1.2	11
1219	Combination of preoperative CEA and CA19-9 improves prediction outcomes in patients with resectable pancreatic adenocarcinoma: results from a large follow-up cohort. OncoTargets and Therapy, 2017, Volume 10, 1199-1206.	1.0	20
1220	An open-label, multicenter, phase I trial of a cremophor-free, polymeric micelle formulation of paclitaxel combined with carboplatin as a first-line treatment for advanced ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3016). Journal of Gynecologic Oncology, 2017, 28, e26.	1.0	10
1221	A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic Cancer. Journal of Cancer, 2017, 8, 1872-1883.	1.2	42
1222	Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer. PLoS ONE, 2017, 12, e0169736.	1.1	16
1223	A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express Î±-gal epitopes. PLoS ONE, 2017, 12, e0184901.	1.1	10
1224	Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer, 2017, 17, 505.	1.1	166
1225	A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol. BMC Cancer, 2017, 17, 576.	1.1	36
1226	Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study. BMC Cancer, 2017, 17, 885.	1.1	11
1227	Chemotherapy and tumor microenvironment of pancreatic cancer. Cancer Cell International, 2017, 17, 68.	1.8	91
1228	Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. Molecular Cancer, 2017, 16, 131.	7.9	93

#	Article	IF	Citations
1229	Risk factors of liver metastasis from advanced pancreatic adenocarcinoma: a large multicenter cohort study. World Journal of Surgical Oncology, 2017, 15, 120.	0.8	13
1230	Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. World Journal of Surgical Oncology, 2017, 15, 183.	0.8	112
1231	Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2). Journal of Experimental and Clinical Cancer Research, 2017, 36, 107.	3.5	63
1232	18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer. Cancer Imaging, 2017, 17, 23.	1.2	6
1233	A long-term survival case treated with conversion surgery following chemotherapy after diagnostic metastasectomy for pancreatic cancer with synchronous liver metastasis. Surgical Case Reports, 2017, 3, 132.	0.2	6
1234	New chemotherapies in gastric adenocarcinoma. Memo - Magazine of European Medical Oncology, 2017, 10, 132-135.	0.3	0
1235	Metabolic profiling of gemcitabine- and paclitaxel-treated immortalized human pancreatic cell lines with K-RAS^{G12D}. Biomedical Research, 2017, 38, 29-40.	0.3	7
1236	Prospective validation of patient fatigue questionnaire (FACITâ€'F) for fatigue assessment in nabâ€'paclitaxel plus gemcitabine therapy. Molecular and Clinical Oncology, 2017, 8, 121-126.	0.4	8
1237	The Improvement of Care in Patients with Pancreatic Cancer. , 2017, , .		0
1238	Synergistic effects of baicalein with gemcitabine or docetaxel on the proliferation, migration and apoptosis of pancreatic cancer cells. International Journal of Oncology, 2017, 51, 1878-1886.	1.4	16
1239	Role of surgery in pancreatic cancer. World Journal of Gastroenterology, 2017, 23, 3765.	1.4	31
1240	Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine. International Journal of Oncology, 2018, 52, 261-269.	1.4	10
1241	Intraoperative radiotherapy: review of techniques and results. Ecancermedicalscience, 2017, 11, 750.	0.6	63
1242	The Value of Survival Gains in Pancreatic Cancer from Novel Treatment Regimens. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 206-213.	0.5	3
1243	Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib. International Journal of Oncology, 2017, 50, 2049-2058.	1.4	15
1244	The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies. Biomedicines, 2017, 5, 10.	1.4	10
1245	Patient-Derived Tumor Xenograft. , 2017, , 429-451.		1
1246	nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial. OncoTargets and Therapy, 2017, Volume 10, 591-596.	1.0	22

#	Article	IF	Citations
1247	From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers. International Journal of Molecular Sciences, 2017, 18, 180.	1.8	16
1248	Use of a genome-wide haploid genetic screen to identify treatment predicting factors: a proof-of-principle study in pancreatic cancer. Oncotarget, 2017, 8, 63635-63645.	0.8	6
1249	Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting. Cancer Management and Research, 2017, Volume 9, 141-148.	0.9	31
1250	Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts. Oncotarget, 2017, 8, 19074-19088.	0.8	28
1251	Addressing the Survivorship Care Needs of Patients Receiving Extended Cancer Treatment. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 674-683.	1.8	18
1252	Role of Stereotactic Body Radiotherapy in the Treatment of Elderly and Poor Performance Status Patients With Pancreatic Cancer. Journal of Oncology Practice, 2017, 13, 157-166.	2.5	21
1253	Pancreatic Adenocarcinoma: Improving Prevention and Survivorship. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 301-310.	1.8	12
1254	Germline Testing for Individuals With Pancreatic Cancer: The Benefits and Challenges to Casting a Wider Net. Journal of Clinical Oncology, 2017, 35, 3375-3377.	0.8	12
1255	Reply to M. Uccello et al. Journal of Clinical Oncology, 2017, 35, 1371-1371.	0.8	1
1256	Locally Advanced Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. Journal of Oncology Practice, 2017, 13, 265-269.	2.5	56
1257	Filamentary Flows and Clump-fed High-mass Star Formation in G22. Proceedings of the International Astronomical Union, 2017, 13, 299-300.	0.0	1
1258	Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. Journal of Oncology Practice, 2017, 13, 261-264.	2.5	26
1259	A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative. Oncotarget, 2017, 8, 83446-83456.	0.8	54
1260	CÃ¡ncer de pÃ¡ncreas. EpidemiologÃa de su mal pronÃ³stico. , 2017, , .		0
1261	Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group. Annals of Gastroenterology, 2017, 31, 65-70.	0.4	10
1262	Response to Drs Von Hoff and Renschler. Therapeutic Advances in Medical Oncology, 2017, 9, 445-446.	1.4	0
1263	Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. Journal of Gastrointestinal Oncology, 2017, 8, 566-571.	0.6	67
1264	Patient-Derived Xenograft Model of Pancreatic Cancer. , 2017, , 229-241.		1

#	Article	IF	Citations
1265	Capecitabine and oxaliplatin as first and second line treatment for locally advanced and metastatic pancreatic ductal adenocarcinoma. Journal of Gastrointestinal Oncology, 2017, 8, 945-952.	0.6	11
1266	Stereotactic body radiotherapy for locally-advanced unresectable pancreatic cancerâ€"patterns of care and overall survival. Journal of Gastrointestinal Oncology, 2017, 8, 766-777.	0.6	18
1267	MicroRNA-1285 inhibits malignant biological behaviors of human pancreatic cancer cells by negative regulation of YAP1. Neoplasma, 2017, 64, 358-366.	0.7	20
1268	Proton beam reirradiation for locally recurrent pancreatic adenocarcinoma. Journal of Gastrointestinal Oncology, 2017, 8, 665-674.	0.6	23
1269	Promising therapeutics of gastrointestinal cancers in clinical trials. Journal of Gastrointestinal Oncology, 2017, 8, 524-533.	0.6	1
1270	Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancerâ€"retrospective analysis of response. Journal of Gastrointestinal Oncology, 2017, 8, 556-565.	0.6	32
1271	A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. Journal of Gastrointestinal Oncology, 2017, 8, 925-935.	0.6	0
1272	Molecularly targeted co-delivery of a histone deacetylase inhibitor and paclitaxel by lipid-protein hybrid nanoparticles for synergistic combinational chemotherapy. Oncotarget, 2017, 8, 14925-14940.	0.8	38
1273	Targeting the microenvironment in solid tumors. Cancer Treatment Reviews, 2018, 65, 22-32.	3.4	342
1274	The challenge of treating older patients with pancreaticobiliary malignancies. Current Problems in Cancer, 2018, 42, 59-72.	1.0	8
1275	Sequentially Triggered Nanoparticles with Tumor Penetration and Intelligent Drug Release for Pancreatic Cancer Therapy. Advanced Science, 2018, 5, 1701070.	5.6	81
1276	Hepatobiliary and Pancreatic Cancer. Cancer Dissemination Pathways, 2018, , .	0.0	2
1277	The use of IRE in multi-modality treatment for oligometastatic pancreatic cancer. American Journal of Surgery, 2018, 216, 106-110.	0.9	15
1278	The Dutch Pancreas Biobank Within the Parelsnoer Institute. Pancreas, 2018, 47, 495-501.	0.5	8
1279	Stroma â€" A Double-Edged Sword in Pancreatic Cancer. Pancreas, 2018, 47, 382-389.	0.5	23
1280	Impact of Palliative Chemotherapy and Travel Distance on Hospice Referral in Patients With Stage IV Pancreatic Cancer: A Retrospective Analysis Within a Veterans Administration Medical Center. American Journal of Hospice and Palliative Medicine, 2018, 35, 875-881.	0.8	4
1281	Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. Journal of the National Cancer Institute, 2018, 110, 1067-1074.	3.0	170
1282	Pancreatic Adenocarcinoma. Cancer Dissemination Pathways, 2018, , 83-97.	0.0	0

#	Article	IF	Citations
1283	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncology, The, 2018, 19, e151-e160.	5.1	51
1284	Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1869, 248-255.	3.3	20
1285	Reprogramming tumor stroma using an endogenous lipid lipoxin A4 to treat pancreatic cancer. Cancer Letters, 2018, 420, 247-258.	3.2	55
1286	Carbon-ion radiotherapy for locoregional recurrence after primary surgery for pancreatic cancer. Radiotherapy and Oncology, 2018, 129, 101-104.	0.3	17
1287	Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2018, 81, 815-821.	1.1	21
1288	Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. Clinical Gastroenterology and Hepatology, 2018, 16, 1300-1306.e3.	2.4	21
1289	Emerging facets in the treatment of patients with hepatopancreaticobiliary malignancies. Current Problems in Cancer, 2018, 42, 8-11.	1.0	0
1290	Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Molecular Therapy, 2018, 26, 1020-1031.	3.7	42
1291	An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study. Expert Review of Pharmacoeconomics and Outcomes Research, 2018, 18, 435-446.	0.7	9
1292	Preoperative Chemoradiation for Borderline Resectable Pancreatic Cancer: The New Standard?. Annals of Surgery, 2018, 268, 223-224.	2.1	6
1293	Vitamin D Supplementation is a Promising Therapy for Pancreatic Ductal Adenocarcinoma in Conjunction with Current Chemoradiation Therapy. Annals of Surgical Oncology, 2018, 25, 1868-1879.	0.7	32
1294	Representation of obese participants in obesity-related cancer randomized trials. Annals of Oncology, 2018, 29, 1582-1587.	0.6	20
1295	Pancreatic Adenocarcinoma Staging in the Era of Preoperative Chemotherapy and Radiation Therapy. Radiology, 2018, 287, 374-390.	3.6	121
1296	Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging. Annals of Surgical Oncology, 2018, 25, 1880-1888.	0.7	127
1297	Î±-cyano-4-hydroxycinnamate impairs pancreatic cancer cells by stimulating the p38 signaling pathway. Cellular Signalling, 2018, 47, 101-108.	1.7	8
1298	Phytosome complex of curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: Results of a prospective phase II trial. Pharmacological Research, 2018, 132, 72-79.	3.1	104
1299	Chemotherapy and Radiofrequency-Induced Mild Hyperthermia Combined Treatment of Orthotopic Pancreatic Ductal Adenocarcinoma Xenografts. Translational Oncology, 2018, 11, 664-671.	1.7	6
1300	Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2â€“3 trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 413-423.	3.7	180

#	Article	IF	Citations
1301	Meeting the needs of breast cancer: A nucleolinâ€™s perspective. Critical Reviews in Oncology/Hematology, 2018, 125, 89-101.	2.0	32
1302	Management of hyperbilirubinaemia in pancreatic cancer patients. European Journal of Cancer, 2018, 94, 26-36.	1.3	7
1303	Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Investigational New Drugs, 2018, 36, 732-741.	1.2	87
1304	Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2018, 36, 1153-1163.	1.7	10
1305	Chemotherapy in patients with unresected pancreatic cancer in Australia: A populationâ€based study of uptake and survival. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 326-336.	0.7	15
1306	Masitinib in treatment of pancreatic cancer. Expert Opinion on Pharmacotherapy, 2018, 19, 759-764.	0.9	12
1308	A phase II study of modified FOLFIRINOX for chemotherapy-naÃ¯ve patients with metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2018, 81, 1017-1023.	1.1	103
1309	Development of chemotherapy and significance of conversion surgery after chemotherapy in unresectable pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Sciences, 2018, 25, 261-268.	1.4	31
1310	Evaluation of curcumin loaded chitosan/PEG blended PLGA nanoparticles for effective treatment of pancreatic cancer. Biomedicine and Pharmacotherapy, 2018, 102, 555-566.	2.5	105
1311	Antibody fragment-conjugated gemcitabine and paclitaxel-based liposome for effective therapeutic efficacy in pancreatic cancer. Materials Science and Engineering C, 2018, 89, 328-335.	3.8	52
1312	Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer. Annals of Surgical Oncology, 2018, 25, 1000-1008.	0.7	77
1313	Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis. Oncologist, 2018, 23, 704-711.	1.9	15
1314	Complex HuR function in pancreatic cancer cells. Wiley Interdisciplinary Reviews RNA, 2018, 9, e1469.	3.2	29
1316	The absence of class III Î²-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients with unresectable pancreatic ductal adenocarcinoma. Human Pathology, 2018, 74, 92-98.	1.1	15
1317	S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2018, 81, 573-578.	1.1	9
1318	Successful conversion surgery for unresectable pancreatic cancer with peritoneal metastases after neoadjuvant albumin-bound paclitaxel and gemcitabine chemotherapy: case report and literature review. International Cancer Conference Journal, 2018, 7, 20-25.	0.2	1
1319	Plants as sources of natural and recombinant anti-cancer agents. Biotechnology Advances, 2018, 36, 506-520.	6.0	151
1320	Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotypeâ€“Phenotype Featuresâ€”An Entity With an Increasing Incidence?. Clinical Colorectal Cancer, 2018, 17, e315-e321.	1.0	13

#	Article	IF	Citations
1321	The importance of quality-of-life management in patients with advanced pancreatic ductal adenocarcinoma. Current Problems in Cancer, 2018, 42, 26-39.	1.0	20
1322	Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer. Journal of Genetic Counseling, 2018, 27, 988-995.	0.9	6
1323	A phase I trial of the Î³-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. British Journal of Cancer, 2018, 118, 793-801.	2.9	90
1324	Imagingâ€based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Cancer, 2018, 124, 1701-1709.	2.0	35
1325	Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring. Oncologist, 2018, 23, 566-572.	1.9	69
1326	Antibody-nanoparticle conjugate constructed with trastuzumab and nanoparticle albumin-bound paclitaxel for targeted therapy of human epidermal growth factor receptorÃ¯Â¿Â½2-positive gastric cancer. Oncology Reports, 2018, 39, 1396-1404.	1.2	22
1327	Magnetic resonanceâ€“guided interstitial high-intensity focused ultrasound for brain tumor ablation. Neurosurgical Focus, 2018, 44, E11.	1.0	45
1328	Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?. Annals of Surgery, 2018, 268, 1-8.	2.1	139
1329	A look at the progress of treating pancreatic cancer over the past 20 years. Expert Review of Anticancer Therapy, 2018, 18, 295-304.	1.1	23
1330	Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wildâ€type BRCA pancreatic ductal adenocarcinoma. Cancer, 2018, 124, 1374-1382.	2.0	91
1336	NF-ÎºB in pancreatic cancer: Its key role in chemoresistance. Cancer Letters, 2018, 421, 127-134.	3.2	71
1337	How to treat borderline resectable pancreatic cancer: current challenges and future directions. Japanese Journal of Clinical Oncology, 2018, 48, 205-213.	0.6	5
1338	Gemcitabine and Taxane Adjuvant Therapy with Chemoradiation in Resected Pancreatic Cancer: A Novel Strategy for Improved Survival?. Annals of Surgical Oncology, 2018, 25, 1052-1060.	0.7	5
1339	Challenges and Perspectives for Immunotherapy in Adenocarcinoma of the Pancreas. Pancreas, 2018, 47, 142-157.	0.5	19
1340	How to Reliably Assess Nodal Status in Distal Pancreatectomy for Adenocarcinoma. Pancreas, 2018, 47, 308-313.	0.5	7
1341	Targeting Multiple Effector Pathways in Pancreatic Ductal Adenocarcinoma with a G-Quadruplex-Binding Small Molecule. Journal of Medicinal Chemistry, 2018, 61, 2500-2517.	2.9	114
1342	A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2018, 81, 609-614.	1.1	8
1343	Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study. Cancer Immunology Research, 2018, 6, 320-331.	1.6	48

#	Article	IF	Citations
1344	Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells. Cancer Research, 2018, 78, 985-1002.	0.4	35
1345	Cure of unresectable, locally advanced pancreatic cancer after multidisciplinary therapy. Journal of Cancer Research and Practice, 2018, 5, 27-31.	0.2	3
1346	Downregulation of MicroRNA-455-3p Links to Proliferation and Drug Resistance of Pancreatic Cancer Cells via Targeting TAZ. Molecular Therapy - Nucleic Acids, 2018, 10, 215-226.	2.3	41
1347	Pancreatic gross tumor volume contouring on computed tomography (CT) compared with magnetic resonance imaging (MRI): Results of an international contouring conference. Practical Radiation Oncology, 2018, 8, 107-115.	1.1	19
1348	Microwave ablation of pancreatic tumors. Minimally Invasive Therapy and Allied Technologies, 2018, 27, 33-40.	0.6	30
1349	Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Clinical Cancer Research, 2018, 24, 1344-1354.	3.2	414
1350	Clinical significance of defining borderline resectable pancreatic cancer. Pancreatology, 2018, 18, 139-145.	0.5	9
1351	Future Perspectives of IRE. , 2018, , 271-280.		0
1352	Medical oncology and pancreatic cancer: what the radiologist needs to know. Abdominal Radiology, 2018, 43, 383-392.	1.0	2
1353	Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers. Seminars in Cancer Biology, 2018, 52, 241-252.	4.3	12
1354	Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?. Clinical Cancer Research, 2018, 24, 2241-2250.	3.2	32
1355	Design and Synthesis of Novel Reactive Oxygen Species Inducers for the Treatment of Pancreatic Ductal Adenocarcinoma. Journal of Medicinal Chemistry, 2018, 61, 1576-1594.	2.9	24
1356	Drug development and clinical trial design in pancreatico-biliary malignancies. Current Problems in Cancer, 2018, 42, 73-94.	1.0	5
1357	Chemotherapy with or Without Definitive Radiation Therapy in Inoperable Pancreatic Cancer. Annals of Surgical Oncology, 2018, 25, 1026-1033.	0.7	9
1358	Thymidylate synthase prompts metastatic progression through the dTMP associated EMT process in pancreatic ductal adenocarcinoma. Cancer Letters, 2018, 419, 40-52.	3.2	7
1359	Locally advanced pancreas cancer: Staging and goals of therapy. Surgery, 2018, 163, 1053-1062.	1.0	53
1360	The high stromal SPARC expression is independently associated with poor survival of patients with resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine in combination with S-1 or adjuvant gemcitabine alone. Pancreatology, 2018, 18, 191-197.	0.5	8
1361	Chemotherapy Use, End-of-Life Care, and Costs of Care Among Patients Diagnosed With Stage IV Pancreatic Cancer. Journal of Pain and Symptom Management, 2018, 55, 1113-1121.e3.	0.6	27

#	Article	IF	Citations
1362	Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4. Journal of the National Cancer Institute, 2018, 110, 109-120.	3.0	134
1363	Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences. Targeted Oncology, 2018, 13, 125-140.	1.7	19
1364	Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer. Japanese Journal of Clinical Oncology, 2018, 48, 535-541.	0.6	10
1365	Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations. BMC Cancer, 2018, 18, 309.	1.1	36
1366	Impact of RUNX2 gene silencing on the gemcitabine sensitivity of p53â€‘mutated pancreatic cancer MiaPaCaâ€‘2 spheres. Oncology Reports, 2018, 39, 2749-2758.	1.2	1
1367	Assessment of response to chemotherapy in pancreatic ductal adenocarcinoma: Comparison between diffusion-weighted MR quantitative parameters and RECIST. European Journal of Radiology, 2018, 104, 49-57.	1.2	22
1368	Multi-institutional Study of Carbon-ion Radiotherapy for Locally Advanced Pancreatic Cancer: Japan Carbon-ion Radiation Oncology Study Group (J-CROS) Study 1403 Pancreas. International Journal of Radiation Oncology Biology Physics, 2018, 101, 1212-1221.	0.4	89
1369	Nimotuzumab: beyond the EGFR signaling cascade inhibition. Seminars in Oncology, 2018, 45, 18-26.	0.8	40
1370	Immunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends. Oncology Research and Treatment, 2018, 41, 286-290.	0.8	6
1371	Status and future directions in the management of pancreatic cancer: potential impact of nanotechnology. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1205-1217.	1.2	12
1372	Endoscopic duodenal stent versus surgical gastrojejunostomy for gastric outlet obstruction in patients with advanced pancreatic cancer. Pancreatology, 2018, 18, 601-607.	0.5	37
1373	Perioperative cytokine levels portend early death after pancreatectomy for ductal adenocarcinoma. Journal of Surgical Oncology, 2018, 117, 1260-1266.	0.8	11
1374	Cholecystokinin Receptor-Targeted Polyplex Nanoparticle Inhibits Growth and Metastasis of Pancreatic Cancer. Cellular and Molecular Gastroenterology and Hepatology, 2018, 6, 17-32.	2.3	17
1375	Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. British Journal of Cancer, 2018, 118, 1419-1424.	2.9	7
1376	Immunotherapy and Prevention of Pancreatic Cancer. Trends in Cancer, 2018, 4, 418-428.	3.8	296
1377	Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells. Cell Death and Disease, 2018, 9, 468.	2.7	64
1378	Pain in pancreatic ductal adenocarcinoma: A multidisciplinary, International guideline for optimized management. Pancreatology, 2018, 18, 446-457.	0.5	46
1379	Therapeutic developments in pancreatic cancer: current and future perspectives. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 333-348.	8.2	762

#	Article	IF	Citations
1380	Clinical Decision-Making in Pancreatic Cancer. , 2018, , 601-632.		0
1381	Chemotherapy for Advanced Pancreatic Cancer. , 2018, , 875-921.		0
1382	Venous Resection in Pancreatic Cancer Surgery. , 2018, , 941-965.		0
1383	Adjuvant Chemotherapy in Pancreatic Cancer. , 2018, , 1039-1071.		0
1384	Stromal Inflammation in Pancreatic Cancer: Mechanisms and Translational Applications. , 2018, , 481-508.		0
1385	Cell Cycle Machinery and Its Alterations in Pancreatic Cancer. , 2018, , 19-49.		2
1386	Role of Radiotherapy in Locally Advanced Pancreatic Cancer. , 2018, , 1435-1460.		0
1387	Neoadjuvant Chemotherapy in Pancreatic Cancer. , 2018, , 1187-1202.		1
1388	Combined Systemic Chemotherapy and CT-Guided High-Dose-Rate Brachytherapy for Isolated Local Manifestation of Pancreatic Cancer after Surgical Resection. Digestion, 2018, 98, 69-74.	1.2	5
1389	Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy. Surgery, 2018, 163, 1090-1096.	1.0	35
1390	A novel tropomyosin-related kinase A inhibitor, KK5101 to treat pancreatic cancer. Cancer Letters, 2018, 426, 25-36.	3.2	6
1391	Immunotherapy for pancreatic cancer: A long and hopeful journey. Cancer Letters, 2018, 425, 143-151.	3.2	35
1392	Pancreatic cancer subtypes: a roadmap for precision medicine. Annals of Medicine, 2018, 50, 277-287.	1.5	69
1393	A Changing Landscape in Pancreatic Cancer. Annals of Surgery, 2018, 268, 9-10.	2.1	7
1394	Current Concepts in the Treatment of Resectable Pancreatic Cancer. Current Oncology Reports, 2018, 20, 39.	1.8	17
1395	Dual controlled delivery of squalenoyl-gemcitabine and paclitaxel using thermo-responsive polymeric micelles for pancreatic cancer. Journal of Materials Chemistry B, 2018, 6, 2230-2239.	2.9	29
1396	Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer. Clinical Cancer Research, 2018, 24, 2873-2885.	3.2	41
1398	Management of Borderline Resectable Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1155-1174.	0.4	48

#	Article	IF	Citations
1399	Drug Delivery in Cancer Therapy, Quo Vadis?. Molecular Pharmaceutics, 2018, 15, 3603-3616.	2.3	85
1400	Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis. Investigational New Drugs, 2018, 36, 939-948.	1.2	5
1401	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 310-320.	2.3	476
1402	Nano-chemotherapy using cationic liposome that strategically targets the cell membrane potential of pancreatic cancer cells with negative charge. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1161-1165.	1.0	11
1403	Small-molecule screening yields a compound that inhibits the cancer-associated transcription factor Hes1 via the PHB2 chaperone. Journal of Biological Chemistry, 2018, 293, 8285-8294.	1.6	23
1404	PAK4 pathway as a potential therapeutic target in pancreatic cancer. Future Oncology, 2018, 14, 579-582.	1.1	19
1405	Differences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer. Nano Letters, 2018, 18, 2195-2208.	4.5	20
1406	A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 128-132.	0.6	5
1407	Use of Radiation Therapy in Locally Advanced Pancreatic Cancer Improves Survival. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 236-241.	0.6	15
1408	Prolonged Neoadjuvant Therapy for Locally Advanced Pancreatic Cancer. Digestive Surgery, 2018, 35, 70-76.	0.6	14
1409	Five-Fraction Stereotactic Body Radiation Therapy (SBRT) and Chemotherapy for the Local Management of Metastatic Pancreatic Cancer. Journal of Gastrointestinal Cancer, 2018, 49, 116-123.	0.6	22
1410	Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer. Gut, 2018, 67, 497-507.	6.1	151
1411	Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: results of a phase-I study. Leukemia and Lymphoma, 2018, 59, 357-362.	0.6	7
1412	Management of unresectable, locally advanced pancreatic adenocarcinoma. Clinical and Translational Oncology, 2018, 20, 113-118.	1.2	3
1413	Vascular beds maintain pancreatic tumour explants for ex vivo drug screening. Journal of Tissue Engineering and Regenerative Medicine, 2018, 12, e318-e322.	1.3	10
1414	Impact of Concurrent Medication Use on Pancreatic Cancer Survivalâ€"SEER-Medicare Analysis. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 766-771.	0.6	32
1415	Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 607-612.	0.6	32
1416	Primary Care Versus Oncology-Based Surveillance Following Adjuvant Chemotherapy in Resected Pancreatic Cancer. Journal of Gastrointestinal Cancer, 2018, 49, 429-436.	0.6	4

#	Article	IF	Citations
1417	Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 656-661.	0.6	13
1418	Toxicity of chemotherapy regimens in advanced and metastatic pancreatic cancer therapy: A network metaâ€analysis. Journal of Cellular Biochemistry, 2018, 119, 5082-5103.	1.2	7
1419	Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. Journal of Surgical Oncology, 2018, 117, 354-362.	0.8	26
1420	Minimally Invasive Gastric Bypass. Updates in Surgery Series, 2018, , 107-113.	0.0	0
1421	Different Survival Benefits of Chinese Medicine for Pancreatic Cancer: How to Choose?. Chinese Journal of Integrative Medicine, 2018, 24, 178-184.	0.7	9
1422	HALO-109â€“301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer. Future Oncology, 2018, 14, 13-22.	1.1	115
1423	Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Gut, 2018, 67, 2142-2155.	6.1	100
1424	Overexpression of FZD1 and CAIX are Associated with Invasion, Metastasis, and Poor-Prognosis of the Pancreatic Ductal Adenocarcinoma. Pathology and Oncology Research, 2018, 24, 899-906.	0.9	17
1425	Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 982-985.	0.6	17
1426	Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?. Cellular and Molecular Life Sciences, 2018, 75, 1001-1012.	2.4	31
1427	Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results. Investigational New Drugs, 2018, 36, 442-450.	1.2	16
1428	Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy. Journal of Gastrointestinal Surgery, 2018, 22, 235-241.	0.9	40
1429	Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: A network metaâ€analysis. Journal of Cellular Physiology, 2018, 233, 3352-3374.	2.0	14
1430	Melatonin: does it have utility in the treatment of haematological neoplasms?. British Journal of Pharmacology, 2018, 175, 3251-3262.	2.7	38
1431	Neurological Complications of Chemotherapy. , 2018, , 275-310.		1
1432	Safety and Efficacy of AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer Mice. Molecular Therapy - Methods and Clinical Development, 2018, 8, 8-20.	1.8	23
1433	Chk1 inhibitor SCH 900776 enhances the antitumor activity of MLN4924 on pancreatic cancer. Cell Cycle, 2018, 17, 191-199.	1.3	10
1434	The clinical benefit of hyperthermia in pancreatic cancer: a systematic review. International Journal of Hyperthermia, 2018, 34, 969-979.	1.1	41

#	Article	IF	Citations
1435	Molecular and cellular mechanisms of chemoresistance in pancreatic cancer. Advances in Biological Regulation, 2018, 68, 77-87.	1.4	132
1436	Ablative Therapies for Locally Advanced Pancreatic Cancer. Pancreas, 2018, 47, 6-11.	0.5	22
1437	KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a031435.	2.9	563
1438	Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2018, 81, 355-364.	1.1	33
1439	Does the surgical waiting list affect pathological and survival outcome in resectable pancreatic ductal adenocarcinoma?. Hpb, 2018, 20, 411-417.	0.1	26
1440	Timing of Pancreatic Resection and Patient Outcomes. Surgical Clinics of North America, 2018, 98, 57-71.	0.5	9
1441	Adjuvant or Neoadjuvant Therapy in the Treatment in Pancreatic Malignancies. Surgical Clinics of North America, 2018, 98, 95-111.	0.5	25
1442	Xanthohumol inhibits angiogenesis by suppressing nuclear factorâ€ºB activation in pancreatic cancer. Cancer Science, 2018, 109, 132-140.	1.7	89
1443	Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. Clinical Cancer Research, 2018, 24, 351-359.	3.2	81
1444	Clinical Factors as a Component of the Personalized Treatment Approach to Advanced Pancreatic Cancer: a Systematic Literature Review. Journal of Gastrointestinal Cancer, 2018, 49, 1-8.	0.6	11
1445	Common Hepatic Artery Abutment or Encasement Is an Adverse Prognostic Factor in Patients with Borderline and Unresectable Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2018, 22, 288-294.	0.9	6
1446	Uptake and Effectiveness of FOLFIRINOX for Advanced Pancreatic Cancer: a Population-based Study. Clinical Oncology, 2018, 30, e16-e21.	0.6	15
1447	18-Fluorodeoxyglucose Positron Emission Tomography Predicts Recurrence in Resected Pancreatic Ductal Adenocarcinoma. Journal of Gastrointestinal Surgery, 2018, 22, 279-287.	0.9	23
1448	Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. Investigational New Drugs, 2018, 36, 96-102.	1.2	150
1449	Recent advances in the management of pancreatic adenocarcinoma. Expert Review of Anticancer Therapy, 2018, 18, 51-62.	1.1	17
1450	Heparanase expression in blood is sensitive to monitor response to anticancer treatment in pancreatic cancer, a pilot study. Pancreatology, 2018, 18, 100-105.	0.5	3
1451	Tumor-Treating Fields: A Fourth Modality in Cancer Treatment. Clinical Cancer Research, 2018, 24, 266-275.	3.2	241
1452	Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. JCO Precision Oncology, 2018, 2018, 1-15.	1.5	129

#	Article	IF	Citations
1453	Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations. JCO Precision Oncology, 2018, 2, 1-9.	1.5	30
1454	Gibt es Fortschritte in der Routinebehandlung von Patienten mit fortgeschrittenem Pankreaskarzinom?. Karger Kompass Onkologie, 2018, 5, 94-95.	0.0	0
1455	Adjuvant therapeutic strategies for resectable pancreatic adenocarcinoma. Annals of Pancreatic Cancer, 2018, 1, 20-20.	1.2	5
1456	The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma. Journal of Gastrointestinal Oncology, 2018, 9, 135-139.	0.6	11
1457	Immunotherapy in pancreatic adenocarcinomaâ€"overcoming barriers to response. Journal of Gastrointestinal Oncology, 2018, 9, 143-159.	0.6	42
1458	Combination immunotherapy and radiation therapy strategies for pancreatic cancerâ€"targeting multiple steps in the cancer immunity cycle. Journal of Gastrointestinal Oncology, 2018, 9, 1014-1026.	0.6	42
1459	Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer. Journal of Gastrointestinal Oncology, 2018, 9, 982-988.	0.6	7
1460	Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospects. Journal of Gastrointestinal Oncology, 2018, 9, 377-389.	0.6	2
1461	Review and current state of radiation therapy for locally advanced pancreatic adenocarcinoma. Journal of Gastrointestinal Oncology, 2018, 9, 1027-1036.	0.6	8
1462	The preoperative modified Glasgow prognostic score for the prediction of survival after pancreatic cancer resection following non-surgical treatment of an initially unresectable disease. Wspolczesna Onkologia, 2018, 22, 229-235.	0.7	5
1463	Retrospective analysis of efficacy and safety of Gemcitabine-based chemotherapy in patients with metastatic pancreatic adenocarcinoma experiencing disease progression on FOLFIRINOX. Journal of Gastrointestinal Oncology, 2018, 9, 806-819.	0.6	5
1464	Retrospective comparison of the efficacy and the toxicity of standard and modified FOLFIRINOX regimens in patients with metastatic pancreatic adenocarcinoma. Journal of Gastrointestinal Oncology, 2018, 9, 694-707.	0.6	21
1465	Gemcitabine plus S-1 for metastatic pancreatic cancer. Medicine (United States), 2018, 97, e12836.	0.4	1
1466	Ultrasonic cavitation induces necrosis and impairs growth in three-dimensional models of pancreatic ductal adenocarcinoma. PLoS ONE, 2018, 13, e0209094.	1.1	9
1467	An observation study of the prognostic effect of waiting times in the management of pancreatic ductal adenocarcinoma. Oncology Letters, 2018, 17, 587-593.	0.8	3
1468	Neoadjuvant Treatment for Nonmetastatic Pancreatic Cancer. , 2018, , .		1
1469	Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. World Journal of Gastrointestinal Oncology, 2018, 10, 421-430.	0.8	25
1470	Entrectinib in TRK and ROS1 Fusion-Positive Metastatic Pancreatic Cancer. JCO Precision Oncology, 2018, 2, 1-7.	1.5	32

#	Article	IF	Citations
1471	Homologous Recombination Deficiency in Patients With Pancreatic Ductal Adenocarcinoma and Response to Chemotherapy. JCO Precision Oncology, 2018, 2, 1-11.	1.5	13
1472	Large database utilization in health outcomes research in pancreatic cancer: an update. Journal of Gastrointestinal Oncology, 2018, 9, 996-1004.	0.6	8
1474	Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases?. World Journal of Gastrointestinal Oncology, 2018, 10, 211-220.	0.8	7
1475	Correlation Between the Acquisition of Resistance to Gemcitabine Therapy and the Expression of HuR in Pancreatic Ductal Adenocarcinoma: A Case Report. International Surgery, 2018, 103, 116-120.	0.0	0
1476	A New Role for Vitamin D: The Enhancement of Oncolytic Viral Therapy in Pancreatic Cancer. Biomedicines, 2018, 6, 104.	1.4	13
1477	Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer. International Journal of Molecular Sciences, 2018, 19, 3505.	1.8	69
1478	Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters. PLoS ONE, 2018, 13, e0206688.	1.1	12
1479	The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. Diseases (Basel, Switzerland), 2018, 6, 103.	1.0	7
1480	The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer. Theranostics, 2018, 8, 5072-5087.	4.6	139
1481	ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. Oncogenesis, 2018, 7, 87.	2.1	40
1482	Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors. Toxins, 2018, 10, 447.	1.5	8
1483	New Horizons in the Treatment of Metastatic Pancreatic Cancer: A Review of the Key Biology Features and the Most Recent Advances to Treat Metastatic Pancreatic Cancer. Targeted Oncology, 2018, 13, 691-704.	1.7	6
1484	Predictive Early Recurrence Factors of Preoperative Clinicophysiological Findings in Pancreatic Cancer. European Surgical Research, 2018, 59, 329-338.	0.6	21
1485	A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort. BMC Cancer, 2018, 18, 986.	1.1	8
1486	Feasibility of Combination Therapy with Nab-paclitaxel Plus Gemcitabine in Patients with Recurrent Pancreatic Cancer. Anticancer Research, 2018, 38, 6537-6542.	0.5	4
1487	Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial. European Journal of Cancer, 2018, 105, 71-78.	1.3	24
1488	KRAS mutations in ctDNA: a promising new biomarker in advanced pancreatic cancer. Annals of Oncology, 2018, 29, 2280-2282.	0.6	4
1489	Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 (BRCA2) Mutation. ACS Nano, 2018, 12, 10785-10796.	7.3	77

#	Article	IF	Citations
1490	Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. BMC Cancer, 2018, 18, 1298.	1.1	63
1491	Development of a Method for Improving the Electric Field Distribution in Patients Undergoing Tumor-Treating Fields Therapy. Journal of the Korean Physical Society, 2018, 73, 1577-1583.	0.3	3
1492	Species difference in paclitaxel disposition correlated with poor pharmacological efficacy translation from mice to humans. Clinical Pharmacology: Advances and Applications, 2018, Volume 10, 165-174.	0.8	3
1493	Metabolic Dependencies in Pancreatic Cancer. Frontiers in Oncology, 2018, 8, 617.	1.3	60
1494	Radioterapia intraoperatoria con IntrabeamÂ® para el tratamiento del adenocarcinoma de pÃ¡ncreas resecable. CirugÃa EspaÃ±ola, 2018, 96, 482-487.	0.1	2
1495	Analysis of dynamic molecular networks for pancreatic ductal adenocarcinoma progression. Cancer Cell International, 2018, 18, 214.	1.8	37
1496	Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression. PLoS ONE, 2018, 13, e0200664.	1.1	13
1497	Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review. Oncotarget, 2018, 9, 21613-21627.	0.8	39
1498	Pivotal prognostic and diagnostic role of the long nonâ€‘coding RNA colon cancerâ€‘associated transcript 1 expression in human cancer (Review). Molecular Medicine Reports, 2019, 19, 771-782.	1.1	21
1499	Itraconazole inhibits invasion and migration of pancreatic cancer cells by suppressing TGF-Î²/SMAD2/3 signaling. Oncology Reports, 2018, 39, 1573-1582.	1.2	16
1500	Functional Genome-wide Screening Identifies Targets and Pathways Sensitizing Pancreatic Cancer Cells to Dasatinib. Journal of Cancer, 2018, 9, 4762-4773.	1.2	25
1502	Dose escalation for locally advanced pancreatic cancer: How high can we go?. Advances in Radiation Oncology, 2018, 3, 693-700.	0.6	30
1503	Pancreatic cancer associated with obesity and diabetes: an alternative approach for its targeting. Journal of Experimental and Clinical Cancer Research, 2018, 37, 319.	3.5	81
1504	Pancreatic cancer chemo-resistance is driven by tumor phenotype rather than tumor genotype. Heliyon, 2018, 4, e01055.	1.4	43
1505	MicroRNAâ€‘221 induces autophagy through suppressing HDAC6 expression and promoting apoptosis in pancreatic cancer. Oncology Letters, 2018, 16, 7295-7301.	0.8	19
1506	Hot water extract of Agaricus blazei Murrill specifically inhibits growth and induces apoptosis in human pancreatic cancer cells. BMC Complementary and Alternative Medicine, 2018, 18, 319.	3.7	15
1507	Targeted Therapies for Pancreatic Cancer and Hurdles Ahead. Anticancer Research, 2018, 38, 6591-6606.	0.5	65
1508	Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma. Cancers, 2018, 10, 467.	1.7	12

#	Article	IF	Citations
1509	Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study. Targeted Oncology, 2018, 13, 715-724.	1.7	19
1510	Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study. BMC Cancer, 2018, 18, 1185.	1.1	26
1511	Glutamine Deprivation Enhances Acetyl-CoA Carboxylase Inhibitor-induced Death of Human Pancreatic Cancer Cells. Anticancer Research, 2018, 38, 6683-6689.	0.5	22
1512	Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death. Oncology Reports, 2018, 39, 1984-1990.	1.2	10
1513	Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models. Clinical Cancer Drugs, 2018, 5, 42-49.	0.3	4
1514	The Management of Older Adults with Pancreatic Adenocarcinoma. Geriatrics (Switzerland), 2018, 3, 85.	0.6	4
1515	Mutant p53 prevents GAPDH nuclear translocation in pancreatic cancer cells favoring glycolysis and 2-deoxyglucose sensitivity. Biochimica Et Biophysica Acta - Molecular Cell Research, 2018, 1865, 1914-1923.	1.9	45
1516	ASO Author Reflections: Neoadjuvant Treatment of Resectable and Borderline-Resectable Pancreatic Head Adenocarcinoma: Is FOLFIRINOX Better than Gem/Nab-Paclitaxel?. Annals of Surgical Oncology, 2018, 25, 808-809.	0.7	6
1517	Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer. Drug Design, Development and Therapy, 2018, Volume 12, 1769-1775.	2.0	17
1518	A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors. OncoTargets and Therapy, 2018, Volume 11, 2399-2407.	1.0	11
1519	Treatment patterns and outcomes of unresectable pancreatic cancer patients in real-life practice: a region-wide analysis. Japanese Journal of Clinical Oncology, 2018, 48, 966-973.	0.6	16
1520	Subgroup analysis reveals molecular heterogeneity and provides potential precise treatment for pancreatic cancers. OncoTargets and Therapy, 2018, Volume 11, 5811-5819.	1.0	3
1521	Advances in Gastrointestinal Surgery. GI Surgery Annual, 2018, , 177-221.	0.0	0
1522	Clinical Implications of Extensive Lymph Node Metastases for Resected Pancreatic Cancer. Annals of Surgical Oncology, 2018, 25, 4004-4011.	0.7	21
1523	The incidence and survival of pancreatic cancer by histology, including rare subtypes: a nationâ€wide cancer registryâ€based study from Taiwan. Cancer Medicine, 2018, 7, 5775-5788.	1.3	27
1525	Role of angiogenesis in pancreatic cancer biology and therapy. Biomedicine and Pharmacotherapy, 2018, 108, 1135-1140.	2.5	46
1526	Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour. BMJ Open, 2018, 8, e017240.	0.8	20
1527	Nano-targeted relaxin impairs fibrosis and tumor growth in pancreatic cancer and improves the efficacy of gemcitabine in vivo. Journal of Controlled Release, 2018, 290, 1-10.	4.8	88

#	Article	IF	Citations
1528	Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma. Oncology Research and Treatment, 2018, 41, 619-625.	0.8	11
1529	Novel Targets in Pancreatic Cancer Therapy - Current Status and Ongoing Translational Efforts. Oncology Research and Treatment, 2018, 41, 596-602.	0.8	17
1530	The Potential of CAR T Cell Therapy in Pancreatic Cancer. Frontiers in Immunology, 2018, 9, 2166.	2.2	92
1531	Current Therapeutic Options for Pancreatic Ductal Adenocarcinoma. Oncology Research and Treatment, 2018, 41, 590-594.	0.8	9
1532	Chemotherapy for pancreatic cancer: the rise of multidrug regimens. The Lancet Gastroenterology and Hepatology, 2018, 3, 659-660.	3.7	2
1533	The role of hepatectomy for synchronous liver metastases from pancreatic adenocarcinoma. Surgical Oncology, 2018, 27, 688-694.	0.8	28
1534	Combination treatment of advanced pancreatic cancer using novel vaccine and traditional therapies. Expert Review of Anticancer Therapy, 2018, 18, 1205-1217.	1.1	14
1535	Pharmacokinetic evaluation of the PNC disassembler metarrestin in wild-type and Pdx1-Cre;LSL-KrasG12D/+;Tp53R172H/+ (KPC) mice, a genetically engineered model of pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2018, 82, 1067-1080.	1.1	9
1536	Inhibition of pancreatic cancer stem cells by Rauwolfia vomitoria extract. Oncology Reports, 2018, 40, 3144-3154.	1.2	13
1537	Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone. BMC Cancer, 2018, 18, 1034.	1.1	7
1538	Organizing pneumonia after pancreatic cancer treatment with nab-paclitaxel and gemcitabine: a case report. BJR|case Reports, 2018, 4, 20170086.	0.1	2
1539	44 Pancreatic Cancers and Cystic Neoplasms. , 2018, , .		0
1540	Efficacy and safety of chemotherapy after endoscopic double stenting for malignant duodenal and biliary obstructions in patients with advanced pancreatic cancer: a single-institution retrospective analysis. BMC Gastroenterology, 2018, 18, 157.	0.8	9
1541	Conversion surgery with gemcitabine plus nabâ€‘paclitaxel for locally advanced unresectable pancreatic cancer: A case report. Molecular and Clinical Oncology, 2018, 9, 389-393.	0.4	1
1542	Predictive role of skin rash in advanced pancreatic cancer patients treated with gemcitabine plus erlotinib: a systematic review and meta-analysis. OncoTargets and Therapy, 2018, Volume 11, 6633-6646.	1.0	1
1543	The integration of pharmacology and pathophysiology into locoregional chemotherapy delivery via mass fluid transfer. Journal of Controlled Release, 2018, 292, 18-28.	4.8	2
1544	Organotypic slice cultures of pancreatic ductal adenocarcinoma preserve the tumor microenvironment and provide a platform for drug response. Pancreatology, 2018, 18, 913-927.	0.5	29
1545	Systemic chemotherapy in combination with liver-directed therapy improves survival in patients with pancreatic adenocarcinoma and synchronous liver metastases. Pancreatology, 2018, 18, 983-989.	0.5	6

#	Article	IF	Citations
1546	Allergenâ€'removed Rhusï¿½verniciflua Stokes suppresses invasion and migration of pancreatic cancer cells through downregulation of the JAK/STAT and Src/FAK signaling pathways. Oncology Reports, 2018, 40, 3060-3068.	1.2	12
1547	Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties. Molecules, 2018, 23, 2608.	1.7	21
1548	Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. British Journal of Cancer, 2018, 119, 1208-1214.	2.9	195
1549	Efficacy and safety of weekly nab-paclitaxel plus cisplatin with concurrent intensity-modulated radiotherapy in patients with inoperable, locally advanced esophageal cancer: a pilot trial. OncoTargets and Therapy, 2018, Volume 11, 6333-6338.	1.0	9
1550	Currently available first-line drug therapies for treating pancreatic cancer. Expert Opinion on Pharmacotherapy, 2018, 19, 1927-1940.	0.9	5
1551	Cost-effectiveness analysis of adjuvant treatment for resected pancreatic cancer in China based on the ESPAC-4 trial. Cancer Management and Research, 2018, Volume 10, 4065-4072.	0.9	7
1552	Assessing Chemotherapeutic Response in Pancreatic Ductal Adenocarcinoma: Histogram Analysis of Iodine Concentration and CT Number in Single-Source Dual-Energy CT. American Journal of Roentgenology, 2018, 211, 1221-1226.	1.0	26
1553	Phase <scp>II</scp> clinical trial of Sâ€1 plus nanoparticle albuminâ€bound paclitaxel in untreated patients with metastatic gastric cancer. Cancer Science, 2018, 109, 3575-3582.	1.7	19
1554	ASO Author Reflections: Neoadjuvant Therapy Versus Upfront Resection for Pancreatic Cancer. Annals of Surgical Oncology, 2018, 25, 810-811.	0.7	0
1555	PAR1 signaling on tumor cells limits tumor growth by maintaining a mesenchymal phenotype in pancreatic cancer. Oncotarget, 2018, 9, 32010-32023.	0.8	25
1556	Simultaneous Inhibition of MEK and Hh Signaling Reduces Pancreatic Cancer Metastasis. Cancers, 2018, 10, 403.	1.7	13
1557	A realâ€world, populationâ€based study of patterns of referral, treatment, and outcomes for advanced pancreatic cancer. Cancer Medicine, 2018, 7, 6385-6392.	1.3	13
1558	Phase I Trial Evaluating the Safety of Preoperative Gemcitabine/nab-Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer. Pancreas, 2018, 47, 1135-1141.	0.5	20
1559	The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences, 2018, 19, 3219.	1.8	60
1560	Intraoperative Radiotherapy With the IntrabeamÂ® Device for the Treatment of Resectable Pancreatic Adenocarcinoma. CirugÃa EspaÃ±ola (English Edition), 2018, 96, 482-487.	0.1	0
1561	Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma. Langenbeck's Archives of Surgery, 2018, 403, 693-700.	0.8	19
1563	A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer. BMC Cancer, 2018, 18, 596.	1.1	110
1564	A single institutional experience of combined carbon-ion radiotherapy and chemotherapy for unresectable locally advanced pancreatic cancer. Radiotherapy and Oncology, 2018, 129, 333-339.	0.3	33

#	Article	IF	Citations
1565	Analysis of DNA Hypermethylation in Pancreatic Cancer Using Methylation-Specific PCR and Bisulfite Sequencing. Methods in Molecular Biology, 2018, 1856, 269-282.	0.4	12
1566	Different Nanoformulations Alter the Tissue Distribution of Paclitaxel, Which Aligns with Reported Distinct Efficacy and Safety Profiles. Molecular Pharmaceutics, 2018, 15, 4505-4516.	2.3	15
1567	Incidence of Pathogenic Variants in Those With a Family History of Pancreatic Cancer. Frontiers in Oncology, 2018, 8, 330.	1.3	4
1568	HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. Journal of Clinical Oncology, 2018, 36, 359-366.	0.8	350
1569	Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma. JAMA Oncology, 2018, 4, 1707.	3.4	86
1570	Trends in treatment and survival of patients with nonresected, nonmetastatic pancreatic cancer: A populationâ€based study. Cancer Medicine, 2018, 7, 4943-4951.	1.3	23
1571	Community Oncologists' Decision-Making for Treatment of Older Patients With Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 301-309.	2.3	55
1572	Portal encasement: Significant CT findings to diagnose local recurrence after pancreaticoduodenectomy for pancreatic cancer. Pancreatology, 2018, 18, 1005-1011.	0.5	2
1573	Circulating microRNA-99 family as liquid biopsy marker in pancreatic adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2377-2390.	1.2	22
1574	Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States. Advances in Therapy, 2018, 35, 1564-1577.	1.3	54
1575	Resectable Distal Pancreas Cancer: Time to Reconsider the Role of Upfront Surgery. Annals of Surgical Oncology, 2018, 25, 4012-4019.	0.7	16
1576	Prognostic significance of circulating tumor microemboli in patients with pancreatic ductal adenocarcinoma. Oncology Letters, 2018, 15, 7376-7382.	0.8	10
1577	Effects of chemoradiotherapy and chemotherapy on survival of patients with locally advanced pancreatic cancer. Medicine (United States), 2018, 97, e12260.	0.4	6
1578	FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma. Journal of Experimental and Clinical Cancer Research, 2018, 37, 224.	3.5	31
1579	The Extracellular Matrix and Pancreatic Cancer: A Complex Relationship. Cancers, 2018, 10, 316.	1.7	208
1580	Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE,) Tj ETQq1 1 0.784314 rgBT /Ove	0.4	104
1581	The Combination of Neutrophilâ€“toâ€“lymphocyte Ratio and Serum Carbohydrate Antigen 19-9 Level as a Prognostic Indicator in Patients with Recurrent Pancreatic Cancer. Anticancer Research, 2018, 38, 5497-5503.	0.5	10
1582	The Role of Consolidation Chemoradiotherapy in Locally Advanced Pancreatic Cancer Receiving Chemotherapy: An Updated Systematic Review and Meta-Analysis. Cancer Research and Treatment, 2018, 50, 562-574.	1.3	16

#	Article	IF	Citations
1583	Proteinâ€Engineered Biomaterials for Cancer Theranostics. Advanced Healthcare Materials, 2018, 7, e1800913.	3.9	26
1584	Rationale for the use of metronomic chemotherapy in gastrointestinal cancer. Expert Opinion on Pharmacotherapy, 2018, 19, 1451-1463.	0.9	5
1585	Impact of targeting transforming growth factor β-2 with antisense OT-101 on the cytokine and chemokine profile in patients with advanced pancreatic cancer. OncoTargets and Therapy, 2018, Volume 11, 2779-2796.	1.0	16
1586	Cancer Epigenetics for Precision Medicine. Methods in Molecular Biology, 2018, , .	0.4	0
1587	Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?. OncoTargets and Therapy, 2018, Volume 11, 4591-4608.	1.0	6
1588	Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. Frontiers in Immunology, 2018, 9, 1878.	2.2	127
1589	Five Cases of Interstitial Pneumonitis Due to Gemcitabine and Nab-Paclitaxel Combination Treatment in Pancreatic Cancer Patients. Pancreas, 2018, 47, e42-e43.	0.5	9
1590	Combination therapy versus gemcitabine monotherapy in the treatment of elderly pancreatic cancer: a meta-analysis of randomized controlled trials. Drug Design, Development and Therapy, 2018, Volume 12, 475-480.	2.0	19
1591	G-CSF associates with neurogenesis and predicts prognosis and sensitivity to chemotherapy in pancreatic ductal adenocarcinoma. Cancer Management and Research, 2018, Volume 10, 2767-2775.	0.9	4
1592	Detection of CTCs in portal vein was associated with intrahepatic metastases and prognosis in patients with advanced pancreatic cancer. Journal of Cancer, 2018, 9, 2038-2045.	1.2	40
1593	Subclinical cancer cell dissemination in peritoneal lavage fluid detected by reverse-transcription polymerase chain reaction identifies patients at high risk for peritoneal recurrence and consequent impaired survival in the setting of preoperative chemoradiation therapy for pancreatic cancer. Surgery, 2018, 164, 1168-1177.	1.0	14
1594	Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer. Cellular Immunology, 2018, 329, 31-40.	1.4	30
1595	Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer. Cancer Research, 2018, 78, 4282-4291.	0.4	83
1596	Osteonectin as a screening marker for pancreatic cancer: A prospective study. Journal of International Medical Research, 2018, 46, 2769-2779.	0.4	13
1597	FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma. Annals of Surgical Oncology, 2018, 25, 1896-1903.	0.7	88
1598	Gemcitabine/nabâ€paclitaxel for pediatric relapsed/refractory sarcomas. Pediatric Blood and Cancer, 2018, 65, e27246.	0.8	8
1599	Ultrasound Doppler as an Imaging Modality for Selection of Murine 4T1 Breast Tumors for Combination Radiofrequency Hyperthermia and Chemotherapy. Translational Oncology, 2018, 11, 864-872.	1.7	7
1600	Characterization of low active ghrelin ratio in patients with advanced pancreatic cancer. Supportive Care in Cancer, 2018, 26, 3811-3817.	1.0	6

#	Article	IF	Citations
1601	Validation of prognostic risk scores for patients undergoing resection for pancreatic cancer. Pancreatology, 2018, 18, 585-591.	0.5	11
1602	Emerging strategies in BRCA-positive pancreatic cancer. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1503-1507.	1.2	37
1603	Revision of Surgical Margin under Frozen Section to Achieve R0 Status on Survival in Patients with Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2018, 22, 1565-1575.	0.9	5
1604	Molecular Diagnostics in the Neoplasms of the Pancreas, Liver, Gallbladder, and Extrahepatic Biliary Tract. Clinics in Laboratory Medicine, 2018, 38, 367-384.	0.7	4
1605	Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors. Pancreas, 2018, 47, 759-771.	0.5	29
1606	The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy. Surgery Today, 2018, 48, 952-962.	0.7	9
1607	A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer. Medical Oncology, 2018, 35, 100.	1.2	13
1608	MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model. Tissue and Cell, 2018, 52, 124-128.	1.0	19
1609	Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discovery, 2018, 8, 1112-1129.	7.7	676
1610	LINC01121 Inhibits Cell Apoptosis While Facilitating Proliferation, Migration, and Invasion Though Negative Regulation of the Camp/PKA Signaling Pathway via GLP1R. Cellular Physiology and Biochemistry, 2018, 47, 1007-1024.	1.1	15
1611	A Multicenter Open-Label Randomized Controlled Trial of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer. Pancreas, 2018, 47, 800-806.	0.5	22
1612	Prediction of overall survival for metastatic pancreatic cancer: Development and validation of a prognostic nomogram with data from open clinical trial and realâ€world study. Cancer Medicine, 2018, 7, 2974-2984.	1.3	32
1613	Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2018, 82, 245-250.	1.1	31
1614	Indications and Perioperative Outcomes for Pancreatectomy with Arterial Resection. Journal of the American College of Surgeons, 2018, 227, 255-269.	0.2	91
1615	Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer. International Journal of Cancer, 2018, 143, 2053-2064.	2.3	76
1616	NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. Cancer Discovery, 2018, 8, 1087-1095.	7.7	189
1617	High compliance with guideline recommendations but low completion rates of adjuvant chemotherapy in resected pancreatic cancer: A cohort study. Annals of Medicine and Surgery, 2018, 32, 32-37.	0.5	13
1618	Triggered release of paclitaxel from magnetic solid lipid nanoparticles by magnetic hyperthermia. Materials Science and Engineering C, 2018, 92, 547-553.	3.8	54

#	Article	IF	Citations
1619	Soluble stromaâ€rrelated biomarkers of pancreaticÂcancer. EMBO Molecular Medicine, 2018, 10, .	3.3	56
1620	Neoadjuvant Nab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX. Anticancer Research, 2018, 38, 4035-4039.	0.5	14
1621	An Extremely Rapid Case of Pneumonitis with the Use of Nivolumab for Pancreatic Adenocarcinoma. Case Reports in Oncological Medicine, 2018, 2018, 1-5.	0.2	4
1622	Mutational burden of resectable pancreatic cancer, as determined by whole transcriptome and whole exome sequencing, predicts a poor prognosis. International Journal of Oncology, 2018, 52, 1972-1980.	1.4	8
1623	Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. Pharmacoeconomics, 2018, 36, 1273-1284.	1.7	9
1624	Towards an Optimal Treatment Algorithm for Metastatic Pancreatic Ductal Adenocarcinoma (PDA). Current Oncology, 2018, 25, 90-94.	0.9	11
1625	Initial experience with intensity modulated proton therapy for intact, clinically localized pancreas cancer: Clinical implementation, dosimetric analysis, acute treatment-related adverse events, and patient-reported outcomes. Advances in Radiation Oncology, 2018, 3, 314-321.	0.6	20
1627	Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer. Advanced Drug Delivery Reviews, 2018, 130, 50-57.	6.6	72
1628	Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative. Clinical Cancer Research, 2018, 24, 5018-5027.	3.2	158
1629	Assessment of Three-Drug Combination Pharmacodynamic Interactions in Pancreatic Cancer Cells. AAPS Journal, 2018, 20, 80.	2.2	12
1630	Clinical Outcomes with First-Line Chemotherapy in a Large Retrospective Study of Patients with Metastatic Pancreatic Cancer Treated in a US Community Oncology Setting. Drugs - Real World Outcomes, 2018, 5, 149-159.	0.7	33
1631	Overexpression of folate receptor alpha is an independent prognostic factor for outcomes of pancreatic cancer patients. Medical Molecular Morphology, 2018, 51, 237-243.	0.4	9
1632	Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer. European Journal of Cancer, 2018, 100, 27-34.	1.3	22
1633	Tumor targeting Salmonella typhimurium A1-R in combination with gemcitabine (GEM) regresses partially GEM-resistant pancreatic cancer patient-derived orthotopic xenograft (PDOX) nude mouse models. Cell Cycle, 2018, 17, 2019-2026.	1.3	18
1634	Effectiveness and Safety of Simultaneous Integrated Boost-Proton Beam Therapy for Localized Pancreatic Cancer. Technology in Cancer Research and Treatment, 2018, 17, 153303381878387.	0.8	15
1635	A Contemporary Review of the Treatment Landscape and the Role of Predictive and Prognostic Biomarkers in Pancreatic Adenocarcinoma. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-10.	0.8	11
1636	Chemoradiotherapy versus chemotherapy for locally advanced unresectable pancreatic cancer: A systematic review and metaâ€analysis. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 392-401.	0.7	9
1637	nabâ€Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e325-e331.	0.7	5

#	Article	IF	Citations
1638	Genomic testing for pancreatic cancer in clinical practice as real-world evidence. Pancreatology, 2018, 18, 647-654.	0.5	35
1639	Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience. BMC Cancer, 2018, 18, 693.	1.1	68
1640	Pancreatic adenocarcinoma: insights into patterns of recurrence and disease behavior. BMC Cancer, 2018, 18, 769.	1.1	37
1641	Localized Controlled Delivery of Gemcitabine via Microsol Electrospun Fibers to Prevent Pancreatic Cancer Recurrence. Advanced Healthcare Materials, 2018, 7, e1800593.	3.9	35
1643	Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis. Targeted Oncology, 2018, 13, 447-459.	1.7	13
1644	A Phase I Study of S-1-based Concurrent Chemoradiotherapy Followed by Gemcitabine and S-1 in Metastatic Pancreatic Adenocarcinoma. Anticancer Research, 2018, 38, 4805-4812.	0.5	3
1646	Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells. BMC Cancer, 2018, 18, 772.	1.1	17
1647	Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer. Radiation Oncology, 2018, 13, 118.	1.2	29
1648	Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma. Pancreatology, 2018, 18, 671-677.	0.5	17
1649	Patients with resectable pancreatic adenocarcinoma: A 15-years single tertiary cancer center study of laparotomy findings, treatments and outcomes. Surgical Oncology, 2018, 27, 619-624.	0.8	2
1650	Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer. Cancer Management and Research, 2018, Volume 10, 1389-1396.	0.9	4
1651	Attenuated FOLFIRINOX in the salvage treatment of gemcitabineâ€refractory advanced pancreatic cancer: a phase II study. Cancer Communications, 2018, 38, 1-8.	3.7	23
1652	Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells. Frontiers in Pharmacology, 2018, 9, 84.	1.6	15
1653	Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics. Frontiers in Physiology, 2018, 9, 335.	1.3	66
1655	LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 871-879.	2.9	80
1656	A phase I pharmacokinetic and pharmacodynamic study of GTI-2040 in combination with gemcitabine in patients with solid tumors. Cancer Chemotherapy and Pharmacology, 2018, 82, 533-539.	1.1	7
1657	Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial. Cancer Chemotherapy and Pharmacology, 2018, 82, 655-660.	1.1	18
1658	Association between NR5A2 and the risk of pancreatic cancer, especially among Caucasians: a meta-analysis of case–control studies. OncoTargets and Therapy, 2018, Volume 11, 2709-2723.	1.0	10

#	Article	IF	Citations
1659	Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer. Cancers, 2018, 10, 35.	1.7	19
1660	Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. Journal of Hematology and Oncology, 2018, 11, 71.	6.9	30
1661	Benefit from the inclusion of surgery in the treatment of patients with stage III pancreatic cancer: a propensity-adjusted, population-based SEER analysis. Cancer Management and Research, 2018, Volume 10, 1907-1918.	0.9	6
1662	Stereotactic Body Radiation Therapy for Locally Progressive and Recurrent Pancreatic Cancer after Prior Radiation. Frontiers in Oncology, 2018, 8, 52.	1.3	13
1663	Next Generation Immunotherapy for Pancreatic Cancer: DNA Vaccination is Seeking New Combo Partners. Cancers, 2018, 10, 51.	1.7	21
1664	Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer. Journal of Translational Medicine, 2018, 16, 190.	1.8	47
1665	Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics. Cancers, 2018, 10, 14.	1.7	26
1666	Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy. Cancers, 2018, 10, 17.	1.7	21
1667	Targeted Therapies for Pancreatic Cancer. Cancers, 2018, 10, 36.	1.7	69
1668	Survival Analysis in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Chemoradiotherapy Followed by Surgery According to the International Consensus on the 2017 Definition of Borderline Resectable Cancer. Cancers, 2018, 10, 65.	1.7	38
1669	Role of Gene Therapy in Pancreatic Cancerâ€"A Review. Cancers, 2018, 10, 103.	1.7	16
1670	A New Strategy to Control and Eradicate â€œUndruggableâ€•Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology. Cancers, 2018, 10, 142.	1.7	17
1671	A Phase II Study of Pelareorep (REOLYSINÂ®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. Cancers, 2018, 10, 160.	1.7	93
1672	Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3Î²/Snail signaling. Oncogene, 2018, 37, 5843-5857.	2.6	92
1673	Prognostic Factors for Pancreatic Cancer Patients Treated with Immune-cell Therapy. Anticancer Research, 2018, 38, 4353-4360.	0.5	6
1674	Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. Pharmacoeconomics, 2018, 36, 1333-1343.	1.7	12
1675	Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 691-697.	3.7	50
1676	Prognostic Roles of Inflammatory Markers in Pancreatic Cancer: Comparison between the Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio. Gastroenterology Research and Practice, 2018, 2018, 1-9.	0.7	27

#	Article	IF	Citations
1678	IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Cancer Immunology Research, 2018, 6, 1014-1024.	1.6	48
1679	Nab-paclitaxel in combination with gemcitabine for the treatment of metastatic pancreas cancer: the South Wales experience. Medical Oncology, 2018, 35, 115.	1.2	9
1680	Advances in oncolytic adenovirus therapy for pancreatic cancer. Cancer Letters, 2018, 434, 56-69.	3.2	33
1681	FOLFIRINOX Chemotherapy in Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis of Retrospective and Phase II Studies. Journal of Clinical Medicine, 2018, 7, 7.	1.0	41
1682	Nabâ€'paclitaxel is effective against intrahepatic cholangiocarcinoma via disruption of desmoplastic stroma. Oncology Letters, 2018, 16, 566-572.	0.8	11
1683	Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis. Gastroenterology Research and Practice, 2018, 2018, 1-7.	0.7	21
1684	The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma. Molecular Cancer, 2018, 17, 95.	7.9	67
1685	Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma. Cancers, 2018, 10, 193.	1.7	16
1686	Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from cholestatic hyperbilirubinaemiaâ€"A retrospective analysis. European Journal of Cancer, 2018, 100, 85-93.	1.3	7
1687	Extract of the Medicinal Plant Pao Pereira Inhibits Pancreatic Cancer Stem-Like Cell In Vitro and In Vivo. Integrative Cancer Therapies, 2018, 17, 1204-1215.	0.8	11
1688	Tumor targeting via EPR: Strategies to enhance patient responses. Advanced Drug Delivery Reviews, 2018, 130, 17-38.	6.6	897
1689	Piperlongumine potentiates the effects of gemcitabine in in vitro and in vivo human pancreatic cancer models. Oncotarget, 2018, 9, 10457-10469.	0.8	21
1690	A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/â^' nab-paclitaxel in elderly pancreatic cancer patients (GrantPax). BMC Cancer, 2018, 18, 747.	1.1	24
1691	Extracellular vesicles as mediators of the progression and chemoresistance of pancreatic cancer and their potential clinical applications. Molecular Cancer, 2018, 17, 2.	7.9	61
1692	MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma. Journal of Experimental and Clinical Cancer Research, 2018, 37, 76.	3.5	58
1693	Walking the line: The fate of nanomaterials at biological barriers. Biomaterials, 2018, 174, 41-53.	5.7	125
1694	What Is the Effect of High-dose Radiation on Bone in Patients With Sacral Chordoma? A CT Study. Clinical Orthopaedics and Related Research, 2018, 476, 520-528.	0.7	17
1695	SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1. Pancreas, 2018, 47, 637-642.	0.5	3

#	Article	IF	Citations
1697	Identification of inhibitors synergizing gemcitabine sensitivity in the squamous subtype of pancreatic ductal adenocarcinoma (PDAC). Apoptosis: an International Journal on Programmed Cell Death, 2018, 23, 343-355.	2.2	38
1698	Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer. Cancer Gene Therapy, 2018, 25, 184-195.	2.2	14
1699	The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration. Current Cancer Drug Targets, 2018, 18, 430-441.	0.8	1
1700	Pancreatic cancer survival analysis defines a signature that predicts outcome. PLoS ONE, 2018, 13, e0201751.	1.1	75
1702	Reversal of pancreatic desmoplasia by re-educating stellate cells with a tumour microenvironment-activated nanosystem. Nature Communications, 2018, 9, 3390.	5.8	249
1703	Urban versus rural residency and pancreatic cancer survival: A Danish nationwide population-based cohort study. PLoS ONE, 2018, 13, e0202486.	1.1	25
1704	A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin inÂlocally advanced or borderline resectable pancreatic adenocarcinoma. European Journal of Cancer, 2018, 102, 95-102.	1.3	50
1705	Final Effectiveness and Safety Results of NABUCCO: Real-World Data From a Noninterventional, Prospective, Multicenter Study in 697 Patients With Metastatic Breast Cancer Treated With nab-Paclitaxel. Clinical Breast Cancer, 2018, 18, e1323-e1337.	1.1	10
1706	Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy. Cancers, 2018, 10, 77.	1.7	30
1707	Differentiation Therapy Targeting the Î²-Catenin/CBP Interaction in Pancreatic Cancer. Cancers, 2018, 10, 95.	1.7	39
1708	Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407). Pancreatology, 2018, 18, 841-845.	0.5	23
1709	From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer. Journal of Cancer, 2018, 9, 1978-1988.	1.2	27
1710	Irreversible Electroporation in pancreatic ductal adenocarcinoma: IsÂthere a role in conjunction with conventional treatment?. European Journal of Surgical Oncology, 2018, 44, 1486-1493.	0.5	11
1711	iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer. Molecular Cancer Therapeutics, 2018, 17, 2377-2388.	1.9	52
1712	Pancreatic Cancerâ€“Induced Cachexia and Relevant Mouse Models. Pancreas, 2018, 47, 937-945.	0.5	43
1713	PDâ€1 Blockade for Improving the Antitumor Efficiency of Polymerâ€“Doxorubicin Nanoprodrug. Small, 2018, 14, e1802403.	5.2	57
1714	Harnessing the Immune System in Pancreatic Cancer. Current Treatment Options in Oncology, 2018, 19, 48.	1.3	17
1715	Phase I study of third-line palliative chemotherapy with low dose paclitaxel for pancreatic cancer. Molecular and Clinical Oncology, 2018, 8, 623-627.	0.4	4

#	Article	IF	Citations
1716	The Modified Appleby Procedure for Locally Advanced Pancreatic Body/Tail Cancer: How I Do It. , 2018, , 177-184.		0
1717	Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma. Seminars in Oncology, 2018, 45, 107-115.	0.8	6
1718	The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression. Molecular Cancer Therapeutics, 2018, 17, 1670-1682.	1.9	79
1719	An onco-geriatric approach to select older patients for optimal treatments of pancreatic adenocarcinoma. Journal of Geriatric Oncology, 2018, 9, 373-381.	0.5	9
1720	Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future. Internal Medicine Journal, 2018, 48, 637-644.	0.5	3
1721	Comparison of endoscopic ultrasound-guided fine-needle aspiration and biopsy with 22-gauge and 25-gauge needles for the â€œprecision medicineâ€•of pancreatic cancer. Medicine (United States), 2018, 97, e11096.	0.4	6
1722	Anemarrhena asphodeloides Bunge and its constituent timosaponinâ€<scp>AIII</scp> induce cell cycle arrest and apoptosis in pancreatic cancer cells. FEBS Open Bio, 2018, 8, 1155-1166.	1.0	25
1723	The Role of the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma and Preclinical Models to Study It. , 2018, , 735-748.		0
1724	Borderline resectable pancreatic cancer. Challenges and controversies. Cancer Treatment Reviews, 2018, 68, 124-135.	3.4	27
1725	Fisetin Enhances the Cytotoxicity of Gemcitabine by Down-regulating ERK-MYC in MiaPaca-2 Human Pancreatic Cancer Cells. Anticancer Research, 2018, 38, 3527-3533.	0.5	20
1726	Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis. Targeted Oncology, 2018, 13, 461-468.	1.7	24
1727	The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis. Scientific Reports, 2018, 8, 8666.	1.6	55
1728	Stromal barriers to nanomedicine penetration in the pancreatic tumor microenvironment. Cancer Science, 2018, 109, 2085-2092.	1.7	70
1729	Sequence therapy in metastatic pancreatic cancer. Zeitschrift Fur Gastroenterologie, 2018, 56, 578-582.	0.2	1
1730	Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer. Cancer Letters, 2018, 432, 251-259.	3.2	59
1731	Early detection of pancreatic cancer in mouse models using a novel antibody, TAB004. PLoS ONE, 2018, 13, e0193260.	1.1	12
1732	Efficacy of Docetaxel and Oxaliplatin Regimen as a Second-Line Therapy for Patients with Advanced Pancreatic Adenocarcinoma. Journal of Gastrointestinal Cancer, 2019, 50, 519-524.	0.6	3
1733	Cyclophosphamide with or without fluorouracil followed by subcutaneous or intravenous interleukin-2 use in solid tumors: A feasibility off-label experience. Cytokine, 2019, 113, 50-60.	1.4	5

#	Article	IF	Citations
1734	A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid Tumors. Oncologist, 2019, 24, 14-e10.	1.9	32
1735	Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Investigational New Drugs, 2019, 37, 159-165.	1.2	28
1736	Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma. International Journal of Cancer, 2019, 144, 981-990.	2.3	40
1737	Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial. Investigational New Drugs, 2019, 37, 127-138.	1.2	0
1738	Management and supportive treatment of frail patients with metastatic pancreatic cancer. Journal of Geriatric Oncology, 2019, 10, 398-404.	0.5	9
1740	Paradigm Shifting of Systemic Chemotherapy for Unresectable Pancreatic Cancer in Japan. Journal of Clinical Medicine, 2019, 8, 1170.	1.0	4
1741	Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy. Cancer Medicine, 2019, 8, 5554-5563.	1.3	3
1742	New Era of Endoscopic Ultrasound-Guided Tissue Acquisition: Next-Generation Sequencing by Endoscopic Ultrasound-Guided Sampling for Pancreatic Cancer. Journal of Clinical Medicine, 2019, 8, 1173.	1.0	27
1744	Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiation Oncology, 2019, 14, 141.	1.2	285
1745	Safety and efficacy of locoregional therapy for metastatic pancreatic ductal adenocarcinoma to the liver: a single-center experience. Journal of Gastrointestinal Oncology, 2019, 10, 688-694.	0.6	6
1746	EMT and Stemnessâ€"Key Players in Pancreatic Cancer Stem Cells. Cancers, 2019, 11, 1136.	1.7	88
1747	Radiofrequency Ablation of Pancreatic Cancer. Digestive Disease Interventions, 2019, 03, 133-137.	0.3	1
1748	Irreversible Electroporation: Expanding the Armamentarium against Pancreatic Cancer. Digestive Disease Interventions, 2019, 03, 138-142.	0.3	0
1749	High-Intensity Focused Ultrasound Ablation of Pancreatic Cancer. Digestive Disease Interventions, 2019, 03, 243-252.	0.3	1
1750	Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis. Journal of Cancer, 2019, 10, 4420-4429.	1.2	20
1751	Acute Pancreatitis, Chronic Pancreatitis and Pancreatic Neoplasms. , 2019, , 103-117.		0
1752	Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2019, 37, 2643-2650.	0.8	126
1753	Perioperative Gemcitabineâ€‰+â€‰Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Annals of Surgical Oncology, 2019, 26, 4489-4497.	0.7	19

#	Article	IF	Citations
1755	Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer. Scientific Reports, 2019, 9, 11131.	1.6	21
1758	FFâ€10832 enables long survival via effective gemcitabine accumulation in a lethal murine peritoneal dissemination model. Cancer Science, 2019, 110, 2933-2940.	1.7	4
1759	Defining Value for Pancreatic Surgery in Early-Stage Pancreatic Cancer. JAMA Surgery, 2019, 154, e193019.	2.2	22
1760	Optimizing pharmacokinetics of intravesical chemotherapy for bladder cancer. Nature Reviews Urology, 2019, 16, 599-612.	1.9	39
1761	Ablative, Endovascular, and Biliary Interventions for Patients with Pancreatic Cancer. Seminars in Interventional Radiology, 2019, 36, 203-212.	0.3	3
1762	Multi-omic molecular comparison of primary versus metastatic pancreatic tumours. British Journal of Cancer, 2019, 121, 264-270.	2.9	15
1763	Impact on healthâ€related quality of life deteriorationâ€free survival of a firstâ€line therapy combining nabâ€paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial. Cancer Medicine, 2019, 8, 5079-5088.	1.3	11
1764	A clinical trial to assess the feasibility and efficacy of nab-paclitaxel plus gemcitabine for elderly patients with unresectable advanced pancreatic cancer. International Journal of Clinical Oncology, 2019, 24, 1574-1581.	1.0	24
1765	Is hepatic artery coil embolization useful in distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic cancer?. World Journal of Surgical Oncology, 2019, 17, 124.	0.8	23
1766	Paclitaxel and Itraconazole Coâ€Encapsulated Micelle Prolongs the Survival of Spontaneous LSLâ€Kras^{G12D/+}, LSLâ€Trp53^{R172H/+}, Pdxâ€1â€Cre Genetically Engineered Mouse Model of Pancreatic Cancer. Advanced Therapeutics, 2019, 2, 1900032.	1.1	4
1767	MEK Inhibition Targets Cancer Stem Cells and Impedes Migration of Pancreatic Cancer CellsIn VitroandIn Vivo. Stem Cells International, 2019, 2019, 1-11.	1.2	11
1768	Xenograft and organoid model systems in cancerÂresearch. EMBO Journal, 2019, 38, e101654.	3.5	257
1769	Better Defining the Role of Total Neoadjuvant Radiation: Changing Paradigms in Locally Advanced Pancreatic Cancer. Annals of Surgical Oncology, 2019, 26, 3701-3708.	0.7	18
1770	Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. Cancers, 2019, 11, 981.	1.7	29
1771	Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study. Cancers, 2019, 11, 939.	1.7	12
1772	Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance. Critical Reviews in Oncology/Hematology, 2019, 141, 153-162.	2.0	21
1773	Phase I/II Study: Experience with the Late Onset of Acute Pancreatitis after the Start of Chemotherapy with Gemcitabine Plus nab-Paclitaxel for Metastatic Pancreatic Cancer. Internal Medicine, 2019, 58, 2957-2962.	0.3	3
1774	Cancer-associated fibroblastsâ€"heroes or villains?. British Journal of Cancer, 2019, 121, 293-302.	2.9	155

#	Article	IF	Citations
1775	Conversion Surgery for Metastatic Pancreatic Mucinous Carcinoma Responsive to Systemic Chemotherapy with Modified FOLFIRINOX: A Case Report. Journal of Nippon Medical School, 2019, 86, 284-290.	0.3	3
1776	Tumor-specific delivery of gemcitabine with activatable liposomes. Journal of Controlled Release, 2019, 309, 277-288.	4.8	42
1777	Acetylation regulates ribonucleotide reductase activity and cancer cell growth. Nature Communications, 2019, 10, 3213.	5.8	49
1778	PARP inhibition â€" opportunities in pancreatic cancer. Nature Reviews Clinical Oncology, 2019, 16, 595-596.	12.5	19
1779	Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy. FEBS Journal, 2019, 286, 3510-3539.	2.2	33
1780	Impact of the Duration of Diabetes Mellitus on the Outcome of Metastatic Pancreatic Cancer Treated with Gemcitabine: A Retrospective Study. Internal Medicine, 2019, 58, 2435-2441.	0.3	4
1781	Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. Cancers, 2019, 11, 976.	1.7	63
1782	Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. JAMA Surgery, 2019, 154, 932.	2.2	97
1783	Research progress and design optimization of CARâ€T therapy for pancreatic ductal adenocarcinoma. Cancer Medicine, 2019, 8, 5223-5231.	1.3	12
1785	A randomized phase II trial of nabâ€paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. Cancer Medicine, 2019, 8, 5148-5157.	1.3	60
1786	Enhancing Nab-Paclitaxel Delivery Using Microbubble-Assisted Ultrasound in a Pancreatic Cancer Model. Molecular Pharmaceutics, 2019, 16, 3814-3822.	2.3	32
1788	A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591985319.	1.4	29
1789	Status of 5-Year Survivors of the Whipple Procedure for Pancreatic Adenocarcinoma. Advances in Surgery, 2019, 53, 253-269.	0.6	4
1790	miRNA Predictors of Pancreatic Cancer Chemotherapeutic Response: A Systematic Review and Meta-Analysis. Cancers, 2019, 11, 900.	1.7	23
1791	Drug-Impregnated Polymer Delivery. , 2019, , 275-296.		0
1792	Pharmacokinetics and pharmacodynamics of new drugs for pancreatic cancer. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 541-552.	1.5	14
1793	A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method. BMC Cancer, 2019, 19, 632.	1.1	21
1794	State of the Art for Metastatic Pancreatic Cancer Treatment: Where Are We Now?. Anticancer Research, 2019, 39, 3405-3412.	0.5	21

#	Article	IF	Citations
1795	Polymer nanoparticles for the release of complex molecules. , 2019, , 135-163.		8
1796	Molecular radionuclide imaging of pancreatic neoplasms. The Lancet Gastroenterology and Hepatology, 2019, 4, 559-570.	3.7	15
1797	Bone metastasis as primary presentation of pancreatic ductal adenocarcinoma: A case report and literature review. Clinical Case Reports (discontinued), 2019, 7, 1972-1976.	0.2	12
1798	The Anatomical Pattern of the Proximal Jejunal Vein as a Prognostic Factor in Patients With Pancreatic Head Cancer Treated With Preoperative Chemoradiation Therapy. Anticancer Research, 2019, 39, 5821-5830.	0.5	2
1799	FOLFIRINOX in Patients With Peritoneal Carcinomatosis From Pancreatic Adenocarcinoma: A Retrospective Study. Current Oncology, 2019, 26, 466-472.	0.9	5
1800	Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer?. Cancers, 2019, 11, 1547.	1.7	10
1801	Targeting Glycolysis with Epigallocatechin-3-Gallate Enhances the Efficacy of Chemotherapeutics in Pancreatic Cancer Cells and Xenografts. Cancers, 2019, 11, 1496.	1.7	36
1802	An update on treatment options for pancreatic adenocarcinoma. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987556.	1.4	144
1803	Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481987866.	1.4	39
1804	Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma. Gastroenterology Research and Practice, 2019, 2019, 1-17.	0.7	8
1805	First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age. Journal of Gastrointestinal Oncology, 2019, 10, 910-917.	0.6	15
1806	Novel discoveries targeting gemcitabineâ€based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?. Cancer Medicine, 2019, 8, 6403-6413.	1.3	17
1807	Clinical candidate and genistein analogue AXP107â€11 has chemoenhancing functions in pancreatic adenocarcinoma through G proteinâ€coupled estrogen receptor signaling. Cancer Medicine, 2019, 8, 7705-7719.	1.3	15
1808	Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer. Journal of Translational Medicine, 2019, 17, 30.	1.8	58
1809	Helical tomotherapy for chemoâ€refractory multiple liver metastases. Cancer Medicine, 2019, 8, 7594-7602.	1.3	4
1810	Indirubin 3â€²-Oxime Inhibits Migration, Invasion, and Metastasis in Mice Bearing Spontaneously Occurring Pancreatic Cancer via Blocking the RAF/ERK, AKT, and SAPK/JNK Pathways. Translational Oncology, 2019, 12, 1574-1582.	1.7	18
1811	ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications. Molecular Cancer Therapeutics, 2019, 18, 1899-1908.	1.9	52
1812	Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shift. Frontiers in Oncology, 2019, 9, 1085.	1.3	48

#	Article	IF	Citations
1813	Evolving Treatment Paradigms for Pancreatic Cancer. Visceral Medicine, 2019, 35, 362-372.	0.5	6
1814	Network Meta-Analysis of Efficacy and Safety of Chemotherapy and Target Therapy in the First-Line Setting of Advanced Pancreatic Cancer. Cancers, 2019, 11, 1746.	1.7	6
1815	Gemcitabine Combination Nano Therapies for Pancreatic Cancer. Pharmaceutics, 2019, 11, 574.	2.0	58
1817	Clinical Significance of Neoadjuvant Chemotherapy With Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma. In Vivo, 2019, 33, 2027-2035.	0.6	8
1818	Pancreatic cancer-educated macrophages protect cancer cells from complement-dependent cytotoxicity by up-regulation of CD59. Cell Death and Disease, 2019, 10, 836.	2.7	29
1819	Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer. Scientific Reports, 2019, 9, 16187.	1.6	16
1820	PAC-5 Gene Expression Signature for Predicting Prognosis of Patients with Pancreatic Adenocarcinoma. Cancers, 2019, 11, 1749.	1.7	13
1821	New therapeutic targets in pancreatic cancer. Cancer Treatment Reviews, 2019, 81, 101926.	3.4	74
1822	Eastern Canadian Gastrointestinal Cancer Consensus Conference 2018. Current Oncology, 2019, 26, 665-681.	0.9	2
1825	A small cytotoxic peptide from frog elicits potent antitumor immunity to prevent local tumor growth and metastases. Future Medicinal Chemistry, 2019, 11, 2505-2525.	1.1	4
1826	Inhibitory Effect of Oat Bran Ethanol Extract on Survival and Gemcitabine Resistance of Pancreatic Cancer Cells. Molecules, 2019, 24, 3829.	1.7	4
1827	An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 23264-23273.	3.3	27
1829	Improvement of Treatment Outcomes for Metastatic Pancreatic Cancer: A Real-world Data Analysis. In Vivo, 2019, 33, 271-276.	0.6	26
1830	Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency. Cancers, 2019, 11, 68.	1.7	78
1831	Critical Aspects of a Sustainable Clinical Research Program in the Community-Based Oncology Practice. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 176-184.	1.8	5
1832	Unravelling the Diagnostic Dilemma: A MicroRNA Panel of Circulating MiR-16 and MiR-877 as A Diagnostic Classifier for Distal Bile Duct Tumors. Cancers, 2019, 11, 1181.	1.7	16
1833	Survival benefit of neoadjuvant therapy in patients with nonâ€metastatic pancreatic ductal adenocarcinoma: A propensity matching and intentionâ€toâ€treat analysis. Journal of Surgical Oncology, 2019, 120, 976-984.	0.8	35
1834	Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy. Oncology Reviews, 2019, 13, 430.	0.8	9

#	Article	IF	Citations
1836	A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2019, 26, 4498-4505.	0.7	34
1837	Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment. Medical Oncology, 2019, 36, 83.	1.2	5
1838	Modulation of redox metabolism negates cancer-associated fibroblasts-induced treatment resistance in a heterotypic 3D culture platform of pancreatic cancer. Biomaterials, 2019, 222, 119421.	5.7	55
1839	Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study. World Journal of Surgical Oncology, 2019, 17, 145.	0.8	16
1841	Markers of pancreatic cancer stem cells and their clinical and therapeutic implications. Molecular Biology Reports, 2019, 46, 6629-6645.	1.0	77
1842	Treatment and survival rates of stage IV pancreatic cancer at VA hospitals: a nation-wide study. Journal of Gastrointestinal Oncology, 2019, 10, 703-711.	0.6	22
1843	Immune Microenvironment of Brain Metastasesâ€"Are Microglia and Other Brain Macrophages Little Helpers?. Frontiers in Immunology, 2019, 10, 1941.	2.2	41
1844	Treatment of hepatic pancreatic ductal adenocarcinoma metastases with high-dose-rate image-guided interstitial brachytherapy: a single center experience. Journal of Contemporary Brachytherapy, 2019, 11, 329-336.	0.4	5
1845	Encapsulating fibrosis following neoadjuvant chemotherapy is correlated with outcomes in patients with pancreatic cancer. PLoS ONE, 2019, 14, e0222155.	1.1	24
1846	Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Murine Pancreatic Cancer Model. Cancer Immunology Research, 2019, 7, 1714-1726.	1.6	72
1847	Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC). Cancers, 2019, 11, 1297.	1.7	21
1848	Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience. Medical Oncology, 2019, 36, 87.	1.2	12
1849	Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987112.	1.4	27
1850	Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosis . International Journal of Nanomedicine, 2019, Volume 14, 6589-6600.	3.3	23
1851	Collagenase Nanoparticles Enhance the Penetration of Drugs into Pancreatic Tumors. ACS Nano, 2019, 13, 11008-11021.	7.3	209
1852	Survival Benefits of Chemotherapy for Patients with Advanced Pancreatic Cancer in A Clinical Real-World Cohort. Cancers, 2019, 11, 1326.	1.7	21
1853	Characteristics and survival of older patients with metastatic pancreatic cancer: a retrospective analysis of the AC Camargo Cancer Center experience. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987465.	1.4	8
1854	ASO Author Reflections: Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer on Surgical Outcomes. Annals of Surgical Oncology, 2019, 26, 739-740.	0.7	2

#	Article	IF	Citations
1855	A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas. Future Oncology, 2019, 15, 3189-3196.	1.1	64
1856	The evaluation of efficacy and tolerability of gemcitabine vs. capecitabine therapy in the second-line setting for metastatic pancreatic cancer patients with poor performance status. Journal of Oncological Science, 2019, 5, 85-89.	0.1	0
1857	Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer. Journal of Hematology and Oncology, 2019, 12, 97.	6.9	88
1858	Environmental Risk Factors of Pancreatic Cancer. Journal of Clinical Medicine, 2019, 8, 1427.	1.0	35
1859	Lung Metastases in Patients with Stage IV Pancreatic Cancer: Prevalence, Risk Factors, and Survival Impact. Journal of Clinical Medicine, 2019, 8, 1402.	1.0	14
1860	A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf Pancreatic Cancer. Journal of Pancreatic Cancer, 2019, 5, 35-42.	1.6	10
1861	PML hyposumoylation is responsible for the resistance of pancreatic cancer. FASEB Journal, 2019, 33, 12447-12463.	0.2	12
1862	Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Annals of Oncology, 2019, 30, 1959-1968.	0.6	37
1863	Prognostic Impact of the Neutrophilâ€toâ€Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection. World Journal of Surgery, 2019, 43, 3153-3160.	0.8	11
1864	Modulated Electro-Hyperthermia as Palliative Treatment for Pancreatic Cancer: A Retrospective Observational Study on 106 Patients. Integrative Cancer Therapies, 2019, 18, 153473541987850.	0.8	33
1865	Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives. Expert Opinion on Pharmacotherapy, 2019, 20, 2121-2137.	0.9	7
1866	Perioperative Clinical Trials for Pancreatic Cancer in the National Clinical Trials Network. Annals of Surgical Oncology, 2019, 26, 4173-4174.	0.7	0
1867	A multi-center, Phase II trial of nab-paclitaxel and gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy . Cancer Management and Research, 2019, Volume 11, 7135-7140.	0.9	5
1868	A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy. PLoS ONE, 2019, 14, e0218642.	1.1	48
1869	Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis. Cancer Treatment Reviews, 2019, 80, 101895.	3.4	32
1870	Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. Clinical Colorectal Cancer, 2019, 18, e394-e401.	1.0	13
1871	Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status. Immunology Letters, 2019, 216, 43-50.	1.1	21
1872	Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481987763.	1.4	5

#	Article	IF	Citations
1873	Vimentin Expression in Tumor Microenvironment Predicts Survival in Pancreatic Ductal Adenocarcinoma: Heterogeneity in Fibroblast Population. Annals of Surgical Oncology, 2019, 26, 4791-4804.	0.7	16
1874	Precision medicine in pancreatic cancer: treating every patient as an exception. The Lancet Gastroenterology and Hepatology, 2019, 4, 805-810.	3.7	29
1875	Dilatation of the main pancreatic duct as first manifestation of small pancreatic ductal adenocarcinomas detected in a hereditary pancreatic cancer surveillance program. Hpb, 2019, 21, 1371-1375.	0.1	7
1876	Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions. International Journal of Molecular Sciences, 2019, 20, 4543.	1.8	68
1877	Plasma IFN-Î³-inducible chemokines CXCL9 and CXCL10 correlate with survival and chemotherapeutic efficacy in advanced pancreatic ductal adenocarcinoma. Pancreatology, 2019, 19, 340-345.	0.5	33
1878	Capecitabine for the treatment of pancreatic cancer. Expert Opinion on Pharmacotherapy, 2019, 20, 399-409.	0.9	26
1879	Antigenic Targets for the Immunotherapy of Acute Myeloid Leukaemia. Journal of Clinical Medicine, 2019, 8, 134.	1.0	6
1880	S-Adenosylmethionine synergistically enhances the antitumor effect of gemcitabine against pancreatic cancer through JAK2/STAT3 pathway. Naunyn-Schmiedeberg's Archives of Pharmacology, 2019, 392, 615-622.	1.4	13
1881	Primarily resectable pancreatic adenocarcinoma â€“ to operate or to refer the patient to an oncologist?. Critical Reviews in Oncology/Hematology, 2019, 135, 95-102.	2.0	6
1882	Protein-driven nanomedicines in oncotherapy. Current Opinion in Pharmacology, 2019, 47, 1-7.	1.7	21
1883	A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer. Molecular Therapy - Oncolytics, 2019, 12, 56-67.	2.0	36
1884	A Polymeric Nanogel-Based Treatment Regimen for Enhanced Efficacy and Sequential Administration of Synergistic Drug Combination in Pancreatic Cancer. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 894-901.	1.3	16
1885	Biological Effects of Nanoparticles on Macrophage Polarization in the Tumor Microenvironment. Nanotheranostics, 2019, 3, 66-88.	2.7	121
1887	Tackling molecular targets beyond PD-1/PD-L1: Novel approaches to boost patientsâ€™ response to cancer immunotherapy. Critical Reviews in Oncology/Hematology, 2019, 135, 21-29.	2.0	23
1888	The functional roles of exosomal long non-coding RNAs in cancer. Cellular and Molecular Life Sciences, 2019, 76, 2059-2076.	2.4	100
1889	A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance). Oncologist, 2019, 24, 589-e160.	1.9	27
1890	Current perspectives of cancer-associated fibroblast in therapeutic resistance: potential mechanism and future strategy. Cell Biology and Toxicology, 2019, 35, 407-421.	2.4	43
1891	Cytosolic 5â€²-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites. EBioMedicine, 2019, 40, 394-405.	2.7	24

#	Article	IF	Citations
1892	Perioperative blood transfusions for vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Identification of clinical targets for optimization. Hpb, 2019, 21, 841-848.	0.1	4
1893	FOLFIRINOX is a cost-effective combination chemotherapy in first-line for advanced pancreatic Cancer. Pancreatology, 2019, 19, 325-330.	0.5	3
1894	Pancreatic cancer in young adults: changes, challenges, and solutions . OncoTargets and Therapy, 2019, Volume 12, 3387-3400.	1.0	15
1895	Concentration changes in gemcitabine and its metabolites after hyperthermia in pancreatic cancer cells assessed using RP-HPLC. Cellular and Molecular Biology Letters, 2019, 24, 30.	2.7	4
1896	Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience . OncoTargets and Therapy, 2019, Volume 12, 3077-3085.	1.0	14
1897	Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma: a population-based analysis. Cmaj, 2019, 191, E574-E580.	0.9	21
1898	Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591984123.	1.4	35
1899	A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma. ChemMedChem, 2019, 14, 1384-1391.	1.6	15
1900	Nanomedicines - Tiny particles and big challenges. Advanced Drug Delivery Reviews, 2019, 151-152, 23-43.	6.6	73
1901	Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). Expert Opinion on Investigational Drugs, 2019, 28, 583-592.	1.9	17
1902	Leflunomide Synergizes with Gemcitabine in Growth Inhibition of PC Cells and Impairs c-Myc Signaling through PIM Kinase Targeting. Molecular Therapy - Oncolytics, 2019, 14, 149-158.	2.0	17
1903	The role of mouse tumour models in the discovery and development of anticancer drugs. British Journal of Cancer, 2019, 121, 101-108.	2.9	119
1904	The efficacy and safety of nab paclitaxel plus gemcitabine in elderly patients over 75Âyears with unresectable pancreatic cancer compared with younger patients. Cancer Chemotherapy and Pharmacology, 2019, 84, 647-654.	1.1	18
1905	Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 20, 102027.	1.7	18
1906	Enzyme-mediated depletion of l-cyst(e)ine synergizes with thioredoxin reductase inhibition for suppression of pancreatic tumor growth. Npj Precision Oncology, 2019, 3, 16.	2.3	28
1907	Checkpoint inhibitors in pancreatic cancer. Cancer Treatment Reviews, 2019, 78, 17-30.	3.4	146
1908	Surgical treatment of metastatic pancreatic ductal adenocarcinoma: AÂreview of current literature. Pancreatology, 2019, 19, 672-680.	0.5	37
1909	The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells. Molecular Cancer Research, 2019, 17, 1815-1827.	1.5	40

#	Article	IF	Citations
1910	Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results. Radiation Oncology, 2019, 14, 95.	1.2	118
1911	Contribution of pancreatic enzyme replacement therapy to survival and quality of life in patients with pancreatic exocrine insufficiency. World Journal of Gastroenterology, 2019, 25, 2430-2441.	1.4	41
1912	Effective Delivery of a Microtubule Polymerization Inhibitor Synergizes with Standard Regimens in Models of Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2019, 25, 5548-5560.	3.2	23
1913	New Perspective in Pancreatic Cancer. , 2019, , 151-161.		0
1914	Pharmacogenetics of treatments for pancreatic cancer. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 437-447.	1.5	20
1915	Pancreatic cancer microenvironment: a current dilemma. Clinical and Translational Medicine, 2019, 8, 2.	1.7	72
1916	Inflammatory and Senescent Phenotype of Pancreatic Stellate Cells Induced by Sqstm1 Downregulation Facilitates Pancreatic Cancer Progression. International Journal of Biological Sciences, 2019, 15, 1020-1029.	2.6	16
1917	Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. Clinical Cancer Research, 2019, 25, 4973-4984.	3.2	118
1918	Pancreatic Ductal Organoids React Kras Dependent to the Removal of Tumor Suppressive Roadblocks. Stem Cells International, 2019, 2019, 1-8.	1.2	2
1919	Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer. Cancer Letters, 2019, 459, 41-49.	3.2	35
1920	Proton Radiotherapy for Isolated Local Recurrence of Primary Resected Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2019, 26, 2587-2594.	0.7	8
1921	Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure. Journal of Clinical Medicine, 2019, 8, 761.	1.0	34
1922	Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence. Cancer Treatment Reviews, 2019, 77, 1-10.	3.4	48
1923	Nowadays pancreatic cancer prognosis. Medicina ClÃnica (English Edition), 2019, 152, 395-396.	0.1	0
1924	Significance of the inflammation-based prognostic score in recurrent pancreatic cancer. Pancreatology, 2019, 19, 722-728.	0.5	18
1925	Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. New England Journal of Medicine, 2019, 381, 317-327.	13.9	1,521
1926	Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy. Cancers, 2019, 11, 749.	1.7	4
1927	Longâ€Term Survivors in Metastatic Pancreatic Ductal Adenocarcinoma: A Retrospective and Matched Pair Analysis. Oncologist, 2019, 24, 1543-1548.	1.9	15

#	Article	IF	Citations
1928	Imaging response evaluation after novel neoadjuvant treatments of pancreatic cancer. European Surgery - Acta Chirurgica Austriaca, 2019, 51, 146-152.	0.3	7
1929	Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma. Scandinavian Journal of Gastroenterology, 2019, 54, 780-786.	0.6	17
1930	Alcoholic/Non-Alcoholic Digestive Diseases. , 2019, , .		0
1931	Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma. Expert Review of Anticancer Therapy, 2019, 19, 473-482.	1.1	26
1932	Preclinical Evaluation of 1,2-Diamino-4,5-Dibromobenzene in Genetically Engineered Mouse Models of Pancreatic Cancer. Cells, 2019, 8, 563.	1.8	5
1933	Combination Chemotherapy in Patients With Advanced Pancreatic Cancer With an Eastern Cooperative Oncology Group Performance Status of 2: Lights and Shadows of a Frail Route. Journal of Clinical Oncology, 2019, 37, 1978-1979.	0.8	1
1934	Bitter melon juice-intake modulates glucose metabolism and lactate efflux in tumors in its efficacy against pancreatic cancer. Carcinogenesis, 2019, 40, 1164-1176.	1.3	12
1935	Next Viable Routes to Targeting Pancreatic Cancer Stemness: Learning from Clinical Setbacks. Journal of Clinical Medicine, 2019, 8, 702.	1.0	13
1936	Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer. JAMA Oncology, 2019, 5, 993.	3.4	209
1937	Impact of Weight Loss During Chemotherapy in Chinese Patients with Unresectable Pancreatic Cancer. Nutrition and Cancer, 2019, 71, 954-970.	0.9	7
1938	Management of ductal pancreatic cancer. European Surgery - Acta Chirurgica Austriaca, 2019, 51, 135-138.	0.3	2
1939	Current Status of Immunotherapies for Treating Pancreatic Cancer. Current Oncology Reports, 2019, 21, 60.	1.8	38
1940	HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1. EBioMedicine, 2019, 44, 403-418.	2.7	20
1941	Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study. BMC Cancer, 2019, 19, 468.	1.1	31
1942	Durable response for ampullary and duodenal adenocarcinoma with a nabâ€paclitaxel plus gemcitabineÂÂ±Âcisplatin combination. Cancer Medicine, 2019, 8, 3464-3470.	1.3	8
1943	Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591985036.	1.4	45
1944	Management of primary squamous cell carcinoma of the pancreas with a nanosomal paclitaxel lipid suspension-based regimen: A case report. Molecular and Clinical Oncology, 2019, 10, 430-434.	0.4	7
1945	Paclitaxel interaction with cucurbit [7]uril and acyclic Cucurbit[4]uril nanocontainers: A computational approach. Journal of Molecular Graphics and Modelling, 2019, 90, 210-218.	1.3	3

#	Article	IF	Citations
1946	The functions and oncogenic roles of CCAT1 in human cancer. Biomedicine and Pharmacotherapy, 2019, 115, 108943.	2.5	46
1947	Association of time interval between cancer diagnosis and initiation of palliative chemotherapy with overall survival in patients with unresectable pancreatic cancer. Cancer Medicine, 2019, 8, 3471-3478.	1.3	11
1948	LW6 enhances chemosensitivity to gemcitabine and inhibits autophagic flux in pancreatic cancer. Journal of Advanced Research, 2019, 20, 9-21.	4.4	21
1949	First line modified Folfirinox versus gemcitabine for advanced pancreatic cancer: A single institution retrospective experience. Journal of Oncological Science, 2019, 5, 1-5.	0.1	3
1950	A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Journal of Pancreatic Cancer, 2019, 5, 12-21.	1.6	2
1951	Treatment strategies and clinical outcomes of locally advanced pancreatic cancer patients treated at high-volume facilities and academic centers. Advances in Radiation Oncology, 2019, 4, 302-313.	0.6	10
1952	The potential of dopamine receptor D2 (DRD2) as a therapeutic target for tackling pancreatic cancer. Expert Opinion on Therapeutic Targets, 2019, 23, 365-367.	1.5	12
1953	Targeted delivery systems for treatment of pancreatic cancer. , 2019, , 411-436.		1
1954	Combination chemotherapy with gemcitabine and nab-paclitaxel for a metastatic pancreatic ductal adenocarcinoma patient undergoing hemodialysis. Clinical Journal of Gastroenterology, 2019, 12, 484-489.	0.4	1
1955	Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers. JAMA Oncology, 2019, 5, 824.	3.4	335
1956	Effect of Sâ€1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7â€year multicenter observational cohort study in Taiwan. Cancer Medicine, 2019, 8, 2085-2094.	1.3	9
1957	Evolution of oncosurgical management of pancreatic cancer. European Surgery - Acta Chirurgica Austriaca, 2019, 51, 165-173.	0.3	6
1958	Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma with synchronous liver metastasis after treatment with FOLFIRINOX. Clinical Journal of Gastroenterology, 2019, 12, 603-608.	0.4	4
1959	Codelivery Nanosystem Targeting the Deep Microenvironment of Pancreatic Cancer. Nano Letters, 2019, 19, 3527-3534.	4.5	55
1960	Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer. Radiotherapy and Oncology, 2019, 136, 37-43.	0.3	34
1961	Identification of MRP4/ABCC4 as a Target for Reducing the Proliferation of Pancreatic Ductal Adenocarcinoma Cells by Modulating the cAMP Efflux. Molecular Pharmacology, 2019, 96, 13-25.	1.0	17
1962	Clinical impact of different exosomesâ€™ protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy. PLoS ONE, 2019, 14, e0215990.	1.1	24
1963	Gemcitabine-induced haemolytic uraemic syndrome in pancreatic adenocarcinoma. BMJ Case Reports, 2019, 12, e228363.	0.2	2

#	Article	IF	Citations
1964	Drug development using pancreatic and lung organoid models. , 2019, , 323-342.		0
1965	Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, 663-668.	0.7	12
1966	ABCC3 is a novel target for the treatment of pancreatic cancer. Advances in Biological Regulation, 2019, 73, 100634.	1.4	18
1967	Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy. Nutrition and Cancer, 2019, 71, 1100-1107.	0.9	9
1968	A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy. Trials, 2019, 20, 242.	0.7	18
1969	Cavitation-induced release of liposomal chemotherapy in orthotopic murine pancreatic cancer models: A feasibility study. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, 669-681.	0.7	9
1970	Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer. Cancer Research, 2019, 79, 2327-2338.	0.4	27
1971	A Single-Institution Validation Study of Lymph Node Staging By the AJCC 8th Edition for Patients with Pancreatic Head Cancer: A Proposal to Subdivide the N2 Category. Annals of Surgical Oncology, 2019, 26, 2112-2120.	0.7	16
1972	Inflammation, Biomarkers and Immuno-Oncology Pathways in Pancreatic Cancer. Journal of Personalized Medicine, 2019, 9, 20.	1.1	14
1974	Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment. Journal of Experimental and Clinical Cancer Research, 2019, 38, 162.	3.5	116
1975	Surgical and local therapeutic concepts of oligometastatic pancreatic cancer in the era of effective chemotherapy. European Surgery - Acta Chirurgica Austriaca, 2019, 51, 153-164.	0.3	5
1976	The Wnt signaling pathway: a potential therapeutic target against cancer. Annals of the New York Academy of Sciences, 2019, 1443, 54-74.	1.8	93
1977	Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. Gastroenterology, 2019, 156, 2242-2253.e4.	0.6	224
1978	Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers, 2019, 11, 588.	1.7	42
1979	Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies. PLoS ONE, 2019, 14, e0215409.	1.1	7
1980	Silver-Nanoparticle-Mediated Therapies in the Treatment of Pancreatic Cancer. ACS Applied Nano Materials, 2019, 2, 1758-1772.	2.4	16
1981	Advances in pancreatic cancer biomarkers. Oncology Reviews, 2019, 13, 410.	0.8	87
1983	Pancreatic cancer: Best supportive care. Presse Medicale, 2019, 48, e175-e185.	0.8	21

#	Article	IF	Citations
1984	TGFÎ² receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2019, 83, 975-991.	1.1	60
1985	MicroRNA-374a promotes pancreatic cancer cell proliferation and epithelial to mesenchymal transition by targeting SRCIN1. Pathology Research and Practice, 2019, 215, 152382.	1.0	14
1986	Molecular Markers for Treatment Response and Toxicity of Gemcitabine. , 2019, , 175-195.		2
1987	HIFU is safe, effective, and feasible in pancreatic cancer patients: a monocentric retrospective study among 523 patients . OncoTargets and Therapy, 2019, Volume 12, 1021-1029.	1.0	38
1988	Organoid models for translational pancreatic cancer research. Current Opinion in Genetics and Development, 2019, 54, 7-11.	1.5	57
1989	Novel Synergistic Combination of Mitotic Arrest and Promotion of Apoptosis for Treatment of Pancreatic Adenocarcinoma. Translational Oncology, 2019, 12, 683-692.	1.7	13
1990	Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer â€“ A subgroup analysis of the pivotal NAPOLI-1 trial. Journal of Geriatric Oncology, 2019, 10, 427-435.	0.5	23
1991	Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation. American Journal of Surgical Pathology, 2019, 43, 334-340.	2.1	19
1992	Obesogenic high-fat diet heightens aerobic glycolysis through hyperactivation of oncogenic KRAS. Cell Communication and Signaling, 2019, 17, 19.	2.7	19
1993	Nanodrug delivery systems in cancer. , 2019, , 31-62.		4
1994	Pancreatic Cancer and Possible Therapeutic Options. , 2019, , 57-85.		0
1995	Analysis of BRCAness with multiplex ligation-dependent probe amplification using formalin-fixed and paraffin-embedded pancreatic ductal adenocarcinoma tissue obtained via endoscopic ultrasound-guided fine-needle aspiration biopsy. Pancreatology, 2019, 19, 419-423.	0.5	3
1996	Integrin Î±11 in pancreatic stellate cells regulates tumor stroma interaction in pancreatic cancer. FASEB Journal, 2019, 33, 6609-6621.	0.2	41
1997	Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis. Cancers, 2019, 11, 278.	1.7	31
1998	Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review. Cancer Treatment Reviews, 2019, 75, 27-38.	3.4	32
1999	Effects of duration of initial treatment on postoperative complications in pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Sciences, 2019, 26, 235-241.	1.4	6
2000	Population-based study of the impact of surgical and adjuvant therapy at the same or a different institution on survival of patients with pancreatic adenocarcinoma. BJS Open, 2019, 3, 85-94.	0.7	5
2001	Combined Effect of Moringa oleifera and Ionizing Radiation on Survival and Metastatic Activity of Pancreatic Cancer Cells. Integrative Cancer Therapies, 2019, 18, 153473541982882.	0.8	18

#	Article	IF	Citations
2002	Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives . OncoTargets and Therapy, 2019, Volume 12, 1455-1463.	1.0	18
2003	CAFs and TGF-Î² Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer. Cancers, 2019, 11, 330.	1.7	71
2004	Palliative Care Consultation and Aggressive Care at End of Life in Unresectable Pancreatic Cancer. Current Oncology, 2019, 26, 28-36.	0.9	15
2005	Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma. Cancer Cell International, 2019, 19, 49.	1.8	19
2006	Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery. Annals of Surgical Oncology, 2019, 26, 1528-1534.	0.7	64
2007	Surgical outcomes of pulmonary metastasis from hepatopancreatobiliary carcinomas: a comparison with pulmonary metastasis from colorectal carcinomas. Surgery Today, 2019, 49, 762-768.	0.7	3
2008	Radioembolization with Yttrium-90 Microspheres for the Treatment of Liver Metastases of Pancreatic Adenocarcinoma: A Multicenter Analysis. Journal of Vascular and Interventional Radiology, 2019, 30, 298-304.e2.	0.2	19
2009	Chemotherapy for pancreatic cancer. Presse Medicale, 2019, 48, e159-e174.	0.8	171
2010	Feasibility and safety of distal pancreatectomy with en bloc celiac axis resection (DP-CAR) combined with neoadjuvant therapy for borderline resectable and unresectable pancreatic body/tail cancer. Langenbeck's Archives of Surgery, 2019, 404, 451-458.	0.8	25
2011	Novel biomarkers distinguishing pancreatic head Cancer from distal cholangiocarcinoma based on proteomic analysis. BMC Cancer, 2019, 19, 318.	1.1	17
2012	Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. Journal of Clinical Oncology, 2019, 37, 336-349.	0.8	101
2013	Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF. Cancer Cell, 2019, 35, 573-587.e6.	7.7	75
2014	Evolution of the chemotherapeutic landscape and survival outcome in patients with metastatic pancreatic cancer: a four-institute cohort study in Taiwan, 2010–2016 . Cancer Management and Research, 2019, Volume 11, 2119-2127.	0.9	9
2015	Immunotherapy of pancreatic cancer. Progress in Molecular Biology and Translational Science, 2019, 164, 189-216.	0.9	41
2016	Successful treatment of a locally advanced unresectable pancreatic cancer patient with interstitial pneumonitis by conversion surgery following gemcitabine plus nabâ€‘paclitaxel chemotherapy: A case report. Molecular and Clinical Oncology, 2019, 10, 419-424.	0.4	1
2017	Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers, 2019, 11, 484.	1.7	79
2018	Plinabulin, an inhibitor of tubulin polymerization, targets KRAS signaling through disruption of endosomal recycling. Biomedical Reports, 2019, 10, 218-224.	0.9	19
2019	Neo-adjuvant therapy for pancreatic cancer: hope for the future. Expert Review of Gastroenterology and Hepatology, 2019, 13, 579-589.	1.4	6

#	Article	IF	Citations
2020	Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine. Cancers, 2019, 11, 519.	1.7	21
2021	Gastrointestinal Cancers: Management of Rectal, Hepatocellular, Pancreatic, and Esophageal Cancers. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1-9.	0.4	2
2022	Modified-FOLFIRINOX combined with deep regional hyperthermia in pancreatic cancer: a retrospective study in Chinese patients. International Journal of Hyperthermia, 2019, 36, 393-401.	1.1	7
2023	Role of the tumor microenvironment in pancreatic cancer. Annals of Gastroenterological Surgery, 2019, 3, 130-137.	1.2	114
2024	Cancer stromaâ€targeting therapy: A new tool for fighting pancreatic cancer?. Annals of Gastroenterological Surgery, 2019, 3, 120-121.	1.2	3
2026	Quercetin-Modified Metalâ€“Organic Frameworks for Dual Sensitization of Radiotherapy in Tumor Tissues by Inhibiting the Carbonic Anhydrase IX. ACS Nano, 2019, 13, 4209-4219.	7.3	85
2027	Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1). Radiation Oncology, 2019, 14, 52.	1.2	15
2028	Therapeutic efficacy of antiâ€MMP9 antibody in combination with nabâ€paclitaxelâ€based chemotherapy in preâ€clinical models of pancreatic cancer. Journal of Cellular and Molecular Medicine, 2019, 23, 3878-3887.	1.6	22
2029	A case of extrahepatic bile duct cancer with distant metastases showing pathological complete response to treatment combining gemcitabine and cisplatin. Clinical Journal of Gastroenterology, 2019, 12, 466-472.	0.4	5
2030	Fibroblasts in Pancreatic Ductal Adenocarcinoma: Biological Mechanisms and Therapeutic Targets. Gastroenterology, 2019, 156, 2085-2096.	0.6	93
2031	Exosomes as Drug Carriers for Cancer Therapy. Molecular Pharmaceutics, 2019, 16, 1789-1798.	2.3	135
2032	Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models. Nature Biomedical Engineering, 2019, 3, 264-280.	11.6	40
2033	Genetics of Familial and Sporadic Pancreatic Cancer. Gastroenterology, 2019, 156, 2041-2055.	0.6	52
2034	Extracellular and intracellular microRNAs in pancreatic cancer: from early diagnosis to reducing chemoresistance. ExRNA, 2019, 1, .	1.0	4
2035	Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues. Surgery Today, 2019, 49, 894-906.	0.7	25
2036	Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2. Journal of Clinical Oncology, 2019, 37, 230-238.	0.8	66
2037	Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313. Journal of Clinical Oncology, 2019, 37, 1062-1069.	0.8	212
2038	CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics, 2019, 18, 788-800.	1.9	27

#	Article	IF	Citations
2039	Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 682-694.	1.3	27
2040	Lifetime alcohol intake and pancreatic cancer incidence and survival: findings from the Melbourne Collaborative Cohort Study. Cancer Causes and Control, 2019, 30, 323-331.	0.8	7
2041	An international comparison of treatment and short-term overall survival for older patients with pancreatic cancer. Journal of Geriatric Oncology, 2019, 10, 584-590.	0.5	3
2042	El pronÃ³stico del cÃ¡ncer de pÃ¡ncreas a dÃa de hoy. Medicina ClÃnica, 2019, 152, 395-396.	0.3	0
2043	Interstitial lung disease associated with nanoparticle albumin-bound paclitaxel treatment in patients with lung cancer. Japanese Journal of Clinical Oncology, 2019, 49, 165-173.	0.6	17
2044	Conversion surgery only for highly selected patients with unresectable pancreatic cancer: a satisfactory outcome in exchange for a lower resection rate. Surgery Today, 2019, 49, 670-677.	0.7	11
2045	The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancer. , 2019, 7, 45.		54
2046	Gastrointestinal Cancers. , 2019, , 265-311.		0
2047	Reflections on depletion of tumor stroma in pancreatic cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 267-272.	3.3	13
2048	Comparative Study Between Gemcitabine-Based and Gemcitabine Plus S1â€“Based Preoperative Chemoradiotherapy for Localized Pancreatic Ductal Adenocarcinoma, With Special Attention to Initially Locally Advanced Unresectable Tumor. Pancreas, 2019, 48, 281-291.	0.5	8
2049	The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma. Pancreas, 2019, 48, 275-280.	0.5	13
2050	Nodal downstaging as a treatment goal for node-positive pancreatic cancer. Surgery, 2019, 165, 1144-1150.	1.0	10
2051	Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer. Scientific Reports, 2019, 9, 1788.	1.6	57
2052	Body Composition Adjusted Dosing of Gemcitabine-Nab-Paclitaxel in Pancreatic Cancer Does Not Predict Toxicity Compared to Body Surface Area Dosing. Nutrition and Cancer, 2019, 71, 624-628.	0.9	10
2053	Ã…ngstromâ€Scale Silver Particles as a Promising Agent for Lowâ€Toxicity Broadâ€Spectrum Potent Anticancer Therapy. Advanced Functional Materials, 2019, 29, 1808556.	7.8	29
2054	Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer. Cell Metabolism, 2019, 29, 1390-1399.e6.	7.2	280
2055	Irreversible electroporation combined with chemotherapy for unresectable pancreatic carcinoma: a prospective cohort study . OncoTargets and Therapy, 2019, Volume 12, 1341-1350.	1.0	14
2056	CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine. Future Oncology, 2019, 15, 1295-1302.	1.1	37

#	Article	IF	Citations
2057	Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E. Journal of Experimental and Clinical Cancer Research, 2019, 38, 66.	3.5	51
2058	Enteral Activation of WR-2721 Mediates Radioprotection and Improved Survival from Lethal Fractionated Radiation. Scientific Reports, 2019, 9, 1949.	1.6	13
2059	Conversion surgery for positive peritoneal washing cytology in pancreatic cancer. BMJ Case Reports, 2019, 12, e229993.	0.2	4
2060	Evolving trends in pancreatic cancer therapeutic development. Annals of Pancreatic Cancer, 2019, 2, 17-17.	1.2	1
2061	Partial splenic embolization to alleviate thrombocytopenia in stage III and IV pancreatic ductal adenocarcinoma patients. Annals of Pancreatic Cancer, 0, 2, 9-9.	1.2	0
2062	How I treat pancreatic cancer. ESMO Open, 2019, 4, e000818.	2.0	11
2063	Development of new therapies for metastatic pancreatic cancer: are they better than FOLFIRINOX?. ESMO Open, 2019, 4, e000537.	2.0	3
2064	Advances in the Treatment of Pancreatic Cancer. , 2019, , .		1
2065	Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?. Oncologist, 2019, 24, 1469-1478.	1.9	25
2066	Target Deconvolution of a Multikinase Inhibitor with Antimetastatic Properties Identifies TAOK3 as a Key Contributor to a Cancer Stem Cellâ€“Like Phenotype. Molecular Cancer Therapeutics, 2019, 18, 2097-2110.	1.9	16
2067	Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma With the Introduction of New Chemotherapeutic Drugs. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 243-246.	0.6	4
2068	Diagnosis of pancreatic cancer. , 2019, , 51-68.		1
2069	Pancreatic cancer resistance to chemotherapy. , 2019, , 171-194.		1
2070	Latest developments in chemotherapy for metastatic pancreatic cancer. , 2019, , 111-139.		0
2071	Genetic manipulations with chemotherapy in pancreatic cancer. , 2019, , 141-152.		0
2072	Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1). BMJ Open, 2019, 9, e033452.	0.8	27
2073	DNA damage repair deficiency as a predictive biomarker for FOLFIRINOX efficacy in metastatic pancreatic cancer. Journal of Gastrointestinal Oncology, 2019, 10, 1133-1139.	0.6	20
2074	Pancreatic Cancer: Recent Advances in Nanoformulation-Based Therapies. Critical Reviews in Therapeutic Drug Carrier Systems, 2019, 36, 59-91.	1.2	18

#	Article	IF	Citations
2075	Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND). Future Oncology, 2019, 15, 4009-4017.	1.1	8
2076	Adding combination immunotherapy consisting of cancer vaccine, anti-PD-1 and anti-CSF1R antibodies to gemcitabine improves anti-tumor efficacy in murine model of pancreatic ductal adenocarcinoma. Annals of Pancreatic Cancer, 2019, 2, 21-21.	1.2	7
2077	A Study Comparing the Effects of Targeted Intra-Arterial and Systemic Chemotherapy in an Orthotopic Mouse Model of Pancreatic Cancer. Scientific Reports, 2019, 9, 15929.	1.6	4
2079	Single molecule characterization of individual extracellular vesicles from pancreatic cancer. Journal of Extracellular Vesicles, 2019, 8, 1685634.	5.5	60
2080	Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives. Cancers, 2019, 11, 1659.	1.7	55
2081	Transcytosis - An effective targeting strategy that is complementary to â€œEPR effectâ€•for pancreatic cancer nano drug delivery. Theranostics, 2019, 9, 8018-8025.	4.6	103
2082	New avenues in pancreatic cancer: exploiting microRNAs as predictive biomarkers and new approaches to target aberrant metabolism. Expert Review of Clinical Pharmacology, 2019, 12, 1081-1090.	1.3	22
2083	Brain metastasis in pancreatic cancer. Medicine (United States), 2019, 98, e14227.	0.4	12
2084	Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel. Pancreas, 2019, 48, 920-926.	0.5	30
2085	Induction Therapy in Localized Pancreatic Cancer. Pancreas, 2019, 48, 913-919.	0.5	7
2086	Prediagnostic Leukocyte Telomere Length and Pancreatic Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1868-1875.	1.1	17
2087	Fatal myositis and spontaneous haematoma induced by combined immune checkpoint inhibitor treatment in a patient with pancreatic adenocarcinoma. BMC Cancer, 2019, 19, 1193.	1.1	6
2088	A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 184-189.	0.6	20
2089	18F-FDG PET/CT in pancreatic adenocarcinoma: On the edge of a paradigm shift?. Diagnostic and Interventional Imaging, 2019, 100, 731-733.	1.8	5
2090	Palliative chemotherapy in pancreatic cancerâ€”treatment sequences. Translational Gastroenterology and Hepatology, 2019, 4, 56-56.	1.5	21
2091	Recent advances in molecular diagnostics and therapeutic targets for pancreatic cancer. , 2019, , 325-367.		2
2092	A Systemic Inflammation Response Index Could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic Cancer. Pancreas, 2019, 48, e45-e47.	0.5	5
2093	Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX. Pancreas, 2019, 48, 837-843.	0.5	22

#	Article	IF	Citations
2094	Accurate Therapeutic Response Assessment of Pancreatic Ductal Adenocarcinoma Using Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging With a Point-of-Care Perfusion Phantom. Investigative Radiology, 2019, 54, 16-22.	3.5	19
2095	Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program. JCO Precision Oncology, 2019, 3, 1-10.	1.5	38
2097	Oxalate nephropathy is a major cause of kidney injury in surgically treated pancreatic adenocarcinoma patients. CKJ: Clinical Kidney Journal, 2019, 12, 821-828.	1.4	1
2098	A Systematic Review of the Etiology, Diagnosis, and Treatment of Hemosuccus Pancreaticus. Pancreas, 2019, 48, e47-e49.	0.5	14
2099	Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications. Cancers, 2019, 11, 1980.	1.7	29
2100	Impact of Changes in the American Joint Committee on Cancer Staging Manual, Eighth Edition, for Pancreatic Ductal Adenocarcinoma. Pancreas, 2019, 48, 876-882.	0.5	4
2101	Pancreatic cancer treatment costs, including patient liability, by phase of care and treatment modality, 2000â€“2013. Medicine (United States), 2019, 98, e18082.	0.4	13
2102	Clinical significance of stromal ER and PR expression in periampullary adenocarcinoma. Biomarker Research, 2019, 7, 26.	2.8	1
2103	Epidermal Growth Factor Receptor and Its Role in Pancreatic Cancer Treatment Mediated by Nanoparticles . International Journal of Nanomedicine, 2019, Volume 14, 9693-9706.	3.3	41
2104	Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer. Annals of Surgery, 2019, 270, 400-413.	2.1	113
2105	Adjuvant and neoadjuvant therapy for pancreatic cancer. Journal of Pancreatology, 2019, 2, 100-106.	0.3	26
2106	A CARE-compliant case report: total pancreatectomy and total gastrectomy to treat pancreatic ductal adenocarcinoma. Medicine (United States), 2019, 98, e18151.	0.4	0
2107	Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. Journal of Hematology and Oncology, 2019, 12, 130.	6.9	64
2108	Alternate Week Gemcitabine and Capecitabine. Pancreas, 2019, 48, 927-930.	0.5	2
2109	Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma. Medicine (United States), 2019, 98, e15341.	0.4	13
2110	DHA-SBT-1214 Taxoid Nanoemulsion and Antiâ€“PD-L1 Antibody Combination Therapy Enhances Antitumor Efficacy in a Syngeneic Pancreatic Adenocarcinoma Model. Molecular Cancer Therapeutics, 2019, 18, 1961-1972.	1.9	14
2111	Pancreatic cancer organoids recapitulate disease and allow personalized drug screening. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26580-26590.	3.3	279
2112	A Qualitative Review of Neoadjuvant Chemotherapy in Resectable Pancreatic Adenocarcinoma. Pancreas, 2019, 48, 973-984.	0.5	11

#	Article	IF	Citations
2113	Outcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 196-201.	0.6	12
2114	LINC01006 promotes cell proliferation and metastasis in pancreatic cancer via miR-2682-5p/HOXB8 axis. Cancer Cell International, 2019, 19, 320.	1.8	22
2115	Evaluation of Phase II Trial Design in Advanced Pancreatic Cancer. Pancreas, 2019, 48, 1274-1284.	0.5	2
2116	Chemoradiotherapy screening in a novel biomimetic polymer based pancreatic cancer model. RSC Advances, 2019, 9, 41649-41663.	1.7	21
2118	Proposal for a definition of "Oligometastatic disease in pancreatic cancer". BMC Cancer, 2019, 19, 1261.	1.1	34
2120	Palbociclib in Patients With Pancreatic and Biliary Cancer WithCDKN2AAlterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology, 2019, 3, 1-8.	1.5	46
2121	Adipose tissueâ€derived stromal cells are sources of cancerâ€associated fibroblasts and enhance tumor progression by dense collagen matrix. International Journal of Cancer, 2019, 144, 1401-1413.	2.3	23
2122	A Novel Approach for Image-Guided 131I Therapy of Pancreatic Ductal Adenocarcinoma Using Mesenchymal Stem Cell-Mediated NIS Gene Delivery. Molecular Cancer Research, 2019, 17, 310-320.	1.5	22
2123	Stromal biology and therapy in pancreatic cancer: ready for clinical translation?. Gut, 2019, 68, 159-171.	6.1	246
2124	Systemic Chemotherapy as First-line Treatment for Metastatic Pancreatic Adenocarcinoma: A Bayesian Analysis. Internal Medicine, 2019, , .	0.3	0
2125	Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?. Journal of Gastrointestinal Cancer, 2019, 50, 860-866.	0.6	2
2126	Immune Checkpoint Inhibitors in Gastrointestinal Malignancies. , 2019, , 77-101.		0
2127	HBXIP protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas. Pathology Research and Practice, 2019, 215, 343-346.	1.0	10
2128	The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment. American Journal of Pathology, 2019, 189, 44-57.	1.9	56
2129	miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma. American Journal of Pathology, 2019, 189, 58-70.	1.9	46
2130	A systematic assessment of statistics, risk factors, and underlying features involved in pancreatic cancer. Cancer Epidemiology, 2019, 58, 104-110.	0.8	92
2131	Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC). Expert Opinion on Investigational Drugs, 2019, 28, 161-177.	1.9	62
2132	Neoadjuvant Treatment for Pancreatic Cancer. Seminars in Oncology, 2019, 46, 19-27.	0.8	76

#	Article	IF	Citations
2133	Systemic treatment of pancreatic cancer revisited. Seminars in Oncology, 2019, 46, 28-38.	0.8	81
2134	Potential use of aptamers for diagnosis and treatment of pancreatic cancer. Journal of Drug Targeting, 2019, 27, 853-865.	2.1	6
2135	Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges. Expert Opinion on Pharmacotherapy, 2019, 20, 535-546.	0.9	22
2136	Pancreas Cancer-Associated Weight Loss. Oncologist, 2019, 24, 691-701.	1.9	99
2137	Advanced pancreatic cancer clinical trials: The continued underrepresentation of older patients. Journal of Geriatric Oncology, 2019, 10, 540-546.	0.5	26
2138	Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. Oncologist, 2019, 24, 945-954.	1.9	13
2139	Genomic Applications in Pancreatic and Gastric Tumors. , 2019, , 401-418.		0
2140	Emerging Evidence for the Clinical Relevance of Pancreatic Cancer Exosomes. Pancreas, 2019, 48, 1-8.	0.5	16
2141	Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models. Cancer Letters, 2019, 442, 82-90.	3.2	40
2142	Energy-modulated x-ray fluorescence and luminescence emissions from therapeutic nanoparticles. Physics in Medicine and Biology, 2019, 64, 035020.	1.6	5
2143	Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Gut, 2019, 68, 742-758.	6.1	68
2144	Clinicoâ€pathological features and survival of patients with malignant exocrine pancreatic neoplasms: The AC Camargo Cancer Center experience. Journal of Surgical Oncology, 2019, 119, 71-78.	0.8	3
2145	A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer. Investigational New Drugs, 2019, 37, 338-344.	1.2	6
2146	Phase 1 study of EUS-guided photodynamic therapy for locally advanced pancreatic cancer. Gastrointestinal Endoscopy, 2019, 89, 390-398.	0.5	68
2147	Desumoylating Isopeptidase 2 (DESI2) Inhibits Proliferation and Promotes Apoptosis of Pancreatic Cancer Cells through Regulating PI3K/AKT/mTOR Signaling Pathway. Pathology and Oncology Research, 2019, 25, 635-646.	0.9	4
2148	Pancreatic Cancer and Immunotherapy: Resistance Mechanisms and Proposed Solutions. Journal of Gastrointestinal Cancer, 2019, 50, 1-8.	0.6	31
2149	ceâ€Subpathway: Identification of ce<scp>RNA</scp>â€mediated subpathways via joint power of ce<scp>RNA</scp>s and pathway topologies. Journal of Cellular and Molecular Medicine, 2019, 23, 967-984.	1.6	23
2150	Reviewing two decades of nanomedicine implementations in targeted treatment and diagnosis of pancreatic cancer: An emphasis on state of art. Journal of Controlled Release, 2019, 293, 21-35.	4.8	42

#	Article	IF	Citations
2151	Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols. Journal of Cancer Research and Clinical Oncology, 2019, 145, 445-455.	1.2	6
2152	Statin treatment and outcomes of metastatic pancreatic cancer: a pooled analysis of two phase III studies. Clinical and Translational Oncology, 2019, 21, 810-816.	1.2	28
2153	TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial). European Journal of Cancer, 2019, 106, 78-88.	1.3	21
2154	Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis. European Journal of Cancer, 2019, 106, 99-105.	1.3	30
2155	A UGT1A1 genotypeâ€guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. Cancer, 2019, 125, 1629-1636.	2.0	27
2156	CKAP4, a DKK1 Receptor, Is a Biomarker in Exosomes Derived from Pancreatic Cancer and a Molecular Target for Therapy. Clinical Cancer Research, 2019, 25, 1936-1947.	3.2	91
2157	Selecting chemotherapy for pancreatic cancer: Far away or so close?. Seminars in Oncology, 2019, 46, 39-47.	0.8	12
2158	Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic Model. Cancers, 2019, 11, 57.	1.7	14
2159	NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. European Journal of Cancer, 2019, 108, 78-87.	1.3	185
2160	KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs. Journal of Controlled Release, 2019, 296, 40-53.	4.8	39
2161	A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Cancer Chemotherapy and Pharmacology, 2019, 83, 589-598.	1.1	16
2162	The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. Biomedicine and Pharmacotherapy, 2019, 111, 835-840.	2.5	10
2163	S-1 combined with paclitaxel may benefit advanced gastric cancer: Evidence from a systematic review and meta-analysis. International Journal of Surgery, 2019, 62, 34-43.	1.1	5
2164	Nanoliposome targeting in breast cancer is influenced by the tumor microenvironment. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 17, 71-81.	1.7	24
2165	Acoustic disruption of tumor endothelium and on-demand drug delivery for cancer chemotherapy. Nanotechnology, 2019, 30, 154001.	1.3	19
2166	Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?. BMC Cancer, 2019, 19, 28.	1.1	44
2167	Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer. BMC Cancer, 2019, 19, 40.	1.1	53
2168	Optimizing the outcomes of pancreatic cancer surgery. Nature Reviews Clinical Oncology, 2019, 16, 11-26.	12.5	546

#	Article	IF	Citations
2169	Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. Pancreatology, 2019, 19, 97-104.	0.5	34
2170	Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study. Pancreatology, 2019, 19, 64-72.	0.5	52
2171	DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth. Gut, 2019, 68, 1465-1476.	6.1	52
2172	Therapeutic potential of targeting the Wnt/Î²â€catenin pathway in the treatment of pancreatic cancer. Journal of Cellular Biochemistry, 2019, 120, 6833-6840.	1.2	36
2173	Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores. Investigational New Drugs, 2019, 37, 584-590.	1.2	13
2174	Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives. Cancer Treatment Reviews, 2019, 72, 1-6.	3.4	46
2175	Claudin 7 as a possible novel molecular target for the treatment of pancreatic cancer. Pancreatology, 2019, 19, 88-96.	0.5	9
2176	Randomized Phase II Study of Consecutive-Day versus Alternate-Day Treatment with S-1 as Second-Line Chemotherapy in Advanced Pancreatic Cancer. Oncology, 2019, 96, 1-7.	0.9	9
2177	Neoepitope targets of tumour-infiltrating lymphocytes from patients with pancreatic cancer. British Journal of Cancer, 2019, 120, 97-108.	2.9	19
2178	The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer. Oncogene, 2019, 38, 1764-1777.	2.6	56
2179	Small molecule tyrosine kinase inhibitors and pancreatic cancerâ€"Trials and troubles. Seminars in Cancer Biology, 2019, 56, 149-167.	4.3	23
2180	First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2019, 26, 619-627.	0.7	8
2181	Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer. Journal of Gastroenterology, 2019, 54, 437-448.	2.3	7
2182	Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer. Clinical Cancer Research, 2019, 25, 2290-2304.	3.2	26
2183	Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma. Pharmacogenomics, 2019, 20, 113-127.	0.6	9
2184	Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer. Clinical and Experimental Medicine, 2019, 19, 149-157.	1.9	10
2185	Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19â€9 is Highâ€Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively Resected Pancreatic Adenocarcinoma. World Journal of Surgery, 2019, 43, 634-641.	0.8	25
2186	Optimal Extent of Superior Mesenteric Artery Dissection during Pancreaticoduodenectomy for Pancreatic Cancer: Balancing Surgical and Oncological Safety. Journal of Gastrointestinal Surgery, 2019, 23, 1373-1383.	0.9	59

#	Article	IF	Citations
2187	Thermoresponsive polymer nanocarriers for biomedical applications. Advanced Drug Delivery Reviews, 2019, 138, 167-192.	6.6	256
2188	Understaging of clinical stage I pancreatic cancer and the impact of multimodality therapy. Surgery, 2019, 165, 307-314.	1.0	17
2189	Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. Investigational New Drugs, 2019, 37, 473-481.	1.2	9
2190	Efficacy of S-1 monotherapy for older patients with unresectable pancreatic cancer: A retrospective cohort study. Journal of Geriatric Oncology, 2019, 10, 420-426.	0.5	4
2191	Targeted therapies in pancreatic cancer: Promises and failures. Journal of Cellular Biochemistry, 2019, 120, 2726-2741.	1.2	17
2192	Identification of Educational Gaps Among Oncologists Who Manage Patients with Pancreatic Cancer. Journal of Gastrointestinal Cancer, 2019, 50, 84-90.	0.6	3
2193	A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers. Journal of Gastrointestinal Cancer, 2019, 50, 62-68.	0.6	51
2194	Updates in pancreatic cancer: Modest gains and hopeful targets. Journal of Oncology Pharmacy Practice, 2019, 25, 101-109.	0.5	4
2195	Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. Annals of Surgery, 2019, 270, 340-347.	2.1	280
2196	The Tipping Point: Key Oncologic Imaging Findings Resulting in Critical Changes in the Management of Malignant Tumors of the Gastrointestinal Tract. Current Problems in Diagnostic Radiology, 2019, 48, 61-74.	0.6	2
2197	Core Set of Patient-reported Outcomes in Pancreatic Cancer (COPRAC). Annals of Surgery, 2019, 270, 158-164.	2.1	44
2198	The Strain Ratio as Obtained by Endoscopic Ultrasonography Elastography Correlates With the Stroma Proportion and the Prognosis of Local Pancreatic Cancer. Annals of Surgery, 2020, 271, 559-565.	2.1	29
2199	Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 2020, 271, 1137-1147.	2.1	47
2200	Are We Choosing Surveillance Imaging in Gastric and Pancreatic Cancers Wisely? A Population-Based Study. Journal of Gastrointestinal Cancer, 2020, 51, 189-195.	0.6	2
2201	Preoperative neutrophili-to-lymphocyte ratio is useful for stratifying the prognosis of tumor markers-negative pancreatic cancer patients. American Journal of Surgery, 2020, 219, 93-98.	0.9	4
2202	Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients. Journal of the Formosan Medical Association, 2020, 119, 97-105.	0.8	3
2203	Clutter Reduction and Target Tracking in Through-the-Wall Radar. IEEE Transactions on Geoscience and Remote Sensing, 2020, 58, 486-499.	2.7	15
2204	How Much Was the Elective Lymph Node Region Covered in Involved-Field Radiation Therapy for Locally Advanced Pancreatic Cancer? Evaluation of Overlap Between Gross Target Volume and Celiac Arteryâ€“Superior Mesenteric Artery Lymph Node Regions. Advances in Radiation Oncology, 2020, 5, 377-387.	0.6	1

#	Article	IF	Citations
2205	Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 106, 124-133.	0.4	28
2206	Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer. JAMA Oncology, 2020, 6, 125.	3.4	53
2207	Phospho-valproic acid (MDC-1112) reduces pancreatic cancer growth in patient-derived tumor xenografts and KPC mice: enhanced efficacy when combined with gemcitabine. Carcinogenesis, 2020, 41, 927-939.	1.3	5
2208	Clinical applications of nanomedicine in cancer therapy. Drug Discovery Today, 2020, 25, 107-125.	3.2	74
2209	Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled for lead time bias and waiting time paradox. Journal of Cancer Research and Clinical Oncology, 2020, 146, 391-399.	1.2	13
2210	Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 295-301.	0.7	13
2211	National Trends in Centralization of Surgical Care and Multimodality Therapy for Pancreatic Adenocarcinoma. Journal of Gastrointestinal Surgery, 2020, 24, 2021-2029.	0.9	8
2212	Outcomes of enteral metallic stent in patients with pancreatic carcinoma and gastric outlet obstruction: A single center experience. Journal of the Formosan Medical Association, 2020, 119, 238-246.	0.8	7
2213	Patients with hepatic oligometastatic pancreatic body/tail ductal adenocarcinoma may benefit from synchronous resection. Hpb, 2020, 22, 91-101.	0.1	32
2214	Pancreatic Ductal Adenocarinoma. , 2020, , 55-70.		0
2215	Effectiveness and safety of nab-paclitaxel/gemcitabine in locally advanced or metastatic pancreatic adenocarcinoma. Journal of Oncology Pharmacy Practice, 2020, 26, 603-611.	0.5	4
2216	Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. Investigational New Drugs, 2020, 38, 800-811.	1.2	106
2217	Efficacy of Neoadjuvant Chemotherapy in Distal Pancreatectomy with En Bloc Celiac Axis Resection (DP-CAR) for Locally Advanced Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2020, 24, 1605-1611.	0.9	29
2218	A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Investigational New Drugs, 2020, 38, 821-830.	1.2	59
2219	Proton beam radiotherapy for pancreas cancer. Journal of Gastrointestinal Oncology, 2020, 11, 166-175.	0.6	15
2220	Sonoporation for Augmenting Chemotherapy of Pancreatic Ductal Adenocarcinoma. Methods in Molecular Biology, 2020, 2059, 191-205.	0.4	14
2221	Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer. Journal of Geriatric Oncology, 2020, 11, 647-651.	0.5	22
2222	Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death. Translational Research, 2020, 215, 41-56.	2.2	7

#	Article	IF	Citations
2223	The Potential to Source a Patientâ€™s Imaginative Powers in Treating Cancer: Illustrated in Three Cases. Complementary Medicine Research, 2020, 27, 55-60.	0.5	0
2224	Realâ€world outcomes of FOLFIRINOX vs gemcitabine and nabâ€paclitaxel in advanced pancreatic cancer: A populationâ€based propensity scoreâ€weighted analysis. Cancer Medicine, 2020, 9, 160-169.	1.3	55
2225	Novel Prognostic Implications of DUPAN-2 in the Era of Initial Systemic Therapy for Pancreatic Cancer. Annals of Surgical Oncology, 2020, 27, 2081-2089.	0.7	12
2226	Interstitial lung disease in advanced pancreatic ductal adenocarcinoma patients treated with gemcitabine and nab-paclitaxel combination therapy: a retrospective analysis. Cancer Chemotherapy and Pharmacology, 2020, 85, 517-523.	1.1	7
2227	Factors correlating with shorter survival after treatment: aiding oncologists to choose who (not) to receive palliative systemic therapy. Annals of Palliative Medicine, 2020, 9, 4430-4445.	0.5	0
2228	Cancer stem cells as therapeutic targets of pancreatic cancer. Fundamental and Clinical Pharmacology, 2020, 34, 202-212.	1.0	17
2229	The Neutrophil-to-Lymphocyte Ratio is a Prognostic Biomarker in An Ethnically Diverse Patient Population with Advanced Pancreatic Cancer. Journal of Gastrointestinal Cancer, 2020, 51, 868-876.	0.6	9
2230	Hic-5 in pancreatic stellate cells affects proliferation, apoptosis, migration, invasion of pancreatic cancer cells and postoperative survival time of pancreatic cancer. Biomedicine and Pharmacotherapy, 2020, 121, 109355.	2.5	15
2231	Pancreatic Cancer: From Genome Discovery to PRECISION-Panc. Clinical Oncology, 2020, 32, 5-8.	0.6	15
2232	Antifibrotic and tumor microenvironment modulating effect of date palm fruit (Phoenix dactylifera) Tj ETQq1 1 0.784314 rgBT /Overlock	2.5	24
2233	The prognostic role of soluble TGFâ€beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy. Cancer Medicine, 2020, 9, 43-51.	1.3	14
2234	Development and validation of a prognostic nomogram to predict survival in patients with advanced pancreatic cancer receiving secondâ€line palliative chemotherapy. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1694-1703.	1.4	10
2235	Prevention of Venous Thromboembolism in Pancreatic Cancer: Breaking Down a Complex Clinical Dilemma. Oncologist, 2020, 25, 132-139.	1.9	15
2236	FGF2 engineered SPIONs attenuate tumor stroma and potentiate the effect of chemotherapy in 3D heterospheroidal model of pancreatic tumor. Nanotheranostics, 2020, 4, 26-39.	2.7	30
2237	Hypoxia: a barricade to conquer the pancreatic cancer. Cellular and Molecular Life Sciences, 2020, 77, 3077-3083.	2.4	45
2238	Update on Management Periampullary/Pancreatic Head Cancer. Indian Journal of Surgery, 2020, , 1.	0.2	1
2239	Targeting the undruggable in pancreatic cancer using nano-based gene silencing drugs. Biomaterials, 2020, 240, 119742.	5.7	46
2240	Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 82-92.	3.2	115

#	Article	IF	Citations
2241	Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotypeâ€"Guided Dosing. Clinical Cancer Research, 2020, 26, 18-24.	3.2	10
2242	Pancreatic stellate cells: Aiding and abetting pancreatic cancer progression. Pancreatology, 2020, 20, 409-418.	0.5	53
2243	Assessing the efficacyâ€effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and populationâ€based, realâ€world data for contemporary parenteral cancer therapeutics. Cancer, 2020, 126, 1717-1726.	2.0	35
2244	Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). Annals of Oncology, 2020, 31, 79-87.	0.6	36
2245	Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. British Journal of Cancer, 2020, 122, 498-505.	2.9	105
2246	Nanoparticle albuminâ€bound paclitaxel in elder patients with advanced squamous nonâ€smallâ€cell lung cancer: A retrospective study. Cancer Medicine, 2020, 9, 1365-1373.	1.3	7
2247	ATM-Mutated Pancreatic Cancer. Pancreas, 2020, 49, 143-147.	0.5	12
2248	External validation of the BesanÃ§on nomogram in Asian patients with advanced pancreatic cancer receiving second-line chemotherapy: A multi-institute experience in Taiwan. Pancreatology, 2020, 20, 116-124.	0.5	1
2249	Are populationâ€based patientâ€reported outcomes associated with overall survival in patients with advanced pancreatic cancer?. Cancer Medicine, 2020, 9, 215-224.	1.3	13
2250	Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma. Annals of Gastroenterological Surgery, 2020, 4, 6-13.	1.2	42
2251	Efficacy of Sâ€1 in secondâ€line chemotherapy after nabâ€paclitaxel plus gemcitabine for patients with advanced pancreatic cancer. Cancer Reports, 2020, 3, e1215.	0.6	11
2252	Reverting chemoresistance of targeted agents by a ultrasoluble dendritic nanocapsule. Journal of Controlled Release, 2020, 317, 67-77.	4.8	6
2253	Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer. Oncogene, 2020, 39, 1831-1845.	2.6	25
2254	Intraductal placement of a fully covered metal stent with a long string for distal malignant biliary obstruction without endoscopic sphincterotomy: Prospective multiâ€center feasibility study. Digestive Endoscopy, 2020, 32, 949-956.	1.3	7
2255	Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs. Pharmaceutical Statistics, 2020, 19, 276-290.	0.7	5
2256	PCN-Fe(III)-PTX nanoparticles for MRI guided high efficiency chemo-photodynamic therapy in pancreatic cancer through alleviating tumor hypoxia. Nano Research, 2020, 13, 273-281.	5.8	53
2257	Bone marrow mesenchymal stem cells-derived exosomes for penetrating and targeted chemotherapy of pancreatic cancer. Acta Pharmaceutica Sinica B, 2020, 10, 1563-1575.	5.7	78
2258	Patterns of care and treatment outcomes in patients age 80 or older with non-metastatic pancreatic cancer. Journal of Geriatric Oncology, 2020, 11, 652-659.	0.5	8

#	Article	IF	Citations
2259	Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2020, 27, 2007-2014.	0.7	35
2260	Prognostic Factors in Patients With Recurrent Pancreatic Cancer: A Multicenter Database Analysis. Anticancer Research, 2020, 40, 293-298.	0.5	6
2261	Imaging and Management of Pancreatic Cancer. Seminars in Ultrasound, CT and MRI, 2020, 41, 139-151.	0.7	7
2262	Unexpected Para-aortic Lymph Node Metastasis in Pancreatic Ductal Adenocarcinoma: a Contraindication to Resection?. Journal of Gastrointestinal Surgery, 2020, 24, 2789-2799.	0.9	12
2263	Preoperative chemoradiotherapy using gemcitabine for pancreatic ductal adenocarcinoma in patients with impaired renal function. Cancer Chemotherapy and Pharmacology, 2020, 85, 537-545.	1.1	0
2264	Carcinoma of the Pancreas. , 2020, , 1342-1360.e7.		1
2265	Pegvorhyaluronidase alfa. , 2020, , 175-204.		3
2266	Nationwide trends in incidence, treatmentÂand survival of pancreatic ductal adenocarcinoma. European Journal of Cancer, 2020, 125, 83-93.	1.3	98
2267	A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer. Pancreatology, 2020, 20, 254-264.	0.5	44
2268	Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question. British Journal of Radiology, 2020, 93, 20190627.	1.0	11
2269	Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. Pancreatology, 2020, 20, 101-109.	0.5	17
2270	From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nature Reviews Clinical Oncology, 2020, 17, 108-123.	12.5	244
2271	Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer. Annals of Surgical Oncology, 2020, 27, 1191-1200.	0.7	46
2272	Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice?. Journal of Gastrointestinal Surgery, 2020, 24, 235-242.	0.9	6
2273	The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer. Pancreatology, 2020, 20, 95-100.	0.5	32
2274	Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial. European Journal of Cancer, 2020, 124, 91-101.	1.3	68
2275	Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes. Annals of Surgical Oncology, 2020, 27, 1400-1406.	0.7	22
2276	A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinomaâ€“TCOG T1211 study. European Journal of Cancer, 2020, 124, 123-130.	1.3	11

#	Article	IF	Citations
2277	Prognostic indicators in pancreatic cancer patients undergoing total pancreatectomy. Surgery Today, 2020, 50, 490-498.	0.7	8
2278	Prediction of Unresectability and Prognosis in Patients Undergoing Surgery on Suspicion of Pancreatic Cancer Using Carbohydrate Antigen 19-9, Interleukin 6, and YKL-40. Pancreas, 2020, 49, 53-61.	0.5	18
2279	Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 1385-1394.	3.2	31
2280	Upregulation of ZIP14 and Altered Zinc Homeostasis in Muscles in Pancreatic Cancer Cachexia. Cancers, 2020, 12, 3.	1.7	29
2281	Probiotic-Treated Super-Charged NK Cells Efficiently Clear Poorly Differentiated Pancreatic Tumors in Hu-BLT Mice. Cancers, 2020, 12, 63.	1.7	36
2282	Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients. Cancer Immunology, Immunotherapy, 2020, 69, 365-372.	2.0	18
2283	Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel. BMC Cancer, 2020, 20, 950.	1.1	10
2284	Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study. BMC Cancer, 2020, 20, 946.	1.1	10
2285	The Immune Microenvironment in Pancreatic Cancer. International Journal of Molecular Sciences, 2020, 21, 7307.	1.8	133
2286	Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: Treatment, sequencing, and effects on survival outcomes. Cancer Medicine, 2020, 9, 8480-8490.	1.3	5
2287	FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094797.	1.4	7
2288	FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592095329.	1.4	21
2289	Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study. Oncologist, 2020, 25, 954-962.	1.9	14
2290	Mechanically stressed cancer microenvironment: Role in pancreatic cancer progression. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188418.	3.3	21
2291	Challenges and Opportunities for Pancreatic Cancer Immunotherapy. Cancer Cell, 2020, 38, 788-802.	7.7	273
2292	FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan. Pancreatology, 2020, 20, 1519-1525.	0.5	6
2293	Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients â€“ Results of the RESPECT-Study. Surgical Oncology, 2020, 35, 285-297.	0.8	6
2294	Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Nature Communications, 2020, 11, 4841.	5.8	129

#	Article	IF	Citations
2295	Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 21, 1-7.	0.7	4
2296	Understanding the influence of experimental factors on bio-interactions of nanoparticles: Towards improving correlation between in vitro and in vivo studies. Archives of Biochemistry and Biophysics, 2020, 694, 108592.	1.4	13
2297	Association between the use of antibiotics and efficacy of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer. Medicine (United States), 2020, 99, e22250.	0.4	14
2298	FOLFIRINOX Deâ€Escalation in Advanced Pancreatic Cancer: A Multicenter Realâ€Life Study. Oncologist, 2020, 25, e1701-e1710.	1.9	10
2299	Pancreatic Ductal Adenocarcinoma (PDAC) Organoids: The Shining Light at the End of the Tunnel for Drug Response Prediction and Personalized Medicine. Cancers, 2020, 12, 2750.	1.7	33
2300	Tumor treating fields (TTF) treatment enhances radiation-induced apoptosis in pancreatic cancer cells. International Journal of Radiation Biology, 2020, 96, 1528-1533.	1.0	9
2301	The treatment sequence may matter in patients undergoing pancreatoduodenectomy for early stage pancreatic cancer in the era of modern chemotherapy. American Journal of Surgery, 2021, 222, 159-166.	0.9	8
2302	Impact of Ninjin'Yoeito on Fatigue in Patients Receiving Nab-Paclitaxel Plus Gemcitabine Therapy: A Prospective, Single-Arm, Phase II Open Label, Nonrandomized, Historically-Controlled Study. Current Therapeutic Research, 2020, 93, 100605.	0.5	4
2303	Precision Therapy of Pancreatic Cancer: From Bench to Bedside. Visceral Medicine, 2020, 36, 373-380.	0.5	3
2304	Cold Atmospheric Plasma Treatment for Pancreatic Cancerâ€"The Importance of Pancreatic Stellate Cells. Cancers, 2020, 12, 2782.	1.7	20
2305	UegWeek 2020 Poster Presentations. United European Gastroenterology Journal, 2020, 8, 144-887.	1.6	7
2306	EUS-guided fine-needle injection for pancreatic cancer: back to the future. Gastrointestinal Endoscopy, 2020, 92, 1053-1054.	0.5	2
2307	Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial. Cytotherapy, 2020, 22, 573-580.	0.3	77
2308	Metachronous hepatic resection for liver only pancreatic metastases. Surgical Oncology, 2020, 35, 169-173.	0.8	20
2309	Dual Delivery of Gemcitabine and Paclitaxel by Wetâ€Spun Coaxial Fibers Induces Pancreatic Ductal Adenocarcinoma Cell Death, Reduces Tumor Volume, and Sensitizes Cells to Radiation. Advanced Healthcare Materials, 2020, 9, e2001115.	3.9	11
2310	Linc01232 promotes the metastasis of pancreatic cancer by suppressing the ubiquitin-mediated degradation of HNRNPA2B1 and activating the A-Raf-induced MAPK/ERK signaling pathway. Cancer Letters, 2020, 494, 107-120.	3.2	55
2311	What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right. ACS Nano, 2020, 14, 12281-12290.	7.3	140
2312	Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2020, 27, 4348-4359.	0.7	14

#	Article	IF	Citations
2313	The prognostic and predictive value of the albumin-bilirubin score in advanced pancreatic cancer. Medicine (United States), 2020, 99, e20654.	0.4	10
2314	A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 5092-5101.	3.2	28
2315	Time intervals to diagnosis and chemotherapy do not influence survival outcome in patients with advanced pancreatic adenocarcinoma.. Digestive and Liver Disease, 2020, 52, 658-667.	0.4	6
2316	Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. JAMA Surgery, 2020, 155, 832.	2.2	105
2317	Cancer cell membrane-derived nanoparticles improve the activity of gemcitabine and paclitaxel on pancreatic cancer cells and coordinate immunoregulatory properties on professional antigen-presenting cells. Materials Advances, 2020, 1, 1775-1787.	2.6	11
2318	Multiple Liver Metastases Rather Than the Presence of Liver Metastasis Is a Significantly Poor Prognostic Factor for Patients With Advanced Pancreatic Cancer. Pancreas, 2020, 49, e63-e65.	0.5	4
2319	The Case of an Asymptomatic Pheochromocytoma Masquerading as a Pancreatic Neuroendocrine Tumor. Pancreas, 2020, 49, e65-e66.	0.5	1
2320	A Case of Pathological Complete Response Following FOLFIRINOX Therapy for Pancreatic Adenocarcinoma with Synchronous Distant Lymph Node Metastases. International Journal of Surgery Case Reports, 2020, 72, 471-476.	0.2	5
2321	Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. Ca-A Cancer Journal for Clinicians, 2020, 70, 375-403.	157.7	237
2322	Should All Patients With Pancreatic Cancer Receive Chemotherapy Before Surgery?. JAMA Surgery, 2020, 155, 840.	2.2	2
2323	Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX. Anticancer Research, 2020, 40, 4011-4015.	0.5	4
2324	Rethinking clinical oncology drug research in an era of valueâ€based cancer care: A role for chemotherapy pathways. Cancer Medicine, 2020, 9, 5306-5311.	1.3	3
2325	Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort study. Cancer Chemotherapy and Pharmacology, 2020, 86, 203-210.	1.1	6
2326	Mechanisms of Taxane Resistance. Cancers, 2020, 12, 3323.	1.7	94
2327	Immunomodulation in Pancreatic Cancer. Cancers, 2020, 12, 3340.	1.7	12
2328	Oligometastatic Pancreatic Cancer to the Liver in the Era of Neoadjuvant Chemotherapy: Which Role for Conversion Surgery? A Systematic Review and Meta-Analysis. Cancers, 2020, 12, 3402.	1.7	23
2329	Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib . Drug Design, Development and Therapy, 2020, Volume 14, 4465-4475.	2.0	10
2330	The Present Status of Immuno-Oncolytic Viruses in the Treatment of Pancreatic Cancer. Viruses, 2020, 12, 1318.	1.5	12

#	Article	IF	Citations
2332	Antibiotics and Adverse Events in Patients with Pancreatic Cancer Treated with Gemcitabine: Looking for Novel Clinical and Preclinical Insights. Oncologist, 2020, 26, e2306-e2307.	1.9	1
2333	Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. ESMO Open, 2020, 5, e000942.	2.0	26
2334	Phytochemical-Based Nanomedicine for Advanced Cancer Theranostics: Perspectives on Clinical Trials to Clinical Use . International Journal of Nanomedicine, 2020, Volume 15, 9125-9157.	3.3	49
2335	Magnolol Suppresses Pancreatic Cancer Development In Vivo and In Vitro via Negatively Regulating TGF-Î²/Smad Signaling. Frontiers in Oncology, 2020, 10, 597672.	1.3	15
2336	Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer. Scientific Reports, 2020, 10, 21194.	1.6	14
2337	Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre. ESMO Open, 2020, 5, e000929.	2.0	4
2338	Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology. International Journal of Molecular Sciences, 2020, 21, 8841.	1.8	28
2339	Liver metastases from pancreatic ductal adenocarcinoma: is there a place for surgery in the modern era?. Journal of Pancreatology, 2020, 3, 81-85.	0.3	6
2340	Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic cancer. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482097491.	1.4	9
2341	Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. Scientific Reports, 2020, 10, 19281.	1.6	8
2342	Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy. Science Advances, 2020, 6, .	4.7	42
2343	Regulation and function of autophagy in pancreatic cancer. Autophagy, 2021, 17, 3275-3296.	4.3	89
2344	Time interval-based indication for liver resection of metastasis from pancreatic cancer. World Journal of Surgical Oncology, 2020, 18, 294.	0.8	16
2345	New insights into benefits of combination treatment with yttrium-90 and gemcitabine in patients with intrahepatic cholangiocarcinoma. Journal of Gastrointestinal Oncology, 2020, 11, 833-835.	0.6	0
2346	Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 30670-30678.	3.3	11
2347	Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option. Canadian Journal of Gastroenterology and Hepatology, 2020, 2020, 1-7.	0.8	1
2348	Chemotherapy in advanced pancreatic cancer with hyperbilirubinemia. Digestive Medicine Research, 2020, 3, 18-18.	0.2	0
2349	Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies. Biomedicines, 2020, 8, 270.	1.4	40

#	Article	IF	Citations
2351	Osalmid, a Novel Identified RRM2 Inhibitor, Enhances Radiosensitivity of Esophageal Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1368-1379.	0.4	13
2352	A machine learning approach identified a diagnostic model for pancreatic cancer through using circulating microRNA signatures. Pancreatology, 2020, 20, 1195-1204.	0.5	41
2353	Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2020, 38, 3185-3194.	0.8	233
2354	Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard?. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093609.	1.4	21
2355	Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093794.	1.4	12
2356	Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer. Frontiers in Oncology, 2020, 10, 1176.	1.3	16
2357	Estimation of Fractional Extracellular Space at CT for Predicting Chemotherapy Response and Survival in Pancreatic Ductal Adenocarcinoma. American Journal of Roentgenology, 2020, 215, 610-616.	1.0	4
2358	Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model. Cancer Letters, 2020, 492, 174-184.	3.2	21
2359	Machine learning model to predict oncologic outcomes for drugs in randomized clinical trials. International Journal of Cancer, 2020, 147, 2537-2549.	2.3	9
2360	Image-Guided Interventions in Oncology. , 2020, , .		1
2362	First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age?. European Journal of Cancer, 2020, 137, 108-116.	1.3	11
2363	Protein arginine methylation promotes therapeutic resistance in human pancreatic cancer. Cytokine and Growth Factor Reviews, 2020, 55, 58-69.	3.2	4
2364	Tumor growth kinetics by CA 19-9 in patients with unresectable pancreatic cancer receiving chemotherapy: A retrospective analysis. Pancreatology, 2020, 20, 1189-1194.	0.5	2
2365	A Phase I Study of Dinaciclib in Combination With MKâ€2206 in Patients With Advanced Pancreatic Cancer. Clinical and Translational Science, 2020, 13, 1178-1188.	1.5	23
2367	Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 5348-5357.	3.2	29
2368	Advanced Pancreatic Ductal Adenocarcinoma: Moving Forward. Cancers, 2020, 12, 1955.	1.7	26
2369	Molecular mediators of peritoneal metastasis in pancreatic cancer. Cancer and Metastasis Reviews, 2020, 39, 1223-1243.	2.7	29
2370	Oncolytic virotherapy for pancreatic ductal adenocarcinoma: A glimmer of hope after years of disappointment?. Cytokine and Growth Factor Reviews, 2020, 56, 141-148.	3.2	8

#	Article	IF	Citations
2371	Survival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 586-590.	0.6	5
2373	Tramadol/Acetaminophen Combination Tablets in Cancer Patients with Chemotherapy-Induced Peripheral Neuropathy: A Single-Arm Phase II Study. Palliative Medicine Reports, 2020, 1, 25-31.	0.4	4
2374	Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactionsÂin pancreatic cancer cells. BMC Cancer, 2020, 20, 1024.	1.1	3
2375	The Tumor Microenvironment of Pancreatic Cancer. Cancers, 2020, 12, 3076.	1.7	17
2376	nalâ€IRI+5â€FU/LV versus 5â€FU/LV in postâ€gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients. Cancer Medicine, 2020, 9, 9396-9408.	1.3	26
2377	Impact on prognosis of early weight loss during palliative chemotherapy in patients diagnosed with advanced pancreatic cancer. Pancreatology, 2020, 20, 1682-1688.	0.5	13
2378	Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse model. Surgery, 2020, 168, 448-456.	1.0	3
2379	Anterior gradient 2 is a novel pro-tumor factor in pancreatic cancer under NF-ÎºB subunit RelA trans-regulation that can be suppressed by eugenic acid. Biomedicine and Pharmacotherapy, 2020, 132, 110830.	2.5	1
2380	Treatment Strategies for the Optimal Management of Locally Advanced Pancreatic Adenocarcinoma With Curative Intent. Pancreas, 2020, 49, 1264-1275.	0.5	5
2381	Clinical Significance of Glucose to Lymphocyte Ratio (GLR) as a Prognostic Marker for Patients With Pancreatic Cancer. Frontiers in Oncology, 2020, 10, 520330.	1.3	29
2383	Assessing consistency in clinical trials with two subgroups and binary endpoints: A new test within the logistic regression model. Statistics in Medicine, 2020, 39, 4551-4573.	0.8	1
2384	The economic burden of metastatic pancreatic cancer. Pancreatology, 2020, 20, 1434-1441.	0.5	3
2385	Neutrophil to lymphocyte ratio predicts prognosis in unresectable pancreatic cancer. Scientific Reports, 2020, 10, 18758.	1.6	54
2386	A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy. Journal of Pancreatic Cancer, 2020, 6, 45-54.	1.6	15
2387	ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer. ESMO Open, 2020, 5, e000804.	2.0	61
2388	What is the role of PARP inhibitors in pancreatic cancer?. Expert Review of Anticancer Therapy, 2020, 20, 913-918.	1.1	3
2389	iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery. Polymers, 2020, 12, 1906.	2.0	45
2390	An RNA-Binding Protein, Hu-antigen R, in Pancreatic Cancer Epithelial to Mesenchymal Transition, Metastasis, and Cancer Stem Cells. Molecular Cancer Therapeutics, 2020, 19, 2267-2277.	1.9	29

#	Article	IF	Citations
2391	Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy. Cells, 2020, 9, 2110.	1.8	17
2392	Predictive implications of decreased <scp>CA19</scp>â€9 at 8â€‰weeks during nabâ€paclitaxel plus gemcitabine for the induction of secondâ€line chemotherapy for patients with advanced pancreatic cancer. Cancer Reports, 2020, 3, e1289.	0.6	9
2393	Deciphering the Role of Innate Immune NF-Ä¸B Pathway in Pancreatic Cancer. Cancers, 2020, 12, 2675.	1.7	12
2394	Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities. Genes, 2020, 11, 1098.	1.0	9
2395	Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results. European Journal of Cancer, 2020, 139, 51-58.	1.3	7
2396	Controlled loading of albumin-drug conjugates ex vivo for enhanced drug delivery and antitumor efficacy. Journal of Controlled Release, 2020, 328, 1-12.	4.8	28
2397	Scoparone as a therapeutic drug in liver diseases: Pharmacology, pharmacokinetics and molecular mechanisms of action. Pharmacological Research, 2020, 160, 105170.	3.1	43
2398	Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer. JAMA Oncology, 2020, 6, 1751.	3.4	20
2399	Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer. Frontiers in Medicine, 2020, 7, 495.	1.2	7
2400	Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma. Frontiers in Oncology, 2020, 10, 1461.	1.3	2
2401	Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer â€“ translational results from the AIO-PK0104 Phase 3 study. British Journal of Cancer, 2020, 123, 1370-1376.	2.9	10
2402	Interventional Pharmacoeconomics. Cancer Journal (Sudbury, Mass), 2020, 26, 330-334.	1.0	8
2403	A new targeted treatment for patients with a germline BRCA mutation: olaparib in pancreatic cancer. Future Oncology, 2020, 16, 2691-2700.	1.1	1
2404	Survival outcomes and rate of missed upper gastrointestinal cancers at routine endoscopy: a single centre retrospective cohort study. European Journal of Gastroenterology and Hepatology, 2020, 32, 1312-1321.	0.8	5
2405	Efficacy of mistletoe extract as a complement to standard treatment in advanced pancreatic cancer: study protocol for a multicentre, parallel group, double-blind, randomised, placebo-controlled clinical trial (MISTRAL). Trials, 2020, 21, 783.	0.7	6
2406	Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib. JCO Precision Oncology, 2020, 4, 865-870.	1.5	15
2407	PARP inhibition in treatment of pancreatic cancer. Expert Review of Anticancer Therapy, 2020, 20, 939-945.	1.1	14
2408	Therapeutic response assessment in pancreatic ductal adenocarcinoma: society of abdominal radiology review paper on the role of morphological and functional imaging techniques. Abdominal Radiology, 2020, 45, 4273-4289.	1.0	15

#	Article	IF	Citations
2409	Carrierâ€Free Nanoassembly of Curcuminâ€“Erlotinib Conjugate for Cancer Targeted Therapy. Advanced Healthcare Materials, 2020, 9, e2001128.	3.9	21
2410	Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 654-659.	0.6	18
2411	Role of lymphadenectomy in resectable pancreatic cancer. Langenbeck's Archives of Surgery, 2020, 405, 889-902.	0.8	6
2412	Effects of Alkalization Therapy on Chemotherapy Outcomes in Advanced Pancreatic Cancer: A Retrospective Case-Control Study. In Vivo, 2020, 34, 2623-2629.	0.6	13
2413	Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study. Cancers, 2020, 12, 2493.	1.7	14
2414	Macrophage-secreted MMP9 induces mesenchymal transition in pancreatic cancer cells via PAR1 activation. Cellular Oncology (Dordrecht), 2020, 43, 1161-1174.	2.1	40
2415	Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies. ESMO Open, 2020, 5, e000578.	2.0	32
2416	Surgical Outcome Results From SWOG S1505. Annals of Surgery, 2020, 272, 481-486.	2.1	155
2417	Multivisceral resection for adenocarcinoma of the pancreatic body and tailâ€”a retrospective single-center analysis. World Journal of Surgical Oncology, 2020, 18, 218.	0.8	11
2418	Successful Treatment for the Recurrent Liver Metastases of the Pancreatic Cancer by Multimodality Therapy. Pancreas, 2020, 49, e75-e76.	0.5	2
2419	Genetic Variants, Fat Malabsorption, and Ancestral Background in a Small Chronic Pancreatitis Cohort. Pancreas, 2020, 49, e76-e78.	0.5	0
2420	Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. Annals of Surgery, 2020, 272, 427-435.	2.1	61
2421	Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patientâ€derived xenograft tumors. Molecular Carcinogenesis, 2020, 59, 1227-1240.	1.3	6
2422	Use and outcomes of chemotherapy for metastatic pancreatic cancer in Australia. Internal Medicine Journal, 2020, , .	0.5	2
2423	CDKN2A-Inactivated Pancreatic Ductal Adenocarcinoma Exhibits Therapeutic Sensitivity to Paclitaxel: A Bioinformatics Study. Journal of Clinical Medicine, 2020, 9, 4019.	1.0	24
2424	Efficacy and feasibility of proton beam radiotherapy using the simultaneous integrated boost technique for locally advanced pancreatic cancer. Scientific Reports, 2020, 10, 21712.	1.6	12
2425	Multi-agent neoadjuvant chemotherapy improves response and survival in patients with resectable pancreatic cancer. Journal of Gastrointestinal Oncology, 2020, 11, 1078-1089.	0.6	4
2426	Cellular Heterogeneity of Pancreatic Stellate Cells, Mesenchymal Stem Cells, and Cancer-Associated Fibroblasts in Pancreatic Cancer. Cancers, 2020, 12, 3770.	1.7	31

#	Article	IF	Citations
2427	The Emerging Role of Microbiota and Microbiome in Pancreatic Ductal Adenocarcinoma. Biomedicines, 2020, 8, 565.	1.4	15
2428	The biological role of metabolic reprogramming in pancreatic cancer. MedComm, 2020, 1, 302-310.	3.1	10
2429	SBRT re-irradiation after prior SBRT in pancreatic cancerâ€"outcomes and a focus on stomach and bowel toxicity. Journal of Radiation Oncology, 2020, 9, 235-241.	0.7	0
2430	Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy in patients with borderline resectable pancreatic cancer. BMC Cancer, 2020, 20, 1184.	1.1	3
2431	The present and future of systemic and microenvironment-targeted therapy for pancreatic adenocarcinoma. Annals of Pancreatic Cancer, 2020, 3, 3-3.	1.2	2
2432	Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma . Cancer Management and Research, 2020, Volume 12, 12657-12666.	0.9	4
2433	Differential Gemcitabine Sensitivity in Primary Human Pancreatic Cancer Cells and Paired Stellate Cells Is Driven by Heterogenous Drug Uptake and Processing. Cancers, 2020, 12, 3628.	1.7	16
2434	FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer . Cancer Management and Research, 2020, Volume 12, 10271-10278.	0.9	7
2435	The Role of Circular RNAs in Pancreatic Ductal Adenocarcinoma and Biliary-Tract Cancers. Cancers, 2020, 12, 3250.	1.7	22
2436	Safety, Efficacy and Pharcacokinetics of Targeted Therapy with The Liposomal RNA Interference Therapeutic Atu027 Combined with Gemcitabine in Patients with Pancreatic Adenocarcinoma. A Randomized Phase Ib/IIa Study. Cancers, 2020, 12, 3130.	1.7	34
2437	Tackling DNA damage repair mechanismsâ€"aÂpromising molecular informed therapeutic approach in pancreatic ductal adenocarcinoma. Memo - Magazine of European Medical Oncology, 2020, 13, 380-384.	0.3	1
2438	Pancreatic Adenocarcinoma Invasiveness and the Tumor Microenvironment: From Biology to Clinical Trials. Biomedicines, 2020, 8, 401.	1.4	5
2439	A contemporary evidence basis for neoadjuvant chemotherapy in upfront resectable pancreatic adenocarcinoma: a systematic review of the literature. Journal of Pancreatology, 2020, 3, 12-20.	0.3	2
2440	A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Oncologist, 2020, 25, e1604-e1613.	1.9	9
2441	Tumor marker recovery rather than major pathological response is a preferable prognostic factor in patients with pancreatic ductal adenocarcinoma with preoperative therapy. Journal of Hepato-Biliary-Pancreatic Sciences, 2020, 27, 487-495.	1.4	7
2442	Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer. Journal of Biological Chemistry, 2020, 295, 8413-8424.	1.6	35
2443	Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab-paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer. Journal of Pancreatology, 2020, 3, 35-41.	0.3	0
2444	FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure. Pancreas, 2020, 49, 574-578.	0.5	11

#	Article	IF	Citations
2445	Duration of therapy for locally advanced pancreatic cancer: Does it matter?. Cancer Medicine, 2020, 9, 4572-4580.	1.3	10
2446	Neoadjuvantâ€modified FOLFIRINOX vs nabâ€paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection. Cancer Medicine, 2020, 9, 4711-4723.	1.3	28
2447	Molecular Targeting of Cancer-Associated PCNA Interactions in Pancreatic Ductal Adenocarcinoma Using a Cell-Penetrating Peptide. Molecular Therapy - Oncolytics, 2020, 17, 250-256.	2.0	19
2448	Genetic Alterations Featuring Biological Models to Tailor Clinical Management of Pancreatic Cancer Patients. Cancers, 2020, 12, 1233.	1.7	5
2449	SMAD4 and the TGFÎ² Pathway in Patients with Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences, 2020, 21, 3534.	1.8	58
2450	Sorafenib and everolimus in patients with advanced solid tumors and KRASâ€mutated NSCLC: A phase I trial with early pharmacodynamic FDGâ€PET assessment. Cancer Medicine, 2020, 9, 4991-5007.	1.3	14
2451	The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort. Scientific Reports, 2020, 10, 7420.	1.6	19
2452	GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 4901-4910.	3.2	191
2453	Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 487-505.	8.2	458
2454	Phase II trial of gemcitabine and nabâ€paclitaxel in patients with recurrent Ewing sarcoma: A report from the National Pediatric Cancer Foundation. Pediatric Blood and Cancer, 2020, 67, e28370.	0.8	15
2455	The tumour microenvironment in pancreatic cancer â€" clinical challenges and opportunities. Nature Reviews Clinical Oncology, 2020, 17, 527-540.	12.5	590
2456	Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients. Cancers, 2020, 12, 1131.	1.7	6
2457	Nanomodified strategies to overcome EGFR-tyrosine kinase inhibitors resistance in non-small cell lung cancer. Journal of Controlled Release, 2020, 324, 482-492.	4.8	16
2458	Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology, 2020, 10, 620.	1.3	6
2459	A bubble bursting-mediated oral drug delivery system that enables concurrent delivery of lipophilic and hydrophilic chemotherapeutics for treating pancreatic tumors in rats. Biomaterials, 2020, 255, 120157.	5.7	21
2460	Targeted Dual Intervention-Oriented Drug-Encapsulated (DIODE) Nanoformulations for Improved Treatment of Pancreatic Cancer. Cancers, 2020, 12, 1189.	1.7	6
2461	Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents. Pharmaceuticals, 2020, 13, 90.	1.7	9
2462	Preoperative Chemotherapy for Pancreatic Cancer Improves Survival and R0 Rate Even in Early Stage I. Journal of Gastrointestinal Surgery, 2020, 24, 2409-2415.	0.9	15

#	Article	IF	Citations
2463	Cisplatin Plus Gemcitabine as Standard of Care for Germline BRCA/PALB2â€Mutated Pancreatic Adenocarcinoma: Are We Moving Too Fast?. Journal of Clinical Oncology, 2020, 38, 2466-2467.	0.8	6
2464	Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials. BMC Cancer, 2020, 20, 421.	1.1	11
2465	Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?. Cancers, 2020, 12, 1341.	1.7	34
2466	Desmoplasia and Biophysics in Pancreatic Ductal Adenocarcinoma. Pancreas, 2020, 49, 313-325.	0.5	18
2467	microRNA-382 suppresses the progression of pancreatic cancer through the PI3K/Akt signaling pathway by inhibition of Anxa3. American Journal of Physiology - Renal Physiology, 2020, 319, G309-G322.	1.6	18
2468	An FGFR/AKT/SOX2 Signaling Axis Controls Pancreatic Cancer Stemness. Frontiers in Cell and Developmental Biology, 2020, 8, 287.	1.8	32
2469	Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models. Cancers, 2020, 12, 1327.	1.7	40
2470	Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092342.	1.4	14
2471	Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy indicated in hepatobiliary malignancies?. World Journal of Surgical Oncology, 2020, 18, 124.	0.8	7
2472	Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study). International Journal of Clinical Oncology, 2020, 25, 1835-1843.	1.0	6
2473	NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials. Medical Oncology, 2020, 37, 61.	1.2	9
2474	Evaluation of targetable biomarkers for chimeric antigen receptor T-cell (CAR-T) in the treatment of pancreatic cancer: a systematic review and meta-analysis of preclinical studies. International Reviews of Immunology, 2020, 39, 223-232.	1.5	5
2475	Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2. Molecular and Cellular Biochemistry, 2020, 472, 187-198.	1.4	10
2476	Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives. Current Opinion in Oncology, 2020, 32, 356-363.	1.1	18
2477	Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network. European Journal of Cancer, 2020, 135, 89-97.	1.3	13
2478	Clinical implications of the serum CA19-9 level in â€œbiological borderline resectabilityâ€•and â€œbiological downstagingâ€•in the setting of preoperative chemoradiation therapy for pancreatic cancer. Pancreatology, 2020, 20, 919-928.	0.5	25
2479	HEATR1 Deficiency Promotes Chemoresistance via Upregulating ZNF185 and Downregulating SMAD4 in Pancreatic Cancer. Journal of Oncology, 2020, 2020, 1-10.	0.6	7
2480	A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer. BMC Cancer, 2020, 20, 515.	1.1	10

#	Article	IF	Citations
2481	Molecular Targeting of a BRAF Mutation in Pancreatic Ductal Adenocarcinoma: Case Report and Literature Review. Targeted Oncology, 2020, 15, 407-410.	1.7	17
2482	Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma. Cancers, 2020, 12, 1428.	1.7	10
2483	Prolonged Response to Liposomal Irinotecan in a Patient with Stage IV Pancreatic/Bile Duct Cancer Previously Treated with FOLFIRINOX and Gemcitabine Plus Nab-Paclitaxel. Current Oncology, 2020, 27, 222-225.	0.9	1
2484	Blood-based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Pancreatic Cancer and its Value to Guide Clinical Treatment. Journal of Cancer, 2020, 11, 4316-4323.	1.2	4
2485	Discovery of New Targets to Control Metastasis in Pancreatic Cancer by Single-cell Transcriptomics Analysis of Circulating Tumor Cells. Molecular Cancer Therapeutics, 2020, 19, 1751-1760.	1.9	31
2486	Fibroblasts as a Biological Marker for Curative Resection in Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences, 2020, 21, 3890.	1.8	24
2487	PAWI-2: A novel inhibitor for eradication of cancer. Medicinal Chemistry Research, 2020, 29, 1147-1159.	1.1	1
2488	En Bloc Celiac Axis Resection for Pancreatic Cancer: Classification of Anatomical Variants Based on Tumor Extent. Journal of the American College of Surgeons, 2020, 231, 8-29.	0.2	42
2489	Characteristics of Lung Metastasis as an Initial Recurrence Pattern After Curative Resection of Pancreatic Cancer. Pancreas, 2020, 49, 699-705.	0.5	8
2490	Young Adults With Pancreatic Cancer. Pancreas, 2020, 49, 341-354.	0.5	12
2491	Regulation of pancreatic cancer microenvironment by an intelligent gemcitabine@nanogel system via in vitro 3D model for promoting therapeutic efficiency. Journal of Controlled Release, 2020, 324, 545-559.	4.8	19
2492	Albumin Nanoparticle of Paclitaxel (Abraxane) Decreases while Taxol Increases Breast Cancer Stem Cells in Treatment of Triple Negative Breast Cancer. Molecular Pharmaceutics, 2020, 17, 2275-2286.	2.3	55
2493	Albumin-to-alkaline phosphatase ratio serves as a prognostic indicator in unresectable pancreatic ductal adenocarcinoma: a propensity score matching analysis. BMC Cancer, 2020, 20, 541.	1.1	9
2494	DBDx-based drug combinations show highly potent therapeutic efficacy against human pancreatic cancer xenografts in athymic mice. Cancer Biology and Therapy, 2020, 21, 749-757.	1.5	2
2495	Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma. Frontiers in Immunology, 2020, 11, 1127.	2.2	9
2496	Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 4814-4822.	3.2	82
2497	Tâ€cell activation and immune memory enhancement induced by irreversible electroporation in pancreatic cancer. Clinical and Translational Medicine, 2020, 10, e39.	1.7	46
2498	Modified gemcitabine plus nabâ€paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Cancer Medicine, 2020, 9, 5406-5415.	1.3	9

#	Article	IF	Citations
2499	An unbiased highâ€throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer. Molecular Oncology, 2020, 14, 1800-1816.	2.1	10
2500	Folfirinox chemotherapy prolongs stent patency in patients with malignant biliary obstruction due to unresectable pancreatic cancer. Hepatobiliary and Pancreatic Diseases International, 2020, 19, 590-595.	0.6	9
2501	Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia. Journal of Gastrointestinal Oncology, 2020, 11, 55-60.	0.6	5
2502	Phase Ib/II study combining tosedostat with capecitabine in patients with advanced pancreatic adenocarcinoma. Journal of Gastrointestinal Oncology, 2020, 11, 61-67.	0.6	5
2503	Effects of Alkalization Therapy on Chemotherapy Outcomes in Metastatic or Recurrent Pancreatic Cancer. Anticancer Research, 2020, 40, 873-880.	0.5	28
2504	A novel natural product, britanin, inhibits tumor growth of pancreatic cancer by suppressing nuclear factor-ÎºB activation. Cancer Chemotherapy and Pharmacology, 2020, 85, 699-709.	1.1	9
2505	A 10-year review of survival among patients with metastatic gastrointestinal cancers: a population-based study. International Journal of Colorectal Disease, 2020, 35, 911-920.	1.0	4
2506	Inhibition of Cholesterol Esterification Enzyme Enhances the Potency of Human Chimeric Antigen Receptor T Cells against Pancreatic Carcinoma. Molecular Therapy - Oncolytics, 2020, 16, 262-271.	2.0	12
2507	Glycogen synthase kinase-3Î²: a novel therapeutic target for pancreatic cancer. Expert Opinion on Therapeutic Targets, 2020, 24, 417-426.	1.5	26
2508	Antibacterial Use Is Associated with an Increased Risk of Hematologic and Gastrointestinal Adverse Events in Patients Treated with Gemcitabine for Stage IV Pancreatic Cancer. Oncologist, 2020, 25, 579-584.	1.9	25
2509	Neoadjuvant Treatment in Pancreatic Cancer. Frontiers in Oncology, 2020, 10, 245.	1.3	145
2510	Opportunity Costs of Receiving Palliative Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma. JCO Oncology Practice, 2020, 16, e678-e687.	1.4	31
2511	Anti-glypican-1 antibodyâ€“drug conjugate is a potential therapy against pancreatic cancer. British Journal of Cancer, 2020, 122, 1333-1341.	2.9	27
2512	Toxicity Syndromes, Patient-Related Clinical Indicator of Toxicity Burden Induced by Intensive Triplet Chemotherapy-Based Regimens in Gastrointestinal Cancers With Metastatic Disease. Frontiers in Oncology, 2020, 10, 172.	1.3	4
2513	Primary Thromboprophylaxis in Pancreatic Cancer Patients: Why Clinical Practice Guidelines Should Be Implemented. Cancers, 2020, 12, 618.	1.7	16
2514	The Utility of Stereotactic Ablative Radiation Therapy for Palliation of Metastatic Pancreatic Adenocarcinoma. Practical Radiation Oncology, 2020, 10, 274-281.	1.1	8
2515	Surgery for synchronous and metachronous single-organ metastasis of pancreatic cancer: a SEER database analysis and systematic literature review. Scientific Reports, 2020, 10, 4444.	1.6	34
2516	The impact of metastatic sites in advanced pancreatic adenocarcinoma, systematic review and meta-analysis of prospective randomized studies. PLoS ONE, 2020, 15, e0230060.	1.1	16

#	Article	IF	Citations
2517	Recurrence patterns of pancreatic cancer after pancreatoduodenectomy: systematic review and a single-centre retrospective study. Hpb, 2020, 22, 1240-1249.	0.1	24
2518	Some unanswered questions about older adults with metastatic pancreatic cancer. Journal of Geriatric Oncology, 2020, 11, 1032-1033.	0.5	1
2519	Supportive roles of brain macrophages in CNS metastases and assessment of new approaches targeting their functions. Theranostics, 2020, 10, 2949-2964.	4.6	25
2520	The potential drug for treatment in pancreatic adenocarcinoma: a bioinformatical study based on distinct drug databases. Chinese Medicine, 2020, 15, 26.	1.6	7
2521	Assessment of Anti-Tumor potential and safety of application of Glutathione stabilized Gold Nanoparticles conjugated with Chemotherapeutics. International Journal of Medical Sciences, 2020, 17, 824-833.	1.1	20
2522	Myeloid derived suppressor cells are reduced and T regulatory cells stabilised in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega 3. Annals of Translational Medicine, 2020, 8, 172-172.	0.7	8
2523	Treatment patterns and outcomes in pancreatic cancer: Retrospective claims analysis. Cancer Medicine, 2020, 9, 3463-3476.	1.3	13
2524	CircFOXK2 Promotes Growth and Metastasis of Pancreatic Ductal Adenocarcinoma by Complexing with RNA-Binding Proteins and Sponging MiR-942. Cancer Research, 2020, 80, 2138-2149.	0.4	106
2525	Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease. Cancer Research, 2020, 80, 3179-3192.	0.4	15
2526	Nanoparticles in Gastrooncology. Visceral Medicine, 2020, 36, 88-94.	0.5	7
2527	All-stage precisional glioma targeted therapy enabled by a well-designed D-peptide. Theranostics, 2020, 10, 4073-4087.	4.6	25
2528	A Case of Rare Cutaneous Metastasis from Advanced Pancreatic Cancer. Case Reports in Oncology, 2020, 13, 49-54.	0.3	5
2529	Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592090540.	1.4	24
2530	Neoadjuvant or Adjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer: Which Is Preferred?. Journal of Clinical Oncology, 2020, 38, 1757-1759.	0.8	19
2531	Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients. Journal of Clinical Medicine, 2020, 9, 648.	1.0	24
2532	Developing effective combination therapy for pancreatic cancer: An overview. Pharmacological Research, 2020, 155, 104740.	3.1	46
2533	Evaluation of preoperative prognostic factors in patients with resectable invasive intraductal papillary mucinous carcinoma. Surgery, 2020, 168, 994-1002.	1.0	6
2534	A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience. Surgical Oncology, 2020, 33, 118-125.	0.8	4

#	Article	IF	Citations
2535	A Phase II Study of Allogeneic GM-CSFâ€“Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 5129-5139.	3.2	67
2536	Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas harboring KRAS and BRCA mutations: case report and whole exome sequencing analysis. BMC Gastroenterology, 2020, 20, 202.	0.8	8
2537	Pancreatic cancer. Lancet, The, 2020, 395, 2008-2020.	6.3	1,376
2538	Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumorâ€™s arsenal. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188387.	3.3	19
2539	Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer. Pancreas, 2020, 49, 744-750.	0.5	10
2540	Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR) Tj ETQq1 1 0.784314 rgBT /O	2.1	34
2541	Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma. Clinical Cancer Research, 2020, 26, 5208-5216.	3.2	23
2542	Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors. Biomolecules, 2020, 10, 973.	1.8	16
2543	Cabozantinib Inhibits Photodynamic Therapy-Induced Auto- and Paracrine MET Signaling in Heterotypic Pancreatic Microtumors. Cancers, 2020, 12, 1401.	1.7	9
2544	Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM). Cancers, 2020, 12, 1681.	1.7	20
2545	The Anti-Tumor Effect of Nab-Paclitaxel Proven by Patient-Derived Organoids . OncoTargets and Therapy, 2020, Volume 13, 6017-6025.	1.0	9
2546	Patients With Acinar Cell Carcinoma of the Pancreas After 2005. Pancreas, 2020, 49, 781-787.	0.5	15
2547	Defining Parallels between the Salivary Glands and Pancreas to Better Understand Pancreatic Carcinogenesis. Biomedicines, 2020, 8, 178.	1.4	9
2548	Complete response of refractory mycosis fungoides to treatment of pancreatic cancer with combination gemcitabine and nab-paclitaxel: ÂÂpossible new regimen for the treatment of advancedÂcutaneous T-cell lymphoma. JAAD Case Reports, 2020, 6, 581-583.	0.4	1
2549	Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. British Journal of Cancer, 2020, 123, 709-713.	2.9	20
2550	Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer. Pancreas, 2020, 49, 822-829.	0.5	2
2551	Inflammatory IFIT3 renders chemotherapy resistance by regulating post-translational modification of VDAC2 in pancreatic cancer. Theranostics, 2020, 10, 7178-7192.	4.6	29
2552	The impact of molecular classification based on the transcriptome of pancreatic cancer: from bench to bedside. Chinese Journal of Academic Radiology, 2020, 3, 67-75.	0.4	0

#	Article	IF	Citations
2553	Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Pancreatology, 2020, 20, 1131-1138.	0.5	16
2554	Efficacy and safety of gemcitabine plus capecitabine in the treatment of advanced or metastatic pancreatic cancer: a systematic review and meta-analysis. Annals of Palliative Medicine, 2020, 9, 1631-1642.	0.5	10
2555	In silicoidentification of therapeutic compounds against microRNA targets in drug-resistant pancreatic ductal adenocarcinoma. Journal of Biomolecular Structure and Dynamics, 2020, 39, 1-9.	2.0	3
2556	CD200 promotes immunosuppression in the pancreatic tumor microenvironment. , 2020, 8, e000189.		52
2557	Stellate Cells in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1263, 67-84.	0.8	10
2558	Neoadjuvant therapy for pancreatic cancer: an intention-to-treat analysis. Langenbeck's Archives of Surgery, 2020, 405, 623-633.	0.8	1
2559	Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens. BMC Cancer, 2020, 20, 633.	1.1	19
2560	Initial Report of an Intradural Extramedullary Metastasis of a Pancreatic Neuroendocrine Tumor to the Cervical Spine: A Case Report and Review of the Literature. World Neurosurgery, 2020, 139, 355-360.	0.7	6
2561	Gemcitabine-retinoid prodrug loaded nanoparticles display in vitro antitumor efficacy towards drug-resilient human PANC-1 pancreatic cancer cells. Materials Science and Engineering C, 2020, 117, 111251.	3.8	10
2562	Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de CancÃ©rologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX). European Journal of Cancer, 2020, 136, 25-34.	1.3	6
2563	FOLFIRINOX Versus Gemcitabine-based Therapy for Pancreatic Ductal Adenocarcinoma: Lessons from Patient-derived Cell Lines. Anticancer Research, 2020, 40, 3659-3667.	0.5	12
2564	Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. British Journal of Surgery, 2020, 107, 1811-1817.	0.1	39
2566	Consolidative Chemoradiotherapy After Induced Chemotherapy Is an Optimal Regimen for Locally Advanced Pancreatic Cancer. Frontiers in Oncology, 2019, 9, 1543.	1.3	6
2567	Isolation and Characterization of Patient-derived Pancreatic Ductal Adenocarcinoma Organoid Models. Journal of Visualized Experiments, 2020, , .	0.2	2
2568	A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches. Expert Opinion on Drug Safety, 2020, 19, 187-204.	1.0	5
2569	Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib â€“ results from a non-interventional multi-center study. BMC Cancer, 2020, 20, 155.	1.1	3
2570	CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma. Cancer Cell, 2020, 37, 340-353.e6.	7.7	114
2571	Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine. Case Reports in Oncology, 2020, 13, 35-42.	0.3	6

#	Article	IF	Citations
2572	Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol?. Annals of Gastroenterological Surgery, 2020, 4, 100-108.	1.2	35
2573	Breast cancer suspected to originate from familial hereditary tumors: A case report. Clinical Case Reports (discontinued), 2020, 8, 648-652.	0.2	0
2574	Incidence and frequency of cancer cachexia during chemotherapy for advanced pancreatic ductal adenocarcinoma. Supportive Care in Cancer, 2020, 28, 5271-5279.	1.0	26
2575	A Multicenter Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Elderly Patients With Advanced Pancreatic Cancer. Pancreas, 2020, 49, 187-192.	0.5	22
2576	Inflammatory networks cultivate cancer cell metastasis to the liver. Cell Cycle, 2020, 19, 642-651.	1.3	8
2577	Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels. Oncogene, 2020, 39, 3102-3113.	2.6	61
2578	Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy. Journal of the American Chemical Society, 2020, 142, 4944-4954.	6.6	153
2579	HHLA2 is expressed in pancreatic and ampullary cancers and increased expression is associated with better post-surgical prognosis. British Journal of Cancer, 2020, 122, 1211-1218.	2.9	26
2580	Inhibition of TGF-Î² signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models. Scientific Reports, 2020, 10, 2935.	1.6	18
2581	Sequential delivery of nanoformulated Î±-mangostin and triptolide overcomes permeation obstacles and improves therapeutic effects in pancreatic cancer. Biomaterials, 2020, 241, 119907.	5.7	61
2582	Charging forward in locally advanced pancreatic cancer. The Lancet Gastroenterology and Hepatology, 2020, 5, 234-236.	3.7	3
2583	Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma. Japanese Journal of Clinical Oncology, 2020, 50, 483-489.	0.6	44
2584	Current status of immunotherapy in gastrointestinal malignancies. Zeitschrift Fur Gastroenterologie, 2020, 58, 542-555.	0.2	5
2585	Complete Radiologic Response of Metastatic Pancreatic Ductal Adenocarcinoma to Microwave Ablation Combined with Second-Line Palliative Chemotherapy. Case Reports in Gastrointestinal Medicine, 2020, 2020, 1-7.	0.2	1
2586	Sequential Treatment of Metastatic Adenocarcinoma of the Pancreatic Duct with Liver Metastasis Following the NAPOLI-1 Study Protocol with nal-Irinotecan plus 5-FU in the Second Line. Case Reports in Oncology, 2020, 13, 79-84.	0.3	4
2587	Development and validation of a novel nomogram for pretreatment prediction of liver metastasis in pancreatic cancer. Cancer Medicine, 2020, 9, 2971-2980.	1.3	9
2588	Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future. Lancet Oncology, The, 2020, 21, e135-e145.	5.1	155
2589	Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. Lancet Oncology, The, 2020, 21, 508-518.	5.1	323

#	Article	IF	Citations
2590	Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study. European Journal of Cancer, 2020, 129, 50-59.	1.3	17
2591	Retrospective evaluation of risk factors of postoperative varices after pancreaticoduodenectomy with combined portal vein resection. Pancreatology, 2020, 20, 522-528.	0.5	9
2592	Upcoming Revolutionary Paths in Preclinical Modeling of Pancreatic Adenocarcinoma. Frontiers in Oncology, 2020, 9, 1443.	1.3	16
2593	Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer. Angewandte Chemie - International Edition, 2020, 59, 3028-3032.	7.2	100
2594	Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. The Lancet Gastroenterology and Hepatology, 2020, 5, 285-294.	3.7	152
2595	Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Pancreatology, 2020, 20, 501-504.	0.5	31
2596	Small molecule inhibitors in pancreatic cancer. RSC Medicinal Chemistry, 2020, 11, 164-183.	1.7	21
2597	Administration sequence for multi-agent oncolytic regimens. Journal of Oncology Pharmacy Practice, 2020, 26, 933-942.	0.5	1
2598	Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. Journal of Clinical Oncology, 2020, 38, 1378-1388.	0.8	265
2599	Proposal of predictive model on survival in unresectable pancreatic cancer receiving systemic chemotherapy. Journal of Cancer, 2020, 11, 1223-1230.	1.2	2
2600	Chemotherapy use and survival in older adults with metastatic pancreatic cancer in the combination therapy era. Journal of Geriatric Oncology, 2020, 11, 640-646.	0.5	5
2601	Pluronic Polymer-Based Ormeloxifene Nanoformulations Induce Superior Anticancer Effects in Pancreatic Cancer Cells. ACS Omega, 2020, 5, 1147-1156.	1.6	4
2602	Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer. Angewandte Chemie, 2020, 132, 3052-3056.	1.6	4
2603	GSK-3: An important kinase in colon and pancreatic cancers. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118626.	1.9	16
2604	Diffusion-weighted MRI predicts the histologic response for neoadjuvant therapy in patients with pancreatic cancer: a prospective study (DIFFERENT trial). Langenbeck's Archives of Surgery, 2020, 405, 23-33.	0.8	16
2605	Tumor Cellâ€"Derived IL1Î² Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer. Cancer Research, 2020, 80, 1088-1101.	0.4	195
2606	The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer. Annals of Surgical Oncology, 2020, 27, 2506-2515.	0.7	18
2607	Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin Î±3 in human pancreatic cancer. Scientific Reports, 2020, 10, 537.	1.6	4

#	Article	IF	Citations
2608	Prognostic impact of tumour-infiltrating lymphocytes and cancer-associated fibroblasts in patients with pancreatic adenocarcinoma of the body and tail undergoing resection. British Journal of Surgery, 2020, 107, 720-733.	0.1	8
2609	High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer. PLoS ONE, 2020, 15, e0226707.	1.1	16
2610	Prophylactic dendritic cell vaccination controls pancreatic cancer growth in a mouse model. Cytotherapy, 2020, 22, 6-15.	0.3	11
2611	Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy. Surgery, 2020, 167, 803-811.	1.0	32
2612	Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients. Cancer Medicine, 2020, 9, 2153-2159.	1.3	26
2613	Prooxidative activity of plumbagin induces apoptosis in human pancreatic ductal adenocarcinoma cells via intrinsic apoptotic pathway. Toxicology in Vitro, 2020, 65, 104788.	1.1	19
2614	Tissue of origin dictates GOT1 dependence and confers synthetic lethality to radiotherapy. Cancer & Metabolism, 2020, 8, 1.	2.4	34
2615	Theranostic nanoparticles enabling the release of phosphorylated gemcitabine for advanced pancreatic cancer therapy. Journal of Materials Chemistry B, 2020, 8, 2410-2417.	2.9	6
2616	CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes. JCO Precision Oncology, 2020, 4, 426-436.	1.5	9
2617	Pharmacological cancer treatment and venous thromboembolism risk. European Heart Journal Supplements, 2020, 22, C2-C14.	0.0	11
2618	Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL). British Journal of Cancer, 2020, 123, 26-32.	2.9	17
2619	Response to Preoperative Therapy in Localized Pancreatic Cancer. Frontiers in Oncology, 2020, 10, 516.	1.3	16
2620	Endoscopic Ultrasound-Guided Treatment of Pancreatic Cancer. Current Gastroenterology Reports, 2020, 22, 27.	1.1	12
2621	Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. British Journal of Cancer, 2020, 122, 1760-1768.	2.9	14
2622	Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening. Cancer Medicine, 2020, 9, 4004-4013.	1.3	25
2623	The role of intraoperative radiation therapy in resectable pancreatic cancer: a systematic review and meta-analysis. Radiation Oncology, 2020, 15, 76.	1.2	9
2624	The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer. Annals of Surgical Oncology, 2020, 27, 3939-3947.	0.7	12
2625	Vitamin and herbal supplementsâ€™ use among patients with advanced gastrointestinal cancers included in eight clinical trials. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2089-2097.	1.2	2

#	Article	IF	Citations
2626	A novel peptide targeting gastrin releasing peptide receptor for pancreatic neoplasm detection. Biomaterials Science, 2020, 8, 2682-2693.	2.6	19
2627	SKA1 regulates actin cytoskeleton remodelling via activating Cdc42 and influences the migration of pancreatic ductal adenocarcinoma cells. Cell Proliferation, 2020, 53, e12799.	2.4	14
2628	Noninvasive Young's modulus visualization of fibrosis progression and delineation of pancreatic ductal adenocarcinoma (PDAC) tumors using Harmonic Motion Elastography (HME) in vivo. Theranostics, 2020, 10, 4614-4626.	4.6	33
2629	Role of Dimerized C16orf74 in Aggressive Pancreatic Cancer: A Novel Therapeutic Target. Molecular Cancer Therapeutics, 2020, 19, 187-198.	1.9	6
2630	Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1625-1645.	1.2	14
2631	Oncolytic Virus-Mediated Targeting of the ERK Signaling Pathway Inhibits Invasive Propensity in Human Pancreatic Cancer. Molecular Therapy - Oncolytics, 2020, 17, 107-117.	2.0	25
2632	Adjuvant and neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma. Journal of Pancreatology, 2020, 3, 1-11.	0.3	13
2633	Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. , 2020, 8, e000587.		62
2634	The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study. Therapeutic Advances in Medical Oncology, 2020, 12, 175883591990087.	1.4	33
2635	Multidisciplinary consensus statement on the clinical management of patients with pancreatic cancer. Clinical and Translational Oncology, 2020, 22, 1963-1975.	1.2	26
2636	Choice of first line systemic treatment in pancreatic cancer among national experts. Pancreatology, 2020, 20, 686-690.	0.5	9
2637	Microenvironmental Determinants of Pancreatic Cancer. Physiological Reviews, 2020, 100, 1707-1751.	13.1	156
2638	Chemotherapy, host response and molecular dynamics in periampullary cancer: the CHAMP study. BMC Cancer, 2020, 20, 308.	1.1	9
2639	Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis. International Journal of Molecular Sciences, 2020, 21, 2814.	1.8	18
2641	New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma. Drugs, 2020, 80, 647-669.	4.9	97
2642	Photothermal augment stromal disrupting effects for enhanced Abraxane synergy chemotherapy in pancreatic cancer PDX mode. Biomaterials Science, 2020, 8, 3278-3285.	2.6	9
2643	Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study. Clinical Cancer Research, 2020, 26, 71-81.	3.2	109
2644	MiR-203a-3p Inhibits Pancreatic Cancer Cell Proliferation, EMT, and Apoptosis by Regulating SLUG. Technology in Cancer Research and Treatment, 2020, 19, 153303381989872.	0.8	28

#	Article	IF	Citations
2645	Comparing the intra-tumoral distribution of Gemcitabine, 5-Fluorouracil, and Capecitabine in a murine model of pancreatic ductal adenocarcinoma. PLoS ONE, 2020, 15, e0231745.	1.1	7
2646	Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy. Cancer Research, 2020, 80, 3101-3115.	0.4	77
2647	A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2020, 26, 3641-3648.	3.2	41
2648	Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma. Clinical Cancer Research, 2020, 26, 828-836.	3.2	35
2649	Predictors of Disease Progression or Performance Status Decline in Patients Undergoing Neoadjuvant Therapy for Localized Pancreatic Head Adenocarcinoma. Annals of Surgical Oncology, 2020, 27, 2961-2971.	0.7	8
2650	Development, Validation and Comparison of Artificial Neural Network Models and Logistic Regression Models Predicting Survival of Unresectable Pancreatic Cancer. Frontiers in Bioengineering and Biotechnology, 2020, 8, 196.	2.0	24
2651	A New Score to Predict the Resectability of Pancreatic Adenocarcinoma: The BACAP Score. Cancers, 2020, 12, 783.	1.7	6
2652	Antireflux metal stent for biliary obstruction: Any benefits?. Digestive Endoscopy, 2021, 33, 310-320.	1.3	16
2653	Initial experience of irreversible electroporation for locally advanced pancreatic cancer in a Korean population. Acta Radiologica, 2021, 62, 164-171.	0.5	5
2654	Gemcitabine plus nab-paclitaxel with initial dose reduction for older patients with advanced pancreatic cancer. Journal of Geriatric Oncology, 2021, 12, 118-121.	0.5	6
2655	Emergence in protein derived nanomedicine as anticancer therapeutics: More than a tour de force. Seminars in Cancer Biology, 2021, 69, 77-90.	4.3	25
2656	Therapeutic resistance of pancreatic cancer: Roadmap to its reversal. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188461.	3.3	68
2657	Tumour treating fields therapy for glioblastoma: current advances and future directions. British Journal of Cancer, 2021, 124, 697-709.	2.9	136
2658	Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients. Cancer Chemotherapy and Pharmacology, 2021, 87, 95-101.	1.1	3
2659	Treatment patterns in pancreatic cancer patients based on a hospital claims database in Japan. Japanese Journal of Clinical Oncology, 2021, 51, 228-234.	0.6	2
2660	Organoid model: A new hope for pancreatic cancer treatment?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188466.	3.3	35
2661	The Effect of Disclosing Life Expectancy Information on Patients' Prognostic Understanding: Secondary Outcomes From a Multicenter Randomized Trial of a Palliative Chemotherapy Educational Intervention. Journal of Pain and Symptom Management, 2021, 61, 1-11.e3.	0.6	13
2662	Upfront resection versus neoadjuvant therapy for T1/T2 pancreatic cancer. Hpb, 2021, 23, 279-289.	0.1	4

#	Article	IF	Citations
2663	Irinotecan and vandetanib create synergies for treatment of pancreatic cancer patients with concomitant TP53 and KRAS mutations. Briefings in Bioinformatics, 2021, 22, .	3.2	19
2664	A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis. Investigational New Drugs, 2021, 39, 175-181.	1.2	7
2665	Phase <scp>II</scp> study evaluating the association of gemcitabine, trastuzumab and erlotinib as firstâ€line treatment in patients with metastatic pancreatic adenocarcinoma (<scp>GATE</scp> 1). International Journal of Cancer, 2021, 148, 682-691.	2.3	23
2666	Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells. Clinical and Translational Oncology, 2021, 23, 110-121.	1.2	9
2667	Is G8 geriatric assessment tool useful in managing elderly patients with metastatic pancreatic carcinoma?. Journal of Geriatric Oncology, 2021, 12, 163-167.	0.5	9
2668	Multidrug regimens for treatment of older patients with metastatic pancreatic cancer. Digestive and Liver Disease, 2021, 53, 117-121.	0.4	1
2669	From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm. Trends in Cancer, 2021, 7, 15-28.	3.8	61
2670	Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation. Advances in Radiation Oncology, 2021, 6, 100506.	0.6	70
2671	Periadventitial dissection of the superior mesenteric artery for locally advanced pancreatic cancer: Surgical planning with the â€œhalo signâ€•and â€œstring signâ€• Surgery, 2021, 169, 1026-1031.	1.0	37
2672	Neoadjuvant gemcitabine and nabâ€paclitaxel for borderline resectable pancreatic cancers: Intentionâ€toâ€treat analysis compared with upfront surgery. Journal of Hepato-Biliary-Pancreatic Sciences, 2021, 28, 143-155.	1.4	29
2673	Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic Cancer. Clinical Cancer Research, 2021, 27, 554-565.	3.2	8
2674	Clinical utility of a newly developed microfluidic device for detecting circulating tumor cells in the blood of patients with pancreaticoâ€biliary malignancies. Journal of Hepato-Biliary-Pancreatic Sciences, 2021, 28, 115-124.	1.4	4
2675	Combinatorial Approaches to Enhance DNA Damage following Enzyme-Mediated Depletion of L-Cys for Treatment of Pancreatic Cancer. Molecular Therapy, 2021, 29, 775-787.	3.7	8
2676	Quality of life and outcome of patients with metastatic pancreatic cancer receiving firstâ€line chemotherapy with nabâ€paclitaxel and gemcitabine: Realâ€life results from the prospective <scp>QOLIXANE</scp> trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry. International Journal of Cancer, 2021, 148, 1478-1488.	2.3	13
2677	Marine bioactive compound dieckol induces apoptosis and inhibits the growth of human pancreatic cancer cells PANCâ€1. Journal of Biochemical and Molecular Toxicology, 2021, 35, e22648.	1.4	8
2678	Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients. International Journal of Clinical Oncology, 2021, 26, 543-551.	1.0	11
2679	A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. Annals of Oncology, 2021, 32, 250-260.	0.6	45
2680	Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1529-1536.	1.2	4

#	Article	IF	Citations
2681	Bidirectional and dynamic interaction between the microbiota and therapeutic resistance in pancreatic cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188484.	3.3	11
2682	Thermosensitive and biodegradable hydrogel encapsulating targeted nanoparticles for the sustained co-delivery of gemcitabine and paclitaxel to pancreatic cancer cells. International Journal of Pharmaceutics, 2021, 593, 120139.	2.6	20
2683	Combined inhibition of Refâ€1 and STAT3 leads to synergistic tumour inhibition in multiple cancers using 3D and in vivo tumour coâ€culture models. Journal of Cellular and Molecular Medicine, 2021, 25, 784-800.	1.6	9
2684	Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice. Gastroenterology, 2021, 160, 1359-1372.e13.	0.6	41
2685	Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106. Japanese Journal of Clinical Oncology, 2021, 51, 235-243.	0.6	20
2686	Clinical Validation of a Machine-learningâ€"derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. Clinical Cancer Research, 2021, 27, 1174-1183.	3.2	28
2687	Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells. Cancer Immunology, Immunotherapy, 2021, 70, 1451-1464.	2.0	23
2688	Net benefit in the presence of correlated prioritized outcomes using generalized pairwise comparisons: A simulation study. Statistics in Medicine, 2021, 40, 553-565.	0.8	5
2689	SPARC, a phase-I trial of preâ€operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer. Radiotherapy and Oncology, 2021, 155, 278-284.	0.3	11
2690	Trametinib and Hydroxychloroquine (HCQ) Combination Treatment in KRAS-Mutated Advanced Pancreatic Adenocarcinoma: Detailed Description of Two Cases. Journal of Gastrointestinal Cancer, 2021, 52, 374-380.	0.6	19
2691	Discordant reporting of VTE in pancreatic cancer: A systematic review and metaâ€analysis of thromboprophylaxis versus chemotherapeutic trials. Journal of Thrombosis and Haemostasis, 2021, 19, 489-501.	1.9	14
2692	New possible silver lining for pancreatic cancer therapy: Hydrogen sulfide and its donors. Acta Pharmaceutica Sinica B, 2021, 11, 1148-1157.	5.7	25
2693	Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort. European Journal of Surgical Oncology, 2021, 47, 699-707.	0.5	18
2694	Multifocal pancreatobiliary malignancies: A diagnostic and therapeutic challenge. Radiology Case Reports, 2021, 16, 289-294.	0.2	0
2695	Benzimidazole-Based Organicâ€"Inorganic Gold Nanohybrids Suppress Invasiveness of Cancer Cells by Modulating EMT Signaling Cascade. ACS Applied Bio Materials, 2021, 4, 470-482.	2.3	1
2696	DIAPH3 promotes pancreatic cancer progression by activating selenoprotein TrxR1â€mediated antioxidant effects. Journal of Cellular and Molecular Medicine, 2021, 25, 2163-2175.	1.6	33
2697	Poly(<scp>ADP</scp>â€ribose) polymerase inhibition in pancreatic cancer. Genes Chromosomes and Cancer, 2021, 60, 373-384.	1.5	11
2698	Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic Cancer. Advances in Radiation Oncology, 2021, 6, 100621.	0.6	10

#	Article	IF	Citations
2699	Efficacy and feasibility of re-irradiation using carbon ions for pancreatic cancer that recurs after carbon-ion radiotherapy. Clinical and Translational Radiation Oncology, 2021, 26, 24-29.	0.9	7
2700	Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1. Pancreatology, 2021, 21, 192-199.	0.5	8
2701	Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study. European Journal of Cancer, 2021, 143, 101-112.	1.3	18
2702	A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel. Investigational New Drugs, 2021, 39, 605-613.	1.2	6
2703	Contemporary management of pancreas cancer in older people. European Journal of Surgical Oncology, 2021, 47, 560-568.	0.5	4
2704	Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA. Clinical Cancer Research, 2021, 27, 226-236.	3.2	15
2705	Detection of risk factors related to administration suspension and severe neutropenia in gemcitabine and nab-paclitaxel treatment. Supportive Care in Cancer, 2021, 29, 3277-3285.	1.0	8
2706	Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial). Cancer Chemotherapy and Pharmacology, 2021, 87, 65-71.	1.1	3
2707	Effect of adoptive T-cell immunotherapy on immunological parameters and prognosis in patients with advanced pancreatic cancer. Cytotherapy, 2021, 23, 137-145.	0.3	10
2708	An evaluation of olaparib for the treatment of pancreatic cancer. Expert Opinion on Pharmacotherapy, 2021, 22, 521-526.	0.9	4
2709	Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research. International Journal of Clinical Oncology, 2021, 26, 335-344.	1.0	6
2710	Successful treatment of advanced pancreatic leiomyosarcoma treated with gemcitabine plus nab-paclitaxel: a case report and literature review. International Cancer Conference Journal, 2021, 10, 63-67.	0.2	2
2711	Elucidating the Causes of Improved Survival in Clinical Trials of Randomized Adjuvant Pancreatic Ductal Adenocarcinoma (PDAC). Annals of Surgical Oncology, 2021, 28, 1060-1068.	0.7	1
2712	Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma. Annals of Gastroenterological Surgery, 2021, 5, 7-23.	1.2	23
2713	Peritoneal Lavage Tumor DNA as a Novel Biomarker for Predicting Peritoneal Recurrence in Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 2277-2286.	0.7	11
2714	Stroma vs epitheliumâ€enhanced prognostics through histologic stratification in pancreatic ductal adenocarcinoma. International Journal of Cancer, 2021, 148, 481-491.	2.3	7
2715	Autophagy as a therapeutic target in pancreatic cancer. British Journal of Cancer, 2021, 124, 333-344.	2.9	116
2716	Pressure-Enabled Drug Delivery Approach in the Pancreas with Retrograde Venous Infusion of Lipiodol with Ex Vivo Analysis. CardioVascular and Interventional Radiology, 2021, 44, 141-149.	0.9	2

#	Article	IF	Citations
2717	Combined systemic inflammation score (SIS) correlates with prognosis in patients with advanced pancreatic cancer receiving palliative chemotherapy. Journal of Cancer Research and Clinical Oncology, 2021, 147, 579-591.	1.2	17
2718	DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. Gut, 2021, 70, 606-617.	6.1	108
2719	Clinical outcomes of FOLFIRINOX and gemcitabineâ€“nab paclitaxel for metastatic pancreatic cancer in the real world setting. Clinical and Translational Oncology, 2021, 23, 812-819.	1.2	11
2720	Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. Annals of Surgery, 2021, 273, 341-349.	2.1	268
2721	Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer. Annals of Surgery, 2021, 273, 579-586.	2.1	101
2722	Management of Locally Advanced Pancreatic Cancer. Annals of Surgery, 2021, 273, 1173-1181.	2.1	47
2723	Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110185.	1.4	9
2724	The treatment and survival of elderly patients with locally advanced pancreatic cancer: A post-hoc analysis of a multicenter registry. Pancreatology, 2021, 21, 163-169.	0.5	9
2725	A novel methylation signature predicts inferior outcome of patients with PDAC. Aging, 2021, 13, 2851-2863.	1.4	5
2726	Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer. Pancreas, 2021, 50, 83-88.	0.5	1
2727	Risk Factors for Pancreatic Cancer and Cholangiocarcinoma. , 2021, , 3-20.		0
2728	Ex vivo culture of intact human patient derived pancreatic tumour tissue. Scientific Reports, 2021, 11, 1944.	1.6	27
2730	Overcoming acquired chemo-resistance to gemcitabine: implications from the perspective of multi-modal therapy including surgery for pancreatic cancer. , 2021, 4, 881-884.		0
2731	Systematic review and trial sequential analysis of high-intensity focused ultrasound combined with chemotherapy versus chemotherapy in the treatment of unresectable pancreatic ductal adenocarcinoma. International Journal of Hyperthermia, 2021, 38, 1375-1383.	1.1	5
2732	CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncology, The, 2021, 22, 118-131.	5.1	177
2733	The efficacy of a new high-intensity focused ultrasound therapy for metastatic pancreatic cancer. International Journal of Hyperthermia, 2021, 38, 288-295.	1.1	10
2734	Treatment Strategies for Frail and Elderly Patients with Pancreatic Cancer. , 2021, , 207-215.		0
2735	Nanoparticles and pancreas cancer. , 2021, , 145-164.		2

#	Article	IF	Citations
2736	Protein-based nanomedicines as anticancer drug delivery platforms. , 2021, , 153-169.		2
2737	Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinomaâ€"Who Will Benefit from a Secondary Resection?. Medicina (Lithuania), 2021, 57, 77.	0.8	1
2738	Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel Regimen for Borderline Resectable Pancreatic Cancer with Arterial Involvement: A Prospective Multicenter Single-Arm Phase II Study Protocol. International Journal of Surgery Protocols, 2021, 25, 55-60.	0.5	3
2739	Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models. MAbs, 2021, 13, 1914883.	2.6	4
2740	The Elderly Patient with Pancreatic Cancer: Trends and Medical Oncology. , 2021, , 595-611.		0
2741	Improving quality of life in pancreatic cancer patients following high-intensity focused ultrasound (HIFU) in two European centers. European Radiology, 2021, 31, 5818-5829.	2.3	21
2742	Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma. OncoImmunology, 2021, 10, 1973710.	2.1	4
2743	Radiation Therapy in the Management of a Pancreatic Cancer. Clinical Gastroenterology, 2021, , 127-143.	0.0	0
2744	A single-institutional analysis of racial disparities in clinicopathologic characteristics, treatment selections, and outcomes in advanced-stage pancreatic cancer patients. Annals of Pancreatic Cancer, 2021, 4, 7-7.	1.2	0
2745	Hepatic Arterial Infusion Chemotherapy for Liver Metastases Following Standard Chemotherapy for Pancreatic Cancer. Internal Medicine, 2021, 60, 223-229.	0.3	1
2746	Resectable, borderline, and locally advanced pancreatic cancerâ€"â€œthe good, the bad, and the uglyâ€• candidates for surgery?. Journal of Gastrointestinal Oncology, 2021, 12, 2450-2460.	0.6	6
2747	Chemotherapy-induced early transient increase and surge of CA 19â€"9 level in patients with pancreatic Adenocarcinomaâ€°. Cancer Treatment and Research Communications, 2021, 28, 100397.	0.7	1
2748	ATDC binds to KEAP1 to drive NRF2-mediated tumorigenesis and chemoresistance in pancreatic cancer. Genes and Development, 2021, 35, 218-233.	2.7	23
2750	The Evolution of Adjuvant Trials in Pancreatic Cancer. , 2021, , 743-761.		1
2751	Circulating Tumor Cells, Circulating Tumor DNA and Other Blood-based Prognostic Scores in Pancreatic Ductal Adenocarcinoma â€" Mini-Review. In Vivo, 2021, 35, 31-39.	0.6	6
2752	Microorganisms in chemotherapy for pancreatic cancer: An overview of current research and future directions. International Journal of Biological Sciences, 2021, 17, 2666-2682.	2.6	10
2753	Novel Endoscopic Focal Therapy for Pancreatic Cancer and Cholangiocarcinoma. , 2021, , 285-298.		0
2754	Conversion Surgery in Pancreatic Cancer. , 2021, , 83-94.		0

#	Article	IF	Citations
2755	Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer. , 2021, , 61-74.		0
2756	Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer. , 2021, , 51-60.		0
2757	Selecting surgical candidates with locally advanced pancreatic cancer: a review for modern pancreatology. Journal of Gastrointestinal Oncology, 2021, 12, 2475-2483.	0.6	10
2758	Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. Journal of Gastrointestinal Oncology, 2021, 12, 2268-2274.	0.6	0
2759	Age-Related Differences in the Prognosis of Pancreatic Cancer According to Perioperative Systemic Therapy. Pancreas, 2021, 50, 37-46.	0.5	0
2760	Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies. Cancers, 2021, 13, 440.	1.7	27
2761	Acute pancreatitis induced by drugs used in the treatment of solid malignant neoplasms. Onkologiya Zhurnal Imeni P A Gertsena, 2021, 10, 46.	0.0	0
2762	Deuterium Depletion Inhibits Cell Proliferation, RNA and Nuclear Membrane Turnover to Enhance Survival in Pancreatic Cancer. Cancer Control, 2021, 28, 107327482199965.	0.7	6
2763	Overcoming Therapeutic Challenges for Pancreatic Ductal with xCT Inhibitors. Advances in Experimental Medicine and Biology, 2021, 1301, 7-24.	0.8	1
2764	Palliative Chemotherapy and Radiotherapy for Cholangiocarcinoma. , 2021, , 379-396.		0
2765	Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel. Pharmacogenomics Journal, 2021, 21, 233-242.	0.9	11
2766	Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoadjuvant FOLFIRINOX and Chemoradiation. Annals of Surgical Oncology, 2021, 28, 4592-4601.	0.7	9
2767	CC Chemokine Receptor 2-Targeting Copper Nanoparticles for Positron Emission Tomography-Guided Delivery of Gemcitabine for Pancreatic Ductal Adenocarcinoma. ACS Nano, 2021, 15, 1186-1198.	7.3	32
2768	Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110030.	1.4	9
2769	Importance of Systemic Chemotherapy in Advanced Peritoneal Metastasis. , 2021, , 239-253.		0
2770	Analysis of the Role of Plasma 25â€Hydroxyvitamin D Levels in Survival Outcomes in Patients from the Phase III MPACT Trial of Metastatic Pancreatic Cancer. Oncologist, 2021, 26, e704-e709.	1.9	5
2771	The implication of liquid biopsies to predict chemoresistance in pancreatic cancer. , 2021, 4, 559-572.		3
2772	Treatment Approach for Pancreatic Cancer with Peritoneal Dissemination. , 2021, , 195-205.		0

#	Article	IF	Citations
2773	Advances in Targeted Therapy and Immunotherapy for Pancreatic Cancer. Advanced Biology, 2021, 5, 1900236.	1.4	13
2774	The Impact of COVID-19 Infection on the Postoperative Outcomes in Pancreatic Cancer Patients. In Vivo, 2021, 35, 1307-1311.	0.6	4
2775	The prognostic impact of tumour location and first-line chemotherapy regimen in locally advanced pancreatic cancer. Japanese Journal of Clinical Oncology, 2021, 51, 728-736.	0.6	5
2776	Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain. Seminars in Oncology, 2021, 48, 34-46.	0.8	7
2777	Adjuvant therapy for patients with resectable pancreatic ductal adenocarcinoma. Suizo, 2021, 36, 12-19.	0.1	0
2778	The Unique Microbiome and Immunity in Pancreatic Cancer. Pancreas, 2021, 50, 119-129.	0.5	8
2779	Tailorâ€Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma. Advanced Science, 2021, 8, 2002545.	5.6	22
2780	Covered selfâ€expandable metal stents versus plastic stents for preoperative biliary drainage in patient receiving neoâ€adjuvant chemotherapy for borderline resectable pancreatic cancer: Prospective randomized study. Digestive Endoscopy, 2021, 33, 1170-1178.	1.3	30
2781	Tumour-Agnostic Therapy for Pancreatic Cancer and Biliary Tract Cancer. Diagnostics, 2021, 11, 252.	1.3	2
2782	Irreversible electroporation of locally advanced pancreatic cancer. Seminars in Oncology, 2021, 48, 84-94.	0.8	10
2783	Relaxin gene delivery modulates macrophages to resolve cancer fibrosis and synergizes with immune checkpoint blockade therapy. Science Advances, 2021, 7, .	4.7	23
2784	Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer. Annals of Translational Medicine, 2021, 9, 251-251.	0.7	22
2785	Preceding Systemic Chemotherapy for Patients with Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology Provides Survival Benefit Compared with Up-Front Surgery. Annals of Surgical Oncology, 2021, 28, 6246-6254.	0.7	8
2786	Recent advances in precision medicine for pancreatic ductal adenocarcinoma. Annals of Gastroenterological Surgery, 2021, 5, 457-466.	1.2	18
2787	Neoadjuvant therapy using Gemcitabine+nab-paclitaxel for borderline resectable pancreatic head cancers. Suizo, 2021, 36, 73-81.	0.1	0
2788	Targeting Redox Metabolism in Pancreatic Cancer. International Journal of Molecular Sciences, 2021, 22, 1534.	1.8	25
2789	Theranostic Nanoparticles for Pancreatic Cancer Treatment. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2021, 21, 203-214.	0.6	9
2790	Immunotherapy for pancreatic ductal adenocarcinoma. Journal of Surgical Oncology, 2021, 123, 751-759.	0.8	18

#	Article	IF	Citations
2791	Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. Cancers, 2021, 13, 987.	1.7	38
2792	Systemic Immune-Inflammation Index and Changes of Neutrophil-Lymphocyte Ratio as Prognostic Biomarkers for Patients With Pancreatic Cancer Treated With Immune Checkpoint Blockade. Frontiers in Oncology, 2021, 11, 585271.	1.3	27
2793	Radiotherapy for locally advanced pancreatic ductal adenocarcinoma. Seminars in Oncology, 2021, 48, 106-110.	0.8	9
2794	Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer. European Journal of Cancer, 2021, 144, 72-80.	1.3	17
2795	Glycemic Control as an Early Prognostic Marker in Advanced Pancreatic Cancer. Frontiers in Oncology, 2021, 11, 571855.	1.3	7
2797	A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma. BMC Cancer, 2021, 21, 165.	1.1	2
2798	Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. Acta Pharmacologica Sinica, 2021, 42, 1725-1741.	2.8	53
2799	Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients. Future Science OA, 2021, 7, FSO644.	0.9	2
2800	Gemcitabine plus nabâ€paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans. Seminars in Oncology, 2021, 48, 69-75.	0.8	4
2801	The Landmark Series: Locally Advanced Pancreatic Cancer and Ablative Therapy Options. Annals of Surgical Oncology, 2021, 28, 4173-4180.	0.7	8
2802	Locally advanced pancreatic carcinoma with jaundice: the benefit of a sequential treatment with stenting followed by CT-guided 125I seeds implantation. European Radiology, 2021, 31, 6500-6510.	2.3	9
2803	Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. Cancers, 2021, 13, 994.	1.7	29
2806	Future directions in drug development in pancreatic cancer. Seminars in Oncology, 2021, 48, 47-56.	0.8	10
2807	Mortality and Survival Among Octogenarians with Localized Pancreatic Head Cancer: a National Cancer Database Analysis. Journal of Gastrointestinal Surgery, 2021, 25, 2582-2592.	0.9	8
2808	Effectiveness of neoadjuvant chemotherapy for patients with resectable pancreatic cancer. Suizo, 2021, 36, 3-11.	0.1	0
2809	Clinical significance of CA19-9 normalization during neoadjuvant chemoradiation therapy for resectable pancreatic cancer. Suizo, 2021, 36, 64-72.	0.1	0
2810	Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer. Frontiers in Immunology, 2021, 12, 643529.	2.2	19
2811	Targeting and Reprograming Cancer-Associated Fibroblasts and the Tumor Microenvironment in Pancreatic Cancer. Cancers, 2021, 13, 697.	1.7	25

#	Article	IF	Citations
2812	Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische OnkologieÂwith an integrated analysis of the â€˜burden of therapyâ€™ method. European Journal of Cancer, 2021, 146, 95-106.	1.3	21
2813	A 14-gene gemcitabine resistance gene signature is significantly associated with the prognosis of pancreatic cancer patients. Scientific Reports, 2021, 11, 6087.	1.6	11
2814	Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma. Pharmaceuticals, 2021, 14, 280.	1.7	11
2815	Excision Repair Cross-Complementation Group 6 Gene Polymorphism Is Associated with the Response to FOLFIRINOX Chemotherapy in Asian Patients with Pancreatic Cancer. Cancers, 2021, 13, 1196.	1.7	0
2816	Challenging anticoagulation cases: Cancer-associated venous thromboembolism and chemotherapy-induced thrombocytopenia â€“ A case-based review of clinical management. Thrombosis Research, 2021, 199, 38-42.	0.8	6
2817	Refining the Molecular Framework for Pancreatic Cancer with Single-cell and Spatial Technologies. Clinical Cancer Research, 2021, 27, 3825-3833.	3.2	8
2818	Is Improved Survival in Early-Stage Pancreatic Cancer Worth the Extra Cost at High-Volume Centers?. Journal of the American College of Surgeons, 2021, 233, 90-98.	0.2	6
2819	Therapeutic efficacy of a paclitaxel-loaded nanofibrillated bacterial cellulose (PTX/NFBC) formulation in a peritoneally disseminated gastric cancer xenograft model. International Journal of Biological Macromolecules, 2021, 174, 494-501.	3.6	13
2820	High Expression of PD-L1 Is Associated with Better Survival in Pancreatic/Periampullary Cancers and Correlates with Epithelial to Mesenchymal Transition. Diagnostics, 2021, 11, 597.	1.3	5
2821	nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial. Medical Oncology, 2021, 38, 35.	1.2	11
2822	Tumorâ€“Stromal Interactions in a Co-Culture Model of Human Pancreatic Adenocarcinoma Cells and Fibroblasts and Their Connection with Tumor Spread. Biomedicines, 2021, 9, 364.	1.4	7
2823	Locoregional Treatment of Metastatic Pancreatic Cancer Utilizing Resection, Ablation and Embolization: A Systematic Review. Cancers, 2021, 13, 1608.	1.7	12
2824	Tumor-penetrating therapy for Î²5 integrin-rich pancreas cancer. Nature Communications, 2021, 12, 1541.	5.8	37
2825	Pancreatic cancer driver mutations are targetable through distant alternative RNA splicing dependencies. Oncotarget, 2021, 12, 525-533.	0.8	4
2826	Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma. JAMA Oncology, 2021, 7, 421.	3.4	159
2827	Clinical Phase I/II Study: Local Disease Control and Survival in Locally Advanced Pancreatic Cancer Treated with Electrochemotherapy. Journal of Clinical Medicine, 2021, 10, 1305.	1.0	28
2828	Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes. Journal of the National Cancer Institute, 2021, 113, 1194-1202.	3.0	35
2829	Current Perspectives on Taxanes: Focus on Their Bioactivity, Delivery and Combination Therapy. Plants, 2021, 10, 569.	1.6	39

#	Article	IF	Citations
2831	ABO Blood Group and Risk of Pancreatic Carcinogenesis in Intraductal Papillary Mucinous Neoplasms. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1020-1028.	1.1	6
2832	Phase II Study of Adjuvant Chemotherapy With Gemcitabine and Nafamostat Mesilate for Pancreatic Cancer. Pancreas, 2021, 50, 313-316.	0.5	3
2833	Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national cancer database analysis. Clinical and Translational Radiation Oncology, 2021, 27, 15-23.	0.9	8
2834	The Uniqueness of Albumin as a Carrier in Nanodrug Delivery. Molecular Pharmaceutics, 2021, 18, 1862-1894.	2.3	209
2835	CCL26 is upregulated by nab-paclitaxel in pancreatic cancer–associated fibroblasts and promotes PDAC invasiveness through activation of the PI3K/AKT/mTOR pathway. Acta Biochimica Et Biophysica Sinica, 2021, 53, 612-619.	0.9	15
2836	Readily available biomarkers predict poor survival in metastatic pancreatic cancer. Biomarkers, 2021, 26, 325-334.	0.9	8
2837	Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel. Cellular Oncology (Dordrecht), 2021, 44, 261-278.	2.1	16
2838	Site of relapse of ductal adenocarcinoma of the pancreas affects survival after multimodal therapy. BMC Surgery, 2021, 21, 110.	0.6	2
2839	Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation. Journal of Pharmacology and Experimental Therapeutics, 2021, 377, 370-384.	1.3	5
2840	Effect and limitation of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma: consideration from a new perspective. World Journal of Surgical Oncology, 2021, 19, 85.	0.8	6
2841	Identification of laminin Î³2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma. European Journal of Cancer, 2021, 146, 125-134.	1.3	7
2842	Invadopodia: A potential target for pancreatic cancer therapy. Critical Reviews in Oncology/Hematology, 2021, 159, 103236.	2.0	14
2843	Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma. Journal of Experimental and Clinical Cancer Research, 2021, 40, 91.	3.5	24
2846	Escin inhibits angiogenesis by suppressing interleukinâ€'8 and vascular endothelial growth factor production by blocking nuclear factorâ€'ÎºB activation in pancreatic cancer cell lines. Oncology Reports, 2021, 45, .	1.2	14
2847	HPB cancers in older patients | inclusion of older/senior patients in clinical trials. European Journal of Surgical Oncology, 2021, 47, 597-602.	0.5	4
2848	Implementation of a stereotactic body radiotherapy program for unresectable pancreatic cancer in an integrated community academic radiation oncology satellite network. Clinical and Translational Radiation Oncology, 2021, 27, 147-151.	0.9	0
2849	Comparison of endoscopic ultrasound-guided choledochoduodenostomy and endoscopic retrograde cholangiopancreatography in first-line biliary drainage for malignant distal bile duct obstruction. Medicine (United States), 2021, 100, e25268.	0.4	5
2850	SEOM clinical guidelines for pancreatic and biliary tract cancer (2020). Clinical and Translational Oncology, 2021, 23, 988-1000.	1.2	23

#	Article	IF	Citations
2851	Systemic inflammation is a determinant of outcomes of CD40 agonistâ€“based therapy in pancreatic cancer patients. JCI Insight, 2021, 6, .	2.3	14
2852	A novel laparoscopic near-infrared fluorescence spectrum system for photodynamic diagnosis of peritoneal dissemination in pancreatic cancer. Photodiagnosis and Photodynamic Therapy, 2021, 33, 102157.	1.3	6
2853	Disparities in access to health care system as determinant of survival for patients with pancreatic cancer in the State of SÃ£o Paulo, Brazil. Scientific Reports, 2021, 11, 6346.	1.6	6
2854	TGFB1/INHBA Homodimer/Nodal-SMAD2/3 Signaling Network: A Pivotal Molecular Target in PDAC Treatment. Molecular Therapy, 2021, 29, 920-936.	3.7	31
2855	Underlying mechanisms and drug intervention strategies for the tumour microenvironment. Journal of Experimental and Clinical Cancer Research, 2021, 40, 97.	3.5	22
2856	Hydrogel Models with Stiffness Gradients for Interrogating Pancreatic Cancer Cell Fate. Bioengineering, 2021, 8, 37.	1.6	11
2857	The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy. International Journal of Clinical Oncology, 2021, 26, 1293-1303.	1.0	25
2858	The potential use for patient reported outcome measures in people with pancreatic cancer, with a specific focus on older patients. European Journal of Surgical Oncology, 2021, 47, 495-502.	0.5	10
2859	Cancer-associated fibroblasts-mediated ATF4 expression promotes malignancy and gemcitabine resistance in pancreatic cancer via the TGF-Î²1/SMAD2/3 pathway and ABCC1 transactivation. Cell Death and Disease, 2021, 12, 334.	2.7	45
2860	Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma. Journal of Surgical Oncology, 2021, 123, 1432-1440.	0.8	20
2861	Tissue-Engineering the Fibrous Pancreatic Tumour Stroma Capsule in 3D Tumouroids to Demonstrate Paclitaxel Response. International Journal of Molecular Sciences, 2021, 22, 4289.	1.8	7
2862	Regulator of calcineurin 1 gene isoform 4 in pancreatic ductal adenocarcinoma regulates the progression of tumor cells. Oncogene, 2021, 40, 3136-3151.	2.6	9
2863	Preoperative risk factors for para-aortic lymph node positivity in pancreatic cancer. Pancreatology, 2021, 21, 606-612.	0.5	4
2864	Intraperitoneal gemcitabine chemotherapy is safe for patients with resected pancreatic cancer: final clinical and pharmacologic data from a phase II protocol and recommended future directions. Journal of Gastrointestinal Oncology, 2021, 12, S99-S109.	0.6	9
2865	Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment. Biomedicines, 2021, 9, 373.	1.4	55
2866	Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA). Journal of Clinical Oncology, 2021, 39, 1108-1118.	0.8	67
2867	Multidisciplinary management of locally advanced pancreatic adenocarcinoma: Biology is King. Journal of Surgical Oncology, 2021, 123, 1395-1404.	0.8	2
2869	Hepatic Artery Infusion of Floxuridine in Combination With Systemic Chemotherapy for Pancreatic Cancer Liver Metastasis: A Propensity Score-Matched Analysis in Two Centers. Frontiers in Oncology, 2021, 11, 652426.	1.3	6

#	Article	IF	Citations
2870	Efficacy and tolerability of the combination of nano-liposomal irinotecan and 5-fluorouracil/leucovorin in advanced pancreatic adenocarcinoma: post-approval clinic experience. Journal of Gastrointestinal Oncology, 2021, 12, 464-473.	0.6	16
2871	Emerging antibody therapies for pancreatic adenocarcinoma: a review of recent phase 2 trials. Expert Opinion on Emerging Drugs, 2021, 26, 103-129.	1.0	2
2872	Patient-derived xenograft models of BRCA-associated pancreatic cancers. Advanced Drug Delivery Reviews, 2021, 171, 257-265.	6.6	12
2873	Seven Glycolysis-Related Genes Predict the Prognosis of Patients With Pancreatic Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 647106.	1.8	10
2874	Dithiocarbazate-Copper Complexes for Bioimaging and Treatment of Pancreatic Cancer. Journal of Medicinal Chemistry, 2021, 64, 5485-5499.	2.9	49
2875	Future of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far. Seminars in Oncology, 2021, 48, 57-68.	0.8	5
2876	Leptomeningeal disease in pancreas ductal adenocarcinoma: A manifestation of longevity. Pancreatology, 2021, 21, 599-605.	0.5	4
2877	Skeletal metastases in advanced pancreatic ductal adenocarcinoma: a retrospective analysis. Journal of Gastrointestinal Oncology, 2021, 12, 455-463.	0.6	2
2878	A proposal to modify the 8th edition of the UICC staging system for pancreatic adenocarcinoma. Langenbeck's Archives of Surgery, 2021, 406, 667-677.	0.8	2
2879	Contemporary trials evaluating neoadjuvant therapy for resectable pancreatic cancer. Journal of Surgical Oncology, 2021, 123, 1423-1431.	0.8	4
2880	Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer. Pancreas, 2021, 50, 595-601.	0.5	7
2881	Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial. Oral Oncology, 2021, 115, 105173.	0.8	15
2882	Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities. Cancers, 2021, 13, 1781.	1.7	17
2883	3d tissue models as tools for radiotherapy screening for pancreatic cancer. British Journal of Radiology, 2021, 94, 20201397.	1.0	17
2884	Prognostic value of an inflammation-based nutritional score for patients with initially unresectable pancreatic adenocarcinoma undergoing conversion surgery following chemo-/radiotherapy. Surgery Today, 2021, 51, 1682-1693.	0.7	4
2885	Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer. Journal of Pancreatic Cancer, 2021, 7, 31-38.	1.6	2
2886	Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer. Frontiers in Pharmacology, 2021, 12, 632818.	1.6	10
2887	Using Exome Sequencing to Improve Prediction of FOLFIRINOX First Efficacy for Pancreatic Adenocarcinoma. Cancers, 2021, 13, 1851.	1.7	2

#	Article	IF	Citations
2888	Advances in research of extracellular mechanisms underlying gemcitabine resistance in pancreatic cancer. World Chinese Journal of Digestology, 2021, 29, 421-434.	0.0	0
2889	Impact of surveillance among patients with resected pancreatic cancer following adjuvant chemotherapy. Journal of Gastrointestinal Oncology, 2021, 12, 446-454.	0.6	0
2890	Radical Resection for Locally Advanced Pancreatic Cancers in the Era of New Neoadjuvant Therapyâ€"Arterial Resection, Arterial Divestment and Total Pancreatectomy. Cancers, 2021, 13, 1818.	1.7	14
2891	Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?. Cancers, 2021, 13, 1986.	1.7	43
2892	Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma. BMC Cancer, 2021, 21, 385.	1.1	24
2893	Cancer Cell B7-H3 Expression Is More Prevalent in the Pancreato-Biliary Subtype of Ampullary Cancer Than in Pancreatic Cancer. Frontiers in Oncology, 2021, 11, 615691.	1.3	3
2894	Association between Low-Grade Chemotherapy-Induced Peripheral Neuropathy (CINP) and Survival in Patients with Metastatic Adenocarcinoma of the Pancreas. Journal of Clinical Medicine, 2021, 10, 1846.	1.0	4
2895	Pancreas cancer: Therapeutic trials in metastatic disease. Journal of Surgical Oncology, 2021, 123, 1475-1488.	0.8	11
2896	<scp>Noncontrast</scp> Magnetic Resonance Radiomics and Multilayer Perceptron Network Classifier: An approach for Predicting Fibroblast Activation Protein Expression in Patients With Pancreatic Ductal Adenocarcinoma. Journal of Magnetic Resonance Imaging, 2021, 54, 1432-1443.	1.9	9
2897	Practical significance of pancreatectomy with lymphadenectomy around the superior mesenteric artery for pancreatic cancer: comparison of prognosis after adjusting for major prognostic factors. Langenbeck's Archives of Surgery, 2021, 406, 703-711.	0.8	1
2898	ESMO 2020 update: Pancreatic cancer. Memo - Magazine of European Medical Oncology, 2021, 14, 176-179.	0.3	1
2899	Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): study protocol for a randomized controlled trial. Trials, 2021, 22, 313.	0.7	11
2900	Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel. Clinical and Translational Oncology, 2021, 23, 2394-2401.	1.2	8
2901	Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis. European Journal of Cancer, 2021, 147, 17-28.	1.3	14
2902	Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG). ESMO Open, 2021, 6, 100049.	2.0	21
2903	Optimal timing of endoscopic retrograde cholangiopancreatography for acute cholangitis associated with distal malignant biliary obstruction. BMC Gastroenterology, 2021, 21, 175.	0.8	6
2904	Evaluation of the validity of pancreatectomy for very elderly patients with pancreatic ductal adenocarcinoma. Langenbeck's Archives of Surgery, 2021, 406, 1081-1092.	0.8	3
2906	Tenâ€yyear experience in optimizing neoadjuvant therapy for localized pancreatic cancerâ€"Medical college of Wisconsin perspective. Journal of Surgical Oncology, 2021, 123, 1405-1413.	0.8	4

#	Article	IF	Citations
2907	Chemotherapy After Diagnosis of Malignant Bowel Obstruction is Associated with Superior Survival for Medicare Patients with Advanced Malignancy. Annals of Surgical Oncology, 2021, 28, 7555-7563.	0.7	7
2908	Human ALKBH6 Is Required for Maintenance of Genomic Stability and Promoting Cell Survival During Exposure of Alkylating Agents in Pancreatic Cancer. Frontiers in Genetics, 2021, 12, 635808.	1.1	11
2909	Therapeutic potential of microbial modulation in pancreatic cancer. Gut, 2021, 70, 1419-1425.	6.1	17
2910	Microsatellite instability status of pancreatic cancer and experience with pembrolizumab treatment. Suizo, 2021, 36, 120-127.	0.1	4
2911	Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience. Clinical and Translational Oncology, 2021, 23, 1838-1846.	1.2	1
2912	miR-30d suppresses proliferation and invasiveness of pancreatic cancer by targeting the SOX4/PI3K-AKT axis and predicts poor outcome. Cell Death and Disease, 2021, 12, 350.	2.7	16
2913	Role of stromal activin A in human pancreatic cancer and metastasis in mice. Scientific Reports, 2021, 11, 7986.	1.6	16
2914	An in vivo genomeâ€wide shRNA screen identifies BCL6 as a targetable biomarker of paclitaxel resistance in breast cancer. Molecular Oncology, 2021, 15, 2046-2064.	2.1	5
2915	Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. Annals of Oncology, 2021, 32, 600-608.	0.6	69
2916	Precision Medicine for Pancreatic Cancer. Advances in Oncology, 2021, 1, 63-71.	0.1	0
2917	Patterns of Palliative Chemotherapy and Survival in Patients With Pancreatic Cancer Focusing on Age. Pancreas, 2021, 50, 685-695.	0.5	4
2918	Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer â€“ A GISCAD phase II randomized trial. European Journal of Cancer, 2021, 148, 422-429.	1.3	8
2919	Pancreatic adenocarcinoma: Beyond first line, where are we?. World Journal of Gastroenterology, 2021, 27, 1847-1863.	1.4	6
2920	Treatment landscape of metastatic pancreatic cancer. Cancer Treatment Reviews, 2021, 96, 102180.	3.4	82
2921	Synchronization of Nanoparticle Sensitization and Radiosensitizing Chemotherapy through Cell Cycle Arrest Achieving Ultralow X-ray Dose Delivery to Pancreatic Tumors. ACS Nano, 2021, 15, 9084-9100.	7.3	16
2922	Comprehensive analysis of DNA damage repair genes reveals pathogenic variants beyond BRCA and suggests the need for extensive genetic testing in pancreatic cancer. BMC Cancer, 2021, 21, 611.	1.1	5
2924	Liver Metastasisâ€“Directed Ablative Radiotherapy in Pancreatic Cancer Offers Prolonged Time Off Systemic Therapy in Selected Patients. Pancreas, 2021, 50, 736-743.	0.5	7
2925	Contemporary Reappraisal of Intraoperative Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. JAMA Surgery, 2021, 156, 489.	2.2	8

#	Article	IF	Citations
2926	Impact of sarcopenia on recurrent biliary obstruction after insertion of selfâ€expandable metallic stent in patients with malignant biliary obstruction. Journal of Hepato-Biliary-Pancreatic Sciences, 2021, 28, 572-580.	1.4	6
2927	Anti-Cancer and Immunomodulatory Activity of a Polyethylene Glycol-Betulinic Acid Conjugate on Pancreatic Cancer Cells. Life, 2021, 11, 462.	1.1	3
2928	Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer. Biomolecules, 2021, 11, 780.	1.8	1
2929	A narrative review of Safety management of 1 L platinum-based chemotherapy and maintenance olaparib in BRCA mutated advanced pancreatic cancer. Translational Cancer Research, 2021, 10, 2488-2495.	0.4	1
2930	Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach. BMC Cancer, 2021, 21, 537.	1.1	27
2931	Development and Validation of a 7-Gene Prognostic Signature to Improve Survival Prediction in Pancreatic Ductal Adenocarcinoma. Frontiers in Molecular Biosciences, 2021, 8, 676291.	1.6	7
2932	A Prospective Feasibility Trial to Challenge Patientâ€“Derived Pancreatic Cancer Organoids in Predicting Treatment Response. Cancers, 2021, 13, 2539.	1.7	26
2933	Ablation in Pancreatic Cancer: Past, Present and Future. Cancers, 2021, 13, 2511.	1.7	12
2934	Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study). Current Oncology, 2021, 28, 1761-1772.	0.9	5
2935	Clinical Effects of Stereotactic Body Radiation Therapy Targeting the Primary Tumor of Liver-Only Oligometastatic Pancreatic Cancer. Frontiers in Oncology, 2021, 11, 659987.	1.3	9
2936	Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study. BMC Cancer, 2021, 21, 545.	1.1	2
2937	Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with Sâ€1 as secondâ€line chemotherapy in metastatic pancreatic cancer. JGH Open, 2021, 5, 679-685.	0.7	11
2938	A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer. Medicine (United States), 2021, 100, e26052.	0.4	5
2939	Proclivity to Explore Locally Advanced Pancreas Cancer Is Not Associated with Surgeon Volume. Journal of Gastrointestinal Surgery, 2021, 25, 2562-2571.	0.9	2
2941	Analysis of factors affecting progression-free survival of first-line chemotherapy in older patients with advanced gastrointestinal cancer. Journal of Geriatric Oncology, 2021, 12, 1200-1207.	0.5	2
2942	KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas. Cancers, 2021, 13, 2429.	1.7	18
2944	SPECT/CT Imaging, Biodistribution and Radiation Dosimetry of a 177Lu-DOTA-Integrin Î±vÎ²6 Cystine Knot Peptide in a Pancreatic Cancer Xenograft Model. Frontiers in Oncology, 2021, 11, 684713.	1.3	7
2945	Heme Oxygenase-1 Inhibition Potentiates the Effects of Nab-Paclitaxel-Gemcitabine and Modulates the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma. Cancers, 2021, 13, 2264.	1.7	14

#	Article	IF	Citations
2946	Role of ARK5 in cancer and other diseases (Review). Experimental and Therapeutic Medicine, 2021, 22, 697.	0.8	9
2947	The importance of multimodal therapy in the management ofÂnonmetastatic adenosquamous carcinoma of the pancreas: AnalysisÂof treatment sequence and strategy. Surgery, 2021, 169, 1102-1109.	1.0	7
2948	Novel Seleno-Aspirinyl Compound AS-10 Induces Apoptosis, G1 Arrest of Pancreatic Ductal Adenocarcinoma Cells, Inhibits Their NF-ÎºB Signaling, and Synergizes with Gemcitabine Cytotoxicity. International Journal of Molecular Sciences, 2021, 22, 4966.	1.8	11
2949	Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts. Advanced Drug Delivery Reviews, 2021, 172, 37-51.	6.6	31
2950	Korean clinical practice guideline for pancreatic cancer 2021: A summary of evidence-based, multi-disciplinary diagnostic and therapeutic approaches. Pancreatology, 2021, 21, 1326-1341.	0.5	7
2951	BRCA mutated pancreatic cancer: A change is coming. World Journal of Gastroenterology, 2021, 27, 1943-1958.	1.4	42
2952	Prospective observational study of prevalence, assessment and treatment of pancreatic exocrine		

#	Article	IF	Citations
2964	Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma â€“ A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials. European Journal of Cancer, 2021, 150, 250-259.	1.3	3
2965	A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403). Oncologist, 2021, 26, e1675-e1682.	1.9	3
2966	Targeted therapy for pancreatic cancer: lessons learned and future opportunities. Digestive Medicine Research, 0, 4, 32-32.	0.2	5
2967	Surgical margin clearance and extended chemotherapy defines survival for synchronous oligometastatic liver lesions of the ductal adenocarcinoma of the pancreas. International Journal of Clinical Oncology, 2021, 26, 1911-1921.	1.0	7
2968	Germline DNA damage repair gene mutations in pancreatic cancer patients with personal/family histories of pancreas/breast/ovarian/prostate cancer in a Japanese population. Annals of Gastroenterological Surgery, 2021, 5, 853-864.	1.2	5
2969	Targeting of elevated cell surface phosphatidylserine with saposin C-dioleoylphosphatidylserine nanodrug as individual or combination therapy for pancreatic cancer. World Journal of Gastrointestinal Oncology, 2021, 13, 550-559.	0.8	2
2970	Telomerase and Pluripotency Factors Jointly Regulate Stemness in Pancreatic Cancer Stem Cells. Cancers, 2021, 13, 3145.	1.7	13
2971	Circulating tumor DNA as a predictive marker for occult metastases in pancreatic cancer patients with radiographically nonâ€metastatic disease. Journal of Hepato-Biliary-Pancreatic Sciences, 2021, 28, 648-658.	1.4	10
2972	Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel Opportunities. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e153-e165.	1.8	12
2973	The Influence of Cell Cycle Regulation on Chemotherapy. International Journal of Molecular Sciences, 2021, 22, 6923.	1.8	97
2974	The pancreatic cancer genome revisited. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 469-481.	8.2	100
2975	Targeting the tumor microenvironment of pancreatic ductal adenocarcinoma using nano-phytomedicines. Seminars in Cancer Biology, 2022, 86, 1155-1162.	4.3	10
2976	Pancreatic Ductal Adenocarcinoma: Relating Biomechanics and Prognosis. Journal of Clinical Medicine, 2021, 10, 2711.	1.0	16
2977	Proteomic Analysis of Malignant Ascites From Patients With Pancreatic Ductal Adenocarcinoma. Anticancer Research, 2021, 41, 2895-2900.	0.5	4
2978	A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma. BMC Cancer, 2021, 21, 672.	1.1	0
2979	Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Annals of Surgical Oncology, 2021, 28, 8297-8308.	0.7	19
2980	Safety and Efficacy of Gemcitabine Plus Nab-Paclitaxel for Metastatic Pancreatic Cancer Patients Undergoing Biliary Stent Placement. Digestive Diseases and Sciences, 2021, , 1.	1.1	1
2982	Intra-Arterial Chemotherapy for Pancreatic Cancer. Journal of Oncology Diagnostic Radiology and Radiotherapy, 2021, 4, 60-68.	0.1	0

#	Article	IF	Citations
2983	Performance status as prognostic factor in phase III trials of firstâ€line chemotherapy of unresectable or metastatic pancreatic cancer: A trialâ€level metaâ€analysis. Asia-Pacific Journal of Clinical Oncology, 2022, 18, 232-239.	0.7	4
2984	Ultrasoundâ€Responsive Microfluidic Microbubbles for Combination Tumor Treatment. Advanced Therapeutics, 2021, 4, 2100050.	1.6	22
2985	Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma. Cellular and Molecular Life Sciences, 2021, 78, 5505-5526.	2.4	20
2986	Surgery for pancreatic tumors in the midst of COVID-19 pandemic. World Journal of Clinical Cases, 2021, 9, 4460-4466.	0.3	2
2987	Immune Cell Modulation of the Extracellular Matrix Contributes to the Pathogenesis of Pancreatic Cancer. Biomolecules, 2021, 11, 901.	1.8	20
2988	Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma. Oncologist, 2021, 26, 825-e1674.	1.9	11
2989	TNF blockade uncouples toxicity from antitumor efficacy induced with CD40 chemoimmunotherapy. JCI Insight, 2021, 6, .	2.3	6
2990	Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial. Pancreatology, 2021, 21, 1342-1348.	0.5	8
2991	Extracellular Vesicles and Pancreatic Cancer: Insights on the Roles of miRNA, lncRNA, and Protein Cargos in Cancer Progression. Cells, 2021, 10, 1361.	1.8	17
2992	Silencing of LRRFIP1 enhances the sensitivity of gemcitabine in pancreatic cancer cells by activating JNK/c-Jun signaling. Pancreatology, 2021, 21, 771-778.	0.5	4
2993	The Use of Heptamethine Cyanine Dyes as Drug-Conjugate Systems in the Treatment of Primary and Metastatic Brain Tumors. Frontiers in Oncology, 2021, 11, 654921.	1.3	19
2994	Intralesional injection of rose bengal augments the efficacy of gemcitabine chemotherapy against pancreatic tumors. BMC Cancer, 2021, 21, 756.	1.1	2
2995	Usefulness of the Novel Snare-over-the-Guidewire Method for Transpapillary Plastic Stent Replacement (with Video). Journal of Clinical Medicine, 2021, 10, 2858.	1.0	2
2996	Advances in the management of pancreatic ductal adenocarcinoma. Cmaj, 2021, 193, E844-E851.	0.9	9
2997	Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer. Japanese Journal of Clinical Oncology, 2021, 51, 1416-1422.	0.6	11
2998	SOX9 is a critical regulator of TSPAN8-mediated metastasis in pancreatic cancer. Oncogene, 2021, 40, 4884-4893.	2.6	22
2999	Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Therapeutic Opportunities and Clinical Challenges. Cancers, 2021, 13, 2860.	1.7	39
3000	Molecular and Phenotypic Profiling for Precision Medicine in Pancreatic Cancer: Current Advances and Future Perspectives. Frontiers in Oncology, 2021, 11, 682872.	1.3	13

#	Article	IF	Citations
3001	Current controversies and advances in the management of pancreatic adenocarcinoma. World Journal of Gastrointestinal Oncology, 2021, 13, 472-494.	0.8	9
3002	Current Status of Treatment for Pancreatic Cancer in Japan and Prospects for the Future. Nihon Ika Daigaku Igakkai Zasshi, 2021, 17, 98-107.	0.0	0
3003	The Impact of Thromboprophylaxis on the Survival of Patients with Advanced Pancreatic Cancer. The Pancreatic Cancer and Tinzaparin (PaCT) Study. Cancers, 2021, 13, 2884.	1.7	11
3004	Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells. PLoS ONE, 2021, 16, e0252917.	1.1	12
3005	Heat shock protein 47 confers chemoresistance on pancreatic cancer cells by interacting with calreticulin and IRE1Î±. Cancer Science, 2021, 112, 2803-2820.	1.7	8
3006	Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study. Cancers, 2021, 13, 2797.	1.7	11
3007	In Vivo Assessment of Hypoxia Levels in Pancreatic Tumors Using a Dual-Modality Ultrasound/Photoacoustic Imaging System. Micromachines, 2021, 12, 668.	1.4	8
3008	Zebularine suppressed gemcitabine-induced senescence and improved the cellular and plasma pharmacokinetics of gemcitabine, augmented by liposomal co-delivery. International Journal of Pharmaceutics, 2021, 602, 120659.	2.6	10
3009	Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review. Advances in Therapy, 2021, 38, 3674-3693.	1.3	12
3010	Pancreatic adenocarcinoma: A review of recent paradigms and advances in epidemiology, clinical diagnosis and management. World Journal of Gastroenterology, 2021, 27, 3158-3181.	1.4	24
3011	Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study). Journal of Geriatric Oncology, 2022, 13, 82-87.	0.5	13
3012	Clinical Outcomes of Conversion Surgery after FOLFIRINOX in Patients with Unresectable Advanced Pancreatic Cancer: A Retrospective Cohort Study at a Single Center. Journal of Clinical Medicine, 2021, 10, 2848.	1.0	2
3013	Differently PEGylated Polymer Nanoparticles for Pancreatic Cancer Delivery: Using a Novel Near-Infrared Emissive and Biodegradable Polymer as the Fluorescence Tracer. Frontiers in Bioengineering and Biotechnology, 2021, 9, 699610.	2.0	4
3014	Impact of Endoscopic Ultrasound-Guided Tissue Acquisition on Decision-Making in Precision Medicine for Pancreatic Cancer: Beyond Diagnosis. Diagnostics, 2021, 11, 1195.	1.3	9
3015	Immunotherapy in Pancreatic Adenocarcinoma: Beyond â€œCopy/Pasteâ€• Clinical Cancer Research, 2021, 27, 6287-6297.	3.2	22
3016	Functional inhibition of lactate dehydrogenase suppresses pancreatic adenocarcinoma progression. Clinical and Translational Medicine, 2021, 11, e467.	1.7	32
3017	Predictors of conversion surgery in patients with pancreatic cancer who underwent neoadjuvant or palliative FOLFIRINOX treatment using baseline and follow-up CT. Abdominal Radiology, 2021, 46, 4765-4778.	1.0	2
3018	Machine learning for MRI radiomics: a study predicting tumor-infiltrating lymphocytes in patients with pancreatic ductal adenocarcinoma. Abdominal Radiology, 2021, 46, 4800-4816.	1.0	9

#	Article	IF	Citations
3019	Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel. Thrombosis and Haemostasis, 2022, 122, 633-645.	1.8	7
3020	Concurrent Nab-paclitaxel and Radiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 469-474.	0.6	4
3021	Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma. Pancreas, 2021, 50, 796-802.	0.5	1
3022	3D Collagen-Nanocellulose Matrices Model the Tumour Microenvironment of Pancreatic Cancer. Frontiers in Digital Health, 2021, 3, 704584.	1.5	21
3023	Immune Subtypes Based on Immune-Related lncRNA: Differential Prognostic Mechanism of Pancreatic Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 698296.	1.8	8
3024	Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma. Clinical Cancer Research, 2021, 27, 6622-6637.	3.2	7
3025	Management of Patients with Pancreatic Ductal Adenocarcinoma in the Real-Life Setting: Lessons from the French National Hospital Database. Cancers, 2021, 13, 3515.	1.7	3
3026	The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer. Scientific Reports, 2021, 11, 14951.	1.6	15
3027	Emerging Treatment Strategies in Pancreatic Cancer. Pancreas, 2021, 50, 773-787.	0.5	3
3028	Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology, 2021, 11, 700315.	1.3	10
3029	Perception versus reality: A National Cohort Analysis of the surgeryâ€first approach for resectable pancreatic cancer. Cancer Medicine, 2021, 10, 5925-5935.	1.3	3
3030	A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma. Clinical Journal of Gastroenterology, 2021, 14, 1571-1577.	0.4	2
3031	Epithelial to Mesenchymal Transition in Patients with Pancreatic Ductal Adenocarcinoma: State-of-the-Art and Therapeutic Opportunities. Pharmaceuticals, 2021, 14, 740.	1.7	9
3032	The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. Frontiers in Oncology, 2021, 11, 688377.	1.3	82
3033	TGF-Î² Alters the Proportion of Infiltrating Immune Cells in a Pancreatic Ductal Adenocarcinoma. Journal of Gastrointestinal Surgery, 2022, 26, 113-121.	0.9	9
3034	Tumor protein p53 mutation in archived tumor samples from a 12â€‘year survivor of stage 4 pancreatic ductal adenocarcinoma may predict longâ€‘term survival with DeltaRexâ€‘G: A case report and literature review. Molecular and Clinical Oncology, 2021, 15, 186.	0.4	3
3035	Application of natural killer cells in pancreatic cancer (Review). Oncology Letters, 2021, 22, 647.	0.8	6
3036	Epigenetic Alterations in Pancreatic Cancer Metastasis. Biomolecules, 2021, 11, 1082.	1.8	28

#	Article	IF	Citations
3037	Obstacles and opportunities in a forward vision for cancer nanomedicine. Nature Materials, 2021, 20, 1469-1479.	13.3	206
3038	The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer. Cancers, 2021, 13, 3470.	1.7	15
3039	First-line liposomal irinotecan with oxaliplatin, 5-fluorouracilÂand leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. European Journal of Cancer, 2021, 151, 14-24.	1.3	18
3040	Comparison of Chemotherapy-induced Nausea and Vomiting Between Gemcitabine Plus Nab-paclitaxel Combination Chemotherapy and Gemcitabine Monotherapy in Patients With Advanced Pancreatic Cancer. Anticancer Research, 2021, 41, 3643-3648.	0.5	2
3041	Distinct forms of the actin cross-linking protein Î±-actinin support macropinosome internalization and trafficking. Molecular Biology of the Cell, 2021, 32, 1393-1407.	0.9	4
3042	Assessing prognostic value of early tumor shrinkage and depth of response in first-line therapy for patients with advanced unresectable pancreatic cancer. BMC Gastroenterology, 2021, 21, 294.	0.8	0
3043	Clinical outcome of patients with inoperable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus Nabâ€'paclitaxel as a firstâ€'line therapy: A retrospective analysis. Medicine International, 2021, 1, .	0.2	0
3044	Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer. JAMA Surgery, 2021, 156, 663.	2.2	30
3045	Incidence, Treatment, and Survival of Synchronous Peritoneal Metastases in Pancreatic Cancer. Pancreas, 2021, 50, 827-833.	0.5	12
3046	A Phase 1b clinical trial of LDE225 (Sonidegib) in combination with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX) in previously untreated locally advanced or metastatic pancreatic adenocarcinoma. Annals of Pancreatic Cancer, 0, 4, 2-2.	1.2	0
3047	Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer. BMC Cancer, 2021, 21, 853.	1.1	4
3048	Predictive Value of Neutrophils Count for Local Tumor Control After Chemoradiotherapy in Patients With Locally Advanced Pancreatic Carcinoma. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1022-1031.	0.4	7
3049	Frailty is associated with poor prognosis after resection for pancreatic cancer. International Journal of Clinical Oncology, 2021, 26, 1938-1946.	1.0	20
3050	Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis. European Journal of Cancer, 2021, 151, 3-13.	1.3	29
3051	The Microbiome as a Potential Target for Therapeutic Manipulation in Pancreatic Cancer. Cancers, 2021, 13, 3779.	1.7	16
3052	Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Cancer Medicine, 2021, 10, 5041-5050.	1.3	35
3053	Borderline resectable pancreatic cancer and vascular resections in the era of neoadjuvant therapy. World Journal of Clinical Cases, 2021, 9, 5398-5407.	0.3	4
3054	Cell death in pancreatic cancer: from pathogenesis to therapy. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 804-823.	8.2	156

#	Article	IF	Citations
3055	Depletion of Psoas Muscle Mass after Systemic Chemotherapy Is Associated with Poor Prognosis in Patients with Unresectable Pancreatic Cancer. Cancers, 2021, 13, 3860.	1.7	2
3056	Risk factors for severe neutropenia in pancreatic cancer patients treated with gemcitabine/nab-paclitaxel combination therapy. PLoS ONE, 2021, 16, e0254726.	1.1	3
3057	Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial. Clinical Cancer Research, 2021, 27, 5020-5027.	3.2	37
3058	Emerging pro-drug and nano-drug strategies for gemcitabine-based cancer therapy. Asian Journal of Pharmaceutical Sciences, 2022, 17, 35-52.	4.3	17
3059	Symptom Burden of Patients with Advanced Pancreas Cancer (APC): A Provincial Cancer Institute Observational Study. Current Oncology, 2021, 28, 2789-2800.	0.9	9
3060	The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduction and Targeted Therapy, 2021, 6, 249.	7.1	131
3061	Concordance of human equilibrative nucleoside transporterâ€1 expressions between murine (10D7G2) and rabbit (SP120) antibodies and association with clinical outcomes of adjuvant chemotherapy for pancreatic cancer: A collaborative study from the JASPAC 01 trial. Cancer Reports, 2021, , e1507.	0.6	3
3062	Targeting the Stroma in the Management of Pancreatic Cancer. Frontiers in Oncology, 2021, 11, 691185.	1.3	14
3063	Gemcitabine Plus Nanoparticle Albuminâ€“bound Paclitaxel Versus FOLFIRINOX for Recurrent Pancreatic Cancer After Resection. Anticancer Research, 2021, 41, 3573-3582.	0.5	6
3064	Myeloid Cell Mediated Immune Suppression in Pancreatic Cancer. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 1531-1542.	2.3	21
3065	Updated evidence on the clinical impact of endoscopic radiofrequency ablation in the treatment of malignant biliary obstruction. Digestive Endoscopy, 2022, 34, 345-358.	1.3	24
3066	Dynamic Stromal Alterations Influence Tumor-Stroma Crosstalk to Promote Pancreatic Cancer and Treatment Resistance. Cancers, 2021, 13, 3481.	1.7	13
3067	Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancerâ€”A Systematic Review and Meta-Analysis. Cancers, 2021, 13, 4326.	1.7	18
3068	Neoadjuvant Radiotherapy is Associated With Improved Pathologic Outcomes and Survival in Resected Stage II-III Pancreatic Adenocarcinoma Treated With Multiagent Neoadjuvant Chemotherapy in the Modern Era. American Surgeon, 2021, 87, 1386-1395.	0.4	3
3069	An exploratory study of body composition as a predictor of dose-limiting toxicity in metastatic pancreatic cancer treated with gemcitabine plus nab-paclitaxel. Clinical Nutrition, 2021, 40, 4888-4892.	2.3	11
3070	Dosing Schedules of Gemcitabine and nab-Paclitaxel for Older Adults With Metastatic Pancreatic Cancer. JNCI Cancer Spectrum, 2021, 5, pkab074.	1.4	2
3071	Multiple-line Chemotherapy for a Patient with Unresectable Mucinous Cystic Neoplasm of the Pancreas. Internal Medicine, 2021, 60, 2607-2612.	0.3	2
3073	Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer Aggressiveness. Cancer Investigation, 2021, 39, 711-720.	0.6	6

#	Article	IF	Citations
3074	Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015). Trials, 2021, 22, 568.	0.7	6
3075	Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation loaded with paclitaxel for the treatment of pancreatic cancer using ultrasound-targeted microbubble destruction. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 165, 374-382.	2.0	12
3076	Improved prognosis of pancreatic cancer patients with peritoneal metastasis. Pancreatology, 2021, 21, 903-911.	0.5	15
3077	Beyond the Front Line: Emerging Data for Maintenance Therapy in Pancreatic Cancer. Journal of Clinical Oncology, 2021, 39, 3199-3206.	0.8	5
3078	Pancreatic Cancer and Immunotherapy: A Clinical Overview. Cancers, 2021, 13, 4138.	1.7	49
3079	Zebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients. Cancers, 2021, 13, 4131.	1.7	8
3080	Tissue factor and its procoagulant activity on cancerâ€associated thromboembolism in pancreatic cancer. Cancer Science, 2021, 112, 4679-4691.	1.7	20
3081	Treatment and Outcomes of Metastatic Pancreatic Cancer in Elderly Patients. Chemotherapy, 2021, 66, 107-112.	0.8	8
3082	Neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 as prognostic markers for advanced pancreatic cancer patients receiving first-line chemotherapy. World Journal of Gastrointestinal Oncology, 2021, 13, 915-928.	0.8	10
3083	Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2021, 27, 5546-5556.	3.2	22
3084	Prognostic Significance of Disease Control at 12 Weeks in Patients With Advanced Pancreatic Cancer Receiving FOLFIRINOX as First-line Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 519-525.	0.6	0
3087	Clinical prognostic value of circulating tumor cells in the treatment of pancreatic cancer with gemcitabine chemotherapy. Experimental and Therapeutic Medicine, 2021, 22, 1140.	0.8	3
3088	Direct Endoplasmic Reticulum Targeting by the Selective Alkylphospholipid Analog and Antitumor Ether Lipid Edelfosine as a Therapeutic Approach in Pancreatic Cancer. Cancers, 2021, 13, 4173.	1.7	11
3089	Challenges and Future Perspectives of Immunotherapy in Pancreatic Cancer. Cancers, 2021, 13, 4235.	1.7	16
3090	Targeted Transcriptome and <i>KRAS</i> Mutation Analysis Improve the Diagnostic Performance of EUS-FNA Biopsies in Pancreatic Cancer. Clinical Cancer Research, 2021, 27, 5900-5911.	3.2	8
3091	è†µç™Œã«å¯¾ã™ã‚‹è¡“å‰åŒ–å¦ç™‚æ³•. Suizo, 2021, 36, 251-256.	0.1	1
3092	A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment. Frontiers in Immunology, 2021, 12, 691605.	2.2	25
3093	Preclinical and Clinical Evidence of Therapeutic Agents for Paclitaxel-Induced Peripheral Neuropathy. International Journal of Molecular Sciences, 2021, 22, 8733.	1.8	12

#	Article	IF	Citations
3095	T Cellâ€“Mediated Antitumor Immunity Cooperatively Induced By TGFÎ²R1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer. Molecular Cancer Therapeutics, 2021, 20, 1926-1940.	1.9	9
3096	UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: Prevent, detect, and treat the disease earlier and better. United European Gastroenterology Journal, 2021, 9, 860-871.	1.6	28
3097	Anlotinib is effective in the treatment of advanced pancreatic cancer. Anti-Cancer Drugs, 2021, Publish Ahead of Print, .	0.7	4
3098	Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation. Biomaterials, 2021, 275, 120910.	5.7	37
3099	Anorexia, pain and peripheral neuropathy are associated with a decrease in quality of life in patients with advanced pancreatic cancer receiving outpatient chemotherapy â€” a retrospective observational study. Journal of Pharmaceutical Health Care and Sciences, 2021, 7, 27.	0.4	4
3100	The Appropriate First-Line Chemotherapy Regimen for Incurable Pancreatic Cancer in Clinical Practice: A Consideration of Patients' Overall Survival and Quality of Life. Journal of Pancreatic Cancer, 2021, 7, 48-56.	1.6	2
3101	Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancer. Future Oncology, 2021, 17, 4561-4570.	1.1	4
3102	CIRBP Knockdown Attenuates Tumourigenesis and Improves the Chemosensitivity of Pancreatic Cancer via the Downregulation of DYRK1B. Frontiers in Cell and Developmental Biology, 2021, 9, 667551.	1.8	3
3103	Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayesian network meta-analysis. Ecancermedicalscience, 2021, 15, 1276.	0.6	2
3104	Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC. Life, 2021, 11, 843.	1.1	5
3105	Unraveling Tumor Heterogeneity by Using DNA Barcoding Technologies to Develop Personalized Treatment Strategies in Advanced-Stage PDAC. Cancers, 2021, 13, 4187.	1.7	4
3106	A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma. Investigational New Drugs, 2022, 40, 81-90.	1.2	3
3107	Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome?. Cancers, 2021, 13, 4396.	1.7	4
3108	An Interdisciplinary Approach to Metastatic Pancreatic Cancer and Comorbid Opioid Use Disorder Treatment Within a VA Health Care System. , 2021, 38, S66-S71.		0
3109	Biliary intervention rates during neoadjuvant therapy for adenocarcinoma of the pancreatic head. Hpb, 2021, 23, 1196-1200.	0.1	4
3110	Analysis of the Curative Effect of Neoadjuvant Therapy on Pancreatic Cancer. Frontiers in Oncology, 2021, 11, 695645.	1.3	3
3111	Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. JCO Precision Oncology, 2021, 5, 1325-1338.	1.5	14
3112	Targeting DNA damage repair pathways in pancreas cancer. Cancer and Metastasis Reviews, 2021, 40, 891-908.	2.7	18

#	Article	IF	Citations
3113	The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer Cell, 2021, 39, 1342-1360.e14.	7.7	119
3114	Conversion therapy, palliative chemotherapy and surgery, which of these is the best treatment for locally advanced and advanced pancreatic cancer?. Anti-Cancer Drugs, 2021, Publish Ahead of Print, .	0.7	1
3115	ERK Inhibition Improves Antiâ€“PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics, 2021, 20, 2026-2034.	1.9	10
3116	Prognostic significance of skeletal muscle decrease in unresectable pancreatic cancer: Survival analysis using the Weibull exponential distribution model. Pancreatology, 2021, 21, 892-902.	0.5	10
3117	Antibody therapy in pancreatic cancer: mAb-ye weâ€™re onto something?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188557.	3.3	6
3118	Esteraseâ€Activatable and Glutathioneâ€Responsive Triptolide Nanoâ€Prodrug for the Eradication of Pancreatic Cancer. Advanced NanoBiomed Research, 2021, 1, 2100040.	1.7	5
3119	Para-aortic lymph nodes and ductal adenocarcinoma of the pancreas: Distant neighbors?. Surgery, 2021, 170, 1807-1814.	1.0	7
3120	Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer. Pancreas, 2021, 50, 957-964.	0.5	5
3121	TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma. Oncogene, 2021, 40, 6007-6022.	2.6	10
3122	Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nabâ€paclitaxel in pancreatic cancer. Clinical and Translational Medicine, 2021, 11, e398.	1.7	1
3124	Artificial exosomes for translational nanomedicine. Journal of Nanobiotechnology, 2021, 19, 242.	4.2	133
3125	The role of radiotherapy in locally advanced pancreatic cancer. British Journal of Radiology, 2021, 94, 20210044.	1.0	2
3126	Proteogenomic characterization of pancreatic ductal adenocarcinoma. Cell, 2021, 184, 5031-5052.e26.	13.5	236
3127	Can Pancreatic Organoids Help in the Treatment of Pancreatic Cancer?. Advances in Surgery, 2021, 55, 215-229.	0.6	0
3128	Integrating Genetic and Transcriptomic Data to Reveal Pathogenesis and Prognostic Markers of Pancreatic Adenocarcinoma. Frontiers in Genetics, 2021, 12, 747270.	1.1	2
3129	Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancer. Pancreatology, 2021, 21, 1466-1471.	0.5	6
3130	Sequestsome-1/p62-targeted small molecules for pancreatic cancer therapy. Drug Discovery Today, 2022, 27, 362-370.	3.2	6
3131	Postoperative and long-term survival in relation to life-expectancy after pancreatic surgery in elderly patients (cohort study). Annals of Medicine and Surgery, 2021, 69, 102724.	0.5	0

#	Article	IF	Citations
3132	Mechanisms of Cancer Cell Death: Therapeutic Implications for Pancreatic Ductal Adenocarcinoma. Cancers, 2021, 13, 4834.	1.7	4
3133	Cholesterol biosynthesis inhibitor RO 48â€‘8071 inhibits pancreatic ductal adenocarcinoma cell viability by deactivating the JNK and ERK/MAPK signaling pathway. Molecular Medicine Reports, 2021, 24, .	1.1	1
3134	Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients. Current Oncology, 2021, 28, 3525-3536.	0.9	2
3135	The development of multi-kinase inhibitors as pancreatic cancer therapeutics. Anti-Cancer Drugs, 2021, 32, 779-785.	0.7	2
3136	Individualized Prediction of Survival Benefits of Pancreatectomy Plus Chemotherapy in Patients With Simultaneous Metastatic Pancreatic Cancer. Frontiers in Oncology, 2021, 11, 719253.	1.3	3
3137	Pancreatic cancer in 2021: What you need to know to win. World Journal of Gastroenterology, 2021, 27, 5851-5889.	1.4	59
3138	SOURCE-PANC: A Prediction Model for Patients With Metastatic Pancreatic Ductal Adenocarcinoma Based on Nationwide Population-Based Data. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1045-1053.	2.3	1
3139	SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer. JCI Insight, 2021, 6, .	2.3	29
3140	Determinants of Homologous Recombination Deficiency in Pancreatic Cancer. Cancers, 2021, 13, 4716.	1.7	9
3141	Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives. Cancers, 2021, 13, 4743.	1.7	8
3142	Clinical Utility of Epigenetic Changes in Pancreatic Adenocarcinoma. Epigenomes, 2021, 5, 20.	0.8	3
3143	The Extracellular Matrix in Pancreatic Cancer: Description of a Complex Network and Promising Therapeutic Options. Cancers, 2021, 13, 4442.	1.7	37
3144	Models of pancreatic ductal adenocarcinoma. Cancer and Metastasis Reviews, 2021, 40, 803-818.	2.7	9
3145	Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer. World Journal of Clinical Oncology, 2021, 12, 787-799.	0.9	12
3146	Penetration Cascade of Size Switchable Nanosystem in Desmoplastic Stroma for Improved Pancreatic Cancer Therapy. ACS Nano, 2021, 15, 14149-14161.	7.3	34
3147	Tumor-Specific Delivery of 5-Fluorouracilâ€“Incorporated Epidermal Growth Factor Receptorâ€“Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models. Gastroenterology, 2021, 161, 996-1010.e1.	0.6	20
3148	The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer. Cancers, 2021, 13, 4733.	1.7	13
3149	Downâ€regulation of metabolic pathways could offset the poor prognosis conferred by coâ€existent diabetes mellitus in pancreatic (head) adenocarcinoma. ANZ Journal of Surgery, 2021, 91, 2466-2474.	0.3	2

#	Article	IF	Citations
3150	Second-line palliative chemotherapy, survival, and prognostic factors in patients with advanced pancreatic cancer. Acta OncolÃ³gica, 2021, 60, 1580-1588.	0.8	4
3151	A Multicenter Randomized Controlled Prospective Study to Assess Efficacy of Laparoscopic Electrochemotherapy in the Treatment of Locally Advanced Pancreatic Cancer. Journal of Clinical Medicine, 2021, 10, 4011.	1.0	12
3152	Nanomedicine Strategies to Enhance Tumor Drug Penetration in Pancreatic Cancer. International Journal of Nanomedicine, 2021, Volume 16, 6313-6328.	3.3	12
3153	Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing. Journal of Medical Genetics, 2022, 59, 793-800.	1.5	12
3154	Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarcinoma. Pancreatology, 2021, 21, 1064-1070.	0.5	3
3155	Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance. Cancer and Metastasis Reviews, 2021, 40, 837-862.	2.7	8
3156	Divulging the Critical Role of HuR in Pancreatic Cancer as a Therapeutic Target and a Means to Overcome Chemoresistance. Cancers, 2021, 13, 4634.	1.7	3
3157	ALK Rearrangementâ€“Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Report. Frontiers in Oncology, 2021, 11, 724815.	1.3	11
3158	Stage 4 pancreatic adenocarcinoma harbouring an FGFR2-TACC2 fusion mutation with complete response to erdafitinib a pan-fibroblastic growth factor receptor inhibitor. BMJ Case Reports, 2021, 14, e244271.	0.2	11
3159	Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer. Cancers, 2021, 13, 4869.	1.7	7
3160	LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1Î± Pathway. Cancer Research, 2021, 81, 5678-5691.	0.4	63
3161	European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer. Cancer Treatment Reviews, 2021, 99, 102208.	3.4	4
3162	Nab-paclitaxel plus S-1 with or without PD-1 inhibitor in pancreatic ductal adenocarcinoma with only hepatic metastases: a retrospective cohort study. Langenbeck's Archives of Surgery, 2021, , 1.	0.8	3
3163	First-In-Human Phase I Study of a Next-Generation, Oral, TGFÎ² Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer. Clinical Cancer Research, 2021, 27, 6666-6676.	3.2	27
3165	Locally advanced pancreatic cancer: a reliable contraindication to resection in the modern era?. Hpb, 2021, , .	0.1	2
3166	Treatment Approach to Adenocarcinoma of the Ampulla of Vater. Current Treatment Options in Oncology, 2021, 22, 103.	1.3	10
3167	Inhibitor Library Screening Identifies Ispinesib as a New Potential Chemotherapeutic Agent for Pancreatic Cancers. Cancer Science, 2021, 112, 4641-4654.	1.7	4
3168	Pancreatic Cancer. JAMA - Journal of the American Medical Association, 2021, 326, 851.	3.8	658

#	Article	IF	Citations
3169	A novel protein-drug conjugate, SSH20, demonstrates significant efficacy in caveolin-1-expressing tumors. Molecular Therapy - Oncolytics, 2021, 22, 555-564.	2.0	9
3170	Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma. Hepatobiliary and Pancreatic Diseases International, 2021, 21, 10-10.	0.6	3
3171	Defective NK cell expansion, cytotoxicity, and lack of ability to differentiate tumors from a pancreatic cancer patient in a long term follow-up: implication in the progression of cancer. Cancer Immunology, Immunotherapy, 2022, 71, 1033-1047.	2.0	9
3172	Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study. Cancers, 2021, 13, 4939.	1.7	3
3173	Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): aÂmulticenter survey. ESMO Open, 2021, 6, 100238.	2.0	12
3174	Evolution of Systemic Therapy in Metastatic Pancreatic Ductal Adenocarcinoma. Surgical Oncology Clinics of North America, 2021, 30, 673-691.	0.6	1
3175	Treatment Paradigms for Older Adults with Pancreatic Cancer: a Nuanced Approach. Current Treatment Options in Oncology, 2021, 22, 104.	1.3	3
3176	Re: Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years. European Journal of Cancer, 2021, 156, 217-221.	1.3	1
3177	Trimetazidine alone or in combination with gemcitabine and/or abraxane decreased cell viability, migration and ATP levels and induced apoptosis of human pancreatic cells. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101632.	0.7	7
3178	Pankreas Kanserinde Hedefsel NanopartikÃ¼l Tedavisi ve Klinik Denemeler. SÃ¼leyman Demirel Ãœniversitesi TÄ±p FakÃ¼ltesi Dergisi, 0, , .	0.0	0
3179	Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants. Cancer Treatment Reviews, 2021, 100, 102262.	3.4	16
3180	Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101607.	0.7	3
3181	Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3). European Journal of Cancer, 2021, 157, 21-30.	1.3	18
3182	The role of autophagy in pancreatic cancer progression. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188592.	3.3	19
3183	Decreasing hyaluronic acid combined with drug-loaded nanoprobes improve the delivery and efficacy of chemotherapeutic drugs for pancreatic cancer. Cancer Letters, 2021, 523, 1-9.	3.2	10
3184	Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110458.	1.4	7
3185	Multimodality Therapy in Operable Pancreatic Cancer: Should We Sequence Surgery Last?. Annals of Surgical Oncology, 2021, 28, 1884-1886.	0.7	4
3186	Pankreas. , 2021, , 621-674.		0

#	Article	IF	Citations
3187	Pankreaskarzinom und zystische Neoplasien im Pankreas. , 2021, , 301-310.		0
3188	The Role of Nutritional Support for Cancer Patients in Palliative Care. Nutrients, 2021, 13, 306.	1.7	36
3189	Cancer du pancrÃ©as. , 2021, , 153-190.e3.		0
3190	Comparative Safety and Efficacy of Therapeutic Options in Resectable and Advanced/Metastatic Pancreatic Cancer: A Systematic Review and Indirect Comparison. Oncology Research and Treatment, 2021, 44, 476-484.	0.8	6
3191	Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial. Yonsei Medical Journal, 2021, 62, 671.	0.9	4
3192	Drug-related pneumonitis with radiographic hypersensitivity pneumonitis pattern: Three case series. Respiratory Medicine Case Reports, 2021, 34, 101498.	0.2	2
3194	Biomarkers in Pancreatic Cancer. , 2021, , 467-487.		1
3196	The role of PARP inhibitors in BRCA mutated pancreatic cancer. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110148.	1.4	21
3197	Imaging Diagnostics in Pancreatic Cancer from the Perspective of an Oncologist. Clinical Gastroenterology, 2021, , 109-126.	0.0	0
3199	Preoperative Therapy in Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer. , 2021, , 729-741.		0
3201	Longitudinal analysis of cell-free mutated KRAS and CA 19â€“9 predicts survival following curative resection of pancreatic cancer. BMC Cancer, 2021, 21, 49.	1.1	19
3202	CÃ¡ncer de pÃ¡ncreas. Medicine, 2021, 13, 1345-1352.	0.0	0
3203	Landmark Series: Immunotherapy and Targeted Therapy for Pancreatic Cancer. Annals of Surgical Oncology, 2021, 28, 1400-1406.	0.7	10
3204	Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study. Cancer Chemotherapy and Pharmacology, 2021, 87, 543-553.	1.1	14
3205	FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study. Cancer Chemotherapy and Pharmacology, 2021, 87, 397-404.	1.1	5
3206	APX005M, a CD40 monoclonal antibody, for patients with pancreatic adenocarcinoma. Lancet Oncology, The, 2021, 22, 10-11.	5.1	3
3207	Randomized Phase II Study of Gemcitabine Monotherapy vs. Gemcitabine with an EPA-Enriched Oral Supplement in Advanced Pancreatic Cancer. Nutrition and Cancer, 2021, , 1-10.	0.9	3
3208	Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy following FOLFIRINOX in Patients with Unresectable Pancreatic Cancer: A Single-Institution, Retrospective Analysis. Chemotherapy, 2021, 66, 58-64.	0.8	3

#	Article	IF	Citations
3209	Molecular Subtyping and Precision Medicine for Pancreatic Cancer. Journal of Clinical Medicine, 2021, 10, 149.	1.0	34
3210	A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer. Journal of Cancer, 2021, 12, 912-917.	1.2	5
3211	Metastatic Pancreatic Cancer Second-Line Treatment Options: Is the Difference Only in Cost?. Journal of Gastrointestinal Cancer, 2021, , 1.	0.6	0
3212	What Should Guide the Performance of Venous Resection During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma with Venous Contact?. Annals of Surgical Oncology, 2021, 28, 6211-6222.	0.7	15
3213	The impact of early tumor shrinkage on conversion surgery and the survival in patients with unresectable locally advanced pancreatic cancer. Surgery Today, 2021, 51, 1099-1107.	0.7	5
3214	The role of intraperitoneal chemotherapy in the surgical management of pancreatic ductal adenocarcinoma: a systematic review. Clinical and Experimental Metastasis, 2021, 38, 187-196.	1.7	9
3215	Surgery for locally advanced pancreatic ductal adenocarcinomaâ€"is it only about the vessels?. Journal of Gastrointestinal Oncology, 2021, 12, 2503-2511.	0.6	4
3216	Treatment Outcome of Nab-paclitaxel Plus Gemcitabine for Leptomeningeal Carcinomatosis from Pancreatic Ductal Adenocarcinoma: An Autopsy Case Report. Internal Medicine, 2021, 60, 3743-3748.	0.3	2
3217	Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110384.	1.4	10
3218	A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study. International Journal of Clinical Oncology, 2021, 26, 941-950.	1.0	15
3219	Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX. Journal of Personalized Medicine, 2021, 11, 83.	1.1	8
3220	The Role of Imaging in Current Treatment Strategies for Pancreatic Adenocarcinoma. Korean Journal of Radiology, 2021, 22, 23.	1.5	35
3221	Covalent and non-covalent albumin binding of Au(<scp>i</scp>) bis-NHCsviapost-synthetic amide modification. Chemical Science, 2021, 12, 7547-7553.	3.7	8
3222	Non-pegylated Liposomal Doxorubicin as Palliative Chemotherapy in pre-Treated Advanced Pancreatic Cancer: A Retrospective Analysis of Twenty-Eight Patients. Technology in Cancer Research and Treatment, 2021, 20, 153303382110421.	0.8	4
3223	Nonsurgical therapies for resected and unresected pancreatic cancer in Europe and USA in 2003â€"2014: a large international populationâ€based study. International Journal of Cancer, 2018, 143, 3227-3239.	2.3	25
3225	Rho-ROCK Signaling in Normal Physiology and as a Key Player in Shaping the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1223, 99-127.	0.8	17
3226	B Cells in the Gastrointestinal Tumor Microenvironment with a Focus on Pancreatic Cancer: Opportunities for Precision Medicine?. Advances in Experimental Medicine and Biology, 2020, 1273, 175-195.	0.8	2
3228	Circulating Tumor Cells in Gastrointestinal Cancer: Current Practices and Future Directions. Cancer Treatment and Research, 2016, 168, 345-376.	0.2	8

#	Article	IF	Citations
3229	Irreversible Electroporation in Clinical Practice. , 2018, , .		8
3230	Vaccine Therapy in Pancreatic Cancer. , 2018, , 281-307.		1
3232	Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. Journal of Gastroenterology, 2020, 55, 369-382.	2.3	48
3233	A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy. Updates in Surgery, 2020, 72, 39-45.	0.9	17
3234	Pancreatic ductal adenocarcinoma: time for a neoadjuvant revolution?. Updates in Surgery, 2020, 72, 321-324.	0.9	8
3235	Signaling adaptor protein Crk is involved in malignant feature of pancreatic cancer associated with phosphorylation of c-Met. Biochemical and Biophysical Research Communications, 2020, 524, 378-384.	1.0	4
3236	Blockade of endothelin receptor A enhances the therapeutic efficacy of gemcitabine in pancreatic cancer cells. Biochemical and Biophysical Research Communications, 2020, 527, 568-573.	1.0	12
3237	The overexpression of CPR and P450 3A4 in pancreatic cancer cells changes the metabolic profile and increases the cytotoxicity and pro-apoptotic activity of acridine antitumor agent, C-1748. Biochemical Pharmacology, 2017, 142, 21-38.	2.0	7
3238	Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. Clinical Colorectal Cancer, 2020, 19, 156-164.	1.0	16
3239	Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review. Cancer Treatment Reviews, 2020, 87, 102028.	3.4	9
3240	Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma. European Journal of Cancer, 2020, 132, 112-121.	1.3	22
3241	G Protein-Coupled Receptor GPR87 Promotes the Expansion of PDA Stem Cells through Activating JAK2/STAT3. Molecular Therapy - Oncolytics, 2020, 17, 384-393.	2.0	10
3242	Pancreatic cancer heterogeneity and response to Mek inhibition. Oncogene, 2017, 36, 5639-5647.	2.6	19
3243	1-Methyl-D-tryptophan Reduces Tumor CD133+ cells, Wnt/Î²-catenin and NF-Î¹Î²p65 while Enhances Lymphocytes NF-Î¹Î²2, STAT3, and STAT4 Pathways in Murine Pancreatic Adenocarcinoma. Scientific Reports, 2018, 8, 9869.	1.6	17
3244	Timeâ€“frequency analysis of serum with proton nuclear magnetic resonance for diagnosis of pancreatic cancer. Scientific Reports, 2020, 10, 21941.	1.6	3
3245	Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels. Bioscience Reports, 2020, 40, .	1.1	24
3247	Making the Case: Intra-arterial Therapy for Less Common Metastases. Seminars in Interventional Radiology, 2017, 34, 132-139.	0.3	12
3248	cRGD-installed docetaxel-loaded mertansine prodrug micelles: redox-triggered ratiometric dual drug release and targeted synergistic treatment of B16F10 melanoma. Nanotechnology, 2017, 28, 295103.	1.3	24

#	Article	IF	Citations
3249	CA 19-9 Response. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 898-902.	0.6	15
3250	Real-world Outcomes Among Patients Treated With Gemcitabine-based Therapy Post-FOLFIRINOX Failure in Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 903-908.	0.6	8
3251	Adjuvant FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 857-860.	0.6	4
3252	Duloxetine improves cancer-associated pain in a mouse model of pancreatic cancer through stimulation of noradrenaline pathway and its antitumor effects. Pain, 2020, 161, 2909-2919.	2.0	14
3253	Conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma: where do we stand in 2018?. Journal of Pancreatology, 2018, 1, 25-29.	0.3	6
3254	Sex Determining Region Y Box 9 Induces Chemoresistance in Pancreatic Cancer Cells by Induction of Putative Cancer Stem Cell Characteristics and Its High Expression Predicts Poor Prognosis. Pancreas, 2017, 46, 1296-1304.	0.5	15
3255	Pancreatoduodenectomy With Arterial Resection for Locally Advanced Pancreatic Cancer of the Head. Pancreas, 2020, 49, 621-628.	0.5	13
3256	Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 2022, 275, e229-e237.	2.1	14
3257	Arterial Resection in Pancreatic Cancer Surgery. Annals of Surgery, 2022, 275, 759-768.	2.1	79
3258	A Call for Caution in Overinterpreting Exceptional Outcomes After Radical Surgery for Pancreatic Cancer. Annals of Surgery, 2021, 274, e82-e84.	2.1	14
3259	Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. Annals of Surgery, 2022, 276, e502-e509.	2.1	6
3260	A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer. Annals of Surgery, 2022, 275, 45-53.	2.1	47
3265	Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLIâ€1 study. Cancer Science, 2020, 111, 513-527.	1.7	32
3266	Autotaxin in ascites promotes peritoneal dissemination in pancreatic cancer. Cancer Science, 2021, 112, 668-678.	1.7	9
3267	Pathological complete response in pancreatic adenocarcinoma with FOLFIRINOX. BMJ Case Reports, 2018, 2018, bcr-2018-225621.	0.2	2
3268	Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response. Clinical Cancer Research, 2019, 25, 6452-6462.	3.2	43
3269	Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2020, 26, 2318-2326.	3.2	54
3270	Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. Clinical Cancer Research, 2020, 26, 3239-3247.	3.2	135

#	Article	IF	Citations
3271	Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. JCI Insight, 2019, 4, .	2.3	102
3272	Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets. JCI Insight, 2020, 5, .	2.3	36
3273	BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo. JCI Insight, 2017, 2, e88032.	2.3	50
3274	Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix. Journal of Clinical Investigation, 2020, 130, 4704-4709.	3.9	80
3275	TPL2 enforces RAS-induced inflammatory signaling and is activated by point mutations. Journal of Clinical Investigation, 2020, 130, 4771-4790.	3.9	20
3276	Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness. Journal of Clinical Investigation, 2016, 126, 4140-4156.	3.9	169
3277	Pure and Hybrid Deep Learning Models can Predict Pathologic Tumor Response to Neoadjuvant Therapy in Pancreatic Adenocarcinoma: A Pilot Study. American Surgeon, 2021, 87, 1901-1909.	0.4	16
3278	Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer. BMC Cancer, 2020, 20, 449.	1.1	39
3279	HE4 overexpression decreases pancreatic cancer Capan-1 cell sensitivity to paclitaxel via cell cycle regulation. Cancer Cell International, 2020, 20, 163.	1.8	6
3280	Long-term survival of two patients with pancreatic cancer after resection of liver and lung oligometastases: a case report. Surgical Case Reports, 2020, 6, 309.	0.2	5
3281	Co-delivery Systems of Multiple Drugs Using Nanotechnology for Future Cancer Therapy. Chemical and Pharmaceutical Bulletin, 2020, 68, 603-612.	0.6	25
3282	Do Patients Diagnosed with Metastatic Pancreatic Cancer Benefit from Primary Tumor Surgery? A Propensity-Adjusted, Population-Based Surveillance, Epidemiology and End Results (SEER) Analysis. Medical Science Monitor, 2019, 25, 8230-8241.	0.5	7
3283	Recent advances in the treatment of pancreatic cancer. F1000Research, 2020, 9, 131.	0.8	52
3284	Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer. World Journal of Clinical Cases, 2020, 8, 3718-3729.	0.3	3
3285	First-line chemotherapy in very elderly patients with metastatic pancreatic cancer: Gemcitabine monotherapy vs combination chemotherapy. World Journal of Clinical Cases, 2020, 8, 4022-4033.	0.3	6
3286	Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens. PLoS ONE, 2015, 10, e0139049.	1.1	31
3287	Decreased TUSC3 Promotes Pancreatic Cancer Proliferation, Invasion and Metastasis. PLoS ONE, 2016, 11, e0149028.	1.1	22
3288	Whole Genome Sequencing of Newly Established Pancreatic Cancer Lines Identifies Novel Somatic Mutation (c.2587G>A) in Axon Guidance Receptor Plexin A1 as Enhancer of Proliferation and Invasion. PLoS ONE, 2016, 11, e0149833.	1.1	21

#	Article	IF	Citations
3289	Prognostic and Functional Significance of MAP4K5 in Pancreatic Cancer. PLoS ONE, 2016, 11, e0152300.	1.1	20
3290	MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts. PLoS ONE, 2016, 11, e0155289.	1.1	21
3291	A Platform for Rapid, Quantitative Assessment of Multiple Drug Combinations Simultaneously in Solid Tumors In Vivo. PLoS ONE, 2016, 11, e0158617.	1.1	9
3292	Targeting Epithelial-Mesenchymal Transition for Identification of Inhibitors for Pancreatic Cancer Cell Invasion and Tumor Spheres Formation. PLoS ONE, 2016, 11, e0164811.	1.1	17
3293	Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability. PLoS ONE, 2017, 12, e0174863.	1.1	23
3294	Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy. PLoS ONE, 2017, 12, e0180628.	1.1	4
3295	Inhibition of ROCK1 kinase modulates both tumor cells and stromal fibroblasts in pancreatic cancer. PLoS ONE, 2017, 12, e0183871.	1.1	65
3296	Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines. PLoS ONE, 2018, 13, e0191766.	1.1	36
3297	Necroptosis in pancreatic cancer promotes cancer cell migration and invasion by release of CXCL5. PLoS ONE, 2020, 15, e0228015.	1.1	78
3298	Usefulness of rapid on-site evaluation specimens from endoscopic ultrasound-guided fine-needle aspiration for cancer gene panel testing: A retrospective study. PLoS ONE, 2020, 15, e0228565.	1.1	9
3299	Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-center retrospective study in Taiwan. PLoS ONE, 2020, 15, e0244487.	1.1	3
3300	Current Controversies in the Stage-Specific Multidisciplinary Management of Pancreatic Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e157-e164.	1.8	5
3301	Immunotherapy for Pancreatic Cancer. Juntendo Medical Journal, 2020, 66, 238-244.	0.1	1
3302	Chemotherapy and Targeted Therapy with Management of Related Complications in Pancreatic Cancer. The Korean Journal of Pancreas and Biliary Tract, 2015, 20, 5-13.	0.0	2
3303	Pattern of care and survival of pancreatic ductal adenocarcinoma in a multi-disciplinary high-volume centre. Gastroenterology & Hepatology (Bartlesville, Okla), 2018, 9, .	0.0	1
3304	Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study. Oncologist, 2020, 25, e808-e815.	1.9	114
3305	Targeting Cancer using Polymeric Nanoparticle mediated Combination Chemotherapy. International Journal of Nanomedicine and Nanosurgery, 2016, 2, .	0.3	28
3306	The Evolving Field of Stereotactic Body Radiation Therapy in Pancreatic Cancer. Pancreas (Fairfax, Va), 2019, 3, 9-14.	1.4	18

#	Article	IF	Citations
3307	Why HALO 301 Failed and Implications for Treatment of Pancreatic Cancer. Pancreas (Fairfax, Va), 2019, 3, e1-e4.	1.4	69
3308	Possibilities of palliative chemotherapy in patients with locally advanced and metastatic pancreatic cancer. IssledovaniÃ¢ I Praktika V Medicine, 2020, 7, 118-134.	0.1	3
3309	More than a Gel & Hyaluronic Acid, a Central Component in the Microenvironment of Pancreatic Cancer. European Oncology and Haematology, 2018, 14, 40.	0.0	11
3310	Long non-coding SBF2-AS1 acting as a competing endogenous RNA to sponge microRNA-142-3p to participate in gemcitabine resistance in pancreatic cancer via upregulating TWF1. Aging, 2019, 11, 8860-8878.	1.4	40
3311	N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012. Oncoscience, 2015, 2, 285-293.	0.9	4
3312	Intratumoral heterogeneity of the therapeutical response to gemcitabine and metformin. Oncotarget, 2016, 7, 56395-56407.	0.8	24
3313	Overexpression of C16orf74 is involved in aggressive pancreatic cancers. Oncotarget, 2017, 8, 50460-50475.	0.8	12
3314	Novel role of miR-29a in pancreatic cancer autophagy and its therapeutic potential. Oncotarget, 2016, 7, 71635-71650.	0.8	60
3315	The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma. Oncotarget, 2016, 7, 75081-75093.	0.8	11
3316	Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models. Oncotarget, 2017, 8, 4399-4409.	0.8	12
3317	An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma. Oncotarget, 2016, 7, 82953-82960.	0.8	22
3318	Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? An analysis from a large multicenter cohort study. Oncotarget, 2016, 7, 85603-85612.	0.8	3
3319	Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?. Oncotarget, 2017, 8, 14173-14191.	0.8	31
3320	Superior mesenteric artery margin in pancreaticoduodenectomy for pancreatic adenocarcinoma. Oncotarget, 2017, 8, 7766-7776.	0.8	9
3321	Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes. Oncotarget, 2017, 8, 9189-9199.	0.8	24
3322	Prognostic significance of positive peritoneal cytology in resectable pancreatic cancer: a systemic review and meta-analysis. Oncotarget, 2017, 8, 15004-15013.	0.8	26
3323	Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. Oncotarget, 2017, 8, 44073-44081.	0.8	63
3324	Germline mutations in pancreatic cancer and potential new therapeutic options. Oncotarget, 2017, 8, 73240-73257.	0.8	40

#	Article	IF	Citations
3325	Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer. Oncotarget, 2017, 8, 44295-44311.	0.8	29
3326	Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen. Oncotarget, 2017, 8, 46337-46347.	0.8	35
3327	Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells. Oncotarget, 2017, 8, 56968-56979.	0.8	59
3328	Prognostic value of c-Met overexpression in pancreatic adenocarcinoma: a meta-analysis. Oncotarget, 2017, 8, 73098-73104.	0.8	26
3329	Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial. Oncotarget, 2017, 8, 92401-92410.	0.8	20
3330	Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma. Oncotarget, 2017, 8, 97769-97786.	0.8	28
3331	Reduced FBXW7 expression in pancreatic cancer correlates with poor prognosis and chemotherapeutic resistance via accumulation of MCL1. Oncotarget, 2017, 8, 112636-112646.	0.8	20
3332	A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer. Oncotarget, 2017, 8, 111346-111355.	0.8	39
3333	Targeted deep sequencing of circulating tumor DNA in metastatic pancreatic cancer. Oncotarget, 2018, 9, 2076-2085.	0.8	42
3334	Fibrosis-related miRNAs as serum biomarkers for pancreatic ductal adenocarcinoma. Oncotarget, 2018, 9, 4451-4460.	0.8	18
3335	Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer. Oncotarget, 2018, 9, 5274-5286.	0.8	24
3336	Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer. Oncotarget, 2018, 9, 8972-8984.	0.8	3
3337	Intra-tumor L-methionine level highly correlates with tumor size in both pancreatic cancer and melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse models. Oncotarget, 2018, 9, 11119-11125.	0.8	35
3338	Neoadjuvant photodynamic therapy augments immediate and prolonged oxaliplatin efficacy in metastatic pancreatic cancer organoids. Oncotarget, 2018, 9, 13009-13022.	0.8	35
3339	Pomalidomide promotes chemosensitization of pancreatic cancer by inhibition of NF-ÎºB. Oncotarget, 2018, 9, 15292-15301.	0.8	7
3340	Pomalidomide enhanced gemcitabine and nab-paclitaxel on pancreatic cancer bothin vitroandin vivo. Oncotarget, 2018, 9, 15780-15791.	0.8	4
3341	Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer. Oncotarget, 2018, 9, 19994-20007.	0.8	10
3342	Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinoma. Oncotarget, 2018, 9, 25617-25629.	0.8	10

#	Article	IF	Citations
3343	The combination of everolimus and zoledronic acid increase the efficacy of gemcitabine in a mouse model of pancreatic adenocarcinoma. Oncotarget, 2018, 9, 28069-28082.	0.8	6
3344	Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study. Oncotarget, 2018, 9, 31861-31876.	0.8	4
3345	Intensification of induction chemotherapy before consolidation chemoradiotherapy improves progression-free survival and time without treatment in patients with locally advanced pancreatic cancers. Oncotarget, 2018, 9, 31999-32009.	0.8	1
3346	Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancer. Oncotarget, 2014, 5, 12978-12989.	0.8	34
3347	Efficient delivery of small interfering RNAs targeting particular mRNAs into pancreatic cancer cells inhibits invasiveness and metastasis of pancreatic tumors. Oncotarget, 2019, 10, 2869-2886.	0.8	19
3348	JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells. Oncotarget, 2015, 6, 458-470.	0.8	83
3349	Application of C. elegans cancer screening test for the detection of pancreatic tumor in genetically engineered mice. Oncotarget, 2019, 10, 5412-5418.	0.8	16
3350	Tumor penetrating nanomedicine targeting both an oncomiR and an oncogene in pancreatic cancer. Oncotarget, 2019, 10, 5349-5358.	0.8	15
3351	Effects of neoadjuvant FOLFIRINOX and gemcitabine-based chemotherapy on cancer cell survival and death in patients with pancreatic ductal adenocarcinoma. Oncotarget, 2019, 10, 7276-7287.	0.8	11
3352	Prognostic and predictive factors in pancreatic cancer. Oncotarget, 2020, 11, 924-941.	0.8	46
3353	An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncotarget, 2020, 11, 1929-1941.	0.8	7
3354	A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike?. Oncotarget, 2020, 11, 3489-3501.	0.8	30
3355	Molecular landscape of pancreatic cancer: implications for current clinical trials. Oncotarget, 2015, 6, 4553-4561.	0.8	85
3356	Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: A single institutional experience. Oncotarget, 2015, 6, 8255-8260.	0.8	14
3357	Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the â€œTHERAPYâ€phase 1-2 trial. Oncotarget, 2015, 6, 12796-12808.	0.8	56
3358	Novel agents for advanced pancreatic cancer. Oncotarget, 2015, 6, 39521-39537.	0.8	29
3359	Targeting cancer cell metabolism in pancreatic adenocarcinoma. Oncotarget, 2015, 6, 16832-16847.	0.8	100
3360	Multistep, effective drug distribution within solid tumors. Oncotarget, 2015, 6, 39564-39577.	0.8	22

#	Article	IF	Citations
3361	Inhibition of Eph receptor A4 by 2,5-dimethylpyrrolyl benzoic acid suppresses human pancreatic cancer growing orthotopically in nude mice. Oncotarget, 2015, 6, 41063-41076.	0.8	17
3362	Fendiline inhibits proliferation and invasion of pancreatic cancer cells by interfering with ADAM10 activation and Î²-catenin signaling. Oncotarget, 2015, 6, 35931-35948.	0.8	37
3363	Simultaneous gene silencing of KRAS and anti-apoptotic genes as a multitarget therapy. Oncotarget, 2016, 7, 3984-3992.	0.8	12
3364	Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer. Oncotarget, 2016, 7, 15492-15506.	0.8	8
3365	Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model. Oncotarget, 2016, 7, 18508-18520.	0.8	75
3366	Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint. Oncotarget, 2016, 7, 18495-18507.	0.8	22
3367	Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine. Oncotarget, 2016, 7, 17103-17110.	0.8	25
3368	Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models. Oncotarget, 2016, 7, 46988-47001.	0.8	10
3369	ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis. Oncotarget, 2016, 7, 35159-35168.	0.8	14
3370	Heterogeneity of metastatic pancreatic adenocarcinoma: Lung metastasis show better prognosis than liver metastasisâ€"a case control study. Oncotarget, 2016, 7, 45649-45655.	0.8	26
3371	Pancreatic cancer: treatment approaches and trends. Journal of Cancer Metastasis and Treatment, 2018, 4, 30.	0.5	23
3372	Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma. , 2020, 3, 572-585.		4
3373	Drug metabolism and pancreatic cancer. Annals of Gastroenterology, 2016, 30, 54-61.	0.4	5
3374	Pancreatic cancer from bench to bedside: molecular pathways and treatment options. Annals of Translational Medicine, 2016, 4, 165-165.	0.7	19
3375	Evaluation bias in objective response rate and disease control rate between blinded independent central review and local assessment: a study-level pooled analysis of phase III randomized control trials in the past seven years. Annals of Translational Medicine, 2017, 5, 481-481.	0.7	11
3376	A combination of platelet-to-lymphocyte ratio and carbohydrate antigen 19-9 predict early recurrence after resection of pancreatic ductal adenocarcinoma. Annals of Translational Medicine, 2019, 7, 461-461.	0.7	13
3377	Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma. Chinese Clinical Oncology, 2017, 6, 31-31.	0.4	12
3378	Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU chemoradiation. Journal of Gastrointestinal Oncology, 2018, 9, 922-935.	0.6	4

#	Article	IF	Citations
3379	Pancreatic Cancer in the Era of Neoadjuvant Therapy: A Narrative Overview. Chirurgia (Romania), 2018, 113, 307.	0.2	6
3380	Targeting Cancer Stem Cells for Chemoprevention of Pancreatic Cancer. Current Medicinal Chemistry, 2018, 25, 2585-2594.	1.2	64
3381	Diverse Targeted Approaches to Battle Multidrug Resistance in Cancer. Current Medicinal Chemistry, 2019, 26, 7059-7080.	1.2	22
3382	Neoadjuvant Therapy is Essential for Resectable Pancreatic Cancer. Current Medicinal Chemistry, 2020, 26, 7196-7211.	1.2	9
3383	A Retrospective Look at Anti-EGFR Agents in Pancreatic Cancer Therapy. Current Drug Metabolism, 2020, 20, 958-966.	0.7	9
3384	Understanding the Mechanism of Cell Death in Gemcitabine Resistant Pancreatic Ductal Adenocarcinoma: A Systems Biology Approach. Current Genomics, 2020, 20, 483-490.	0.7	3
3385	Blocking IL-6/GP130 Signaling Inhibits Cell Viability/Proliferation, Glycolysis, and Colony Forming Activity in Human Pancreatic Cancer Cells. Current Cancer Drug Targets, 2019, 19, 417-427.	0.8	22
3386	Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study. Current Cancer Drug Targets, 2020, 20, 887-895.	0.8	8
3387	Overview of Current Immunotherapies Targeting Mutated KRAS Cancers. Current Topics in Medicinal Chemistry, 2019, 19, 2158-2175.	1.0	4
3388	Impact of Hybrid-polar Histone Deacetylase Inhibitor m-Carboxycinnamic Acid bis-Hydroxyamide on Human Pancreatic Adenocarcinoma Cells. Anti-Cancer Agents in Medicinal Chemistry, 2019, 19, 750-759.	0.9	3
3389	Inhibition of Fatty Acid Synthesis Induces Apoptosis of Human Pancreatic Cancer Cells. Anticancer Research, 2016, 36, 4655-4660.	0.5	42
3390	Gemcitabine and S-1 Induction Chemotherapy Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancers. Anticancer Research, 2017, 37, 233-238.	0.5	1
3391	Phase I Study of Nabâ€“Paclitaxel plus Gemcitabine as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer. Anticancer Research, 2017, 37, 853-858.	0.5	41
3392	Z-360 Suppresses Tumor Growth in MIA PaCa-2-bearing Mice via Inhibition of Gastrin-induced Anti-Apoptotic Effects. Anticancer Research, 2017, 37, 4127-4137.	0.5	3
3393	Impact of Nabâ€“Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer. , 2017, 37, 5533-5539.		13
3394	Perioperative Red Blood Cell Transfusion Is Associated with Poor Long-term Survival in Pancreatic Adenocarcinoma. , 2017, 37, 5863-5870.		12
3395	Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-paclitaxel Reduces the Number of Cancer-associated Fibroblasts Through Depletion of Pancreatic Stroma. Anticancer Research, 2018, 38, 337-343.	0.5	33
3396	Locally Advanced or Metastatic Pancreatic Adenocarcinoma: Easily Available Factors of Predictive Prolonged Survival Under Gemcitabine. In Vivo, 2017, 31, 731-735.	0.6	6

#	Article	IF	Citations
3397	A granulocyte colony-stimulating factor-producing pancreatic adenocarcinoma treated with nab-paclitaxel plus gemcitabine chemotherapy. Suizo, 2018, 33, 768-775.	0.1	2
3398	Overexpression of B2M and loss of ALK7 expression are associated with invasion, metastasis, and poor-prognosis of the pancreatic ductal adenocarcinoma. Cancer Biomarkers, 2015, 15, 735-743.	0.8	17
3399	Ductal Pancreatic Adenocarcinoma. Deutsches Ärzteblatt International, 2014, 111, 396-402.	0.6	23
3400	PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer. Health Technology Assessment, 2018, 22, 1-114.	1.3	82
3401	Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group. Ecancermedicalscience, 2020, 14, 1048.	0.6	7
3402	Neural Regulation of Pancreatic Cancer: A Novel Target for Intervention. Cancers, 2015, 7, 1292-1312.	1.7	18
3403	Metabolic Adaptation during nab-Paclitaxel Resistance in Pancreatic Cancer Cell Lines. Cells, 2020, 9, 1251.	1.8	12
3404	Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer. Genes, 2021, 12, 33.	1.0	23
3405	Promising Effect of a New Ketogenic Diet Regimen in Patients with Advanced Cancer. Nutrients, 2020, 12, 1473.	1.7	33
3406	Pancreatic biomarkers: Could they be the answer?. World Journal of Gastroenterology, 2014, 20, 7819.	1.4	8
3407	Personalising pancreas cancer treatment: When tissue is the issue. World Journal of Gastroenterology, 2014, 20, 7849.	1.4	22
3408	Translational research in pancreatic ductal adenocarcinoma: Current evidence and future concepts. World Journal of Gastroenterology, 2014, 20, 10769.	1.4	20
3409	MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer. World Journal of Gastroenterology, 2014, 20, 11199.	1.4	40
3410	Adjuvant therapy in pancreatic cancer. World Journal of Gastroenterology, 2014, 20, 14733.	1.4	36
3411	S-1 in the treatment of pancreatic cancer. World Journal of Gastroenterology, 2014, 20, 15110.	1.4	41
3412	Icotinib plus gemcitabine for metastatic pancreatic cancer: A case report. World Journal of Gastroenterology, 2015, 21, 3441-3446.	1.4	3
3413	Metastatic pancreatic cancer: Is there a light at the end of the tunnel?. World Journal of Gastroenterology, 2015, 21, 4788.	1.4	56
3414	New targeted therapies in pancreatic cancer. World Journal of Gastroenterology, 2015, 21, 6127.	1.4	43

#	Article	IF	Citations
3415	Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection. World Journal of Gastroenterology, 2015, 21, 6384.	1.4	39
3416	Gastrointestinal cancers in the era of theranostics: Updates and future perspectives. World Journal of Gastroenterology, 2015, 21, 8473.	1.4	5
3417	Robotic radiosurgery in pancreatic cancer: A systematic review. World Journal of Gastroenterology, 2015, 21, 9420.	1.4	12
3418	Advanced pancreatic cancer - how to choose an adequate treatment option. World Journal of Gastroenterology, 2015, 21, 10709.	1.4	3
3419	Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy. World Journal of Gastroenterology, 2015, 21, 11168.	1.4	20
3420	Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update. World Journal of Gastroenterology, 2015, 21, 11793.	1.4	29
3421	Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer. World Journal of Gastroenterology, 2016, 22, 4446.	1.4	13
3422	Viro-immune therapy: A new strategy for treatment of pancreatic cancer. World Journal of Gastroenterology, 2016, 22, 748.	1.4	16
3423	Management of pancreatic cancer in the elderly. World Journal of Gastroenterology, 2016, 22, 764.	1.4	113
3424	Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy. World Journal of Gastroenterology, 2016, 22, 6065.	1.4	23
3425	FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. World Journal of Gastroenterology, 2016, 22, 6987.	1.4	68
3426	Therapeutic potential of targeting acinar cell reprogramming in pancreatic cancer. World Journal of Gastroenterology, 2016, 22, 7046.	1.4	24
3427	Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma. World Journal of Gastroenterology, 2016, 22, 7080.	1.4	10
3428	Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy. World Journal of Gastroenterology, 2016, 22, 9378.	1.4	34
3429	Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability. World Journal of Gastroenterology, 2016, 22, 10024.	1.4	28
3430	Updated therapeutic outcome for patients with periampullary and pancreatic cancer related to recent translational research. World Journal of Gastroenterology, 2016, 22, 10502.	1.4	3
3431	Advanced pancreatic ductal adenocarcinoma - Complexities of treatment and emerging therapeutic options. World Journal of Gastroenterology, 2017, 23, 2276.	1.4	13
3432	Early radiological assessment of locally advanced pancreatic cancer treated with electrochemotherapy. World Journal of Gastroenterology, 2017, 23, 4767.	1.4	53

#	Article	IF	Citations
3433	Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions. World Journal of Gastroenterology, 2017, 23, 5875.	1.4	70
3434	Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: A case report and literature review. World Journal of Gastroenterology, 2017, 23, 7478-7488.	1.4	23
3435	ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward?. World Journal of Gastroenterology, 2018, 24, 3222-3238.	1.4	77
3436	p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation. World Journal of Gastroenterology, 2018, 24, 3709-3723.	1.4	33
3437	Use of zebrafish embryos as avatar of patients with pancreatic cancer: A new xenotransplantation model towards personalized medicine. World Journal of Gastroenterology, 2020, 26, 2792-2809.	1.4	23
3438	Effectiveness and feasibility of concurrent chemoradiotherapy using simultaneous integrated boost-intensity modulated radiotherapy with and without induction chemotherapy for locally advanced pancreatic cancer. Radiation Oncology Journal, 2018, 36, 200-209.	0.7	10
3439	High mobility group ATâ€'hook 2 and câ€'MYC as potential prognostic factors in pancreatic ductal adenocarcinoma. Oncology Letters, 2020, 19, 1584-1592.	0.8	2
3440	High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in pancreatic cancer. Oncology Reports, 2020, 44, 252-262.	1.2	10
3441	Curcumin enhances antiâ€'cancer efficacy of either gemcitabine or docetaxel on pancreatic cancer cells. Oncology Reports, 2020, 44, 1393-1402.	1.2	13
3442	Inflammatory markers as prognostic indicators in pancreatic cancer patients who underwent gemcitabine-based palliative chemotherapy. Korean Journal of Internal Medicine, 2020, 35, 171-184.	0.7	10
3443	microRNA-218 promotes gemcitabine sensitivity in human pancreatic cancer cells by regulating HMGB1 expression. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015, 27, 267-78.	0.7	14
3444	Advances of stereotactic body radiotherapy in pancreatic cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015, 27, 349-57.	0.7	14
3445	Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015, 27, 376-91.	0.7	16
3446	Current and future systemic treatment options in metastatic pancreatic cancer. Journal of Gastrointestinal Oncology, 2014, 5, 280-95.	0.6	33
3447	Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis. Journal of Gastrointestinal Oncology, 2015, 6, 511-5.	0.6	22
3448	Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma. Journal of Gastrointestinal Oncology, 2016, 7, 234-8.	0.6	8
3449	Chemotherapy for advanced cancers. Annals of Palliative Medicine, 2014, 3, 203-28.	0.5	11
3450	Translational assessment of mitochondrial dysfunction of pancreatic cancer from in vitro gene microarray and animal efficacy studies, to early clinical studies, via the novel tumor-specific anti-mitochondrial agent, CPI-613. Annals of Translational Medicine, 2014, 2, 91.	0.7	17

#	Article	IF	Citations
3451	Pancreatic cancer - lessons from the past decade. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 73-76.	0.1	3
3452	Should every patient with pancreatic cancer receive perioperative/neoadjuvant therapy?. Indian Journal of Medical and Paediatric Oncology, 2016, 37, 211-213.	0.1	3
3453	The role of endoscopic ultrasound in pancreatic cancer screening. Endoscopic Ultrasound, 2016, 5, 8.	0.6	47
3454	The personalized medicine for pancreatic ductal adenocarcinoma patients: The oncologist perspective. Endoscopic Ultrasound, 2017, 6, 66.	0.6	3
3455	Experience with non-cremophor-based paclitaxel-gemcitabine regimen in advanced pancreatic cancer: Results from a single tertiary cancer centre. Indian Journal of Medical Research, 2018, 148, 284.	0.4	5
3456	p21-Activated Kinase 4 (PAK4) as a Predictive Marker of Gemcitabine Sensitivity in Pancreatic Cancer Cell Lines. Cancer Research and Treatment, 2015, 47, 501-508.	1.3	29
3457	Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy. Cancer Research and Treatment, 2016, 48, 1264-1273.	1.3	40
3458	An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021). Cancer Research and Treatment, 2018, 50, 195-203.	1.3	59
3459	Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Cancer Research and Treatment, 2020, 52, 254-262.	1.3	14
3460	A Case Series of Patients with Pancreatic Cancer and Cholangiocarcinoma Treated with <i>nab</i>-Paclitaxel at a Single Institution. Journal of Cancer Therapy, 2014, 05, 605-610.	0.1	2
3461	Current role of palliative interventions in advanced pancreatic cancer. World Journal of Gastrointestinal Surgery, 2018, 10, 75-83.	0.8	19
3462	Irreversible electroporation and the pancreas: What we know and where we are going?. World Journal of Gastrointestinal Surgery, 2015, 7, 138.	0.8	9
3463	Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer. World Journal of Gastrointestinal Oncology, 2018, 10, 505-515.	0.8	26
3464	Shattering the castle walls: Anti-stromal therapy for pancreatic cancer. World Journal of Gastrointestinal Oncology, 2018, 10, 202-210.	0.8	25
3465	Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. World Journal of Gastrointestinal Oncology, 2019, 11, 1021-1030.	0.8	11
3466	FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study. World Journal of Gastrointestinal Oncology, 2020, 12, 182-194.	0.8	40
3467	FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study. World Journal of Gastrointestinal Oncology, 2020, 12, 332-346.	0.8	7
3468	Management of borderline resectable pancreatic cancer. World Journal of Gastrointestinal Oncology, 2015, 7, 241.	0.8	27

#	Article	IF	Citations
3469	State of the art biological therapies in pancreatic cancer. World Journal of Gastrointestinal Oncology, 2016, 8, 55.	0.8	30
3470	Neoadjuvant radiotherapeutic strategies in pancreatic cancer. World Journal of Gastrointestinal Oncology, 2016, 8, 186.	0.8	13
3471	Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival. World Journal of Gastrointestinal Oncology, 2016, 8, 248.	0.8	22
3472	Is metastatic pancreatic cancer an untargetable malignancy?. World Journal of Gastrointestinal Oncology, 2016, 8, 297.	0.8	8
3473	Molecular therapeutics in pancreas cancer. World Journal of Gastrointestinal Oncology, 2016, 8, 366.	0.8	18
3474	Targeting inflammation in pancreatic cancer: Clinical translation. World Journal of Gastrointestinal Oncology, 2016, 8, 380.	0.8	19
3475	Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib. World Journal of Gastrointestinal Oncology, 2016, 8, 555.	0.8	32
3476	Role of the preoperative usefulness of the pathological diagnosis of pancreatic diseases. World Journal of Gastrointestinal Oncology, 2016, 8, 656.	0.8	13
3477	Pancreatic cancer: New hopes after first line treatment. World Journal of Gastrointestinal Oncology, 2016, 8, 682.	0.8	20
3478	Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression. World Journal of Gastrointestinal Oncology, 2017, 9, 235.	0.8	19
3479	Evolving treatment landscape for early and advanced pancreatic cancer. World Journal of Gastrointestinal Oncology, 2017, 9, 281.	0.8	26
3480	Assessment of the Risk of Colorectal Cancer Survivors Developing a Second Primary Pancreatic Cancer. Gut and Liver, 2017, 11, 728-732.	1.4	17
3481	Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer. Gut and Liver, 2018, 12, 728-735.	1.4	8
3482	Comprehensive Cancer Panel Sequencing Defines Genetic Diversity and Changes in the Mutational Characteristics of Pancreatic Cancer Patients Receiving Neoadjuvant Treatment. Gut and Liver, 2019, 13, 683-689.	1.4	12
3483	Neoadjuvant treatment for resectable pancreatic adenocarcinoma. World Journal of Clinical Oncology, 2016, 7, 1.	0.9	11
3484	Histone deacetylases, microRNA and leptin crosstalk in pancreatic cancer. World Journal of Clinical Oncology, 2017, 8, 178.	0.9	25
3485	Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations. World Journal of Clinical Oncology, 2017, 8, 230.	0.9	52
3486	Distinct Risk Factor Profiles of Gemcitabine Plus Nab-paclitaxel-induced Neutropenia in Patients with Pancreatic Cancer. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2018, 44, 107-116.	0.0	1

#	Article	IF	Citations
3487	Systemic treatment for inoperable pancreatic adenocarcinoma: review and update. Chinese Journal of Cancer, 2014, 33, 267-276.	4.9	17
3488	Current Systemic Treatment Options for Metastatic and Unresectable Pancreatic Cancer. , 0, , .		1
3489	Pathological Complete Response after S-1 Therapy for an Unresectable Pancreatic Head Cancer with Liver Metastasis. Japanese Journal of Gastroenterological Surgery, 2017, 50, 461-468.	0.0	1
3490	Quantitative Imaging Assessment for Clinical Trials in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1505-1511.	2.3	4
3491	Benefits of High-Volume Medical Oncology Care for Noncurable Pancreatic Adenocarcinoma: A Population-Based Analysis. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 297-303.	2.3	8
3492	Patient Satisfaction and Quality of Life Before and After Treatment of Pancreatic and Periampullary Cancer: A Prospective Multicenter Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 704-711.	2.3	14
3493	Impact of Geography on Care Delivery and Survival for Noncurable Pancreatic Adenocarcinoma: A Population-Based Analysis. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1642-1650.	2.3	7
3494	Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 439-457.	2.3	564
3495	U.S. Food and Drug Administration approves paclitaxel protein-bound particles (AbraxaneÂ®) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer. JOP: Journal of the Pancreas, 2013, 14, 686-8.	1.5	29
3497	Regulation mechanisms of the hedgehog pathway in pancreatic cancer: a review. JOP: Journal of the Pancreas, 2015, 16, 25-32.	1.5	11
3498	Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country. Asian Pacific Journal of Cancer Prevention, 2015, 16, 6001-6006.	0.5	6
3499	Change of SPARC expression after chemotherapy in gastric cancer. Cancer Biology and Medicine, 2015, 12, 33-40.	1.4	7
3500	Systemic therapy of non-colorectal gastrointestinal malignancies in the elderly. Cancer Biology and Medicine, 2015, 12, 284-91.	1.4	5
3501	Regression of Stage IV Pancreatic Cancer to Curative Surgery and Introduction of a Novel Ex-Vivo Chemosensitivity Assay. Cureus, 2015, 7, e423.	0.2	5
3502	How to select the most appropriate adjuvant treatment after neoadjuvant treatment and resection for locally advanced pancreatic cancer?. Journal of Gastrointestinal Oncology, 2021, 12, 2521-2535.	0.6	0
3503	Impact of Renal Function on S-1 + Radiotherapy for Locally Advanced Pancreatic Cancer. Pancreas, 2021, 50, 965-971.	0.5	1
3504	First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, , 1-8.	2.3	6
3505	Application of Text Mining Technologies Based on Indexing Model & Public Databases. , 2021, , .		0

#	Article	IF	Citations
3506	Use of nab-paclitaxel and gemcitabine in pancreatic cancer without granulocyte colony-stimulating factor: A multicenter real-world experience. Journal of Oncology Pharmacy Practice, 2021, , 107815522110386.	0.5	0
3507	ERAP2 is a novel target involved in autophagy and activation of pancreatic stellate cells via UPR signaling pathway. Pancreatology, 2022, 22, 9-19.	0.5	7
3508	Investigation of Conversion Surgery for Initial UR-PDAC: Is Adjuvant Chemotherapy Still Necessary?. Japanese Journal of Gastroenterological Surgery, 2021, 54, 665-678.	0.0	0
3509	The clinical outcomes of second-line chemotherapy in patients with advanced pancreatic cancer: a retrospective study. Yeungnam University Journal of Medicine, 2022, 39, 124-132.	0.7	2
3510	Systemic Therapy for Metastatic Pancreatic Cancer. Current Treatment Options in Oncology, 2021, 22, 106.	1.3	33
3511	Carfilzomib and Paclitaxel Co-Loaded Protein Nanoparticles an Effective Therapy Against Pancreatic Adenocarcinomas. International Journal of Nanomedicine, 2021, Volume 16, 6825-6841.	3.3	7
3512	The PDAC Extracellular Matrix: A Review of the ECM Protein Composition, Tumor Cell Interaction, and Therapeutic Strategies. Frontiers in Oncology, 2021, 11, 751311.	1.3	48
3513	Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapyâ€"A Review of the Literature. Biomolecules, 2021, 11, 1469.	1.8	9
3514	Pancreaticobiliary Malignancies in the Emergency Room: Management of Acute Complications and Oncological Emergencies. Journal of Gastrointestinal Cancer, 2021, , 1.	0.6	2
3515	Long-Term Response to Gemcitabine, Cisplatin, and Nab-Paclitaxel Followed by Maintenance Therapy for Advanced Gallbladder Cancer: A Case Report and Literature Review. Frontiers in Oncology, 2021, 11, 733955.	1.3	3
3516	Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis. Scientific Reports, 2021, 11, 20152.	1.6	11
3517	Weight loss during neoadjuvant therapy for pancreatic cancer does not predict poor outcomes. American Journal of Surgery, 2022, 223, 927-932.	0.9	4
3518	PRMT5: An Emerging Target for Pancreatic Adenocarcinoma. Cancers, 2021, 13, 5136.	1.7	11
3519	Gender-specific side effects of chemotherapy in pancreatic cancer patients. Canadian Journal of Physiology and Pharmacology, 2022, 100, 371-377.	0.7	5
3520	DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives. Frontiers in Cell and Developmental Biology, 2021, 9, 749490.	1.8	6
3521	Cobimetinib Plus Gemcitabine: An Active Combination in KRAS G12R-Mutated Pancreatic Ductal Adenocarcinoma Patients in Previously Treated and Failed Multiple Chemotherapies. Journal of Pancreatic Cancer, 2021, 7, 65-70.	1.6	6
3523	Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1. Oncogene, 2021, 40, 6759-6771.	2.6	13
3524	Importance of BRCA mutation for the current treatment of pancreatic cancer beyond maintenance. World Journal of Gastroenterology, 2021, 27, 6515-6521.	1.4	0

#	Article	IF	Citations
3525	Identification of Candidate Biomarker ASXL2 and Its Predictive Value in Pancreatic Carcinoma. Frontiers in Oncology, 2021, 11, 736694.	1.3	7
3526	Exceptional Response to Second-Line Gemcitabine/Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma. Cureus, 2021, 13, e18756.	0.2	1
3527	Heterogeneity in Pancreatic Cancer Fibroblastsâ€"TGFÎ² as a Master Regulator?. Cancers, 2021, 13, 4984.	1.7	9
3528	Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer. Cancer Biology and Therapy, 2021, 22, 564-570.	1.5	7
3529	Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer. World Journal of Gastroenterology, 2021, 27, 6775-6793.	1.4	12
3530	Eicosanoid regulation of debris-stimulated metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	12
3531	AGIG Chemo-Immunotherapy in Patients With Advanced Pancreatic Cancer: A Single-Arm, Single-Center, Phase 2 Study. Frontiers in Oncology, 2021, 11, 693386.	1.3	1
3532	The Diverse Applications of Pancreatic Ductal Adenocarcinoma Organoids. Cancers, 2021, 13, 4979.	1.7	9
3533	MicroRNA biomarkers in whole blood for detection of pancreatic cancer.. Journal of Clinical Oncology, 2013, 31, 4052-4052.	0.8	2
3534	Clinical study report. , 2013, , 289-291.		4
3535	Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Recurrent Advanced Pancreatic Cancerâ€"A Potential Strategy for Improved Survival. Journal of Cancer Therapy, 2014, 05, 1072-1091.	0.1	2
3536	Perspective of preoperative therapy for pancreatic cancer. Suizo, 2014, 29, 873-877.	0.1	1
3537	EBM-based Clinical Guidelines for Pancreatic Cancer (2013): perspectives on chemotherapy. Suizo, 2014, 29, 892-897.	0.1	0
3538	Progress and perspectives of post-operative adjuvant chemotherapy for adenocarcinoma of the pancreas. Suizo, 2014, 29, 878-884.	0.1	0
3539	The current status of FOLFIRINOX for unresectable pancreatic cancer. Suizo, 2014, 29, 885-891.	0.1	0
3540	RAS Genes and Cancer. , 2014, , 157-171.		0
3541	A case of pathological complete response after chemotherapy by S-1 and gemcitabine for a pancreatic cancer with para-aortic lymph node metastasis. Suizo, 2014, 29, 898-904.	0.1	5
3542	Pancreatic Cancer Metastasis. , 2014, , 3410-3413.		0

#	Article	IF	Citations
3544	Summary of Gastrointestinal Cancer Chemotherapy Symposium on August 5, 2014. “Fudan University - Juntendo University”. Juntendo Medical Journal, 2014, 60, 518-519.	0.1	0
3545	Mistletoe Treatment for Cancer. Deutsches Ärzteblatt International, 2014, 111, 491-2.	0.6	0
3546	Efficacy of Taxane-Based Regimens in a First-line Setting for Recurrent and/or Metastatic Chinese Patients with Esophageal Cancer. Asian Pacific Journal of Cancer Prevention, 2014, 15, 5493-5498.	0.5	5
3547	Genomic Applications in Colorectal and Pancreatic Tumors. , 2015, , 415-434.		0
3548	Clinical Management of Pancreatic Cancer. Journal of the Advanced Practitioner in Oncology, 2014, 5, .	0.2	8
3549	Liver Metastases from Pancreatic Adenocarcinoma. , 2015, , 95-109.		0
3550	Increasing Bioavailability of Cytotoxic Agents through Prolonged Therapy and Addition of Polymechanistic Antiangiogenic Agents Enhances Antitumor Response in Pancreatic Cancer. Biochemistry & Pharmacology: Open Access, 2015, 04, .	0.2	0
3551	Research Gaps in Pancreatic Cancer Research and Comparative Effectiveness Research Methodologies. Cancer Treatment and Research, 2015, 164, 165-194.	0.2	0
3552	Targeted Therapies for Pancreatic Cancer. Current Clinical Pathology, 2015, , 127-135.	0.0	0
3553	Advances in Gastrointestinal Surgery. GI Surgery Annual, 2015, , 179-237.	0.0	0
3554	Pancreatic Head Cancer with Paraaortic Lymph Node Metastases Successfully Resected after Gemcitabine+S-1 Chemotherapy. Japanese Journal of Gastroenterological Surgery, 2015, 48, 698-705.	0.0	0
3556	Erlotinib for advanced pancreatic cancer. The Cochrane Library, 0, , .	1.5	0
3557	E28 Literaturhinweise und Internetadressen. , 2015, , e1-e79.		0
3558	Malignome des Gastrointestinaltrakts. , 2015, , 579-693.		0
3559	Clinical Observation of High Intensity Focused Ultrasound (HIFU) Ablation Combined with Qingyihuaji Formula for Salvage Treatment for Advanced Pancreatic Cancer Patients Failed to Systemic Chemotherapy. Asian Case Reports in Oncology, 2015, 04, 1-7.	0.0	0
3560	Advanced pancreatic cancer. , 2015, , 99-108.		0
3562	Current Treatment Options for Metastatic Pancreatic Adenocarcinoma.. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2015, 25, 263-274.	0.1	1
3563	Extended Survival after Complete Pathological Response in Metastatic Pancreatic Ductal Adenocarcinoma Following Induction Chemotherapy, Chemoradiotherapy, and a Novel Immunotherapy Agent, IMM-101. Cureus, 2015, 7, e435.	0.2	7

#	Article	IF	Citations
3564	Pathological Complete Response Induced by Preoperative Chemoradiation Therapy with Gemcitabine Plus nab-Paclitaxel in a Patient with Borderline Resectable Pancreatic Cancer. Japanese Journal of Gastroenterological Surgery, 2016, 49, 666-672.	0.0	1
3565	Combination Development. , 2016, , 151-174.		0
3566	Adjuvant Chemotherapy in Pancreatic Cancer. , 2016, , 1-34.		0
3567	A case of more than 10-year survival of locally advanced unresectable pancreatic head cancer treated with chemoradiotherapy. Suizo, 2016, 31, 841-848.	0.1	0
3568	Hyperthermia Combined with Chemotherapy: Pancreatic Cancer. , 2016, , 275-285.		0
3569	Cranial Bone Metastasis from Pancreatic Cancer Associated with Dysphagia. Japanese Journal of Gastroenterological Surgery, 2016, 49, 1023-1028.	0.0	1
3570	Role of methylphenidate in the treatment of fatigue in advanced pancreatic cancer population. Annals of Gastroenterology, 2016, 29, 536-543.	0.4	4
3571	Prognostic factors in patients with unresectable pancreatic cancer. Suizo, 2016, 31, 631-637.	0.1	3
3572	Identification and functional analysis of an EMT-accelerating factor induced in pancreatic cancer cells by an anticancer agent. Suizo, 2016, 31, 76-84.	0.1	1
3573	Observations et propositions sur le coÃ»t des nouveaux traitements et solidaritÃ© nationale. Bulletin De L'Academie Nationale De Medecine, 2016, 200, 623-637.	0.0	0
3574	A Case of Locally Advanced Pancreatic Cancer Successfully Resected after 14 Months Therapy with Gemcitabine and Meriva^{Â®}. International Journal of Pharmacology Phytochemistry and Ethnomedicine, 0, 2, 1-4.	0.0	0
3575	Therapy-Associated Myeloid Dysplasia in a Long-Surviving Patient with Pancreatic Cancer. Cureus, 2016, 8, e687.	0.2	1
3576	Radiotherapy in treatment of pancreatic adenocarcinoma. Onkologie (Czech Republic), 2016, 10, 185-188.	0.0	1
3577	Novel Therapeutic Modalities for Metastatic Pancreatic Cancer. The Korean Journal of Pancreas and Biliary Tract, 2016, 21, 185-190.	0.0	1
3578	Pankreas. , 2017, , 199-226.		0
3579	Two patients with stage IVb pancreatic ductal adenocarcinoma who underwent margin-negative resection after long-term favorable response to gemcitabine monotherapy. Suizo, 2017, 32, 78-86.	0.1	2
3580	Pancreatic Cancer: Background and Clinical Evidence. , 2017, , 73-90.		0
3581	Development of Hypoxia: Activated Cytotoxic Prodrug. , 2017, , 243-252.		0

#	Article	IF	Citations
3582	Venous Resection in Pancreatic Cancer Surgery. , 2017, , 1-26.		0
3583	Indications and Pitfalls of the Modified Distal Pancreatectomy with Celiac Axis En Bloc Resection for Pancreatic Cancer. , 2017, , 189-209.		0
3584	A Case of Local Advanced Pancreatic Body and Tail Cancer Treated with Distal Pancreatectomy Using En Bloc Celiac Axis Resection and Hepatic Artery-Jejunal Artery Bypass after Neoadjuvant Chemotherapy. Journal of the Nihon University Medical Association, 2017, 76, 83-86.	0.0	0
3585	Pancreatic Ductal Adenocarcinoma Harboring Germline BRCA 2 Mutation, A Case Report and Review of The Literature. Pancreatic Disorders & Therapy, 2017, 07, .	0.3	0
3586	A case of pathological complete response after 2nd line chemotherapy with gemcitabine and nab-paclitaxel for a pancreatic cancer with multiple liver metastases. Suizo, 2017, 32, 775-781.	0.1	1
3587	Chemotherapy in the Management of Pancreatic Cancer. , 2017, , 387-419.		0
3588	Chemotherapy for Advanced Pancreatic Cancer. , 2017, , 1-48.		0
3589	Cell Cycle Machinery and Its Alterations in Pancreatic Cancer. , 2017, , 1-31.		0
3590	Basics of Chemotherapy. , 2017, , 1-10.		0
3591	Malignome des Gastrointestinaltrakts. , 2017, , 605-724.		0
3592	Complete Response after Multidisciplinary Therapy for cStage IV Pancreatic Body Cancer with Liver Metastasis. Japanese Journal of Gastroenterological Surgery, 2017, 50, 897-904.	0.0	1
3593	Stromal Inflammation in Pancreatic Cancer: Mechanisms and Translational Applications. , 2017, , 1-28.		0
3594	Benign and Malignant Neoplasms of the Exocrine Pancreas. , 2017, , 1-27.		0
3595	è†µè‡“æ²»ç™‚ã®å‰¯ä½œç”¨ã«ã‚¯ãƒãƒ¼ã‚ºã‚¢ãƒƒãƒ—ã™ã‚‹æ¶ˆåŒ–å¨ çŠ„æ²»ç™‚ã®æ™‚ä»£ã. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese Colle	0.0	0
3597	Neoadjuvant Chemotherapy in Pancreatic Cancer. , 2017, , 1-16.		0
3599	What Advanced Practitioners Need to Know About the Diagnosis and Treatment of Patients With Pancreatic Cancer. Journal of the Advanced Practitioner in Oncology, 2017, 8, 255-260.	0.2	0
3600	The Management of Locally Advanced Nonmetastatic Pancreas Cancer. , 2018, , 183-204.		0
3601	Current and Emerging Therapies in Pancreatic Cancer. , 2018, , 119-134.		0

#	Article	IF	Citations
3602	Synthetic Lethality: Achilles Heel in Select Patient Subpopulations. , 2018, , 257-270.		0
3603	Cytotoxic Therapy in Advanced Pancreatic Cancer: Where We Are and Where We Are Headed. , 2018, , 205-217.		0
3604	Current and Emerging Therapies in Pancreatic Cancer: Do They Provide Value?. , 2018, , 361-367.		0
3605	Staging and Prognostic Implications. , 2018, , 109-118.		0
3606	Virotherapies in Pancreatic Cancer. , 2018, , 309-322.		0
3607	Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget, 2017, 8, 87163-87173.	0.8	0
3608	Incidence and Oncological Implications of Previously Undetected Tumor Multicentricity Following Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in Patients Undergoing Salvage Pancreatectomy. Anticancer Research, 2017, 37, 5269-5275.	0.5	1
3609	Enoxacin with UVA Irradiation Induces Apoptosis in the AsPC1 Human Pancreatic Cancer Cell Line Through ROS Generation. Anticancer Research, 2017, 37, 6211-6214.	0.5	9
3611	Relevance of the stroma in pancreatic ductal adenocarcinoma and its challenges for translational research. Journal of Cancer Treatment & Diagnosis, 2017, 2, 1-15.	0.9	1
3612	Long Lasting Response in Metastatic Pancreatic Exocrine Cancer: Abnormality or Diagnostic Miss? A Case Report with Brief Literature Review. Pancreatic Disorders & Therapy, 2018, 08, .	0.3	0
3613	Pancreatic ductal adenocarcinoma: Role of chemotherapy & future perspectives. Indian Journal of Medical Research, 2018, 148, 254.	0.4	2
3614	Stellenwert der systemischen Chemotherapie bei fortgeschrittener peritonealer Metastasierung. , 2018, , 245-260.		0
3615	Characterization of the Stem Cell Fraction in Pancreatobiliary Carcinomas: The Notch Signaling Pathway as a Potential Therapeutic Target. Journal of Cancer Therapy, 2018, 09, 480-502.	0.1	1
3616	Total Pancreatectomy for Recurrent Pancreatic Cancer in the Remnant Pancreas : The Advantages of Pancreatogastrostomy. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2018, 79, 25-30.	0.0	0
3617	4ï¼Žå^‡é™ä¸èƒ½è†µç™Œã«å¯¾ã™ã‚‹æ²»ç™‚æˆ¦ç•¥ã®ç¾Šã•è¤‡é¡Œ. Suizo, 2018, 33, 37-47.	0.1	0
3618	Pankreas. , 2018, , 483-529.		0
3619	Leitsymptom. , 2018, , 29-66.		0
3621	In Vitro Elucidation of Drug Combination Synergy in Treatment of Pancreatic Ductal Adenocarcinoma. Anticancer Research, 2018, 38, 1967-1977.	0.5	2

#	Article	IF	Citations
3623	Pancreatic Cancer: Feasibility and Outcome After Radiochemotherapy with High Dose External Radiotherapy for Non-resected and R1 Resected Patients. Cureus, 2018, 10, e2713.	0.2	4
3624	Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer. In Vivo, 2018, 32, 653-657.	0.6	8
3625	Dosage Adjustments for Chemotherapy and Targeted Therapies in Colorectal and Pancreatic Cancer Patients with Hepatic Impairment. Cureus, 2018, 10, e2798.	0.2	1
3627	Gemcitabineï¼‹<i>nab</i>-Paclitaxelä½µç”¨ç™‚æ³•å¾Œã«å˜ç™ºè‚ºè»¢ç§»ã•ã£ãŸå±€æ‰€é€²è¡Œå˜ç™ºè†µç™Œã		
3628	Liquid biopsy in pancreatic cancer. Gastroenterology & Hepatology (Bartlesville, Okla), 2018, 9, .	0.0	0
3630	A Review of Regional Hyperthermia for Digestive Cancers: Current Status and Future Directions. Thermal Medicine, 2018, 34, 35-44.	0.0	0
3631	Hepatopancreaticobiliary Surgery. , 2018, , .		0
3632	Nab-paclitaxel in a long-term patient with metastatic pancreatic carcinoma. Onkologie (Czech) Tj ETQq1 1 0.784314 rgBT /Overlock 1	0.0	0
3633	GERMINAL MUTATIONS IN HOMOLOGOUS RECOMBINATION GENES IN A POPULATION OF PATIENTS WITH PANCREATIC CANCER: A SINGLE CENTRE EXPERIENCE. Malignant Tumours, 2018, 8, 5-12.	0.1	0
3634	Pancreas cancer, careful improvements and human connections. Journal of Gastrointestinal Oncology, 2018, 9, 979-981.	0.6	1
3635	Digestive Organ Aging and Cancer. , 2019, , 1-22.		0
3636	Treatment of Advanced Pancreatic Carcinoma. , 2019, , 255-268.		0
3637	Treatment Sequencing for Locally Advanced Pancreatic Cancer. , 2019, , 105-112.		0
3638	Treatment Sequencing for Borderline Resectable Pancreatic Cancer. , 2019, , 55-65.		0
3639	A Case of Pancreatic Head Cancer with a Hepatic Metastasis that Showed Complete Response to Administration of Gemcitabine + Nab-Paclitaxel Therapy. Nihon Gekakei Rengo Gakkaishi (Journal of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5		0
3641	The Role of Hypoxia Inducible Factor-1Î± in Pancreatic Cancer and Diabetes Mellitus. , 2019, , 173-181.		0
3642	The effects of aranose, cisplatin or paclitaxel in monotherapy and in combination on the expression of Pdâ€“l1 and Pdâ€“l2 in melanoma cells. , 2019, 17, 71-80.	0.3	1
3643	Multidisciplinary Management of Liver, Pancreatic, and Gastric Malignancies in Older Adults. , 2019, , 1-28.		0

#	Article	IF	Citations
3644	Pancreatic Diseases: The Role of Stem Cells. Pancreatic Islet Biology, 2019, , 49-71.	0.1	0
3645	Research Progress on the Treatment of Pancreatic Cancer. Advances in Clinical Medicine, 2019, 09, 638-644.	0.0	0
3646	Stromal Barriers Within the Tumor Microenvironment and Obstacles to Nanomedicine. , 2019, , 57-89.		3
3647	Novel Strategies on the Horizon for Metastatic Pancreatic Cancer Management. Oncology & Hematology Review, 2019, 15, 27.	0.2	2
3648	Novel Targeted Treatment Approaches in Pancreatic Cancer. , 2019, , 479-491.		0
3649	è…¹è†œè»¢ç§»ã,'æœ‰ã•™ã,‹è†µå°¾éƒ¨ç™Œã«å¯¾ã•—ã¦S-1ï¼‹paclitaxelçµŒé•™è„ˆãƒ»è…¹è…”å†…æŠ•ä¸Žä½µç”¨ç™‚æ³•ã§Œã«co		
3652	Long-term survival following multidisciplinary therapy for liver metastasis from pancreatic cancer. Suizo, 2019, 34, 172-180.	0.1	0
3653	Endoscopic ultrasound and PDT for pancreatic cancer. , 2019, , .		0
3656	Short- and long-term outcomes after pancreatectomy for pancreatic ductal adenocarcinoma in octogenarians. Suizo, 2019, 34, 195-205.	0.1	0
3659	Micellar paclitaxel in the treatment of patients with tumors of the female reproductive system. Opuholi Zenskoj Reproduktivnoj Sistemy, 2019, 15, 37-43.	0.1	0
3660	Toxicity and efficacy of gemcitabine plus nab-paclitaxel (paclitaxel + albumin) in a Russian patient population: results of a multicenter retrospective study. Malignant Tumours, 2019, 9, 20-30.	0.1	0
3661	DUPLICATE: Imaging and Management of Pancreatic Cancer. Seminars in Ultrasound, CT and MRI, 2019, , .	0.7	0
3662	Factors affecting the efficacy of gemcitabine and nab-paclitaxel (paclitaxel + albumin) combination in the Russian patient population: results of a multicenter retrospective study. Meditsinskiy Sovet, 2019, , 74-82.	0.1	0
3663	Exosomal Long NonCoding Rnas as Cancer Biomarkers and Therapeutic Targets. KreativnaÃ¢ HirurgiÃ¢ I OnkologiÃ¢, 2020, 9, 297-304.	0.1	2
3664	Stories of drug repurposing for pancreatic cancer treatmentâ€"Past, present, and future. , 2020, , 231-272.		1
3665	Adenocarcinoma of the Pancreas. , 2020, , 415-435.		0
3666	A Case of Unresectable Pancreatic Cancer with UGT1A1ï¼Š6/ï¼Š28 Treated Effectively with FOLFIRINOX Therapy. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2020, 81, 755-760.	0.0	0
3667	Chemotherapy for patients with unresesctable pancreatic cancer is recommended in the Clinical Practice Guidelines for Pancreatic Cancer 2019. Suizo, 2020, 35, 69-74.	0.1	0

#	Article	IF	Citations
3668	Prognosis of distal pancreatic cancers controlled by stage. Experimental and Therapeutic Medicine, 2020, 20, 1091-1097.	0.8	8
3670	A Case Report of Partial Remission of End-stage Pancreatic Cancer Patient with Liver Metastasis Treated with Chemotherapy and Integrated Medicine Therapy. The Journal of Internal Korean Medicine, 2020, 41, 166-176.	0.0	1
3673	Outcomes of Patients With Advanced Gastrointestinal Cancer in Relationship to Opioid Use: Findings From Eight Clinical Trials. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 575-581.	2.3	9
3675	P-Glycoprotein Efflux Transporters and Its Resistance Its Inhibitors and Therapeutic Aspects. , 0, , .		2
3676	Promising Gene Therapy Using an Adenovirus Vector Carrying REIC/Dkk-3 Gene for the Treatment of Biliary Cancer. Current Gene Therapy, 2020, 20, 64-70.	0.9	11
3678	Assessment of the treatment effects of chemoradiotherapy in patients with pancreatic cancer. Suizo, 2020, 35, 280-292.	0.1	1
3679	Phase I Study of Preoperative Chemoradiotherapy Using Gemcitabine Plus Nab-Paclitaxel for Patients Who Have Localized Pancreatic Ductal Adenocarcinoma With Contact or Invasion to Major Arteries. Pancreas, 2021, 50, 1230-1235.	0.5	0
3680	Laser-cut-type versus braided-type covered self-expandable metallic stents for distal biliary obstruction caused by pancreatic carcinoma: a retrospective comparative cohort study. Clinical Endoscopy, 2022, 55, 434-442.	0.6	4
3681	Improving Palliative Care and Quality of Life in Pancreatic Cancer Patients. Journal of Palliative Medicine, 2022, 25, 720-727.	0.6	22
3683	Oncogenic KRAS-Induced Feedback Inflammatory Signaling in Pancreatic Cancer: An Overview and New Therapeutic Opportunities. Cancers, 2021, 13, 5481.	1.7	11
3684	Current status and future perspectives of robotic-assisted pancreatectomy. Suizo, 2021, 36, 293-300.	0.1	0
3685	Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer. Annals of Surgical Oncology, 2022, 29, 1579-1591.	0.7	29
3687	Successful conversion surgery of distal pancreatectomy with celiac axis resection (DP-CAR) with double arterial reconstruction using saphenous vein grafting for locally advanced pancreatic cancer: a case report. Surgical Case Reports, 2020, 6, 302.	0.2	3
3689	Systemic Inflammation Scores Predict the Activity of First-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma. Cancer Investigation, 2021, 39, 55-61.	0.6	1
3691	A phaseÂI study of preoperative (neoadjuvant) chemotherapy with gemcitabine plus nabâ€‘paclitaxel for resectable pancreatic cancer. Molecular and Clinical Oncology, 2020, 14, 26.	0.4	2
3692	Precision medicine for pancreatic cancer: real-world evidence from the Know Your Tumor programme. Digestive Medicine Research, 0, 3, 88-88.	0.2	0
3693	Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution. Current Oncology, 2021, 28, 209-219.	0.9	2
3694	Difference between carbohydrate antigen 19â€9 and fluorineâ€18 fluorodeoxyglucose positron emission tomography in evaluating the treatment efficacy of neoadjuvant treatment in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma: Results of a dualâ€center study. Annals of Gastroenterological Surgery, 2021, 5, 381-389.	1.2	7

#	Article	IF	Citations
3695	Nonsurgical Management of Pancreatic Adenocarcinoma. , 2021, , 1-22.		0
3696	Analysis of the methylation of CpG islands in the CDO1, TAC1 and CHFR genes in pancreatic ductal cancer. Oncology Letters, 2020, 19, 2197-2204.	0.8	7
3697	Digestive Organ Aging and Cancer. , 2020, , 245-267.		0
3699	ERKRANKUNGEN DER VERDAUUNGSORGANE. , 2020, , pA-1-pA7.8-14.		0
3700	In Frail Elderly Patients, Low-Dose Gemcitabine over 6-Hour Infusion Is Equally Effective and Less Toxic Than the Standard Gemcitabine Protocol for Advanced Pancreatic Adenocarcinoma: A Randomized Phase II Trial. Journal of Cancer Therapy, 2020, 11, 124-141.	0.1	2
3701	Chemotherapy: Knowing When to Start, Evaluate for Response, and Stop. The Korean Journal of Pancreas and Biliary Tract, 2020, 25, 40-45.	0.0	0
3703	Tumours of the pancreas. , 2020, , 3227-3238.		0
3704	Benign and Malignant Neoplasms of the Exocrine Pancreas. , 2020, , 875-902.		0
3705	Quality of Life During Chemotherapy in Japanese Patients with Unresectable Advanced Pancreatic Cancer. Asian Journal of Human Services, 2020, 19, 42-54.	0.2	1
3706	Treatment of Concomitant Malignant Biliary Stricture and Gastric Outlet Obstruction. , 2020, , 1-15.		0
3707	PET in Gastrointestinal, Pancreatic, and Liver Cancers. , 2020, , 597-625.		0
3708	Quadruplex nucleic acids in KRAS targeted-cancer therapy. Annual Reports in Medicinal Chemistry, 2020, 54, 325-359.	0.5	1
3709	Tumoren van lever, galwegen en pancreas. , 2020, , 345-365.		0
3710	Multidisciplinary Management of Liver, Pancreatic, and Gastric Malignancies in Older Adults. , 2020, , 731-757.		1
3711	Pancreatic cancer: Ukrainian and world tendencies. Practical Oncology, 2020, 3, 42-45.	0.1	1
3712	Taxanes â€“ The Backbone of Medical Oncology. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 221-234.	0.1	1
3713	Pancreatic cancer treatment. Suizo, 2020, 35, 193-200.	0.1	0
3714	Identification of Preoperative Risk Factors for Poor Survival in Patients with Resectable Pancreatic Cancer Treated with Upfront Surgery. Digestive Surgery, 2021, 38, 352-360.	0.6	3

#	Article	IF	Citations
3715	Nuclear Receptor 4A2 (NR4A2/NURR1) Regulates Autophagy and Chemoresistance in Pancreatic Ductal Adenocarcinoma. Cancer Research Communications, 2021, 1, 65-78.	0.7	7
3716	Emerging agents for metastatic pancreatic cancer: spotlight on early phase clinical trials. Expert Opinion on Investigational Drugs, 2021, 30, 1089-1107.	1.9	1
3717	The role of coeliac axis resection in resected ductal adenocarcinoma of the distal pancreas: A result of tumour topography or a prognostic factor?. Pancreatology, 2021, 22, 112-112.	0.5	1
3718	BDNF Acts as a Prognostic Factor Associated with Tumor-Infiltrating Th2 Cells in Pancreatic Adenocarcinoma. Disease Markers, 2021, 2021, 1-22.	0.6	6
3719	Bioinspired adhesive microneedle patch with gemcitabine encapsulation for pancreatic cancer treatment. Chemical Engineering Journal, 2022, 431, 133362.	6.6	29
3720	Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy, 2022, 22, 39-51.	1.1	0
3721	Clinical Impact of Molecular Subtyping of Pancreatic Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 743908.	1.8	29
3722	Evaluation of Early Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Receiving Gemcitabine Together With Nab-paclitaxel. Cancer Diagnosis & Prognosis, 2021, 1, 399-409.	0.3	2
3723	OXCT1 Enhances Gemcitabine Resistance Through NF-Î¹B Pathway in Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology, 2021, 11, 698302.	1.3	4
3724	Context Mattersâ€"Why We Need to Change From a One Size Fits all Approach to Made-to-Measure Therapies for Individual Patients With Pancreatic Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 760705.	1.8	3
3725	Treatment of Concomitant Malignant Biliary Stricture and Gastric Outlet Obstruction. , 2022, , 1435-1449.		0
3726	Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study. BMC Cancer, 2021, 21, 1176.	1.1	7
3728	Modulated Electro-Hyperthermic (mEHT) Treatment in the Therapy of Inoperable Pancreatic Cancer Patientsâ€"A Single-Center Case-Control Study. Diseases (Basel, Switzerland), 2021, 9, 81.	1.0	5
3729	Local Endoscopic Treatment of Locally Advanced Pancreatic Cancer. The Korean Journal of Pancreas and Biliary Tract, 2020, 25, 83-92.	0.0	0
3730	Updates of Chemotherapy and Radiotherapy for Pancreatic Cancer. The Korean Journal of Pancreas and Biliary Tract, 2020, 25, 72-82.	0.0	1
3731	Advances in the Management of Pancreatic Adenocarcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 958-961.	2.3	2
3732	Adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for resected pancreatic ductal adenocarcinoma: A single center experience in China. World Journal of Clinical Cases, 2020, 8, 2778-2786.	0.3	1
3733	BODY COMPOSITION IMPACT ON SURVIVAL AND TOXICITY OF TREATMENT IN PANCREATIC CANCER: CROSS-SECTIONAL PILOT STUDY. Arquivos De Gastroenterologia, 2020, 57, 278-282.	0.3	3

#	Article	IF	Citations
3734	Early detection and diagnosis of thrombotic microangiopathy in two patients induced by gemcitabine treatment of pancreatic cancer. Suizo, 2020, 35, 403-411.	0.1	0
3735	Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece. Journal of Oncology, 2020, 2020, 1-10.	0.6	0
3736	Combined resection of the hepatic artery without reconstruction in pancreaticoduodenectomy: a case report of pancreatic cancer with an aberrant hepatic artery. Surgical Case Reports, 2020, 6, 228.	0.2	2
3737	Immunotherapy in Pancreatic Cancer. Digestive Disease Interventions, 2020, 04, 351-357.	0.3	1
3738	Emerging Ablative and Transarterial Therapies for Pancreatic Cancer. Digestive Disease Interventions, 2020, 04, 389-394.	0.3	2
3739	Shorter Treatment-NaÃ¯ve Leukocyte Telomere Length is Associated with Poorer Overall Survival of Patients with Pancreatic Ductal Adenocarcinoma. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 210-216.	1.1	2
3740	Saudi Oncology Society clinical management guideline series. Pancreatic cancer 2014. Journal of King Abdulaziz University, Islamic Economics, 2014, 35, 1534-7.	0.5	2
3741	Clinical Management of Pancreatic Cancer. Journal of the Advanced Practitioner in Oncology, 2014, 5, 356-64.	0.2	15
3742	Novel adjuvant therapies for pancreatic adenocarcinoma. Journal of Gastrointestinal Oncology, 2015, 6, 430-5.	0.6	3
3743	The crown jewelry of the surgeries for pancreatic cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015, 27, 318-20.	0.7	0
3744	Cytoplasmic EpCAM over-expression is associated with favorable clinical outcomes in pancreatic cancer patients with Hepatitis B virus negative infection. International Journal of Clinical and Experimental Medicine, 2015, 8, 22204-16.	1.3	10
3745	Patient and caregiver awareness of pancreatic cancer treatments and clinical trials. Journal of Gastrointestinal Oncology, 2016, 7, 228-33.	0.6	5
3746	Molecular profiling of a case of advanced pancreatic cancer identifies an active and tolerable combination of targeted therapy with backbone chemotherapy. Journal of Gastrointestinal Oncology, 2016, 7, E6-E12.	0.6	1
3747	Use of molecular studies for treatment of metastatic pleomorphic large cell pancreatic cancers-a novel strategy. Journal of Gastrointestinal Oncology, 2016, 7, E17-21.	0.6	0
3748	Long non-coding RNA CCAT1 that can be activated by c-Myc promotes pancreatic cancer cell proliferation and migration. American Journal of Translational Research (discontinued), 2016, 8, 5444-5454.	0.0	39
3749	Compatibility and Stability of Nab-Paclitaxel in Combination with Other Drugs. Kobe Journal of Medical Sciences, 2017, 63, E9-E16.	0.2	0
3750	A randomised controlled trial of gemcitabine hydrochloride plus S-1 combination therapy versus gemcitabine hydrochloride therapy alone in pancreatic cancer patients aged â‰¥75 years: a study protocol for an open-label randomised feasibility study. BMJ Open Gastroenterology, 2018, 5, e000187.	1.1	2
3753	Perioperative and Survival Outcomes Following Neoadjuvant FOLFIRINOX versus Gemcitabine Abraxane in Patients with Pancreatic Adenocarcinoma. JOP: Journal of the Pancreas, 2018, 19, 75-85.	1.5	16

#	Article	IF	Citations
3754	AMPK-related kinase 5 (ARK5) enhances gemcitabine resistance in pancreatic carcinoma by inducing epithelial-mesenchymal transition. American Journal of Translational Research (discontinued), 2018, 10, 4095-4106.	0.0	10
3755	Gemcitabine enhances OSI-027 cytotoxicity by upregulation of miR-663a in pancreatic ductal adenocarcinoma cells. American Journal of Translational Research (discontinued), 2019, 11, 473-485.	0.0	4
3756	Evaluation of fatigue in patients with pancreatic cancer receiving chemotherapy treatment: a cross-sectional observational study. Acta Biomedica, 2018, 89, 18-27.	0.2	12
3757	Inhibition of invasive pancreatic cancer: restoring cell apoptosis by activating mitochondrial p53. American Journal of Cancer Research, 2019, 9, 390-405.	1.4	7
3758	Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study. Nagoya Journal of Medical Science, 2019, 81, 233-239.	0.6	3
3759	PAK inhibition by PF-3758309 enhanced the sensitivity of multiple chemotherapeutic reagents in patient-derived pancreatic cancer cell lines. American Journal of Translational Research (discontinued), 2019, 11, 3353-3364.	0.0	3
3760	USP44 suppresses pancreatic cancer progression and overcomes gemcitabine resistance by deubiquitinating FBP1. American Journal of Cancer Research, 2019, 9, 1722-1733.	1.4	12
3761	CREPT is a novel predictor of the response to adjuvant therapy or concurrent chemoradiotherapy in esophageal squamous cell carcinoma. International Journal of Clinical and Experimental Pathology, 2019, 12, 3301-3310.	0.5	2
3762	Management of Pancreatic Cancer During COVID-19 Pandemic: To Treat or Not to Treat?. JOP: Journal of the Pancreas, 2020, 21, 27-28.	1.5	6
3763	Myelodysplastic Syndrome in Patients with Gastro-Pancreatic Malignancies: A Case Series and Review of Literature. , 2021, 4, 52-59.		0
3764	New Developments in the Treatment of Pancreatic Cancer: Highlights from the 44th ASCO Annual Virtual Meeting, May 29-31, 2020. JOP: Journal of the Pancreas, 2020, 21, 108-111.	1.5	1
3765	A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer. American Journal of Cancer Research, 2020, 10, 3047-3060.	1.4	3
3766	A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer. Medical Science Monitor, 2020, 26, e927654.	0.5	1
3767	Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells. American Journal of Cancer Research, 2021, 11, 236-250.	1.4	2
3768	G2M checkpoint pathway alone is associated with drug response and survival among cell proliferation-related pathways in pancreatic cancer. American Journal of Cancer Research, 2021, 11, 3070-3084.	1.4	3
3769	Prognostic stratification based on a novel nomogram for left-sided pancreatic adenocarcinoma after surgical resection: a multi-center study. American Journal of Cancer Research, 2021, 11, 2754-2768.	1.4	0
3770	OX40 agonist combined with irreversible electroporation synergistically eradicates established tumors and drives systemic antitumor immune response in a syngeneic pancreatic cancer model. American Journal of Cancer Research, 2021, 11, 2782-2801.	1.4	0
3771	Doxycycline potentiates the anti-proliferation effects of gemcitabine in pancreatic cancer cells. American Journal of Cancer Research, 2021, 11, 3515-3536.	1.4	1

#	Article	IF	Citations
3772	From Screening to Treatment of Pancreatic Cancer: A Comprehensive Review. JOP: Journal of the Pancreas, 2021, 22, 70-79.	1.5	0
3773	Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patientsâ€™ experience within a population-based study. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110582.	1.4	5
3774	Pankreaskarzinom und zystische Neoplasien im Pankreas. , 2022, , 273-282.		0
3775	Nanocarriers targeting the diseases of the pancreas. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 170, 10-23.	2.0	10
3776	Tumor treating fields: An emerging treatment modality for thoracic and abdominal cavity cancers. Translational Oncology, 2022, 15, 101296.	1.7	7
3777	Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan. Value in Health Regional Issues, 2022, 28, 54-60.	0.5	1
3778	Metastatic pancreatic adenocarcinoma treated with liposomal irinotecan in combination with 5-fluorouracil and leucovorin as a II line chemotherapy. OnCOReview, 2021, 11, 44-47.	0.1	1
3779	Application of two lines of chemotherapy: gemcitabine with nab-paclitaxel and liposomal irinotecan with 5-fluorouracil and leucovorin in patient with advanced pancreatic adenocarcinoma. OnCOReview, 2021, 11, 68-72.	0.1	1
3780	Borderline Resectable and Locally Advanced Pancreatic Cancers. Pancreas, 2021, 50, 1243-1249.	0.5	3
3781	A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems. Surgery, 2022, 172, 257-264.	1.0	9
3782	Insights into the role of gut and intratumor microbiota in pancreatic ductal adenocarcinoma as new key players in preventive, diagnostic and therapeutic perspective. Seminars in Cancer Biology, 2022, 86, 997-1007.	4.3	8
3783	Anti-Cancer Activity Profiling of Chemotherapeutic Agents in 3D Co-Cultures of Pancreatic Tumor Spheroids with Cancer-Associated Fibroblasts and Macrophages. Cancers, 2021, 13, 5955.	1.7	12
3784	Validation of SFRP1 Promoter Hypermethylation in Plasma as a Prognostic Marker for Survival and Gemcitabine Effectiveness in Patients with Stage IV Pancreatic Adenocarcinoma. Cancers, 2021, 13, 5717.	1.7	9
3785	Intravenous Administration of Dehydroxymethylepoxyquinomicin With Polymer Enhances the Inhibition of Pancreatic Carcinoma Growth in Mice. Anticancer Research, 2021, 41, 6003-6012.	0.5	2
3786	Realâ€world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma. Cancer Medicine, 2021, 10, 8934-8943.	1.3	5
3787	The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer. JAMA Network Open, 2021, 4, e2133388.	2.8	3
3788	Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials. British Journal of Cancer, 2022, 126, 440-448.	2.9	15
3789	ATG4B Inhibitor UAMC-2526 Potentiates the Chemotherapeutic Effect of Gemcitabine in a Panc02 Mouse Model of Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology, 2021, 11, 750259.	1.3	5

#	Article	IF	Citations
3790	Microbiomeâ€"Friend or Foe of Pancreatic Cancer?. Journal of Clinical Medicine, 2021, 10, 5624.	1.0	3
3791	CD109 expression in tumor cells and stroma correlates with progression and prognosis in pancreatic cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 819-829.	1.4	1
3792	Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC). BMC Cancer, 2021, 21, 1239.	1.1	16
3793	Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience. Journal of the Chinese Medical Association, 2022, 85, 42-50.	0.6	6
3794	Advanced Nanoengineering Approach for Targetâ€Specific, Spatiotemporal, and Ratiometric Delivery of Gemcitabineâ€"Cisplatin Combination for Improved Therapeutic Outcome in Pancreatic Cancer. Small, 2022, 18, e2104449.	5.2	18
3795	Recent advances in artificial intelligence for pancreatic ductal adenocarcinoma. World Journal of Gastroenterology, 2021, 27, 7480-7496.	1.4	13
3796	Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Nature Communications, 2021, 12, 6738.	5.8	10
3798	Optimizing Chemotherapy Choice in the Treatment of Advanced Pancreatic Cancerâ€"It Is Complicated. JAMA Network Open, 2021, 4, e2134458.	2.8	4
3799	Dendronization: A practical strategy to improve the performance of molecular systems used in biomedical applications. European Journal of Medicinal Chemistry, 2022, 229, 113988.	2.6	2
3800	The association between quality care and outcomes for a real-world population of Australian patients diagnosed with pancreatic cancer. Hpb, 2022, 24, 950-962.	0.1	3
3801	Apoptosis-associated speck-like protein containing a CARD regulates the growth of pancreatic ductal adenocarcinoma. Scientific Reports, 2021, 11, 22351.	1.6	6
3802	Pancreatic cancer with synchronous liver and colon metastases: A case report. World Journal of Clinical Cases, 2021, 9, 10265-10272.	0.3	0
3803	ROR1 and ROR2 expression in pancreatic cancer. BMC Cancer, 2021, 21, 1199.	1.1	4
3805	Loss of adipose tissue or skeletal muscle during firstâ€line gemcitabine/nabâ€paclitaxel therapy is associated with worse survival after secondâ€line therapy of advanced pancreatic cancer. Asia-Pacific Journal of Clinical Oncology, 2022, 18, .	0.7	5
3806	5-epi-Sinuleptolide from Soft Corals of the Genus Sinularia Exerts Cytotoxic Effects on Pancreatic Cancer Cell Lines via the Inhibition of JAK2/STAT3, AKT, and ERK Activity. Molecules, 2021, 26, 6932.	1.7	7
3807	IMB5036 inhibits human pancreatic cancer growth primarily through activating necroptosis. Basic and Clinical Pharmacology and Toxicology, 2022, 130, 375-384.	1.2	8
3808	A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact. European Journal of Cancer, 2021, 159, 215-223.	1.3	17
3809	Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial. ESMO Open, 2021, 6, 100318.	2.0	9

#	Article	IF	Citations
3810	Surgical approach to pancreaticoduodenectomy for pancreatic adenocarcinoma: uncomplicated ends justify the means. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 4912-4922.	1.3	6
3811	Assessment of Response to Chemotherapy in Pancreatic Cancer with Liver Metastasis: CT Texture as a Predictive Biomarker. Diagnostics, 2021, 11, 2252.	1.3	1
3812	MWCNT modified glassy carbon electrode in presence of cationic surfactant for the electro-analysis of paclitaxel. Results in Chemistry, 2021, 3, 100243.	0.9	5
3814	Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110561.	1.4	7
3815	The effect of the low stromal ratio induced by neoadjuvant chemotherapy on recurrence patterns in borderline resectable pancreatic ductal adenocarcinoma. Clinical and Experimental Metastasis, 2022, 39, 311-322.	1.7	5
3816	Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies. Theranostics, 2022, 12, 1030-1060.	4.6	49
3817	SOX8 Affects Tumoral SPARC Expression by Regulating EZH2 to Attenuate Effectiveness of albumin-bound paclitaxel in PDAC. International Journal of Biological Sciences, 2022, 18, 911-922.	2.6	2
3818	The impact of nutritional status on pancreatic cancer therapy. Expert Review of Anticancer Therapy, 2022, 22, 155-167.	1.1	8
3819	Selenium Induces Pancreatic Cancer Cell Death Alone and in Combination with Gemcitabine. Biomedicines, 2022, 10, 149.	1.4	5
3820	Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal Imaging. Analytical Chemistry, 2022, 94, 1795-1803.	3.2	20
3821	Phospho-Aspirin (MDC-22) inhibits pancreatic cancer growth in patient-derived tumor xenografts and KPC mice by targeting EGFR: Enhanced efficacy in combination with irinotecan. Neoplasia, 2022, 24, 133-144.	2.3	3
3822	Hydroxyapatite-binding albumin nanoclusters for enhancing bone tumor chemotherapy. Journal of Controlled Release, 2022, 342, 111-121.	4.8	15
3824	A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer. Medical Science Monitor, 2020, 26, e927654.	0.5	7
3825	Protective Desmoplasia in Pancreatic Adenocarcinoma: High Vitamin D Receptor Expression and Collagen Content. Anticancer Research, 2020, 40, 6457-6464.	0.5	2
3826	High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancer. International Journal of Oncology, 2020, 58, 57-69.	1.4	3
3827	An Observational Study of Exploratory Using Anti-PD-1 Antibody in the Treatment of Advanced Pancreatic Cancer. Advances in Clinical Medicine, 2021, 11, 6097-6105.	0.0	0
3828	Perspective on the Immunotherapy of Pancreatic Cancer. , 2021, , 257-270.		0
3829	Surgery After Response to Chemotherapy for Locally Advanced Pancreatic Ductal Adenocarcinoma: A Guide for Management. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 459-467.	2.3	5

#	Article	IF	Citations
3830	Prolongation of survival time and improvement of the quality of life after treatment with irinotecan liposomal in the patient with metastatic pancreatic adenocarcinoma. OnCOReview, 2021, 11, 77-79.	0.1	1
3831	PARP Inhibitors in Pancreatic Cancer. Cancer Journal (Sudbury, Mass), 2021, 27, 465-475.	1.0	18
3832	Nanomedicine in Pancreatic Cancer: Current Status and Future Opportunities for Overcoming Therapy Resistance. Cancers, 2021, 13, 6175.	1.7	20
3833	MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC). Radiation Oncology, 2022, 17, 18.	1.2	10
3834	Republication: A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate-Activated Killer (ZAK) Cells â€“ An Analysis for Patients With Incurable Pancreatic Cancer. Anticancer Research, 2022, 42, 1181-1187.	0.5	1
3835	A case of pathologically complete response after preoperative chemotherapy in a pancreatic acinar cell carcinoma patient with portal vein tumor thrombosis. Clinical Journal of Gastroenterology, 2022, , 1.	0.4	3
3836	Molecular Features and Clinical Management of Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer. International Journal of Molecular Sciences, 2022, 23, 1205.	1.8	13
3837	Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nabâ€“paclitaxel or FOLFIRINOX: A postâ€“hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study). BMC Cancer, 2022, 22, 19.	1.1	7
3838	Neglected geriatric assessment and overtreatment of older patients with pancreatic cancer - Results from a prospective phase IV clinical trial. Journal of Geriatric Oncology, 2022, 13, 662-666.	0.5	3
3839	Vemurafenib Combined With Trametinib Significantly Benefits the Survival of a Patient With Stage IV Pancreatic Ductal Adenocarcinoma With BRAF V600E Mutation: A Case Report. Frontiers in Oncology, 2021, 11, 801320.	1.3	5
3840	Kras Gene Analysis Using Liquid-Based Cytology Specimens Predicts Therapeutic Responses and Prognosis in Patients with Pancreatic Cancer. Cancers, 2022, 14, 551.	1.7	6
3841	Gene Therapy Using Nanocarriers for Pancreatic Ductal Adenocarcinoma: Applications and Challenges in Cancer Therapeutics. Pharmaceutics, 2022, 14, 137.	2.0	4
3842	FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer. Journal of Chemotherapy, 2022, 34, 465-471.	0.7	5
3843	Comparison of outcomes between secondary fully covered and uncovered self-expandable metal stents in the treatment of recurrent biliary obstruction of pancreatic cancer. Surgical Endoscopy and Other Interventional Techniques, 2022, , 1.	1.3	0
3844	Prognosis and survival analysis of patients with pancreatic cancer: retrospective experience of a single institution. World Journal of Surgical Oncology, 2022, 20, 11.	0.8	22
3845	Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. British Journal of Cancer, 2022, 126, 1394-1400.	2.9	5
3846	Arterial Administration of DNA Crosslinking Agents with Restraint of Homologous Recombination Repair by Intravenous Low-Dose Gemcitabine Is Effective for Locally Advanced Pancreatic Cancer. Cancers, 2022, 14, 220.	1.7	1
3847	Novel Use of Hypoxia-Inducible Polymerizable Protein to Augment Chemotherapy for Pancreatic Cancer. Pharmaceutics, 2022, 14, 128.	2.0	1

#	Article	IF	Citations
3848	Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan. JAMA Network Open, 2022, 5, e2145515.	2.8	6
3849	Macrophage C/EBPÎ´ Drives Gemcitabine, but Not 5-FU or Paclitaxel, Resistance of Pancreatic Cancer Cells in a Deoxycytidine-Dependent Manner. Biomedicines, 2022, 10, 219.	1.4	4
3850	Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer. Diagnostics, 2022, 12, 286.	1.3	20
3851	Evolving pancreatic cancer treatment: From diagnosis to healthcare management. Critical Reviews in Oncology/Hematology, 2022, 169, 103571.	2.0	17
3852	A non-surgical COMBO-therapy approach for locally advanced unresectable pancreatic adenocarcinoma: preliminary results of a prospective study. Radiologia Medica, 2022, 127, 214-219.	4.7	18
3853	circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis. Molecular Cancer, 2022, 21, 24.	7.9	60
3854	Optimizing Patient Selection for Irreversible Electroporation of Locally Advanced Pancreatic Cancer: Analyses of Survival. Frontiers in Oncology, 2021, 11, 817220.	1.3	7
3855	A Review of Potential Role of Capsule Endoscopy in the Work-Up for Chemotherapy-Induced Diarrhea. Healthcare (Switzerland), 2022, 10, 218.	1.0	1
3856	Pancreatic cancer treatment after FOLFIRINOX: prognostic importance of chemotherapy dose intensity and albumin/globulin ratio in second line. Journal of Health Sciences and Medicine, 2022, 5, 156-160.	0.0	0
3857	Moving towards dawn: KRas signaling and treatment in pancreatic ductal adenocarcinoma. Current Molecular Pharmacology, 2022, 15, .	0.7	0
3858	Endoscopic ultrasoundâ€guided hepaticogastrostomy versus hepaticogastrostomy with antegrade stenting for malignant distal biliary obstruction. Journal of Hepato-Biliary-Pancreatic Sciences, 2022, 29, 703-712.	1.4	12
3859	Exploring the Clinical Utility of Pancreatic Cancer Circulating Tumor Cells. International Journal of Molecular Sciences, 2022, 23, 1671.	1.8	18
3860	Evaluation of risk factors associated with carboplatin and nab-paclitaxel treatment suspension in patients with non-small cell lung cancer. Supportive Care in Cancer, 2022, 30, 4081.	1.0	2
3861	The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy. Cancers, 2022, 14, 217.	1.7	24
3862	Synopsis of a clinical practice guideline for pancreatic ductal adenocarcinoma with peritoneal dissemination in Japan; Japan Peritoneal Malignancy Study Group. Journal of Hepato-Biliary-Pancreatic Sciences, 2022, 29, 600-608.	1.4	8
3863	FXYD3 promotes the proliferation, migration, and invasion of pancreatic cancer cells by regulating the cGMP-PKG signaling pathway. Molecular and Cellular Toxicology, 2022, 18, 371-381.	0.8	2
3864	Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling. Visceral Medicine, 2022, 38, 20-29.	0.5	7
3865	Clinical outcomes of EUS-guided radiofrequency ablation for unresectable pancreatic cancer: A prospective observational study. Endoscopic Ultrasound, 2022, 11, 68.	0.6	16

#	Article	IF	Citations
3866	Pancreatic Cancer Organoids in the Field of Precision Medicine: A Review of Literature and Experience on Drug Sensitivity Testing with Multiple Readouts and Synergy Scoring. Cancers, 2022, 14, 525.	1.7	7
3867	Prognostic models to predict survival in patients with pancreatic cancer: a systematic review. Hpb, 2022, , .	0.1	1
3868	Identification and Validation of Constructing the Prognostic Model With Four DNA Methylation-Driven Genes in Pancreatic Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 709669.	1.8	3
3869	Latest Advances in the Use of Therapeutic Focused Ultrasound in the Treatment of Pancreatic Cancer. Cancers, 2022, 14, 638.	1.7	16
3870	Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 37-44.	2.3	7
3871	Pevonedistat Suppresses Pancreatic Cancer Growth via Inactivation of the Neddylation Pathway. Frontiers in Oncology, 2022, 12, 822039.	1.3	4
3872	PTPN2, A Key Predictor of Prognosis for Pancreatic Adenocarcinoma, Significantly Regulates Cell Cycles, Apoptosis, and Metastasis. Frontiers in Immunology, 2022, 13, 805311.	2.2	8
3873	Risk factors for interstitial lung disease induced by gemcitabine plus albumin-bound paclitaxel therapy in pancreatic ductal adenocarcinoma patients. Journal of Pharmaceutical Health Care and Sciences, 2022, 8, 5.	0.4	2
3875	Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: An analysis of the National Cancer Database. Surgery, 2022, 171, 1464-1470.	1.0	15
3876	Impact of Controlling nutritional status (CONUT) in patients with unresectable advanced pancreatic cancer receiving multi-agent chemotherapy: A single center, retrospective cohort study. Pancreatology, 2022, 22, 304-310.	0.5	3
3877	Chemotherapy in pancreatic ductal adenocarcinoma: When cytoreduction is the aim. A systematic review and meta-analysis. Cancer Treatment Reviews, 2022, 104, 102338.	3.4	4
3878	PET imaging and treatment of pancreatic cancer peritoneal carcinomatosis after subcutaneous intratumoral administration of a novel oncolytic virus, CF33-hNIS-antiPDL1. Molecular Therapy - Oncolytics, 2022, 24, 331-339.	2.0	6
3879	Desolvation-induced formation of recombinant camel serum albumin-based nanocomposite for glutathione colorimetric determination. Sensors and Actuators B: Chemical, 2022, 357, 131417.	4.0	6
3880	Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients. Cancer Treatment Reviews, 2022, 104, 102357.	3.4	4
3881	Pancreatic Ductal Adenocarcinoma: New Insights into the Actions of Vitamin A. Oncology Research and Treatment, 2022, 45, 291-298.	0.8	7
3882	Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity. Annals of Surgical Oncology, 2022, 29, 2456-2468.	0.7	12
3883	Novel systemic treatment approaches for metastatic pancreatic cancer. Expert Opinion on Investigational Drugs, 2022, 31, 249-262.	1.9	12
3884	Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas. Frontiers in Oncology, 2022, 12, 815900.	1.3	18

#	Article	IF	Citations
3885	The Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: A Retrospective Monocentric Study. Cancer Management and Research, 2022, Volume 14, 535-546.	0.9	5
3886	A DNA-Methylation-Driven Genes Based Prognostic Signature Reveals Immune Microenvironment in Pancreatic Cancer. Frontiers in Immunology, 2022, 13, 803962.	2.2	13
3887	Collagen Biomarkers Quantify Fibroblast Activity In Vitro and Predict Survival in Patients with Pancreatic Ductal Adenocarcinoma. Cancers, 2022, 14, 819.	1.7	17
3888	Systemic Therapy for Resected Pancreatic Adenocarcinoma: How Much is Enough?. Annals of Surgical Oncology, 2022, 29, 3463-3472.	0.7	3
3889	Ketogenic diet and chemotherapy combine to disrupt pancreatic cancer metabolism and growth. Med, 2022, 3, 119-136.e8.	2.2	31
3890	Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study). Trials, 2022, 23, 119.	0.7	6
3891	Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy. Journal of Experimental and Clinical Cancer Research, 2022, 41, 56.	3.5	20
3892	Mesoporous Silica Nanoparticle-Based Drug Delivery Systems for the Treatment of Pancreatic Cancer: A Systematic Literature Overview. Pharmaceutics, 2022, 14, 390.	2.0	11
3893	BRCA1 and RAD51C promotor methylation in human resectable pancreatic adenocarcinoma. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101880.	0.7	1
3894	Comparing jurisdiction-specific pharmaco-economic evaluations using medical purchasing power parities. Journal of Medical Economics, 2021, 24, 34-41.	1.0	6
3895	Current update of treatment strategies for borderline resectable pancreatic cancer: a narrative review. Journal of Gastrointestinal Oncology, 2021, 13, 0-0.	0.6	0
3897	Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer. Fukushima Journal of Medical Sciences, 2022, 68, 1-10.	0.1	2
3898	Multiple Gastric Metastases after Distal Pancreatectomy for Pancreatic Cancer. Internal Medicine, 2022, 61, 2741-2746.	0.3	2
3899	Pankreas. , 2022, , 421-448.		0
3901	Neurological complications of GI cancers. , 2022, , 365-386.		0
3902	Optimal Relative Dose Intensity in the First 4 Weeks During Nab-Paclitaxel Plus Gemcitabine for Older Patients With Advanced Pancreatic Cancer in Japan. Pancreas, 2022, 51, e4-e6.	0.5	2
3903	Stroma-Targeted Nanoparticles Remodel Stromal Alignment to Enhance Drug Delivery and Improve Anti-Tumor Efficacy of Nab-Paclitaxel in Pancreatic Ductal Adenocarcinoma. SSRN Electronic Journal, 0, , .	0.4	0
3904	Targeting Myeloid Suppressive Cells Revives Cytotoxic Anti-Tumor Responses in Pancreatic Cancer. SSRN Electronic Journal, 0, , .	0.4	0

#	Article	IF	Citations
3905	A New Era: Tumor Microenvironment in Chemoresistance of Pancreatic Cancer. Journal of Cancer Science and Clinical Therapeutics, 2022, 06, 61-86.	0.2	3
3906	Integrative analysis of metabolome and gut microbiota in Patients with pancreatic ductal adenocarcinoma. Journal of Cancer, 2022, 13, 1555-1564.	1.2	9
3907	Circulating tumour DNA: a challenging innovation to develop â€œprecision onco-surgeryâ€•in pancreatic adenocarcinoma. British Journal of Cancer, 2022, 126, 1676-1683.	2.9	8
3908	Overall Survival and Prognostic Factors among Older Patients with Metastatic Pancreatic Cancer: A Retrospective Analysis Using a Hospital Database. Cancers, 2022, 14, 1105.	1.7	2
3909	The potential feasibility of nab-paclitaxel as the first-line chemotherapy for ovarian cancer: clinical development and future perspectives. Archives of Gynecology and Obstetrics, 2022, 306, 1417-1429.	0.8	3
3910	Clinical Efficacy and Safety of Traditional Medicine Preparations Combined With Chemotherapy for Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2022, 12, 828450.	1.3	3
3911	Synergistic effect of Abraxane that combines human IL15 fused with an albuminâ€bbinding domain on murine models of pancreatic ductal adenocarcinoma. Journal of Cellular and Molecular Medicine, 2022, 26, 1955-1968.	1.6	4
3912	SOX9 Triggers Different Epithelial to Mesenchymal Transition States to Promote Pancreatic Cancer Progression. Cancers, 2022, 14, 916.	1.7	6
3913	Naturally occurring, natural product inspired and synthetic heterocyclic anti-cancer drugs. ChemistrySelect, 2022, .	0.7	3
3914	Survival and Robotic Approach for Pancreaticoduodenectomy: A Propensity Score-Match Study. Journal of the American College of Surgeons, 2022, 234, 677-684.	0.2	9
3915	Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. European Journal of Surgical Oncology, 2022, 48, 1198-1208.	0.5	3
3916	A Review on the Efficacy and Safety of Nab-Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer. Life, 2022, 12, 327.	1.1	4
3917	Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment. Cancers, 2022, 14, 985.	1.7	25
3918	Stereotactic Body Radiation Therapy versus Concurrent Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis. Cancers, 2022, 14, 1166.	1.7	3
3919	Modulation of Type I Interferon Responses to Influence Tumor-Immune Cross Talk in PDAC. Frontiers in Cell and Developmental Biology, 2022, 10, 816517.	1.8	4
3920	Mitochondrial-Associated Protein LRPPRC is Related With Poor Prognosis Potentially and Exerts as an Oncogene Via Maintaining Mitochondrial Function in Pancreatic Cancer. Frontiers in Genetics, 2021, 12, 817672.	1.1	10
3921	Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report. Frontiers in Immunology, 2022, 13, 799026.	2.2	4
3922	The clinical benefits of performing staging laparoscopy for pancreatic cancer treatment. Pancreatology, 2022, 22, 636-643.	0.5	3

#	Article	IF	Citations
3923	Experimental and Computational Investigation on the Interaction of Anticancer Drug Gemcitabine with Human Plasma Protein: Effect of Copresence of Ibuprofen on the Binding. Molecules, 2022, 27, 1635.	1.7	7
3924	Systemic therapy in pancreatic ductal adenocarcinomas (PDACs)â€"basis and current status. Ecancermedicalscience, 0, 16, .	0.6	0
3925	Long-term survival after distal pancreatectomy with celiac axis resection and hepatic artery reconstruction in the setting of locally advanced unresectable pancreatic cancer. Clinical Journal of Gastroenterology, 2022, 15, 635-641.	0.4	3
3926	Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01). Annals of Surgery, 2022, 275, 1043-1049.	2.1	47
3928	Multifunctional Lipid Bilayer Nanocarriers for Cancer Immunotherapy in Heterogeneous Tumor Microenvironments, Combining Immunogenic Cell Death Stimuli with Immune Modulatory Drugs. ACS Nano, 2022, 16, 5184-5232.	7.3	32
3929	Multidisciplinary treatment of pancreatic cancer: a case report. Gland Surgery, 2022, 11, 628-636.	0.5	0
3930	Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors. , 2022, 10, e003982.		25
3931	Nomogram Predicts Risk and Prognostic Factors for Bone Metastasis of Pancreatic Cancer: A Population-Based Analysis. Frontiers in Endocrinology, 2021, 12, 752176.	1.5	39
3932	Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort. Annals of Translational Medicine, 2022, 10, 294-294.	0.7	5
3933	Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study. Annals of Surgical Oncology, 2022, 29, 5038-5050.	0.7	16
3934	Prediction of local tumor control and recurrenceâ€free survival in patients with pancreatic cancer undergoing curative resection after neoadjuvant chemoradiotherapy. Journal of Surgical Oncology, 2022, 126, 292-301.	0.8	5
3935	A Patient With Stage III Locally Advanced Pancreatic Adenocarcinoma Treated With Intra-Arterial Infusion FOLFIRINOX: Impressive Tumoral Response and Death due to Legionella pneumophila Infection: A Unique Case Report. Frontiers in Oncology, 2022, 12, 877334.	1.3	2
3936	Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel. PLoS ONE, 2022, 17, e0264653.	1.1	5
3937	Management and Outcomes of Pancreatic Cancer in French Real-World Clinical Practice. Cancers, 2022, 14, 1675.	1.7	3
3938	Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. EBioMedicine, 2022, 77, 103897.	2.7	29
3939	Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit. Cancers, 2022, 14, 1354.	1.7	6
3940	CK1 Is a Druggable Regulator of Microtubule Dynamics and Microtubule-Associated Processes. Cancers, 2022, 14, 1345.	1.7	7
3941	Increased clostridium difficile infection in the era of preoperative chemotherapy for pancreatic cancer. Pancreatology, 2022, 22, 258-263.	0.5	1

#	Article	IF	Citations
3942	Impact of sarcopenia on prediction of progression-free survival and overall survival of patients with pancreatic ductal adenocarcinoma receiving first-line gemcitabine and nab-paclitaxel chemotherapy. Pancreatology, 2022, 22, 277-285.	0.5	15
3943	Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic Cancer. Frontiers in Oncology, 2022, 12, 782730.	1.3	4
3944	Translational advances in pancreatic ductal adenocarcinoma therapy. Nature Cancer, 2022, 3, 272-286.	5.7	90
3945	Liposome Nanoparticles as a Novel Drug Delivery System for Therapeutic and Diagnostic Applications. Current Drug Delivery, 2023, 20, 41-56.	0.8	3
3946	GPC1-Targeted Immunotoxins Inhibit Pancreatic Tumor Growth in Mice via Depletion of Short-lived GPC1 and Downregulation of Wnt Signaling. Molecular Cancer Therapeutics, 2022, 21, 960-973.	1.9	4
3947	Subtypes in pancreatic ductal adenocarcinoma based on niche factor dependency show distinct drug treatment responses. Journal of Experimental and Clinical Cancer Research, 2022, 41, 89.	3.5	13
3948	The Role of PDGFRA in Predicting Oncological and Immune Characteristics in Pancreatic Ductal Adenocarcinoma. Journal of Oncology, 2022, 2022, 1-16.	0.6	0
3949	Is There a Benefit to Adjuvant Chemotherapy in Resected, Early Stage Pancreatic Ductal Adenocarcinoma?. Annals of Surgical Oncology, 2022, 29, 4610-4619.	0.7	6
3950	Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial. Practical Radiation Oncology, 2022, 12, 511-523.	1.1	5
3951	Actively targeted delivery of SN38 by ultrafine iron oxide nanoparticle for treating pancreatic cancer. Investigational New Drugs, 2022, 40, 546-555.	1.2	5
3952	Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma. Oncologist, 2022, , .	1.9	2
3953	Interstitial Lung Disease Associated with <i>Agaricus blazei</i> Murill in a Patient with Pancreatic Ductal Adenocarcinoma Receiving Gemcitabine-Based Therapy. Case Reports in Gastroenterology, 2022, 16, 229-234.	0.3	1
3954	Machine-Learning-Based Bibliometric Analysis of Pancreatic Cancer Research Over the Past 25 Years. Frontiers in Oncology, 2022, 12, 832385.	1.3	10
3955	Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors. , 2022, 10, e003255.		26
3956	The identification of the anthracycline aclarubicin as an effective cytotoxic agent for pancreatic cancer. Anti-Cancer Drugs, 2022, 33, 614-621.	0.7	2
3957	Penetrating Micelle for Reversing Immunosuppression and Drug Resistance in Pancreatic Cancer Treatment. Small, 2022, 18, e2107712.	5.2	9
3958	Clinical Characteristics and Risk Factors of Lung Injury Induced by Nab-Paclitaxel. Drug Design, Development and Therapy, 2022, Volume 16, 759-767.	2.0	5
3959	High-Dose Planned Adaptive Intensity-Modulated Radiation Therapy with Simultaneous Integrated Boost for Synchronous Oligometastatic Pancreatic Cancer. Cancer Investigation, 2022, , 1-5.	0.6	0

#	Article	IF	Citations
3960	Pancreatic cancer and oligonucleotide therapy: Exploring novel therapeutic options and targeting chemoresistance. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101911.	0.7	5
3961	Natural Compounds Targeting Cancer-Associated Fibroblasts against Digestive System Tumor Progression: Therapeutic Insights. Biomedicines, 2022, 10, 713.	1.4	13
3962	Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5â€fluorouracil and leucovorin. Journal of Hepato-Biliary-Pancreatic Sciences, 2022, 29, 670-681.	1.4	4
3963	Recent advances in targeted drug delivery for the treatment of pancreatic ductal adenocarcinoma. Expert Opinion on Drug Delivery, 2022, 19, 281-301.	2.4	1
3964	Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Nonâ€“squamous Nonâ€“small Cell Lung Cancer After Progression on Platinum and Pemetrexed. Clinical Lung Cancer, 2022, 23, e310-e316.	1.1	1
3965	Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response. Clinical Cancer Research, 2022, 28, 3296-3307.	3.2	27
3966	Contrast-enhanced harmonic endoscopic ultrasonography for predicting the efficacy of first-line gemcitabine and nab-paclitaxel chemotherapy in pancreatic cancer. Pancreatology, 2022, 22, 525-533.	0.5	6
3967	Endoscopic ultrasound guided interventions in the management of pancreatic cancer. World Journal of Gastrointestinal Endoscopy, 2022, 14, 191-204.	0.4	1
3969	Early-onset pancreatic cancer: Clinical characteristics and survival outcomes. Pancreatology, 2022, 22, 507-515.	0.5	12
3970	Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy. Acta OncolÃ³gica, 2022, 61, 583-590.	0.8	4
3971	Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment. Journal of Pathology, 2022, 257, 607-619.	2.1	13
3972	Advanced iron oxide nanotheranostics for multimodal and precision treatment of pancreatic ductal adenocarcinoma. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2022, 14, e1793.	3.3	3
3973	Deubiquitinase ubiquitinâ€specific peptidase 10 maintains cysteine rich angiogenic inducer 61 expression via Yes1 associated transcriptional regulator to augment immune escape and metastasis of pancreatic adenocarcinoma. Cancer Science, 2022, 113, 1868-1879.	1.7	11
3974	Minnelide synergizes with conventional chemotherapy by targeting both cancer and associated stroma components in pancreatic cancer. Cancer Letters, 2022, 537, 215591.	3.2	7
3975	Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy. EBioMedicine, 2022, 78, 103958.	2.7	15
3976	Surgical management of pancreatic cancer liver oligometastases. Critical Reviews in Oncology/Hematology, 2022, 173, 103654.	2.0	3
3977	Hyperbaric oxygen regulates tumor mechanics and augments Abraxane and gemcitabine antitumor effects against pancreatic ductal adenocarcinoma by inhibiting cancer-associated fibroblasts. Nano Today, 2022, 44, 101458.	6.2	22
3978	ONIVYDE - New treatment option for better survival in patients with metastatic pancreatic adenocarcinoma. Onkologie (Czech Republic), 2021, 15, 182-186.	0.0	0

#	Article	IF	Citations
3979	Complete remission and long-term response to gemcitabine + nab-paclitaxel in patient with metastatic pancreatic adenocarcinoma. Onkologie (Czech Republic), 2021, 15, 252-254.	0.0	0
3980	Targeted FGFR/VEGFR/PDGFR inhibition with dovitinib enhances the effects of nab-paclitaxel in preclinical gastric cancer models. Cancer Biology and Therapy, 2021, 22, 619-629.	1.5	7
3981	Inclusion of cancer-associated fibroblasts in drug screening assays to evaluate pancreatic cancer resistance to therapeutic drugs. Journal of Physiology and Biochemistry, 2021, , 1.	1.3	3
3982	Realâ€world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma. International Journal of Cancer, 2022, 150, 1654-1663.	2.3	11
3983	Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. Nature Communications, 2021, 12, 7041.	5.8	43
3984	Consistent Response on Challenge and Rechallenge of Liposomal Irinotecan in a Patient with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine plus Nab-Paclitaxel: A Case Report. Case Reports in Oncology, 2022, 14, 1882-1888.	0.3	0
3985	Regional and age differences in specialised palliative care for patients with pancreatic cancer. BMC Palliative Care, 2021, 20, 192.	0.8	6
3986	A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study. British Journal of Cancer, 2022, 126, 1018-1026.	2.9	11
3988	Surgical resection is associated with improved long-term survival of patients with resectable pancreatic head cancer compared to multiagent chemotherapy. Hpb, 2022, 24, 1153-1161.	0.1	2
3989	Is FOLFIRINOX Better In Primary Resected Metastatic Pancreatic Cancer ?. Celal Bayar Ãœniversitesi SaÄŸlÄ±k Bilimleri EnstitÃ¼sÃ¼ Dergisi, 0, , .	0.1	1
3990	Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a secondâ€line treatment regimen for unresectable pancreatic cancer: A realâ€world analysis. Cancer Medicine, 2022, 11, 1088-1098.	1.3	4
3991	EUS-FNA Biopsies to Guide Precision Medicine in Pancreatic Cancer: Results of a Pilot Study to Identify KRAS Wild-Type Tumours for Targeted Therapy. Frontiers in Oncology, 2021, 11, 770022.	1.3	4
3992	Treatment Patterns, Toxicity, and Outcomes of Older Adults With Advanced Pancreatic Cancer Receiving First-line Palliative Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2022, 45, 55-60.	0.6	5
3993	Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy. Human Vaccines and Immunotherapeutics, 2024, 17, 5563-5572.	1.4	8
3994	Safety and efficacy of combination chemotherapy regimens in older adults with pancreatic ductal adenocarcinoma: a systematic review. Journal of Gastrointestinal Oncology, 2021, 12, 2591-2599.	0.6	1
3996	Study of Gemcitabine Plus Nab-Paclitaxel-Based Chemotherapy Regimen as First-Line Treatment in Metastatic Pancreatic Carcinoma. South Asian Journal of Cancer, 0, , .	0.2	0
3997	The m6A RNA methylation regulators related transcriptome for identification of pancreatic cancer subtypes and prognostic markers. , 2021, , .		0
3998	Gene expression profiling reveals the genomic changes caused by MLN4924 and the sensitizing effects of NAPEPLD knockdown in pancreatic cancer. Cell Cycle, 2022, 21, 152-171.	1.3	2

#	Article	IF	Citations
3999	Efficacy and Safety of Reirradiation with Stereotactic Body Radiation Therapy for Locally Recurrent Pancreatic Adenocarcinoma. Clinical Oncology, 2021, , .	0.6	1
4000	A New Oxadiazole-Based Topsentin Derivative Modulates Cyclin-Dependent Kinase 1 Expression and Exerts Cytotoxic Effects on Pancreatic Cancer Cells. Molecules, 2022, 27, 19.	1.7	26
4001	Stearoyl-CoA desaturase 1 inhibitor supplemented with gemcitabine treatment reduces the viability and fatty acid content of pancreatic cancer cells in vitro. Journal of Pancreatology, 2021, 4, 170-177.	0.3	1
4002	Treatment optimization of locally advanced and metastatic pancreatic cancer (Review). International Journal of Oncology, 2021, 59, .	1.4	10
4003	Modulated Electro-Hyperthermia Supports the Effect of Gemcitabine Both in Sensitive and Resistant Pancreas Adenocarcinoma Cell Lines. Pathology and Oncology Research, 2021, 27, 1610048.	0.9	3
4004	Clinical outcomes of first line FOLFIRINOX vs. gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital System. Journal of Gastrointestinal Oncology, 2021, 12, 2547-2556.	0.6	1
4005	Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer. Acta OncolÃ³gica, 2022, 61, 277-285.	0.8	6
4006	Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial chemotherapy (GASPACHO study): a multicenter retrospective study. Japanese Journal of Clinical Oncology, 2022, 52, 134-142.	0.6	5
4007	Novel Compound C150 Inhibits Pancreatic Cancer Cell Epithelial-to-Mesenchymal Transition and Tumor Growth in Mice. Frontiers in Oncology, 2021, 11, 773350.	1.3	1
4008	Mining Cancer Cell Line-Based Drugs to Benefit KRAS^(G12D) Pancreatic Adenocarcinoma Patients. , 2021, , .		0
4009	Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients. BMC Cancer, 2021, 21, 1319.	1.1	12
4011	Analysis of the efficacy and safety of paclitaxel (albumin-bound) combined with S-1 and oxaliplatin combined with S-1 in the first-line treatment of advanced gastric cancer: a cohort study. Journal of Gastrointestinal Oncology, 2022, 13, 630-636.	0.6	1
4012	Clinicopathological Significance of BRCAness in Resectable Pancreatic Ductal Adenocarcinoma and Its Association With Anticancer Drug Sensitivity in Pancreatic Cancer Cells. Pancreas, 2022, 51, 183-189.	0.5	0
4013	Sarcopenia. Pancreas, 2022, 51, 148-152.	0.5	10
4014	Outcome Analysis of Patients Treated with Gemcitabine and Nab-Paclitaxelfor Unresectable Pancreatic Cancer. Journal of the Nihon University Medical Association, 2022, 81, 35-38.	0.0	0
4015	Expression, Prognostic Value, and Functional Mechanism of the KDM5 Family in Pancreatic Cancer. Frontiers in Cell and Developmental Biology, 2022, 10, 887385.	1.8	8
4016	Elderly Patients with Nondistant Metastatic Pancreatic Head Adenocarcinoma Cannot Benefit from More Radical Surgery. International Journal of Endocrinology, 2022, 2022, 1-11.	0.6	0
4017	The evolution of clinical outcomes in metastatic pancreatic adenocarcinoma: a 10-year experience at a tertiary referral center. Expert Review of Gastroenterology and Hepatology, 2022, , 1-8.	1.4	1

#	Article	IF	Citations
4018	A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein Î²ig-h3. Journal of Personalized Medicine, 2022, 12, 623.	1.1	2
4020	CD44-targeting hydrophobic phosphorylated gemcitabine prodrug nanotherapeutics augment lung cancer therapy. Acta Biomaterialia, 2022, 145, 200-209.	4.1	14
4021	Can Surgical Resection of Metastatic Lesions Be Beneficial to Pancreatic Ductal Adenocarcinoma Patients with Isolated Lung Metastasis?. Cancers, 2022, 14, 2067.	1.7	7
4022	Time to Neoadjuvant Chemotherapy Initiation is not Associated With Survival in Pancreatic Cancer. Journal of Surgical Research, 2022, 276, 369-378.	0.8	2
4029	Prognostic Significance of Intraoperative Peritoneal Lavage Cytology in Patients with Pancreatic Ductal Adenocarcinoma: A Single-Center Experience and Systematic Review of the Literature. Annals of Surgical Oncology, 2022, 29, 5972-5983.	0.7	2
4030	The MK2/Hsp27 axis is a major survival mechanism for pancreatic ductal adenocarcinoma under genotoxic stress. Science Translational Medicine, 2021, 13, eabb5445.	5.8	5
4031	A randomised controlled trial of gemcitabine hydrochloride plus S-1 combination therapy versus gemcitabine hydrochloride therapy alone in pancreatic cancer patients aged â‰¥75 years: a study protocol for an open-label randomised feasibility study. BMJ Open Gastroenterology, 2018, 5, e000187.	1.1	3
4036	Ablative Radiotherapy (ART) for Locally Advanced Pancreatic Cancer (LAPC): Toward a New Paradigm?. Life, 2022, 12, 465.	1.1	3
4042	Management of BRCA Mutation Carriers With Pancreatic Adenocarcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 469-473.	2.3	3
4045	Pancreatic cancer in 2014. JOP: Journal of the Pancreas, 2014, 15, 84-6.	1.5	1
4046	MM-398 achieves primary endpoint of overall survival in phase III study in patients with gemcitabine refractory metastatic pancreatic cancer. JOP: Journal of the Pancreas, 2014, 15, 278-9.	1.5	7
4047	Phase 1 trials in pancreatic cancer. JOP: Journal of the Pancreas, 2014, 15, 326-8.	1.5	0
4048	Locally advanced unresectable pancreatic cancer. JOP: Journal of the Pancreas, 2014, 15, 329-31.	1.5	0
4049	Adjuvant treatment for pancreatic cancer. JOP: Journal of the Pancreas, 2014, 15, 348-50.	1.5	1
4050	Role of neoadjuvant therapy in management of pancreatic cancer. JOP: Journal of the Pancreas, 2014, 15, 354-7.	1.5	0
4052	Glycolysis in the progression of pancreatic cancer.. American Journal of Cancer Research, 2022, 12, 861-872.	1.4	1
4053	Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210971.	1.4	1
4054	Pancreatic cancer â€“ the past, the present, and the future. Scandinavian Journal of Gastroenterology, 2022, 57, 1169-1177.	0.6	15

#	Article	IF	Citations
4055	Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC). Journal of Clinical Oncology, 2022, 40, 3180-3189.	0.8	29
4056	Multidisciplinary Management of Pancreatic Cancer. Journal of the Advanced Practitioner in Oncology, 2022, 13, 311-314.	0.2	0
4058	Risk factors for biliary stent infections in malignant biliary obstruction secondary to unresectable malignancies. Supportive Care in Cancer, 2022, , .	1.0	0
4059	Establishment of patient-derived organoids and a characterization-based drug discovery platform for treatment of pancreatic cancer. BMC Cancer, 2022, 22, 489.	1.1	6
4060	Updates on Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma. Advances in Oncology, 2022, 2, 35-45.	0.1	0
4061	Microangiopathy associated with gemcitabine: a drug interaction with nab-paclitaxel? A case series and literature review. European Journal of Clinical Pharmacology, 2022, , 1.	0.8	3
4062	Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer. PLoS ONE, 2022, 17, e0267623.	1.1	2
4063	A randomized phase <scp>II</scp> study of <scp>SM</scp>â€88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond. Cancer Medicine, 2022, 11, 4169-4181.	1.3	4
4064	Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma. Clinical Cancer Research, 2022, 28, 3156-3169.	3.2	4
4065	Prognostic values of B7-H3, B7-H4, and HHLA2 expression in human pancreatic cancer tissues based on mIHC and spatial distribution analysis. Pathology Research and Practice, 2022, 234, 153911.	1.0	5
4066	Stereotactic body radiation therapy for the treatment of locally recurrent pancreatic cancer after surgical resection. Journal of Gastrointestinal Oncology, 2021, .	0.6	3
4067	Case Report: Maintenance Nivolumab in Complete Responder After Multimodality Therapy in Metastatic Pancreatic Adenocarcinoma. Frontiers in Immunology, 2022, 13, 870406.	2.2	0
4068	S-1 Maintenance Therapy After First-Line Treatment With Nab-Paclitaxel Plus S-1 for Advanced Pancreatic Adenocarcinoma: A Real-World Study. Frontiers in Oncology, 2022, 12, .	1.3	3
4070	The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer. Scientific Reports, 2022, 12, 8244.	1.6	8
4071	Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer. BMJ Open, 2022, 12, e048833.	0.8	1
4072	First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population. Future Oncology, 2022, 18, 2521-2532.	1.1	5
4073	Current Update on Nanotechnology-Based Approaches in Ovarian Cancer Therapy. Reproductive Sciences, 2023, 30, 335-349.	1.1	4
4074	Enhanced effect of autologous EVs delivering paclitaxel in pancreatic cancer. Journal of Controlled Release, 2022, 347, 330-346.	4.8	18

#	Article	IF	Citations
4075	The Molecular Landscape of Pancreatobiliary Cancers for Novel Targeted Therapies From Real-World Genomic Profiling. Journal of the National Cancer Institute, 2022, 114, 1279-1286.	3.0	8
4076	Baseline Factors Predictive of the Receipt of Second-Line Chemotherapy After Nab-Paclitaxel Plus Gemcitabine for Patients With Advanced Pancreatic Cancer. Pancreas, 2022, 51, 278-281.	0.5	5
4077	The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan.. American Journal of Cancer Research, 2022, 12, 1884-1898.	1.4	0
4080	Inhibition of a Mitochondrial Potassium Channel in Combination with Gemcitabine and Abraxane Drastically Reduces Pancreatic Ductal Adenocarcinoma in an Immunocompetent Orthotopic Murine Model. Cancers, 2022, 14, 2618.	1.7	11
4081	Outcomes of patients with malignant duodenal obstruction after receiving self-expandable metallic stents: A single center experience. PLoS ONE, 2022, 17, e0268920.	1.1	4
4082	Activated Stromal Cells in the Development of Pancreatic Ductal Adenocarcinoma and Therapeutic Approaches to Stroma Remodeling. Cell and Tissue Biology, 2022, 16, 193-202.	0.2	0
4083	FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study. Future Oncology, 0, , .	1.1	0
4084	The Next Frontier in Pancreatic Cancer: Targeting the Tumor Immune Milieu and Molecular Pathways. Cancers, 2022, 14, 2619.	1.7	7
4085	Understanding Tricky Cellular and Molecular Interactions in Pancreatic Tumor Microenvironment: New Food for Thought. Frontiers in Immunology, 2022, 13, .	2.2	7
4086	Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review. Cancers, 2022, 14, 2486.	1.7	29
4087	The Synergistic Role of Irreversible Electroporation and Chemotherapy for Locally Advanced Pancreatic Cancer. Frontiers in Oncology, 0, 12, .	1.3	3
4088	Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities. Cancers, 2022, 14, 2588.	1.7	7
4089	Smart hypoxia-responsive transformable and charge-reversible nanoparticles for the deep penetration and tumor microenvironment modulation of pancreatic cancer. Biomaterials, 2022, 287, 121599.	5.7	28
4090	Pancreatic Adenocarcinoma: Emerging Systemic Therapy Options. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 600-602.	2.3	0
4091	Molecular Landscape and Prognostic Biomarker Analysis of Advanced Pancreatic Cancer and Predictors of Treatment Efficacy of AG Chemotherapy. Frontiers in Oncology, 0, 12, .	1.3	2
4092	Development of a Prognostic Model Based on Pyroptosis-Related Genes in Pancreatic Adenocarcinoma. Disease Markers, 2022, 2022, 1-28.	0.6	4
4093	Tumor-Stroma Interaction in PDAC as a New Approach for Liquid Biopsy and its Potential Clinical Implications. Frontiers in Cell and Developmental Biology, 2022, 10, .	1.8	4
4094	A phase I/<scp>II</scp> study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma. International Journal of Cancer, 2022, 151, 1565-1577.	2.3	8

#	Article	IF	Citations
4095	Human amniotic fluid mesenchymal stem cells attenuate pancreatic cancer cell proliferation and tumor growth in an orthotopic xenograft mouse model. Stem Cell Research and Therapy, 2022, 13, .	2.4	8
4096	Intraperitoneal chemotherapy in the management of pancreatic adenocarcinoma: A systematic review and meta-analysis. European Journal of Surgical Oncology, 2022, 48, 1911-1921.	0.5	8
4097	Synergistic effects of natural compounds and conventional chemotherapeutic agents: recent insights for the development of cancer treatment strategies. Heliyon, 2022, 8, e09519.	1.4	25
4098	Useful preclinical clues that a proposed new therapy would work in the clinic: to make a medicinal chemistâ€™s dreams come true. Medicinal Chemistry Research, 0, , .	1.1	0
4099	Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nature Medicine, 2022, 28, 1167-1177.	15.2	112
4100	Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer. Cancer, 2022, 128, 2958-2966.	2.0	2
4101	Exercise-induced engagement of the IL-15/IL-15RÎ± axis promotes anti-tumor immunity in pancreatic cancer. Cancer Cell, 2022, 40, 720-737.e5.	7.7	67
4102	Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment. Advanced Drug Delivery Reviews, 2022, 187, 114357.	6.6	20
4106	Trends in the surgical treatment for pancreatic cancer in the last 30 years. BioScience Trends, 2022, 16, 198-206.	1.1	4
4107	Health-related quality of life scores of metastatic pancreatic cancer patients responsive to first line chemotherapy compared to newly derived EORTC QLQ-C30 reference values. BMC Cancer, 2022, 22, .	1.1	4
4108	Albumin Paclitaxel Compared with 5-Penfluorouracil, Lobaplatin, and Albumin Paclitaxel Combined with 5-Penfluorouracil in the Treatment of Human Gastric Cancer Cell AGS Line Autophagy and Apoptosis. Canadian Journal of Gastroenterology and Hepatology, 2022, 2022, 1-14.	0.8	2
4109	Class III Î²-Tubulin Expression Is of Value in Selecting nab-Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer. Pancreas, 2022, 51, 372-379.	0.5	3
4110	An Optimally Fabricated Platform Guides Cancerâ€Specific Activation of Chemotherapeutic Drugs and Toxicityâ€Free Cancer Treatment. Advanced Healthcare Materials, 2022, 11, .	3.9	3
4111	Survival benefits and safety of chemotherapy regimens for pancreatic cancer: An umbrella review of meta-analyses of randomized controlled trials. , 2022, 4, 001-020.		1
4112	ChemoSensitivity Assay Guided Metronomic Chemotherapy Is Safe and Effective for Treating Advanced Pancreatic Cancer. Cancers, 2022, 14, 2906.	1.7	3
4113	Diabetes Mellitus and Pancreatic Ductal Adenocarcinomaâ€”Prevalence, Clinicopathological Variables, and Clinical Outcomes. Cancers, 2022, 14, 2840.	1.7	7
4114	Targeting autophagy as a therapeutic strategy against pancreatic cancer. Journal of Gastroenterology, 2022, 57, 603-618.	2.3	12
4116	Adaptive Dynamic Therapy and Survivorship for Operable Pancreatic Cancer. JAMA Network Open, 2022, 5, e2218355.	2.8	5

#	Article	IF	Citations
4117	Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present. Biomolecules, 2022, 12, 815.	1.8	15
4118	Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer. Critical Reviews in Oncology/Hematology, 2022, 176, 103749.	2.0	37
4120	Endogenous Pancreatic Cancer Cell PD-1 Activates MET and Induces Epithelial-Mesenchymal Transition to Promote Cancer Progression. Cancers, 2022, 14, 3051.	1.7	1
4121	Cellular metabolism in pancreatic cancer as a tool for prognosis and treatment (Review). International Journal of Oncology, 2022, 61, .	1.4	12
4122	Tumor-infiltrating OX40+ lymphocytes is an independent positive prognostic factor for patients with pancreatic ductal adenocarcinoma. Clinical and Translational Oncology, 0, , .	1.2	1
4123	Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-Î³, TNF-Î± and PD-1/PD-L1 in comparison to established serum tumor markers. Journal of Cancer Research and Clinical Oncology, 2023, 149, 2463-2474.	1.2	3
4124	Is Biannual Surveillance for Pancreatic Cancer Sufficient in Individuals With Genetic Syndromes or Familial Pancreatic Cancer?. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 663-673.e12.	2.3	3
4125	Case Report: Successful Immunotherapy Improved the Prognosis of the Unfavorable Subset of Cancer of Unknown Primary. Frontiers in Immunology, 0, 13, .	2.2	2
4126	Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival. Oncotarget, 2022, 13, 828-841.	0.8	9
4127	Self-emulsifying Drug Delivery System for Oral Anticancer Therapy: Constraints and Recent Development. Current Pharmaceutical Design, 2022, 28, 2538-2553.	0.9	7
4128	Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study. Pancreatology, 2022, 22, 789-796.	0.5	10
4129	Analysis of the Pancreatic Cancer Microbiome Using Endoscopic Ultrasoundâ€“Guided Fine-Needle Aspirationâ€“Derived Samples. Pancreas, 2022, 51, 351-357.	0.5	3
4130	Construction and Validation of a Necroptosis-Related Gene Signature for Predicting Prognosis and Tumor Microenvironment of Pancreatic Cancer. Disease Markers, 2022, 2022, 1-15.	0.6	3
4132	Endoscopic ultrasound as a reliable tool for assessment of pancreatic adenocarcinoma treatment: Example of in situ gene therapy. Endoscopy International Open, 2022, 10, E910-E916.	0.9	0
4133	Cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs); where do they stand in tumorigenesis and how they can change the face of cancer therapy?. European Journal of Pharmacology, 2022, 928, 175087.	1.7	13
4134	Association between progression-free survival and metal stent patency in patients with advanced pancreatic cancer. Journal of Gastrointestinal Oncology, 2022, .	0.6	0
4135	A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Cancer. Internal Medicine, 2023, 62, 327-334.	0.3	2
4136	Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer. JNCI Cancer Spectrum, 2022, 6, .	1.4	4

#	Article	IF	Citations
4137	Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care. Cancers, 2022, 14, 3239.	1.7	11
4138	Tumor Location in the Pancreatic Tail Is Associated with Decreased Likelihood of Receiving Chemotherapy for Pancreatic Adenocarcinoma. Journal of Gastrointestinal Surgery, 2022, 26, 2136-2147.	0.9	1
4139	Precision Approaches to Pancreatic Cancer Therapy: What Now and What Next?. Current Treatment Options in Gastroenterology, 0, , .	0.3	0
4141	Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers. Frontiers in Immunology, 0, 13, .	2.2	11
4142	Context Matters: Response Heterogeneity to Collagen-Targeting Approaches in Desmoplastic Cancers. Cancers, 2022, 14, 3132.	1.7	6
4144	Oncological Outcome of Conversion Surgery After Preoperative Chemotherapy for Metastatic Pancreatic Cancer. Annals of Surgery, 2023, 277, e1089-e1098.	2.1	24
4145	Management of elderly patients with unresectable pancreatic cancer. Japanese Journal of Clinical Oncology, 0, , .	0.6	1
4146	CEND-1: a game changer for pancreatic cancer chemotherapy?. The Lancet Gastroenterology and Hepatology, 2022, 7, 900-902.	3.7	6
4147	Circulating Protein Biomarkers for Prognostic Use in Patients with Advanced Pancreatic Ductal Adenocarcinoma Undergoing Chemotherapy. Cancers, 2022, 14, 3250.	1.7	4
4148	A Critical Review of the Role of Local Therapy for Oligometastatic Gastrointestinal Cancer. International Journal of Radiation Oncology Biology Physics, 2022, , .	0.4	1
4149	Dual Î±V-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study. The Lancet Gastroenterology and Hepatology, 2022, 7, 943-951.	3.7	25
4150	Prediction of R Status in Resections for Pancreatic Cancer Using Simplified Radiological Criteria. Annals of Surgery, 2022, 276, 222-223.	2.1	0
4151	Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation. International Journal of Radiation Oncology Biology Physics, 2022, 114, 444-453.	0.4	4
4152	Facts and Hopes in Immunotherapy of Pancreatic Cancer. Clinical Cancer Research, 2022, 28, 4606-4617.	3.2	23
4153	Ecoevolutionary biology of pancreatic ductal adenocarcinoma. Pancreatology, 2022, , .	0.5	2
4154	Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population. Asia-Pacific Journal of Clinical Oncology, 0, , .	0.7	1
4155	Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL. Cancer Research, 2022, 82, 3375-3393.	0.4	2
4156	GOBLET: a phase I/II study of pelareorep and atezolizumab +/- chemo in advanced or metastatic gastrointestinal cancers. Future Oncology, 2022, 18, 2871-2878.	1.1	5

#	Article	IF	Citations
4157	Supportive Oncology Care at Home Intervention for Patients With Pancreatic Cancer. JCO Oncology Practice, 2022, 18, e1587-e1593.	1.4	6
4158	Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 2022, 40, 3929-3939.	0.8	66
4159	Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer: A Rare Phenomenon?. Medicines (Basel, Switzerland), 2022, 9, 39.	0.7	1
4160	Antibody-Based Approaches to Target Pancreatic Tumours. Antibodies, 2022, 11, 47.	1.2	7
4161	Multimodal Therapies against Pancreatic Ductal Adenocarcinoma: A Review on Synergistic Approaches toward Ultimate Nanomedicine Treatments. Advanced Therapeutics, 2022, 5, .	1.6	8
4162	Case Report: A Case of Locally Advanced Pancreatic Cancer Which Achieved Progression Free for Over 12 Months by Subsequent Therapy with Anlotinib Hydrochloride Plus Tegafur-Gimeracil-Oteracil Potassium (TS-1). Frontiers in Oncology, 0, 12, .	1.3	4
4163	MARK2 regulates chemotherapeutic responses through class IIa HDAC-YAP axis in pancreatic cancer. Oncogene, 2022, 41, 3859-3875.	2.6	6
4164	Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma. World Journal of Gastrointestinal Oncology, 2022, 14, 1252-1264.	0.8	11
4165	Is Cell-Free DNA Testing in Pancreatic Ductal Adenocarcinoma Ready for Prime Time?. Cancers, 2022, 14, 3453.	1.7	4
4166	Deepâ€Penetrating Tripleâ€Responsive Prodrug Nanosensitizer Actuates Efficient Chemoradiotherapy in Pancreatic Ductal Adenocarcinoma Models. Small, 2022, 18, .	5.2	12
4167	Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial. Lancet Oncology, The, 2022, 23, 1009-1020.	5.1	44
4168	An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study. Gastroenterology, 2022, 163, 1252-1266.e2.	0.6	35
4169	Sequential therapy for pancreatic cancer patients with synchronous oligo-hepatic metastatic lesions. Tumori, 0, , 030089162211102.	0.6	0
4170	Efficacy in randomised trials: the time matters. Lancet Oncology, The, 2022, 23, 839-840.	5.1	0
4171	Pancreatic ductal adenocarcinoma: Emerging therapeutic strategies. Surgical Oncology, 2022, 43, 101803.	0.8	5
4172	Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial. European Journal of Cancer, 2022, 172, 300-310.	1.3	19
4173	Detection of actionable mutations in cytological specimens obtained by endoscopic ultrasound-guided fine needle aspiration with rapid onsite evaluation in pancreatic cancer. Annals of Diagnostic Pathology, 2022, 60, 152008.	0.6	2
4174	Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Pancreatic Adenocarcinoma. Annals of the Academy of Medicine, Singapore, 2015, 44, 388-396.	0.2	4

#	Article	IF	Citations
4175	Mild forms of thrombotic microangiopathy in patients with advanced pancreatic cancer receiving gemcitabine and nab-paclitaxel. Journal of Oncology Pharmacy Practice, 2023, 29, 738-745.	0.5	1
4176	microRNA-497 prevents pancreatic cancer stem cell gemcitabine resistance, migration, and invasion by directly targeting nuclear factor kappa B 1. Aging, 2022, 14, 5908-5924.	1.4	12
4177	Neoadjuvant chemo(radio)therapy in upfront resectable pancreatic cancer â€“ can we stratify patients better in the future?. Scandinavian Journal of Gastroenterology, 0, , 1-2.	0.6	0
4178	Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenocarcinoma. Hpb, 2022, 24, 1878-1887.	0.1	15
4179	Phase I Trial of nab-Paclitaxel Administered Concurrently With Radiotherapy in Patients With Locally Advanced Inoperable Pancreatic Adenocarcinoma. Pancreas, 0, Publish Ahead of Print, .	0.5	0
4180	The role of the microbiome in pancreatic oncogenesis. International Immunology, 2022, 34, 447-454.	1.8	5
4181	Effectiveness and safety of gemcitabine plus nab-paclitaxel in elderly patients with advanced pancreatic cancer: a single-center retrospective cohort study. Investigational New Drugs, 2022, 40, 1106-1116.	1.2	2
4182	Amphiphilic Dendritic Nanomicelle-Mediated Delivery of Gemcitabine for Enhancing the Specificity and Effectiveness. International Journal of Nanomedicine, 0, Volume 17, 3239-3249.	3.3	7
4183	Novel dual action anti-neoplastic drugs. Technium BioChemMed, 2022, 3, 120-126.	0.2	0
4184	Repositioning of Old Drugs for Novel Cancer Therapies: Continuous Therapeutic Perfusion of Aspirin and Oseltamivir Phosphate with Gemcitabine Treatment Disables Tumor Progression, Chemoresistance, and Metastases. Cancers, 2022, 14, 3595.	1.7	3
4185	Genomic profiling amplifies the utility of endoscopic ultrasound-guided fine needle biopsy by identifying clinically applicable druggable mutations in pancreatic cancer. Annals of Diagnostic Pathology, 2022, 60, 152016.	0.6	2
4186	Arsenic trioxide-loaded nanoparticles enhance the chemosensitivity of gemcitabine in pancreatic cancer via the reversal of pancreatic stellate cell desmoplasia by targeting the AP4/galectin-1 pathway. Biomaterials Science, 2022, 10, 5989-6002.	2.6	8
4187	Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer. Anticancer Research, 2022, 42, 3889-3894.	0.5	3
4188	Treatment of Pancreatic Cancer with Trousseau Syndrome at Our Hospital. Japanese Journal of Gastroenterological Surgery, 2022, 55, 407-416.	0.0	0
4189	Do antihypertensive drugs really have antitumor effects? Baseline differences in hypertensive and non-hypertensive patients with advanced pancreatic cancer. Medicine (United States), 2022, 101, e29532.	0.4	3
4190	A Novel Delivery System of RGD-HSA Loaded GEM/CUR Nanoparticles for the Treatment of Pancreatic Cancer Therapy. Drug Design, Development and Therapy, 0, Volume 16, 2395-2406.	2.0	7
4191	Postoperative Chemotherapy is Associated with Improved Survival in Patients with Nodeâ€Positive Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy. World Journal of Surgery, 2022, 46, 2751-2759.	0.8	5
4193	Ablative Radiation Therapy in Oligometastatic Pancreatic Cancer to Delay Polyprogression, Limit Chemotherapy, and Improve Outcomes. International Journal of Radiation Oncology Biology Physics, 2022, 114, 792-802.	0.4	9

#	Article	IF	Citations
4194	Neoadjuvant therapy in pancreatic cancer: a review and update on recent trials. Current Opinion in Gastroenterology, 2022, 38, 521-531.	1.0	8
4195	A Ketogenic Diet in Combination with Gemcitabine Increases Survival in Pancreatic Cancer KPC Mice. Cancer Research Communications, 2022, 2, 951-965.	0.7	7
4196	Myofibroblastic CAF Density, Not Activated Stroma Index, Indicates Prognosis after Neoadjuvant Therapy of Pancreatic Carcinoma. Cancers, 2022, 14, 3881.	1.7	5
4198	Linderalactone Suppresses Pancreatic Cancer Development In Vitro and In Vivo via Negatively Regulating PI3K/AKT Signaling Pathway. Journal of Oncology, 2022, 2022, 1-12.	0.6	1
4199	Systemic inflammatory response index is aÂprognostic biomarker in unresectable pancreatic adenocarcinoma and identifies patients for more intensive treatment. Memo - Magazine of European Medical Oncology, 0, , .	0.3	0
4200	Prognostic factors in conversion surgery following nabâ€paclitaxel with gemcitabine and subsequent chemoradiotherapy for unresectable locally advanced pancreatic cancer: Results of a dualâ€center study. Annals of Gastroenterological Surgery, 2023, 7, 157-166.	1.2	7
4201	Comparison of acute gastrointestinal toxicities between 3-dimensional conformal radiotherapy and intensity-modulated radiotherapy including prophylactic regions in chemoradiotherapy with S-1 for pancreatic cancerâ€"importance of dose volume histogram parameters in the stomach as the predictive factors-. Journal of Radiation Research, 0, , .	0.8	2
4202	Chemotherapy effectiveness and age-group analysis of older adult patients with metastatic pancreatic cancer: A Japanese cancer registry cohort study. Journal of Geriatric Oncology, 2022, 13, 1208-1215.	0.5	5
4203	Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?. Frontiers in Immunology, 0, 13, .	2.2	4
4204	Identification of stromal microenvironment characteristics and key molecular mining in pancreatic cancer. Discover Oncology, 2022, 13, .	0.8	1
4205	Patient-caregiver dyads in pancreatic cancer: identification of patient and caregiver factors associated with caregiver well-being. Journal of Behavioral Medicine, 2022, 45, 935-946.	1.1	6
4206	Metastatic ovarian tumor from pancreatic cancer treated with combined immunotherapy: A case report. Oncology Letters, 2022, 24, .	0.8	3
4208	Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver. Annals of Surgical Oncology, 2022, 29, 8503-8510.	0.7	9
4210	Long-Term Survival of FOLFIRINOX +toripalimab in a Patient with Metastatic Pancreatic Ductal Adenocarcinoma: A Case Report. OncoTargets and Therapy, 0, Volume 15, 883-890.	1.0	1
4211	Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer. Internal Medicine, 2022, 61, 2255-2261.	0.3	0
4212	Anti-tumour activity and toxicological studies of combination treatment of Orthosiphon stamineus and gemcitabine on pancreatic xenograft model. World Journal of Gastroenterology, 2022, 28, 4620-4634.	1.4	0
4213	Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer. Clinical and Translational Oncology, 0, , .	1.2	1
4214	Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer. Revista Espanola De Patologia, 2022, , .	0.6	0

#	Article	IF	Citations
4215	Pancreatic adenocarcinoma and pancreatic high-grade neuroendocrine carcinoma: two sides of the moon. , 2022, 39, .		2
4216	A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma. Oncologist, 0, , .	1.9	0
4217	Expression of cartilage oligomeric matrix protein in periampullary adenocarcinoma is associated with pancreatobiliary-type morphology, higher levels of fibrosis and immune cell exclusion. OncoImmunology, 2022, 11, .	2.1	3
4218	Systemic Therapy of Advanced Well-differentiated Small Bowel Neuroendocrine Tumors Progressive on Somatostatin Analogues. Current Treatment Options in Oncology, 2022, 23, 1233-1246.	1.3	1
4219	Recent nanotechnology advancements to treat multidrug-resistance pancreatic cancer: Pre-clinical and clinical overview. Frontiers in Pharmacology, 0, 13, .	1.6	4
4220	Pan-cancer efficacy of pralsetinib in patients with RET fusionâ€“positive solid tumors from the phase 1/2 ARROW trial. Nature Medicine, 2022, 28, 1640-1645.	15.2	83
4221	Insight of pancreatic cancer: recommendations for improving its therapeutic efficacy in the next decade. Journal of Pancreatology, 2022, 5, 58-68.	0.3	1
4222	The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma. Nature Communications, 2022, 13, .	5.8	35
4223	Effect of Mirogabalin on Chemotherapy-Induced Peripheral Neuropathy Caused by Gemcitabine plus Nab-Paclitaxel Therapy in Pancreatic Cancer Patients: A Pilot Study. , 2022, 1, 36-42.		0
4224	Heterogeneity of Cancer-Associated Fibroblasts and the Tumor Immune Microenvironment in Pancreatic Cancer. Cancers, 2022, 14, 3994.	1.7	16
4225	Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer. Oncologist, 2022, 27, e774-e782.	1.9	3
4226	Unexpected favorable outcome to sintilimab monotherapy in a relapse pancreatic ductal adenocarcinoma patient with high tumor mutational burden: a case report. Anti-Cancer Drugs, 0, Publish Ahead of Print, .	0.7	1
4227	Beyond Formulation: Contributions of Nanotechnology for Translation of Anticancer Natural Products into New Drugs. Pharmaceutics, 2022, 14, 1722.	2.0	14
4229	A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma â€“ The Taiwan Cooperative Oncology Group T1217 study. European Journal of Cancer, 2022, 173, 123-132.	1.3	3
4230	Biomimetic cancer cell-coated albumin nanoparticles for enhanced colloidal stability and homotypic targeting of breast cancer cells. Journal of Drug Delivery Science and Technology, 2022, 75, 103698.	1.4	2
4231	Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry. European Journal of Cancer, 2022, 174, 102-112.	1.3	9
4232	Multimodal survival prediction in advanced pancreatic cancer using machine learning. ESMO Open, 2022, 7, 100555.	2.0	9
4233	The trilogy of P21 activated kinase, autophagy and immune evasion in pancreatic ductal adenocarcinoma. Cancer Letters, 2022, 548, 215868.	3.2	9

#	Article	IF	Citations
4234	IgG+ Extracellular Vesicles Measure Therapeutic Response in Advanced Pancreatic Cancer. Cells, 2022, 11, 2800.	1.8	1
4235	Novel Regulators of Macropinocytosis-Dependent Growth Revealed by Informer Set Library Screening in Pancreatic Cancer Cells. Metabolites, 2022, 12, 831.	1.3	0
4236	Impact of pathological complete response following neoadjuvant chemotherapy (gemcitabine,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 66 of literature. Surgical Case Reports, 2022, 8, .	0.2	0
4237	Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncology, The, 2022, 23, 1261-1273.	5.1	117
4238	Regulation of pancreatic cancer therapy resistance by chemokines. Seminars in Cancer Biology, 2022, 86, 69-80.	4.3	11
4239	Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers. Advanced Drug Delivery Reviews, 2022, 190, 114525.	6.6	22
4240	Nonsurgical Management of Pancreatic Adenocarcinoma. , 2022, , 535-556.		0
4241	Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211180.	1.4	13
4242	MicroRNA-based therapeutic strategies for cancer. , 2022, , 503-520.		0
4243	Transformable nanoparticles to bypass biological barriers in cancer treatment. Nanoscale Advances, 0, , .	2.2	3
4244	Hyperthermia-induced stellate cell deactivation to enhance dual chemo and pH-responsive photothermal therapy for pancreatic cancers. Nanoscale, 2022, 14, 15735-15748.	2.8	11
4245	A Pancreatic Cancer Patient-Derived Xenograft Model for Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes. , 2022, 1, 1122-1123.		0
4246	A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211195.	1.4	7
4247	Impact of the COVID-19 Pandemic on the Management and End-of-life Care of Unresectable Pancreatic Cancer. Internal Medicine, 2022, 61, 3641-3649.	0.3	6
4248	Pharmacological Ascorbate Enhances Chemotherapies in Pancreatic Ductal Adenocarcinoma. Pancreas, 2022, 51, 684-693.	0.5	3
4249	è†µå°¾éƒ¨ç™Œã«å•ä½µã–ãŸå·¦å•é–€è„ˆåœ§äº¢é€²ç—‡ã«ä¼´ã†èƒƒé™è„ˆç˜¤ç ´è£‚ã«éƒ¨åˆ†çš„è„¾å‹•è„ˆå¡žæ“è¡“ã [illegible]	0.1	[illegible]
4250	Development and validation of a competing risk model for second primary pancreatic ductal adenocarcinoma: A population-based study. Frontiers in Surgery, 0, 9, .	0.6	1
4251	Treatment Effect and Safety of Nanoliposomal Irinotecan with Fluorouracil and Folinic Acid after Gemcitabine-Based Therapy in Patients with Advanced Pancreatic Cancer: A Multicenter, Prospective Observational Study. Journal of Clinical Medicine, 2022, 11, 5084.	1.0	3

#	Article	IF	Citations
4253	HCA (2-Hydroxy-Docosahexaenoic Acid) Induces Apoptosis and Endoplasmic Reticulum Stress in Pancreatic Cancer Cells. International Journal of Molecular Sciences, 2022, 23, 9902.	1.8	0
4254	A pyroptosis-related gene signature for prognosis and immune microenvironment of pancreatic cancer. Frontiers in Genetics, 0, 13, .	1.1	5
4255	Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma. Cancers, 2022, 14, 4209.	1.7	9
4256	The Role of the Microbiome in Pancreatic Cancer. Cancers, 2022, 14, 4479.	1.7	12
4258	Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance. Drug Resistance Updates, 2022, 64, 100864.	6.5	16
4259	Comparative Proteomic Analysis Identifies Key Metabolic Regulators of Gemcitabine Resistance in Pancreatic Cancer. Molecular and Cellular Proteomics, 2022, 21, 100409.	2.5	6
4260	Transarterial Radioembolization for Hepatic Metastases of Pancreatic Adenocarcinoma: A Systematic Review.. Journal of Vascular and Interventional Radiology, 2022, , .	0.2	1
4261	Predictive factors for early recurrence after pancreaticoduodenectomy in patients with resectable pancreatic head cancer: A multicenter retrospective study. Surgery, 2022, 172, 1782-1790.	1.0	7
4262	Management of Advanced Pancreatic Cancer through Stromal Depletion and Immune Modulation. Medicina (Lithuania), 2022, 58, 1298.	0.8	0
4263	Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer. Japanese Journal of Clinical Oncology, 0, , .	0.6	3
4265	Therapeutic potential of chrysin nanoparticle-mediation inhibition of succinate dehydrogenase and ubiquinone oxidoreductase in pancreatic and lung adenocarcinoma. European Journal of Medical Research, 2022, 27, .	0.9	1
4266	Identification of Molecular Targets and Underlying Mechanisms of Xiaoji Recipe against Pancreatic Cancer Based on Network Pharmacology. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-17.	0.7	1
4267	NEDD8-Activating Enzyme Inhibitor MLN4924 Inhibits Both the Tumor Stroma and Angiogenesis in Pancreatic Cancer via Gli1 and REDD1. Digestive Diseases and Sciences, 2023, 68, 1351-1363.	1.1	2
4268	The Role of Immunotherapy in Pancreatic Cancer. Current Oncology, 2022, 29, 6864-6892.	0.9	18
4269	Covered versus uncovered double bare self-expandable metal stent for palliation of unresectable extrahepatic malignant biliary obstruction: a randomized controlled multicenter trial. Gastrointestinal Endoscopy, 2023, 97, 132-142.e2.	0.5	6
4270	Cytotoxic Chemotherapy in Advanced Pancreatic Cancer. Hematology/Oncology Clinics of North America, 2022, 36, 1011-1018.	0.9	2
4271	A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas. Cancer Research Communications, 2022, 2, 1326-1333.	0.7	2
4272	Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer. Scientific Reports, 2022, 12, .	1.6	6

#	Article	IF	Citations
4273	The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence. Medicine (United States), 2022, 101, e30566.	0.4	0
4274	Radiotherapy for Pancreatic Adenocarcinoma. Hematology/Oncology Clinics of North America, 2022, , .	0.9	2
4275	Body composition as a predictor of chemotherapy-related toxicity in pancreatic cancer patients: A systematic review. Frontiers in Oncology, 0, 12, .	1.3	6
4276	Palliative and Supportive Care for Individuals with Pancreatic Adenocarcinoma. Hematology/Oncology Clinics of North America, 2022, , .	0.9	1
4277	Combination immunotherapy for pancreatic cancer: challenges and future considerations. Expert Review of Clinical Immunology, 2022, 18, 1173-1186.	1.3	4
4278	Efficacy of a dedicated plastic stent in endoscopic ultrasound-guided hepaticogastrostomy during the learning curve: cumulative multi-center experience. Scandinavian Journal of Gastroenterology, 2023, 58, 296-303.	0.6	4
4279	Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation. Frontiers in Immunology, 0, 13, .	2.2	5
4280	Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine-induced hypo-vascularization. European Journal of Nuclear Medicine and Molecular Imaging, 0, , .	3.3	0
4281	Targeting the Metabolic Rewiring in Pancreatic Cancer and Its Tumor Microenvironment. Cancers, 2022, 14, 4351.	1.7	15
4282	The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences, 2022, 23, 10279.	1.8	3
4283	Pharmacologic inhibition of <scp>LAT1</scp> predominantly suppresses transport of large neutral amino acids and downregulates global translation in cancer cells. Journal of Cellular and Molecular Medicine, 2022, 26, 5246-5256.	1.6	13
4284	Pancreatic Adenocarcinoma Management. JCO Oncology Practice, 2023, 19, 19-32.	1.4	17
4285	Simultaneous inhibition of Chk1 and Bcl-xL induces apoptosis inÂvitro and represses tumour growth in an inÂvivo xenograft model. Journal of Chemotherapy, 2023, 35, 435-447.	0.7	0
4286	Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity. Cancer Communications, 0, , .	3.7	1
4287	<scp>FOLFIRINOX</scp> or gemcitabine/nabâ€paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decisionâ€making in realâ€world. International Journal of Cancer, 2023, 152, 458-469.	2.3	3
4288	Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nabâ€paclitaxel: A retrospective study. Oncology Letters, 2022, 24, .	0.8	2
4289	Risk factors and predictive nomograms for early death of patients with pancreatic cancer liver metastasis: A large cohort study based on the SEER database and Chinese population. Frontiers in Oncology, 0, 12, .	1.3	4
4290	Nanoparticle-Based Therapeutic Strategies for Enhanced Pancreatic Ductal Adenocarcinoma Immunotherapy. Pharmaceutics, 2022, 14, 2033.	2.0	5

#	Article	IF	Citations
4291	Realâ€world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as firstâ€line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma. Asia-Pacific Journal of Clinical Oncology, 2023, 19, .	0.7	1
4292	Protocol of a randomized phase II/III study of gemcitabine plus nab-paclitaxel combination therapy versus modified FOLFIRINOX versus S-IROX for metastatic or recurrent pancreatic cancer: JCOG1611 (GENERATE). Japanese Journal of Clinical Oncology, 0, , .	0.6	1
4293	Pentraxin 3 is an adipose tissueâ€related serum marker for pancreatic cancer cachexia predicting subsequent muscle mass and visceral fat loss. Cancer Science, 2022, 113, 4311-4326.	1.7	4
4294	GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma. Gut, 2023, 72, 535-548.	6.1	10
4295	Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma. Pharmaceuticals, 2022, 15, 1199.	1.7	9
4296	Outcomes of neoadjuvant gemcitabine plus Sâ€1 and radiation therapy for borderline resectable pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Sciences, 2023, 30, 493-502.	1.4	3
4297	Efficacy of chemotherapy for patients with metastatic or recurrent pancreatic adenosquamous carcinoma: A multicenter retrospective analysis. Pancreatology, 2022, 22, 1159-1166.	0.5	2
4298	Meta-analysis of gemcitabine plus nab-paclitaxel combined with targeted agents in the treatment of metastatic pancreatic cancer. World Journal of Clinical Cases, 2022, 10, 9703-9713.	0.3	0
4299	An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms. Nature Communications, 2022, 13, .	5.8	8
4300	Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines. Discover Oncology, 2022, 13, .	0.8	4
4301	Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)â€”a randomized phase II trial of the AIO pancreatic cancer group. Annals of Oncology, 2023, 34, 91-100.	0.6	37
4302	The prognostic role of fatigue, depression and anxiety on postoperative outcomes after pancreatectomy for pancreatic cancer. A prospective observational study (FAT-PRO study). Pancreatology, 2022, 22, 1035-1040.	0.5	1
4303	Pancreatic Cancer: A Review of Current Treatment and Novel Therapies. Journal of Investigative Surgery, 2023, 36, .	0.6	54
4304	Novel compound C150 inhibits pancreatic cancer through induction of ER stress and proteosome assembly. Frontiers in Oncology, 0, 12, .	1.3	1
4305	A case of pathological complete response with liposomal irinotecanâ€‰+â€‰5-FU/LV for unresectable locally advanced pancreatic cancer. Surgical Case Reports, 2022, 8, .	0.2	0
4306	Pancreatic Adenocarcinoma: An Evolving Yet Unimpressive Treatment Landscape. JCO Oncology Practice, 0, , .	1.4	0
4307	Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with elevated pre-chemotherapy CA19-9 levels. Hpb, 2023, 25, 100-108.	0.1	4
4308	A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arterial Involvement. Annals of Surgical Oncology, 2023, 30, 193-202.	0.7	6

#	Article	IF	Citations
4309	Long-term outcomes of standard versus extended lymphadenectomy in pancreatoduodenectomy for pancreatic ductal adenocarcinoma: A Chinese multi-center prospective randomized controlled trial. Journal of Advanced Research, 2023, 49, 151-157.	4.4	3
4310	Inhibition of pancreatic cancer-cell growth and metastasis in vivo by a pyrazole compound characterized as a cell-migration inhibitor by an in vitro chemotaxis assay. Biomedicine and Pharmacotherapy, 2022, 155, 113733.	2.5	1
4311	Management of Resectable and Borderline Resectable Disease: Radiation Oncology. , 2022, , 153-171.		0
4312	Artificial intelligence in pancreatic cancer. Theranostics, 2022, 12, 6931-6954.	4.6	28
4313	Prioritizing the Patient Experience: Early Integration of Supportive/Palliative Care in Pancreatic Cancer Management. , 2022, , 343-350.		0
4314	Molecular Profiling and Precision Medicine for Pancreatic Cancer. , 2022, , 255-267.		0
4315	Management of Locally Advanced/Metastatic Disease: Medical Oncology. , 2022, , 97-106.		0
4316	Safety and efficiency of combination treatment including high-intensity focused ultrasound therapy in patients with pancreatic cancer. Onkologiya Zhurnal Imeni P A Gertsena, 2022, 11, 11.	0.0	0
4317	A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma. Journal of Gastrointestinal Oncology, 2022, 13, 3216-3226.	0.6	6
4318	Chemotherapy is associated with improved survival in a national cohort of stage IV pancreatic adenosquamous carcinoma. Journal of Gastrointestinal Oncology, 2022, .	0.6	0
4319	Eight Months' Recurrence-free Survival after Tumorectomy and Fractionated Stereotactic Radiotherapy for Brain Metastasis of a Pancreatic Tumor. Nihon Rinsho Geka Gakkai Zasshi (Journal of) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.1	1
4320	EUS-Guided Local Therapies. , 2022, , 219-228.		0
4321	Chemotherapeutic Protocols for the Treatment of Gastrointestinal Tract Cancer. , 2022, , 125-200.		0
4322	Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma. Cancer Control, 2022, 29, 107327482211344.	0.7	1
4324	Development of a Clinicalâ€“Biological Model to Assess Tumor Progression in Metastatic Pancreatic Cancer: Post Hoc Analysis of the PRODIGE4/ACCORD11 Trial. Cancers, 2022, 14, 5068.	1.7	0
4325	Stereotactic Body Radiotherapy (SBRT) of Pancreatic Cancerâ€”A Critical Review and Practical Consideration. Biomedicines, 2022, 10, 2480.	1.4	6
4326	Co-Delivery of Paclitaxel Prodrug, Gemcitabine and Porphine by Micelles for Pancreatic Cancer Treatment via Chemo-Photodynamic Combination Therapy. Pharmaceutics, 2022, 14, 2280.	2.0	4
4327	3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. Journal of Clinical Investigation, 2022, 132, .	3.9	9

#	Article	IF	Citations
4328	hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2022, 28, 5115-5120.	3.2	10
4329	Establishment of the diagnostic and prognostic nomograms for pancreatic cancer with bone metastasis. Scientific Reports, 2022, 12, .	1.6	2
4331	Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review. Frontiers in Immunology, 0, 13, .	2.2	5
4332	Systemic immune changes accompany combination treatment with immunotoxin <scp>LMB</scp>â€100 and nabâ€paclitaxel. Cancer Medicine, 2023, 12, 4236-4249.	1.3	2
4333	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. Journal of Hematology and Oncology, 2022, 15, .	6.9	59
4335	Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma. Cancer Research Communications, 2022, 2, 1418-1425.	0.7	1
4336	Decision-Making Regarding Perioperative Therapy in Individuals with Localized Pancreatic Adenocarcinoma. Hematology/Oncology Clinics of North America, 2022, 36, 961-978.	0.9	2
4337	Use of DNAâ€alkylating pyrroleâ€imidazole polyamides for antiâ€cancer drug sensitivity screening in pancreatic ductal adenocarcinoma. Cancer Medicine, 2023, 12, 5821-5832.	1.3	2
4338	Gastrojejunostomy versus endoscopic duodenal stent placement for gastric outlet obstruction in patients with unresectable pancreatic cancer: a propensity score-matched analysis. Surgical Endoscopy and Other Interventional Techniques, 0, , .	1.3	0
4339	A Cross-Sectional and Longitudinal Analysis of Pre-Diagnostic Blood Plasma Biomarkers for Early Detection of Pancreatic Cancer. International Journal of Molecular Sciences, 2022, 23, 12969.	1.8	3
4340	Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study. BMC Cancer, 2022, 22, .	1.1	3
4341	Impact of First-Line FOLFIRINOX-Induced Peripheral Neuropathy on the Efficacy of Second-Line GnP in Patients with Unresectable Advanced Pancreatic Cancer. Journal of Clinical Medicine, 2022, 11, 5895.	1.0	0
4342	Current trends in the use of human serum albumin for drug delivery in cancer. Expert Opinion on Drug Delivery, 2022, 19, 1449-1470.	2.4	16
4343	Impact of margin accentuation with intraoperative irreversible electroporation on local recurrence in resected pancreatic cancer. Surgery, 2022, , .	1.0	1
4344	Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine. Military Medical Research, 2022, 9, .	1.9	13
4345	Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?. Pharmaceutics, 2022, 14, 2326.	2.0	2
4346	Nano-drug delivery system for pancreatic cancer: A visualization and bibliometric analysis. Frontiers in Pharmacology, 0, 13, .	1.6	8
4347	NME1 functions as a metastasis suppressor in pancreatic cancer. Molecular and Cellular Toxicology, 0, , .	0.8	0

#	Article	IF	Citations
4348	Prognostic value of circulating proteins in patients undergoing surgery for pancreatic cancer. Cancer Medicine, 0, , .	1.3	2
4349	Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers. Frontiers in Oncology, 0, 12, .	1.3	1
4351	The Effects of Radiotherapy on Pancreatic Ductal Adenocarcinoma in Patients with Liver Metastases. Current Oncology, 2022, 29, 7912-7924.	0.9	1
4352	Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity. Cancer Medicine, 2023, 12, 4294-4305.	1.3	3
4353	PD-L1-directed PlGF/VEGF blockade synergizes with chemotherapy by targeting CD141+ cancer-associated fibroblasts in pancreatic cancer. Nature Communications, 2022, 13, .	5.8	17
4354	Eficacia y seguridad de FOLFIRINOX vs. Gemcitabina + Nab-Paclitaxel (GemNab) en primera lÃnea de tratamiento de cÃ¡ncer de pÃ¡ncreas metastÃ¡sico. , 2022, 25, .		0
4355	Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study. Clinical Cancer Research, 2022, 28, 5254-5262.	3.2	24
4356	Anticancer Nanotherapeutics in Clinical Trials: The Work behind Clinical Translation of Nanomedicine. International Journal of Molecular Sciences, 2022, 23, 13368.	1.8	10
4357	FGFR2 fusion in metastatic pancreatic ductal adenocarcinoma: Is there hope?. European Journal of Cancer, 2022, 176, 168-170.	1.3	5
4358	Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancreatic cancer. Frontiers in Oncology, 0, 12, .	1.3	0
4359	Actionable tests and treatments for patients with gastrointestinal cancers and historically short median survival times. PLoS ONE, 2022, 17, e0276492.	1.1	0
4360	Surgeon-Led Clinical Trials in Pancreatic Cancer. Surgical Oncology Clinics of North America, 2022, , .	0.6	1
4361	Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma. Expert Opinion on Emerging Drugs, 2022, 27, 345-368.	1.0	4
4362	Targeting myeloid suppressive cells revives cytotoxic anti-tumor responses in pancreatic cancer. IScience, 2022, 25, 105317.	1.9	10
4363	Routine neoadjuvant chemotherapy for all patients with resectable pancreatic ductal adenocarcinoma? A review of the evidence. Current Opinion in Pharmacology, 2022, 67, 102305.	1.7	1
4364	Natural History of Stage IV Pancreatic Cancer. Identifying Survival Benchmarks for Curative-intent Resection in Patients With Synchronous Liver-only Metastases. Annals of Surgery, 2023, 278, e798-e804.	2.1	5
4365	A histopathological study of artery wall involvement in pancreatic cancer surgery. Langenbeck's Archives of Surgery, 2022, 407, 3501-3511.	0.8	2
4366	Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data. Oncologist, 0, , .	1.9	2

#	Article	IF	Citations
4367	The efficacy and safety of modified FOLFIRINOX for unresectable advanced pancreatic cancer in elderly versus young patients: A multicenter retrospective cohort study. Pancreatology, 2022, , .	0.5	0
4368	Inhibitory Effect of Î±1 Receptor Antagonists on Paclitaxel-Induced Peripheral Neuropathy in a Rodent Model and Clinical Database. Toxics, 2022, 10, 669.	1.6	0
4371	Selection bias due to delayed comprehensive genomic profiling in Japan. Cancer Science, 2023, 114, 1015-1025.	1.7	9
4372	Systemic Chemotherapy With or Without Hepatic Arterial Infusion Chemotherapy for Liver Metastases From Pancreatic Cancer: A Propensity Score Matching Analysis. Clinical Colorectal Cancer, 2023, 22, 111-119.	1.0	0
4373	Tumor and stroma COL8A1 secretion induces autocrine and paracrine progression signaling in pancreatic ductal adenocarcinoma. Matrix Biology, 2022, 114, 84-107.	1.5	5
4374	Circulating CD8+CD122+ T cells as a prognostic indicator of pancreatic cancer. BMC Cancer, 2022, 22, .	1.1	3
4375	Systemic Therapy for Patients With Pancreatic Cancer: Current Approaches and Opportunities for Novel Avenues Toward Precision Medicine. Clinical Colorectal Cancer, 2023, 22, 2-11.	1.0	5
4376	Prognostic Impact of Positive Peritoneal Lavage Cytology on Resectable Pancreatic Body and Tail Cancer: A Retrospective Study. World Journal of Surgery, 2023, 47, 729-739.	0.8	1
4377	Epidemiology and prognostic analysis of patients with pancreatic signet ring cell carcinoma: a population-based study. BMC Gastroenterology, 2022, 22, .	0.8	2
4378	Two-Stage SN38 Release from a Coreâ€“Shell Nanoparticle Enhances Tumor Deposition and Antitumor Efficacy for Synergistic Combination with Immune Checkpoint Blockade. ACS Nano, 2022, 16, 21417-21430.	7.3	22
4380	Liposomal co-delivery system encapsulating celastrol and paclitaxel displays highly enhanced efficiency and low toxicity against pancreatic cancer. Journal of Drug Delivery Science and Technology, 2022, 78, 103947.	1.4	0
4381	Skp2-mediated Zeb1 expression facilitates cancer migration by a ubiquitination-independent pathway. Life Sciences, 2022, 311, 121135.	2.0	4
4382	Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?. ESMO Open, 2022, 7, 100638.	2.0	11
4383	Consolidatory ablative stereotactic body radiation therapy after induction chemotherapy for unresectable pancreatic cancer: A single center experience. Frontiers in Oncology, 0, 12, .	1.3	1
4384	Clinical significance and functional role of adhesion G-protein-coupled receptors in human pancreatic ductal adenocarcinoma. British Journal of Cancer, 2023, 128, 321-330.	2.9	0
4385	Pharmacotherapeutic options for pancreatic ductal adenocarcinoma. Expert Opinion on Pharmacotherapy, 0, , .	0.9	4
4386	Possibility of Neoadjuvant Treatment for Radiologically Judged Resectable Pancreatic Cancer. Journal of Clinical Medicine, 2022, 11, 6792.	1.0	2
4387	Thermoresponsive polymers: Phase behavior, drug delivery, and biomedical applications. , 2023, , 47-64.		0

#	Article	IF	Citations
4388	A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Real-World Study. Cancer Control, 2022, 29, 107327482211412.	0.7	1
4389	Liver Endothelium Microenvironment Promotes HER3-mediated Cell Growth in Pancreatic Ductal Adenocarcinoma. Journal of Cancer Science and Clinical Therapeutics, 2022, 06, .	0.2	3
4390	CA19-9 Reduction After 4 Months of Treatment Is a Prognostic Factor for Locally Advanced Pancreatic Cancer. In Vivo, 2022, 36, 2844-2851.	0.6	2
4391	Pancreatic cancers. Advances in Magnetic Resonance Technology and Applications, 2023, , 315-340.	0.0	0
4392	Overcoming resistance of stroma-rich pancreatic cancer with focal adhesion kinase inhibitor combined with G47Î” and immune checkpoint inhibitors. Molecular Therapy - Oncolytics, 2023, 28, 31-43.	2.0	5
4393	Screening for Pancreatic Cancer: Current Status and Future Directions. European Medical Journal (Chelmsford, England), 0, , 59-67.	3.0	1
4394	Targeted Cancer Therapy: KRAS-Specific Treatments for Pancreatic Cancer. , 2022, , 1-34.		0
4395	Ductal Adenocarcinoma and Variants. Encyclopedia of Pathology, 2022, , 41-59.	0.0	0
4396	Thermal ablation in pancreatic cancer: A scoping review of clinical studies. Frontiers in Oncology, 0, 12, .	1.3	3
4397	Clinical Response to Seribantumab, an Antiâ€“Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an NRG1 Fusion. JCO Precision Oncology, 2022, , .	1.5	2
4398	Efficacy and safety of immune checkpoint inhibitors in advanced pancreatic cancer: A real world study in Chinese cohort. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	3
4399	Short-term survival of patients with advanced pancreatic cancer admitted to intensive care unit: a retrospective cohort study. Ecancermedicalscience, 0, 16, .	0.6	0
4400	Efficacy of dabrafenib/trametinib in pancreatic ductal adenocarcinoma with BRAF NVTAP deletion: A case report. Frontiers in Oncology, 0, 12, .	1.3	1
4401	Effectiveness of Abdominal Ultrasonography for Improving the Prognosis of Pancreatic Cancer during Medical Checkup: A Single Center Retrospective Analysis. Diagnostics, 2022, 12, 2913.	1.3	0
4402	Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma. Oncologist, 2023, 28, e115-e123.	1.9	8
4403	Incidence and appropriate management of drugâ€induced interstitial lung disease in Japanese patients with unresectable pancreatic cancer: A multicenter retrospective study. Asia-Pacific Journal of Clinical Oncology, 2023, 19, 533-541.	0.7	3
4404	BRAF-Driven Pancreatic Cancer: Prevalence, Molecular Features, and Therapeutic Opportunities. Molecular Cancer Research, 2023, 21, 293-300.	1.5	2
4405	Nanoparticles of folic acidâ€methylâ€Î²â€cyclodextrin (<scp>FAâ€MÎ²CD</scp>)/adamantaneâ€albumin exhibit enhanced antitumor activity compared with <scp>FAâ€MÎ²CD</scp> alone. FEBS Open Bio, 0, , .	1.0	0

#	Article	IF	Citations
4406	Health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the vignette-based approach in Japan. Health Economics Review, 2022, 12, .	0.8	1
4407	Initial treatment is associated with improved survival and end-of-life outcomes for patients with pancreatic cancer: a cohort study. BMC Cancer, 2022, 22, .	1.1	1
4408	Repeated irreversible electroporation in a locally advanced pancreatic cancer. IssledovaniÃ¢ I Praktika V Medicine, 2022, 9, 114-122.	0.1	1
4410	Chemotherapy in advanced pancreatic adenosquamous carcinoma: a retrospective multicenter <scp>AGEO</scp> study. International Journal of Cancer, 0, , .	2.3	0
4411	A Transcriptomic-Based Tool to Predict Gemcitabine Sensitivity in Advanced Pancreatic Adenocarcinoma. Gastroenterology, 2023, 164, 476-480.e4.	0.6	2
4412	Overcoming pancreatic cancer immune resistance by codelivery of CCR2 antagonist using a STING-activating gemcitabine-based nanocarrier. Materials Today, 2023, 62, 33-50.	8.3	9
4413	Necroptosis activation is associated with greater methylene blue-photodynamic therapy-induced cytotoxicity in human pancreatic ductal adenocarcinoma cells. Photochemical and Photobiological Sciences, 2023, 22, 729-744.	1.6	3
4414	Systematic Analysis of Molecular Subtypes Based on the Expression Profile of Immune-Related Genes in Pancreatic Cancer. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-28.	1.9	4
4415	Barriers and opportunities for gemcitabine in pancreatic cancer therapy. American Journal of Physiology - Cell Physiology, 2023, 324, C540-C552.	2.1	16
4416	Health-Related Quality of Life of Patients with Metastatic Pancreatic Cancer: A Systematic Literature Review. Cancer Management and Research, 0, Volume 14, 3383-3403.	0.9	1
4417	Inflammatory Cytokines and Radiotherapy in Pancreatic Ductal Adenocarcinoma. Biomedicines, 2022, 10, 3215.	1.4	2
4418	Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv). British Journal of Cancer, 0, , .	2.9	0
4419	Current treatment landscape of pancreatic cancer patients in a network of office-based oncologists in Germany. Future Oncology, 0, , .	1.1	0
4420	JNK inhibitor IX restrains pancreatic cancer through p53 and p21. Frontiers in Oncology, 0, 12, .	1.3	3
4421	Effect of acoustic cluster therapy (ACTÂ®) combined with chemotherapy in a patient-derived xenograft mouse model of pancreatic cancer. Journal of Controlled Release, 2022, 352, 1134-1143.	4.8	6
4422	Sarcopenia in pancreatic cancer: Effect on patient outcomes. World Journal of Gastrointestinal Oncology, 0, 14, 2302-2312.	0.8	4
4423	Survival impact of occult liver metastasis and peritoneal dissemination compared with radiologically defined distant organ metastasis in pancreatic ductal adenocarcinoma. Pancreatology, 2023, 23, 73-81.	0.5	0
4424	Association between Body Composition and Peripheral Neurotoxicity in Cancer Patients from North China Taking Nab-Paclitaxel. Nutrition and Cancer, 0, , 1-10.	0.9	1

#	Article	IF	Citations
4425	A Tumor Microenvironment Model of Pancreatic Cancer to Elucidate Responses toward Immunotherapy. Advanced Healthcare Materials, 2023, 12, .	3.9	3
4426	The Microbiome in PDACâ€"Vantage Point for Future Therapies?. Cancers, 2022, 14, 5974.	1.7	5
4427	Enhanced effect of X-rays in the presence of a static magnetic field within a 3D pancreatic cancer model. British Journal of Radiology, 2023, 96, .	1.0	1
4428	Landmarks in pancreatic cancer studies. Cancer Cell International, 2022, 22, .	1.8	1
4429	NGS-based targeted gene mutational profiles in Korean patients with pancreatic cancer. Scientific Reports, 2022, 12, .	1.6	2
4430	Sotorasib in KRAS p.G12Câ€"Mutated Advanced Pancreatic Cancer. New England Journal of Medicine, 2023, 388, 33-43.	13.9	95
4431	Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy. JAMA Oncology, 2023, 9, 316.	3.4	13
4432	Clinicopathologic and Molecular Features of Pancreatic Ductal Adenocarcinomas Harboring Alterations in COMPASS-like Complex Genes. Archives of Pathology and Laboratory Medicine, 2023, 147, 1050-1059.	1.2	1
4433	Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU). Frontiers in Immunology, 0, 13, .	2.2	13
4434	Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Journal of Clinical Oncology, 2023, 41, 2007-2019.	0.8	32
4435	Where Do We Stand with Immunotherapy for Advanced Pancreatic Ductal Adenocarcinoma: A Synopsis of Clinical Outcomes. Biomedicines, 2022, 10, 3196.	1.4	6
4436	Head-to-head comparison of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in advanced pancreatic cancer: a target trial emulation using real-world data. Annals of Epidemiology, 2023, 78, 28-34.	0.9	2
4437	Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer. BMC Cancer, 2022, 22, .	1.1	1
4438	Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer. Cancer Discovery, 2023, 13, 298-311.	7.7	91
4439	Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma. Cancers, 2022, 14, 6223.	1.7	6
4440	First-Line Gemcitabine, Nab-Paclitaxel, and Oxaliplatin Chemotherapy With Itraconazole in Patients With Metastatic Pancreatic Cancer: A Single Institution Experience. Anticancer Research, 2022, 42, 6063-6069.	0.5	4
4441	A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). European Journal of Cancer, 2023, 181, 135-144.	1.3	15
4442	CD73 Inhibits cGASâ€"STING and Cooperates with CD39 to Promote Pancreatic Cancer. Cancer Immunology Research, 2023, 11, 56-71.	1.6	20

#	Article	IF	Citations
4443	Neoadjuvant Treatment Versus Upfront Surgery in Resectable Pancreatic Cancer: A Cost-Effectiveness Analysis. JCO Oncology Practice, 2023, 19, e439-e448.	1.4	2
4444	Extracellular matrix modulating enzyme functionalized biomimetic Au nanoplatform-mediated enhanced tumor penetration and synergistic antitumor therapy for pancreatic cancer. Journal of Nanobiotechnology, 2022, 20, .	4.2	10
4445	Spatial Alignment of Organoids Tracking Subclonal Chemotherapy Resistance in Pancreatic and Ampullary Cancer. Bioengineering, 2023, 10, 91.	1.6	0
4446	Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer. Cancers, 2023, 15, 358.	1.7	1
4447	Role of Surgery for Pancreatic Ductal Adenocarcinoma in the Era of Multidisciplinary Treatment. Journal of Clinical Medicine, 2023, 12, 465.	1.0	2
4448	Discussion on gemcitabine combined with targeted drugs in the treatment of pancreatic cancer. World Journal of Gastroenterology, 0, 29, 579-581.	1.4	3
4449	Enhanced glypican-3-targeted identification of hepatocellular carcinoma with liver fibrosis by pre-degrading excess fibrotic collagen. Acta Biomaterialia, 2023, 158, 435-448.	4.1	9
4450	GATA6 and CK5 Stratify the Survival of Patients With Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy. Modern Pathology, 2023, 36, 100102.	2.9	2
4451	Modulation of myeloid and T cells in vivo by Brutonâ€™s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma. , 2023, 11, e005425.		4
4452	Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine. Cancers, 2023, 15, 416.	1.7	6
4453	Andrographis Reverses Gemcitabine Resistance through Regulation of ERBB3 and Calcium Signaling Pathway in Pancreatic Ductal Adenocarcinoma. Biomedicines, 2023, 11, 119.	1.4	2
4454	Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma. JAMA Network Open, 2023, 6, e2249720.	2.8	5
4455	A prognostic model based on tumor microenvironment-related lncRNAs predicts therapy response in pancreatic cancer. Functional and Integrative Genomics, 2023, 23, .	1.4	5
4457	Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival. Neuro-Oncology, 2023, 25, 1017-1028.	0.6	12
4458	Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer. Frontiers in Immunology, 0, 14, .	2.2	7
4459	Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic immune responses that inhibit liver metastasis in an orthotopic model. , 2023, 11, e006133.		5
4460	Giant Gallbladder Tumor, Unusual Cancerâ€”Case Report and Short Review of Literature. Diagnostics, 2023, 13, 194.	1.3	0
4461	Normalization of tumor markers and a clear resection margin affect progression-free survival of patients with unresectable pancreatic cancer who have undergone conversion surgery. BMC Cancer, 2023, 23, .	1.1	0

#	Article	IF	Citations
4462	Nanoparticles in the diagnosis and treatment of cancer metastases: Current and future perspectives. Cancer Letters, 2023, 556, 216066.	3.2	18
4463	Real World Data for Pancreatic Adenocarcinoma from a Population-Based Study in France. Cancers, 2023, 15, 525.	1.7	0
4464	Liver metastasis of pancreatic cancer: the new choice at the crossroads. Hepatobiliary Surgery and Nutrition, 2023, 12, 88-91.	0.7	1
4465	Telomerase: A prominent oncological target for development of chemotherapeutic agents. European Journal of Medicinal Chemistry, 2023, 249, 115121.	2.6	5
4466	Borderline Resectable Pancreatic Cancer: Challenges for Clinical Management. Cancer Management and Research, 0, Volume 14, 3589-3598.	0.9	1
4467	Pathologic complete response following FOLFIRINOX and olaparib treatment for hepatic metastasized pancreatic ductal adenocarcinoma with a germline BRCA mutation. Clinical Journal of Gastroenterology, 2023, 16, 283-288.	0.4	1
4468	Comparison the efficacy and safety of different neoadjuvant regimens for resectable and borderline resectable pancreatic cancer: a systematic review and network meta-analysis. European Journal of Clinical Pharmacology, 0, , .	0.8	2
4469	Preclinical evaluation of pentagamavunone-1 as monotherapy and combination therapy for pancreatic cancer in multiple xenograft models. Scientific Reports, 2022, 12, .	1.6	2
4470	Stroma-targeting strategies in pancreatic cancer: a double-edged sword. Journal of Physiology and Biochemistry, 2023, 79, 213-222.	1.3	7
4471	Influence of a biliary stent in patients with advanced pancreatic cancer treated with modified FOLFIRINOX. Medicine (United States), 2022, 101, e32150.	0.4	1
4472	Time to Onset of Gemcitabine-induced Thrombotic Microangiopathy in a Japanese Population: A Case Series and Large-scale Pharmacovigilance Analysis. Cancer Diagnosis & Prognosis, 2022, 3, 115-123.	0.3	0
4473	A population-based study of synchronous distant metastases and prognosis in patients with PDAC at initial diagnosis. Frontiers in Oncology, 0, 13, .	1.3	2
4474	Perspective Chapter: Appraisal of Paclitaxel (Taxol) Pros and Cons in the Management of Cancer - Prospects in Drug Repurposing. , 0, , .		1
4475	A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer. Frontiers in Endocrinology, 0, 14, .	1.5	0
4476	Therapeutic Strategies to Overcome Fibrotic Barriers to Nanomedicine in the Pancreatic Tumor Microenvironment. Cancers, 2023, 15, 724.	1.7	2
4477	Combination, Modulation and Interplay of Modern Radiotherapy with the Tumor Microenvironment and Targeted Therapies in Pancreatic Cancer: Which Candidates to Boost Radiotherapy?. Cancers, 2023, 15, 768.	1.7	2
4478	Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis. Npj Genomic Medicine, 2023, 8, .	1.7	15
4479	Synergistic Combination of Irinotecan and Rapamycin Orally Delivered by Nanoemulsion for Enhancing Therapeutic Efficacy of Pancreatic Cancer. Pharmaceutics, 2023, 15, 473.	2.0	1

#	Article	IF	Citations
4480	Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer. Clinical Cancer Research, 2023, 29, 1267-1278.	3.2	7
4481	A microfluidic-based PDAC organoid system reveals the impact of hypoxia in response to treatment. Cell Death Discovery, 2023, 9, .	2.0	13
4482	The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study. World Journal of Surgical Oncology, 2023, 21, .	0.8	0
4483	Hypercapnic Tissue Gene Expression and Survival in Early-Stage Pancreatic Ductal Adenocarcinoma. Journal of the American College of Surgeons, 0, Publish Ahead of Print, .	0.2	2
4484	Relevant Study: Patient and Clinician Perspectives on Clinically-Meaningful Outcomes in Advanced Pancreatic Cancer. Cancers, 2023, 15, 738.	1.7	2
4485	Examining the efficacy of localised gemcitabine therapy for the treatment of pancreatic cancer using a hybrid agent-based model. PLoS Computational Biology, 2023, 19, e1010104.	1.5	2
4486	Perturbation of Autophagy by a Beclin 1-Targeting Stapled Peptide Induces Mitochondria Stress and Inhibits Proliferation of Pancreatic Cancer Cells. Cancers, 2023, 15, 953.	1.7	2
4490	Recent Advances in Well-Designed Therapeutic Nanosystems for the Pancreatic Ductal Adenocarcinoma Treatment Dilemma. Molecules, 2023, 28, 1506.	1.7	2
4491	Oncologic resection of pancreatic cancer with isolated liver metastasis: Favorable outcomes in select patients. Journal of Hepato-Biliary-Pancreatic Sciences, 2023, 30, 1025-1035.	1.4	5
4492	Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board. Targeted Oncology, 2023, 18, 257-267.	1.7	5
4493	Design, Synthesis, and Anti-Cancer Evaluation of Novel Cyclic Phosphate Prodrug of Gemcitabine. Journal of Medicinal Chemistry, 2023, 66, 4150-4166.	2.9	3
4494	Efficacy Analysis of Suprapapillary versus Transpapillary Self-Expandable Metal Stents According to the Level of Obstruction in Malignant Extrahepatic Biliary Obstruction. Gut and Liver, 2023, , .	1.4	1
4495	Combating pancreatic cancer with ovarian cancer cells. Aging, 2023, 15, 2189-2207.	1.4	0
4496	Impact of neoadjuvant therapy on gut microbiome in patients with resectable/borderline resectable pancreatic ductal adenocarcinoma. Pancreatology, 2023, 23, 367-376.	0.5	2
4497	Oncolytic adenoviruses and the treatment of pancreatic cancer: a review of clinical trials. Journal of Cancer Research and Clinical Oncology, 2023, 149, 8117-8129.	1.2	2
4498	Regulation of metabolism in pancreatic ductal adenocarcinoma via nanotechnology-enabled strategies. Cancer Letters, 2023, 560, 216138.	3.2	3
4499	Pancreatic cancer: Advances and challenges. Cell, 2023, 186, 1729-1754.	13.5	142
4500	Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial. EClinicalMedicine, 2023, 58, 101897.	3.2	3

#	Article	IF	Citations
4501	Clinical benefit of subsequent chemotherapy after drug-induced interstitial lung disease in pancreatic cancer patients: a multicenter retrospective study from Japan. BMC Cancer, 2023, 23, .	1.1	2
4502	Comparative Effectiveness of FOLFIRINOX Versus Gemcitabine and Nab-paclitaxel in Initially Unresectable Locally Advanced Pancreatic Cancer: A Population-based Study to Assess Subsequent Surgical Resection and Overall Survival. Clinical Oncology, 2023, 35, e303-e311.	0.6	0
4503	Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs. Drug Resistance Updates, 2023, 68, 100960.	6.5	36
4504	Ultrasound and Microbubbles Increase the Uptake of Platinum in Murine Orthotopic Pancreatic Tumors. Ultrasound in Medicine and Biology, 2023, 49, 1275-1287.	0.7	5
4505	A Novel 3DNAÂ® Nanocarrier effectively delivers payloads to pancreatic tumors. Translational Oncology, 2023, 32, 101662.	1.7	1
4506	Adoptive neoantigen-reactive T cell therapy: improvement strategies and current clinical researches. Biomarker Research, 2023, 11, .	2.8	2
4507	Visual Investigation of Tumorâ€Promoting Fibronectin Potentiated by Obesity in Pancreatic Ductal Adenocarcinoma Using an MR/NIRF Dualâ€Modality Dendrimer Nanoprobe. Advanced Healthcare Materials, 2023, 12, .	3.9	2
4508	Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment. Biomedicine and Pharmacotherapy, 2023, 161, 114567.	2.5	5
4509	Pancreatic Cancer: Nanoparticle Targeted Therapy Via Epidermal Growth Factor Receptor. , 2022, , 111-128.		0
4510	A rare case of sporadic mismatch repair deficient pancreatic ductal adenocarcinoma that responded to ipilimumab and nivolumab combination treatment: case report. Journal of Gastrointestinal Oncology, 2023, 14, 458-462.	0.6	1
4511	An ultra-small bispecific protein augments tumor penetration and treatment for pancreatic cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 1765-1779.	3.3	4
4513	A biomimetic nanodrug for enhanced chemotherapy of pancreatic tumors. Journal of Controlled Release, 2023, 354, 835-850.	4.8	7
4514	Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey. ESMO Open, 2023, 8, 100777.	2.0	2
4515	Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice. Cancers, 2023, 15, 900.	1.7	3
4516	Narrative Review of Drug-Associated Nail Toxicities in Oncologic Patients. Dermatology Practical and Conceptual, 0, , e2023064.	0.5	1
4517	Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis. Journal of the American College of Surgeons, 2023, 236, 1126-1136.	0.2	4
4518	Treatment of pancreatic cancer in 2022. , 2023, 1, .		0
4519	The role of local treatment including pancreatectomy for pancreatic ductal adenocarcinoma patients with isolated synchronous liver metastasis: Propensity scoreâ€matched analyses. Journal of Hepato-Biliary-Pancreatic Sciences, 2023, 30, 1036-1045.	1.4	2

#	Article	IF	Citations
4521	CDK4/6 Inhibitors in Pancreatobiliary Cancers: Opportunities and Challenges. Cancers, 2023, 15, 968.	1.7	3
4522	Targeting chemoresistant senescent pancreatic cancer cells improves conventional treatment efficacy. Molecular Biomedicine, 2023, 4, .	1.7	5
4523	Partial response in non-resectable adenosquamous carcinoma of the pancreas with high tumour mutation burden treated with gemcitabine, nab-paclitaxel and pembrolizumab. BMJ Case Reports, 2023, 16, e251936.	0.2	0
4524	Prognostic impact of osteosarcopenia in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel. Pancreatology, 2023, 23, 275-282.	0.5	4
4525	Prognosis of Pancreatic Cancer Based on Resectability: A Single Center Experience. Cancers, 2023, 15, 1101.	1.7	3
4526	Are Aspects of Integrative Concepts Helpful to Improve Pancreatic Cancer Therapy?. Cancers, 2023, 15, 1116.	1.7	1
4527	Research trends and hotspots of neoadjuvant therapy in pancreatic cancer: a bibliometric analysis based on the Web of Science Core Collection. Clinical and Experimental Medicine, 2023, 23, 2473-2485.	1.9	2
4528	Establishment and Molecular Characterization of Two Patient-Derived Pancreatic Ductal Adenocarcinoma Cell Lines as Preclinical Models for Treatment Response. Cells, 2023, 12, 587.	1.8	1
4529	Use of timeâ€‘density curves of dynamic contrastâ€‘enhanced computed tomography for determination of the histological therapeutic effects of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma. Oncology Reports, 2023, 49, .	1.2	0
4530	Implication of Skeletal Muscle Loss in the Prognosis of Patients with Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy. Internal Medicine, 2023, 62, 2783-2793.	0.3	2
4531	Development of novel biliary metal stent with coil-spring structure and its application in vivo swine biliary stricture model. Frontiers in Oncology, 0, 13, .	1.3	1
4532	Spatially restricted tumour-associated and host-associated immune drivers correlate with the recurrence sites of pancreatic cancer. Gut, 2023, 72, 1523-1533.	6.1	6
4533	Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy. Cancers, 2023, 15, 1235.	1.7	9
4534	microRNAs Associated with Gemcitabine Resistance via EMT, TME, and Drug Metabolism in Pancreatic Cancer. Cancers, 2023, 15, 1230.	1.7	5
4536	Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature. Journal of Gastrointestinal Oncology, 2023, 14, 352-365.	0.6	0
4537	Phase Ib and Expansion Study of Gemcitabine,Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. Oncologist, 2023, 28, 425-432.	1.9	1
4539	Challenges in Diagnosis and Treatment of Pancreatic Exocrine Insufficiency among Patients with Pancreatic Ductal Adenocarcinoma. Cancers, 2023, 15, 1331.	1.7	6
4541	Photochemical Internalization Using Natural Anticancer Drugs, Antimetabolites, and Nanoformulations: A Systematic Study against Breast and Pancreatic Cancer Cell Lines. Molecular Pharmaceutics, 2023, 20, 1818-1841.	2.3	2

#	Article	IF	Citations
4543	Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study. MedComm, 2023, 4, .	3.1	9
4544	FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study. BMC Cancer, 2023, 23, .	1.1	1
4545	Patientâ€centered outcomes in the POLO study of active maintenance olaparib for germline BRCAâ€mutated metastatic pancreatic cancer. Cancer, 2023, 129, 1411-1418.	2.0	2
4546	Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma. British Journal of Cancer, 2023, 128, 1672-1680.	2.9	2
4547	Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Nature, 2023, 615, 168-174.	13.7	89
4548	Targeting UBE2T Potentiates Gemcitabine Efficacy in PancreaticÂCancer by Regulating Pyrimidine Metabolism and Replication Stress. Gastroenterology, 2023, 164, 1232-1247.	0.6	7
4549	Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan. Gut and Liver, 2023, , .	1.4	1
4550	Endobiliary radiofrequency ablation for unresectable malignant biliary strictures: Survival benefit perspective. Digestive Endoscopy, 2023, 35, 584-591.	1.3	2
4551	Bench-to-Bedside Studies of Arginine Deprivation in Cancer. Molecules, 2023, 28, 2150.	1.7	9
4552	Pancreatic Cancer with Vascular Involvement: Adherence to Current Standard-of-Care Associated with Improved Survival. American Surgeon, 2023, 89, 5535-5544.	0.4	0
4553	Adjuvant Gemcitabine and Nab-Paclitaxel Misses the Target in Pancreas Adenocarcinoma: Or Did an Effective Therapy Fall to the Definition of Recurrence?. Journal of Clinical Oncology, 2023, 41, 1972-1975.	0.8	3
4555	Molecular Research in Pancreatic Cancer: Small Molecule Inhibitors, Their Mechanistic Pathways and Beyond. Current Issues in Molecular Biology, 2023, 45, 1914-1949.	1.0	2
4556	Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden. Frontiers in Oncology, 0, 13, .	1.3	0
4557	Integrated analysis of Dendrobium nobile extract Dendrobin A against pancreatic ductal adenocarcinoma based on network pharmacology, bioinformatics, and validation experiments. Frontiers in Pharmacology, 0, 14, .	1.6	3
4558	Fluoropyrimidine combination therapy versus fluoropyrimidine monotherapy for gemcitabine-refractory advanced pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials. PLoS ONE, 2023, 18, e0282360.	1.1	0
4559	RRM1 is mediated by histone acetylation through gemcitabine resistance and contributes to invasiveness and ECM remodeling in pancreatic cancer. International Journal of Oncology, 2023, 62, .	1.4	1
4560	Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospective observational study. Supportive Care in Cancer, 2023, 31, .	1.0	3
4561	Stuttering as a signal of encephalopathy associated with toripalimab in a pancreatic ductal adenocarcinoma patient: a case report. BMC Neurology, 2023, 23, .	0.8	1

#	Article	IF	Citations
4562	Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinoma. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592311576.	1.4	2
4564	Nanomedicine for autophagy modulation in cancer therapy: a clinical perspective. Cell and Bioscience, 2023, 13, .	2.1	9
4565	Pancreatic cancer: a glimmer of hope. Trends in Urology & Men's Health, 2023, 14, 5-10.	0.2	0
4566	Trop-2 is a ubiquitous and promising target in pancreatic adenocarcinoma. Clinics and Research in Hepatology and Gastroenterology, 2023, 47, 102108.	0.7	1
4567	Urokinase-Type Plasminogen Activator Receptor (uPAR) Cooperates with Mutated KRAS in Regulating Cellular Plasticity and Gemcitabine Response in Pancreatic Adenocarcinomas. Cancers, 2023, 15, 1587.	1.7	2
4568	Contemporary Treatment Paradigms are Associated with Improved Survival in Pancreatic Cancer. American Surgeon, 0, , 000313482311578.	0.4	0
4569	Immune response and drug therapy based on ac4C-modified gene in pancreatic cancer typing. Frontiers in Immunology, 0, 14, .	2.2	5
4571	The Potent G-Quadruplex-Binding Compound QN-302 Downregulates S100P Gene Expression in Cells and in an In Vivo Model of Pancreatic Cancer. Molecules, 2023, 28, 2452.	1.7	5
4572	Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma. Journal of Gastrointestinal Oncology, 2023, 14, 1175-1177.	0.6	1
4574	A radiomics nomogram model for predicting prognosis of pancreatic ductal adenocarcinoma after high-intensity focused ultrasound surgery. International Journal of Hyperthermia, 2023, 40, .	1.1	0
4575	Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer. Advances in Cancer Research, 2023, , 113-143.	1.9	2
4576	Quality of Life in Patients with Pancreatic Cancerâ€"A Literature Review. International Journal of Environmental Research and Public Health, 2023, 20, 4895.	1.2	3
4577	Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198). European Journal of Cancer, 2023, 189, 112847.	1.3	1
4579	Impact of Sarcopenia on Survival in Patients Treated with FOLFIRINOX in a First-Line Setting for Metastatic Pancreatic Carcinoma. Journal of Clinical Medicine, 2023, 12, 2211.	1.0	0
4580	Survival for Patients with Radiographically Occult Metastatic Pancreatic Cancer in the Era of Modern Multiagent Chemotherapy. Annals of Surgical Oncology, 0, , .	0.7	0
4581	Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. British Journal of Cancer, 2023, 128, 1916-1921.	2.9	5
4582	Neoadjuvant therapy for pancreatic cancer. Nature Reviews Clinical Oncology, 2023, 20, 318-337.	12.5	61
4583	Malignant ascites in pancreatic cancer: Pathophysiology, diagnosis, molecular characterization, and therapeutic strategies. Frontiers in Oncology, 0, 13, .	1.3	1

#	Article	IF	Citations
4584	Adherence to NCCN Genetic Testing Guidelines in Pancreatic Cancer and Impact on Treatment. Oncologist, 2023, 28, 486-493.	1.9	0
4585	Case report: Preliminary response to tislelizumab plus S-1 in patients with metastatic gallbladder carcinoma: A report of five cases and a literature review. Frontiers in Immunology, 0, 14, .	2.2	1
4586	Pancreatic adenocarcinoma with brain metastases. BMJ Case Reports, 2023, 16, e253557.	0.2	0
4587	The application of pancreatic cancer organoids for novel drug discovery. Expert Opinion on Drug Discovery, 2023, 18, 429-444.	2.5	0
4588	The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naÃ¯ve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients. Journal of Geriatric Oncology, 2023, 14, 101474.	0.5	3
4589	Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival. Function, 2023, 4, .	1.1	6
4590	Circulating tumor DNA in molecular assessment feasibly predicts early progression of pancreatic cancer that cannot be identified via initial imaging. Scientific Reports, 2023, 13, .	1.6	3
4591	Noncoding RNAs as regulators of STAT3 pathway in gastrointestinal cancers: Roles in cancer progression and therapeutic response. Medicinal Research Reviews, 2023, 43, 1263-1321.	5.0	26
4592	The Gut Microbiome and Pancreatic Cancer Development and Treatment. Cancer Journal (Sudbury,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.0	3
4593	Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy. JAMA Network Open, 2023, 6, e234254.	2.8	14
4594	A population-based nomogram to individualize treatment modality for pancreatic cancer patients underlying surgery. Scientific Reports, 2023, 13, .	1.6	1
4595	Aptamer and Peptide-Engineered Polydopamine Nanospheres for Target Delivery and Tumor Perfusion in Synergistic Chemo-Phototherapy of Pancreatic Cancer. ACS Applied Materials & Interfaces, 2023, 15, 16539-16551.	4.0	7
4596	Human Microbiome Modulation: A Potential Therapeutic Strategy for Pancreatic Cancer. , 2023, , 205-242.		0
4597	Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study. Journal of Hematology and Oncology, 2023, 16, .	6.9	3
4598	Heat shock protein 90 (HSP90) inhibitors in gastrointestinal cancer: where do we currently stand?â€"A systematic review. Journal of Cancer Research and Clinical Oncology, 2023, 149, 8039-8050.	1.2	0
4599	Anticancer Activity of Novel Difluorinated Curcumin Analog and Its Inclusion Complex with 2-Hydroxypropyl-Î²-Cyclodextrin against Pancreatic Cancer. International Journal of Molecular Sciences, 2023, 24, 6336.	1.8	3
4600	Efficacy and tolerance of LV5FU2-carboplatin chemotherapy in patients with advanced pancreatic ductal adenocarcinoma after failure of standard regimens. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592311637.	1.4	1
4601	Gemcitabine+nab-paclitaxelä½µç"¨è¡"å‰åŒ–å¦ç™‚æ³•ã«ã‚ˆã‚Špathological complete responseã•Œå¾—ã‚‰ã‚Œæ¹æ²»çš„åˆ‡é™¤ã•Œ Surgery, 2023, 56, 165-172.	0.0	0

#	Article	IF	Citations
4602	Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights. Current Oncology, 2023, 30, 3871-3885.	0.9	4
4604	Overcoming the Limitations of Therapeutic Strategies to Combat Pancreatic Cancer Using Nanotechnology. Current Cancer Drug Targets, 2023, 23, .	0.8	1
4605	Analysis of oncological drugs authorised in Spain in the last decade: association between clinical benefit and reimbursement. European Journal of Health Economics, 2024, 25, 257-267.	1.4	1
4606	Preoperative downstaging of pancreatic cancer is associated with improved survival after multi-agent chemotherapy, but not after radiation. Surgical Oncology, 2023, 48, 101939.	0.8	0
4607	Neoadjuvant chemotherapy associated with isotoxic highâ€dose stereotactic body radiotherapy does not increase postoperative complications after pancreaticoduodenectomy for nonmetastatic pancreatic cancer. Journal of Surgical Oncology, 2023, 128, 33-40.	0.8	0
4608	Early and late recurrence patterns of pancreatic ductal adenocarcinoma after pancreaticoduodenectomy: a multicenter study. International Journal of Surgery, 2023, 109, 785-793.	1.1	3
4609	A decision support system based on artificial intelligence and systems biology for the simulation of pancreatic cancer patient status. CPT: Pharmacometrics and Systems Pharmacology, 2023, 12, 916-928.	1.3	2
4610	Circulating Cell-Free Nucleic Acids as Biomarkers for Diagnosis and Prognosis of Pancreatic Cancer. Biomedicines, 2023, 11, 1069.	1.4	1
4611	Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRASG12D mutated pancreatic cancer in vivo model. Cell Death Discovery, 2023, 9, .	2.0	3
4612	FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review. Annals of Surgical Oncology, 2023, 30, 4417-4428.	0.7	10
4613	Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report. Frontiers in Oncology, 0, 13, .	1.3	2
4614	The impact of early palliative care on the quality of life of patients with advanced pancreatic cancer: The IMPERATIVE case-crossover study. Supportive Care in Cancer, 2023, 31, .	1.0	7
4615	Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan. Journal of Gastroenterology, 2023, 58, 575-585.	2.3	6
4616	The efficacy and safety of nanoparticle albumin boundâ€paclitaxelâ€based regimen as secondâ€or thirdâ€line treatment in patients with advanced esophageal squamous cell carcinoma. Thoracic Cancer, 2023, 14, 1392-1397.	0.8	2
4617	PSMD12 interacts with CDKN3 and facilitates pancreatic cancer progression. Cancer Gene Therapy, 2023, 30, 1072-1083.	2.2	1
4618	Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma. Journal of Gastrointestinal Oncology, 2023, .	0.6	0
4619	Sex and gender differences in treatment intention, quality of life and performance status in the first 100 patients with periampullary cancer enrolled in the CHAMP study. BMC Cancer, 2023, 23, .	1.1	1
4621	Chronic effects of pulsed high intensity focused ultrasound aided delivery of gemcitabine in a mouse model of pancreatic cancer. Ultrasonics, 2023, 132, 106993.	2.1	2

#	Article	IF	Citations
4622	Sensitivity of cytology in liver tumor biopsy and its significance in the prompt clinical diagnosis of nonâ€hepatocellular carcinoma. Cancer Medicine, 0, , .	1.3	0
4623	New Treatment Options in Metastatic Pancreatic Cancer. Cancers, 2023, 15, 2327.	1.7	4
4624	A case of multiple myeloma with pancreatic involvement diagnosed via endoscopic ultrasoundâ€guided fine needle aspiration. Clinical Case Reports (discontinued), 2023, 11, .	0.2	0
4625	Preserved correlation matrices pinpoint extracellular matrix organization as a critical factor in pancreatic ductal adenocarcinoma. F1000Research, 0, 12, 418.	0.8	0
4626	Chinese herbal medicine for the treatment of cardiovascular diseases â”€ targeting cardiac ion channels. Pharmacological Research, 2023, , 106765.	3.1	1
4627	Health Disparities in Presentation, Treatment, Genomic Testing, and Outcomes of Pancreatic Cancer in Hispanic and Non-Hispanic Patients. Journal of Racial and Ethnic Health Disparities, 0, , .	1.8	1
4629	Role for Neoadjuvant Systemic Therapy for Potentially Resectable Pancreatic Cancer. Cancers, 2023, 15, 2377.	1.7	2
4630	The Efficacy and Safety of Treatment Regimens Used in the First-Line Setting in Metastatic Pancreatic Cancer Patients. Pancreas, 2022, 51, 1153-1159.	0.5	1
4632	A Selfâ€Assembly Combined Nanoâ€Prodrug to Overcome Gemcitabine Chemoâ€Resistance of Pancreatic Tumors. Advanced Functional Materials, 2023, 33, .	7.8	3
4633	Tumor heterogeneity: An oncogenic driver of PDAC progression and therapy resistance under stress conditions. Advances in Cancer Research, 2023, , .	1.9	0
4634	Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort. European Journal of Cancer, 2023, 188, 90-97.	1.3	10
4699	Endoscopic Ultrasound-Guided Fine-Needle Biopsies to Generate Preclinical Disease Models to Study Inflammation in Pancreatic Ductal Adenocarcinoma. Methods in Molecular Biology, 2023, , 43-54.	0.4	0
4700	Pancreatic Adenocarcinoma and Ageing: Understanding the Menace for Better Management. Journal of Pancreatology, 0, Publish Ahead of Print, .	0.3	0
4722	Immunotherapy for Pancreatic Cancer. , 2023, , 1-27.		0
4731	Current Clinical Landscape of Immunotherapeutic Approaches in Pancreatic Cancer Treatment. , 2023, , 327-380.		0
4761	Biological Barriers for Drug Delivery to Cancer Stem Cells. , 2023, , 271-288.		0
4767	Targeted Cancer Therapy: KRAS-Specific Treatments for Pancreatic Cancer. , 2023, , 2139-2172.		0
4820	Therapeutic developments in pancreatic cancer. Nature Reviews Gastroenterology and Hepatology, 2024, 21, 7-24.	8.2	7

#	Article	IF	Citations
4844	Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening. , 0, , .		0
4848	Macro understanding of the therapeutic role of phospholipase and their metabolites in pancreatic ductal and periampullary adenocarcinoma. , 2023, , 181-208.		0
4887	Case Report: Overcoming challenges in pancreatic cancer with liver metastases: a personalized therapeutic odyssey of TACE, ablation, and immunotherapy. Frontiers in Immunology, 0, 14, .	2.2	0
4923	Clinical practice guidelines for interventional treatment of pancreatic cancer. , 2024, , 345-373.		0
4930	Immunotherapy in Pancreatic Cancer. , 2023, , 97-146.		0
4939	Borderline Resectable and Locally Advanced Pancreatic Cancer. , 2023, , 19-35.		0
4941	Therapy for Metastatic Pancreatic Cancer. , 2023, , 57-65.		0
4942	Resectable Pancreatic Cancer: Neoadjuvant and Adjuvant Therapy. , 2023, , 1-18.		0
4943	Targeted Therapies for Pancreatic Cancer. , 2023, , 67-95.		0
4949	Artificial Intelligence for Cancer Diagnosis and Prognosis: Current Status and Future Directions. , 2023, , .		0
4974	Metastatic pancreatic cancer with multiple metastases confined to the large intestine: a case report and literature review. Clinical Journal of Gastroenterology, 0, , .	0.4	0
4994	UCP2 and pancreatic cancer: conscious uncoupling for therapeutic effect. Cancer and Metastasis Reviews, 0, , .	2.7	0
5033	A case of metachronous oligo-hepatic and peritoneal metastases of pancreatic cancer with a favorable outcome after conversion surgery combined with perioperative sequential chemotherapy. Clinical Journal of Gastroenterology, 2024, 17, 371-381.	0.4	0
5046	Update on the management of older patients with pancreatic adenocarcinoma: a perspective from medical oncology. Clinical and Translational Oncology, 0, , .	1.2	0
5052	Case report: Diverse immune responses in advanced pancreatic ductal adenocarcinoma treated with immune checkpoint inhibitor-based conversion therapies. Frontiers in Immunology, 0, 15, .	2.2	0
5056	Malignome des Gastrointestinaltrakts. , 2024, , 675-799.		0